[go: up one dir, main page]

WO2007030531A2 - Reagents for testing and molecular imaging of liver cancer - Google Patents

Reagents for testing and molecular imaging of liver cancer Download PDF

Info

Publication number
WO2007030531A2
WO2007030531A2 PCT/US2006/034703 US2006034703W WO2007030531A2 WO 2007030531 A2 WO2007030531 A2 WO 2007030531A2 US 2006034703 W US2006034703 W US 2006034703W WO 2007030531 A2 WO2007030531 A2 WO 2007030531A2
Authority
WO
WIPO (PCT)
Prior art keywords
human
protein
precursor
receptor
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034703
Other languages
French (fr)
Other versions
WO2007030531A3 (en
Inventor
Jay M. D. Wohlgemuth
Kirk Fry
Rheal Antoine Towner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Molecular Image Inc
Original Assignee
Oklahoma Medical Research Foundation
Molecular Image Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Molecular Image Inc filed Critical Oklahoma Medical Research Foundation
Publication of WO2007030531A2 publication Critical patent/WO2007030531A2/en
Publication of WO2007030531A3 publication Critical patent/WO2007030531A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/143Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the methods and reagents described herein generally relate to the identification of molecular targets which are specific to disease and the development of affinity reagents to the argets.
  • the affinity reagent may be utilized as a diagnostic in a diagnostic assay.
  • a contrast or ignal emitting source may be incorporated into the reagent, to generate a target-specific imaging eagent.
  • Medical diagnosis and monitoring utilize a variety of imaging techniques. Standard adiography, fluoroscopy, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Ultrasound are all useful methods in clinical practice. These techniques all have their unique advantages and drawbacks. The clinical utility of all of these techniques could be greatly enhanced by using contrast or signal emitting reagents which are targeted to disease specific molecules. This approach (molecular imaging) could provide added sensitivity for detection of disease or anatomical extent of disease and specificity to help differentiate anatomical findings due to disease from normal or non-diseased tissue. The potential applications of this approach are clear in every medical discipline and disease category.
  • ng may also be targeted to a biological process as opposed to a specific antigen. Examples of would be targeting angiogenesis or macrophage transit into the blood vessel wall.
  • Molecular imaging approaches may be utilized in numerous clinical situations in oncology. Diagnosis of disease may be improved in this way. Cancer marker specific imaging affinity reagents may provide added sensitivity for small tumors vs. standard imaging or clinical monitoring. Also, this approach may be more specific and allow distinction of cancer tissue from normal tissue or benign processes. Clearly, it may also provide a less invasive means of diagnosis compared to invasive procedures such as endoscopy or biopsy. Upon diagnosis of cancer, staging and risk stratification is necessary to plan surgery and guide radiation and chemotherapy usage. One possibility is for molecular imaging to be performed before completion of cancer surgery to ensure that there has been complete tumor removal ("molecular imaging margins").
  • the tumor may be treated differently on this basis alone. Imaging may also be done after cancer surgery to check for complete excision if the imaging target is cancer specific. This can be difficult with non-molecular imaging because of anatomical changes from surgery and sensitivity limitations.
  • molecular imaging may provide a sensitive way to monitor for recurrence.
  • the primary tumor tissue may be obtained at the time of biopsy or surgery and assessed for the expression of the molecular target. Subsequently the tumor spread or recurrence can be imaged with the appropriate agent that the rimary tumor is found to express.
  • Molecular imaging approaches may be extremely valuable in hemotherapeutic drug trials as patient selection tools or as a surrogate endpoint.
  • Hepatocellular carcinoma often occurs in patients with cirrhotic liver disease from hepatis B or C, alcohol or other processes. This presents a difficult diagnostic dilemma as cirrhosis s associated with nodule formation and scarring in the liver tissue which makes detection of a ancer nodule nearly impossible at an early stage using standard anatomical imaging techniques ound, MRI, CT). Biopsy is not a very helpful modality in this setting either as it is very ult to know where to sample this very large organ for monitoring for onset of cancer and patients with liver disease often have underlying clotting disorders or platelet abnormalities which create a risk of excessive bleeding.
  • hepatocellular cancer can occur any time over many years in cirrhotic patients which makes monitoring modality selection critical. Hepatocellular carcinoma can be cured by liver lobar resection if the cancer is clearly restricted to one area. In addition, a patient with this cancer could have a transplant if the risk of spread beyond the liver is extremely low. Molecular imaging may help make this determination.
  • a target-specific imaging reagent composed of an affinity agent coupled to an imaging agent, where the affinity agent specifically binds to a biological molecule, and where the expression of the biological molecule is predictive of a disease or a disease state.
  • a "disease state” refers to the current status of a disease which may have been previously diagnosed, such prognosis, risk-stratification, assessment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patient's health status over time.
  • imaging agents detectable by at least one of computed tomography, ultrasound, magnetic resonance, nuclear imaging (PET or SPECT), or optical imaging, where the optical imaging is by Diffuses Optical Tomography, Optical Coherence Tomography, Confocal Laser Scanning Microscopy, Fluorescence Correlation Microscopy, Fluorescence Resonance Energy Transfer, or Fluorescence Lifetime Imaging.
  • affinity agents which can be used, including antibodies, small molecules, or peptides. Such affinity agents can be used with or without the imaging agent to dentify the biological molecule in body fluids. Such body fluids include blood or serum.
  • biological molecules which can be used, including cell surface roteins, secreted proteins, cell surface polysaccharides, RNA, or DNA.
  • diseases which can be diagnosed or monitored including cancer as lung cancer, melanoma, breast cancer, prostate cancer, neuroendocrine, stomach cancer, ymphoma, head and neck cancer, pancreatic cancer, ovarian cancer, liver cancer, cancer of the entral nervous system, or testicular cancer), cardiovascular disease, a condition caused by hematopoietic stem cell transplantation, neurologic disease, autoimmune disease, chronic nflammatory disease, gynecologic disease, or infectious disease.
  • cancer as lung cancer, melanoma, breast cancer, prostate cancer, neuroendocrine, stomach cancer, ymphoma, head and neck cancer, pancreatic cancer, ovarian cancer, liver cancer, cancer of the entral nervous system, or testicular cancer
  • cardiovascular disease a condition caused by hematopoietic stem cell transplantation
  • neurologic disease autoimmune disease
  • chronic nflammatory disease gynecologic disease
  • infectious disease infectious disease.
  • the disease is hepatocellular carcinoma or liver cancer and the biological molecule used is a hepatocellular carcinoma antigen, such as Glypican-3 or MAGE-I .
  • the imaging method may be chosen from one of computed tomography, ultrasound, magnetic resonance, nuclear imaging, or optical imaging.
  • the optical imaging may be by Diffuses Optical Tomography, Optical Coherence Tomography, Confocal Laser Scanning Microscopy, Fluorescence Correlation Microscopy, Fluorescence Resonance Energy Transfer, or Fluorescence Lifetime Imaging.
  • the disease may be chosen from cancer, cardiovascular disease, a condition caused by hematopoietic stem cell transplantation, neurologic disease, utoimmune disease, chronic inflammatory disease, gynecologic disease, or infectious disease.
  • the ancer may be chosen from lung cancer, melanoma, breast cancer, prostate cancer, neuroendocrine, tomach cancer, lymphoma, head and neck cancer, pancreatic cancer, ovarian cancer, liver cancer, ancer of the central nervous system, or testicular cancer.
  • the disease is hepatocellular carcinoma or liver r and the protein chosen from Table 2 is a hepatocellular carcinoma antigen, such as Glypican- 3 or MAGE-I.
  • the target-specific affinity agents of the invention may be used in diagnostic assays to identify the biological agents in blood or serum.
  • the diagnostic assay may be in the form of a kit.
  • a target-specific imaging reagent composed of an antibody coupled to an imaging agent detectable by magnetic resonance, where the antibody specifically binds to Glypican-3 or MAGE-I and where expression of Glypican-3 or MAGE-I is predictive of iver cancer.
  • the invention provides methods of diagnosing liver cancer by administering to a mammal the target-specific imaging reagent described above, imaging the mammal using magnetic resonance, and diagnosing liver cancer.
  • Figure 1 shows an axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with lighter color indication difference caused by SPIO effect.
  • Figure 2 is a difference image from Figure 1 with region of interest (ROI) corresponding to the difference regions. Values for T 2 are in Figure 3.
  • ROI region of interest
  • Figure 3 shows T 2 values for the ROI in Figure 2.
  • Figure 4 shows an axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with darker color indication ence caused by Gd effect.
  • Figure 5 is a difference image from Figure 4 with ROI corresponding to the difference regions. Values for T 1 are in Figure 6.
  • Figure 6 shows Ti values for the ROI in Figure 5.
  • Figure 7 shows a axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with darker color indication difference caused by Gd effect.
  • Figure 8 is a difference image from Figure 7 with ROI corresponding to the difference regions. Values for Ti are in Figure 9.
  • Figure 9 shows Ti values for the ROI in Figure 8.
  • RNA and DNA may also be targets, particularly when the process in on results in apoptosis or necrosis which lead to exposure of these molecular to the ellular environment.
  • Data may be available or may be generated to help identify and prioritize the most appropriate targets for a given clinical indication.
  • Such data may take the form of gene expression, proteomics, glycomics, cell sorting (fluorescence activated cell sorting), sequence databases or other such information.
  • Information may come from public literature or databases or in vitro studies nvolving diseased tissue, animal models or studies utilizing human subjects.
  • o Data used may be derived from gene expression (e.g. microarray, SAGE) or proteomic (e.g. ELISA, protein array, mass spec or other)
  • gene expression e.g. microarray, SAGE
  • proteomic e.g. ELISA, protein array, mass spec or other
  • o Data can be generated using tissue samples (disease and control) derived from human specimens or animal models or from cell culture / in vitro experiments.
  • Tissue arrays can also be utilized to help define the expression patterns of markers and the specificity for diseased tissue (see ubb et al. 2003, Tsiambas et al. 2006, Divito et al. 2004).
  • animals with and without a disease can have issues compared or can compare disease to control tissues within individual animals.
  • Human tissues can be obtained from biopsies or specimens removed at surgery.
  • a wide variety of gene expression and genomic data set analytical tools are available and well known which can be applied to data sets to help identify those candidate targets with the most desirable expression features. These include tools which identify individual genes or proteins which are significantly correlated with a disease state as well as clustering tools which can group sets of genes into pathways which have some expression or functional relationship. Examples of such tools can be found in Alizadeh et al. 2000, Golub et al. 1999, Hastie et al. 2000, Perou et al. 2000, Tibshirani et al. 2002, Eisen et al. 1998, Tusher et al. 2001.
  • sequence analysis tools can be applied to predict which of these are secreted or have extracellular domains which may be accessible for targeting.
  • maging Technology 0058 Development of molecular imaging targets for specific disease states can be done without regards to downstream label or contrast agent for imaging technology. Modalities differ espect to spatial resolution and sensitivity, which are usually mutually exclusive. Suitability maging modality for molecular imaging is judged on the criteria of spatial resolution, mical coverage, reproducibility, potential for quantification, support of image-guided drug elivery and, finally, the ability to image molecular targets.
  • Computed Tomography has good spatial resolution.
  • CT scanning xposes the subject to ionizing radiation.
  • the high spatial resolution makes x-ray-based imaging mportant for hybrid systems such as PET-CT (see below).
  • Ultrasound has a wide range of applications but is restricted to anatomical regions that re closer to a surface which is accessible to the ultrasound probe. Ultrasound does allow the use of microbubbles as a contrast agent and other ultrasound contrast agents have recently been developed hat allow imaging of smaller molecular targets.
  • Magnetic Resonance can visualize anatomy with good spatial resolution, is applicable to all body regions and will allow reproducible and quantitative imaging. It can also be used for intravascular and needle image-guided drug delivery, but not for a broad range of drugs due to safety aspects. MR can partly assess molecular information, for example through spectroscopy, but is limited by sensitivity. However, highly sensitive contrast agents have recently been used to allow imaging of molecular targets and gene expression. Since MR allows reproducible quantitative imaging without radiation it has significant potential for molecular imaging. Magnetic Resonance Spectroscopy (MRS) is also available as a method of evaluation of molecular content of tissues.
  • MRS Magnetic Resonance Spectroscopy
  • Nuclear Imaging comprising PET (Huang et al., 1980) and SPECT is a molecular maging technique with excellent sensitivity and whole-body applications with good reproducibility nd quantitation.
  • PET Human et al., 1980
  • SPECT is a molecular maging technique with excellent sensitivity and whole-body applications with good reproducibility nd quantitation.
  • its poor spatial resolution makes it unsuitable for image-guided drug ry, and it requires relatively long scan times.
  • Using nuclear imaging with harmaceutical agents enables drug tracing, including the study of pharmacokinetics in vivo.
  • PET has produced images of gene expression that show promise for future applications in monitoring of gene therapy.
  • PET requires isotopes which are generally short lived and thus a cyclotron needs to be within 2 hours of the scanning site.
  • the advantage of this is a short period of exposure to ionizing adiation.
  • PET is more sensitive than SPECT.
  • SPECT tracers are 99Tc or 201 Tl.
  • SPECT is everal-fold inferior to PET with respect to sensitivity and special resolution.
  • Mobile PET units are being developed. There are about 200 PET centers in the US. PET/CT combinations are replacing PET alone. A PET/CT scanner is $2M vs. $1.3M for PET alone.
  • PET/CT combined scanning allows anatomical and molecular information to be collected on the same piece of equipment which helps combine sensitivity to specific cells or molecules with anatomical information.
  • Optical Imaging is a relatively new imaging technique that, because of its lower penetration depth, is currently limited to endoscopic and microscopic applications in humans and animals. Optical imaging may eventually be used to retrieve information from deeper areas. Potential is seen in screening applications where only a yes/no answer is required rather than spatially resolved information. There are a number of specific optical approaches:
  • DOT - Diffuses Optical Tomography which can penetrate several centimetres.
  • an affinity reagent/agent which binds in a specific manner to the target is developed.
  • Humanized monoclonal antibodies may be used and avoid problems with sensitization seen with murine antibodies.
  • Small molecules may also be developed that bind to targets using computational tools and databases. Small molecule design technologies may be employed in this way. Some antibodies may have high molecular weight and limited uptake in target sites along with slow blood clearance resulting in high signal to noise (Fischman et al., 1993).
  • Peptides are readily synthesized via solid phase synthesis and other parallel approaches as well as phage display. They are cheaper and more stable for labeling, less immunogenic, and have better tissue penetration and blood clearance than antibodies.
  • a peptide is identified which binds a specific receptor and then is taken downstream for imaging reagent development.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen.
  • antibody encompasses not only whole antibody molecules, but also antibody multimers and antibody fragments as well as nts (including derivatives) of antibodies, antibody multimers and antibody fragments.
  • scFvs single chain Fvs
  • Fab fragments fragments
  • Fab' fragments fragments
  • F(ab')2 disulfide linked Fvs
  • Fvs fragments comprising or alternatively consisting of, either a VL or a VH domain.
  • single chain Fv or “scFv” as used herein refers to a polypeptide comprising a VL domain of antibody linked to a VH domain of an antibody.
  • Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, anti- idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), intracellularly-made antibodies (i.e., intrabodies), and epitope-binding fragments of any of the above.
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG b IgG 2 , IgG 3 , IgG 4 , IgAi and IgA 2 ) or subclass of immunoglobulin molecule.
  • an antibody of the invention comprises, or alternatively consists of, a VH domain, VH CDR, VL domain, or VL CDR having an amino acid sequence of any one of those referred to in Table 2, or a fragment or variant thereof.
  • the immunoglobulin is an IgGl isotype.
  • the immunoglobulin is an IgG4 isotype.
  • Immunoglobulins may have both a heavy and light chain.
  • An array of IgG, IgE, IgM, IgD, IgA, and IgY heavy chains may be paired with a light chain of the kappa or lambda forms.
  • Antibodies of the invention may also include multimeric forms of antibodies.
  • antibodies of the invention may take the form of antibody dimers, trimers, or higher-order multimers of monomelic immunoglobulin molecules. Dimers of whole immunoglobulin molecules or of F(ab') 2 fragments are tetravalent, whereas dimers of Fab fragments or scFv molecules are bivalent.
  • Individual monomers within an antibody multimer may be identical or different, i.e., they may be heteromeric or homomeric antibody multimers.
  • individual antibodies within a multimer may have the same or different binding specificities.
  • Multimerization of antibodies may be accomplished through natural aggregation of odies or through chemical or recombinant linking techniques known in the art. For example, percentage of purified antibody preparations (e.g., purified IgGl molecules) spontaneously form protein aggregates containing antibody homodimers, and other higher-order antibody multimers. Alternatively, antibody homodimers may be formed through chemical linkage techniques known in the art.
  • heterobifunctional crosslinking agents including, but not limited to, SMCC (succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate) and SATA (N- succinimidyl S-acethylthio-acetate) (available, for example, from Pierce Biotechnology, Inc. (Rockford, 111.)) can be used to form antibody multimers.
  • SMCC succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate
  • SATA N- succinimidyl S-acethylthio-acetate
  • Antibody homodimers can be converted to Fab'2 homodimers through digestion with pepsin. Another way to form antibody homodimers is through the use of the autophilic Tl 5 peptide described in Zhao and Kohler, The Journal of Immunology (2002) 25:396-404, which is hereby incorporated by reference in its entirety.
  • antibodies can be made to multimerize through recombinant DNA techniques.
  • IgM and IgA naturally form antibody multimers through the interaction with the J chain polypeptide.
  • Non-IgA or non-IgM molecules such as IgG molecules, can be engineered to contain the J chain interaction domain of IgA or IgM, thereby conferring the ability to form higher order multimers on the non-IgA or non-IgM molecules, (see, for example, Chintalacharuvu et al., (2001) Clinical Immunology 101:21-31.
  • ScFv dimers can also be formed through recombinant techniques known in the art; an example of the construction of scFv dimers is iven in Goel et al., (2000) Cancer Research 60:6964-6971 which is hereby incorporated by eference in its entirety.
  • Antibody multimers may be purified using any suitable method known in he art, including, but not limited to, size exclusion chromatography.
  • phage display methods functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them.
  • DNA equences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or e cDNA libraries of lymphoid tissues) or synthetic cDNA libraries.
  • the DNA encoding the nd VL domains are joined together by an scFv linker by PCR and cloned into a phagemid vector (e.g., pCANTAB 6 or pComb 3 HSS).
  • the vector is electroporated in E. coli and the E. coli s infected with helper phage.
  • Phage used in these methods are typically filamentous phage ncluding fd and Ml 3 and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII.
  • Phage expressing an antigen binding domain that binds to an antigen of interest i.e., a GMAD polypeptide or a fragment thereof
  • an antigen of interest i.e., a GMAD polypeptide or a fragment thereof
  • Examples of phage display methods that can be used to make the antibodies of the present invention nclude, but are not limited to, those disclosed in Brinkman et al., J. Immunol.
  • VH and VL domains of one or more scFvs referred to in Table 2 may be useful to express the VH and VL domains of one or more scFvs referred to in Table 2 as single chain antibodies or Fab fragments in a phage display library.
  • the cDNAs encoding the VH and VL domains of the scFvs referred to in Table 2 may be expressed in all possible combinations using a phage display library, allowing for the selection of VH/VL combinations that bind a GMAD polypeptide with preferred binding characteristics such as improved affinity or improved off rates.
  • VH and VL segments may be mutated in vitro.
  • Expression of VH and VL domains with "mutant" CDRs in a phage display library allows for the selection of VH/VL combinations that bind a GMAD polypeptides with preferred binding characteristics such as improved affinity or improved off rates.
  • kits for generating phage display libraries e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAP.TM. phage display kit, catalog no. 240612).
  • kits for generating phage display libraries e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAP.TM. phage display kit, catalog no. 240612).
  • methods and reagents that can be used in generating and screening antibody display libraries (see, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. PCT Publication No. WO 92/18619; Dower et al. PCT Publication No. WO 91/17271; Winter et al. PCT Publication No.
  • polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant.
  • an immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections.
  • the immunizing agent may include a protein encoded by a nucleic acid of Table 2 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized.
  • immunogenic proteins include but are not limited to keyhole limpet hemocyanin, erum albumin, bovine thyroglobulin, and soybean trypsin inhibitor.
  • adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one killed in the art without undue experimentation.
  • the antibodies may, alternatively, be monoclonal antibodies.
  • Monoclonal antibodies e prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 95 (1975).
  • a hybridoma method a mouse, hamster, or other appropriate host animal, is ypically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the ymphocytes may be immunized in vitro.
  • the immunizing agent will typically include a polypeptide encoded by a nucleic acid of Table 2, a fragment thereof, or a fusion protein thereof.
  • peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)).
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell ines are employed.
  • the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, mmortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, mmortalized cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
  • Humanized forms of antibodies are chimeric immunoglobulins in which residues from a complementary determining region (CDR) of human antibody are replaced by residues from a CDR of a non-human species such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • An example of a chimeric humanized antibody is a molecule having a human variable egion and a non-human (e.g., murine) immunoglobulin constant region.
  • Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., J. Immunol.
  • Chimeric antibodies comprising one or more CDRs from human species and framework ns from a non-human immunoglobulin molecule (e.g., framework regions from a murine, e or feline immunoglobulin molecule) (or vice versa) can be produced using a variety of ques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos.
  • chimeric antibodies comprise a human CDR3 having an amino acid sequence of any one of the VH CDR3s or VL CDR3s of a VH or VL domain of one or more of the scFvs and non-human framework regions or human framework regions different from those of the frameworks in the corresponding scFvs.
  • framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding.
  • These framework substitutions are dentified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 352:323 (1988), which are incorporated herein by reference in their entireties.)
  • Human antibodies can be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. MoI. Biol. 227:381 (1991); Marks et al., J. MoI. Biol. 222:581 (1991)).
  • the techniques of Cole et al. and Boemer et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boemer et al., J. Immunol. 147(l):86-95 (1991)).
  • human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Pat. Nos.
  • a number of methods have been devised to generate peptide libraries and methods of using the libraries to identify a peptide sequence that is complementary to a receptor or antibody.
  • Pirrung et al. WO 90/15070, incorporated herein by reference for all purposes, describes a method of synthesizing a large number of polymer sequences on a solid substrate using light directed methods.
  • Dower et al. U.S. application Ser. No. 07/762,522, also incorporated by reference herein for all purposes, describes a method of synthesizing a library of polymers and a method of use thereof.
  • the polymers are synthesized on beads, for example. A first monomer is attached to a pool of beads. Thereafter, the pool of beads is divided, and a second monomer is attached. The process is repeated until a desired, diverse set of polymers is synthesized.
  • Houghten et al. "Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery," Nature (1991) 354:84-86, disclose a method of generating peptide libraries that are used for screening peptides for biological activity (see also, Houghton et al., "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides,” Peptide Research (1992) 5:351-358).
  • Houghten synthesized a peptide combinatorial ibrary (SPCL) composed of some 34x10 6 hexapeptides and screened it to identify antigenic determinants that are recognized by a monoclonal antibody.
  • Furka et al. "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures," Int. J. Peptide Protein Res. (1991) 37:487- 493, discusses a method of synthesizing multicomponent peptide mixtures.
  • Furka proposed pooling as a general method for the rapid synthesis of milticomponent peptide mixtures and illustrated its application by synthesizing a mixture of 27 tetrapeptides and 180 pentapeptides.
  • Lam et al. "A new of synthetic peptide library for identifying ligand-binding activity," Nature (1991) 354:82-84 pooling to generate a pentapeptide bead library that was screened for binding to a monoclonal ody.
  • Lam's synthetic peptide library consists of a large number of beads, each bead containing peptide molecules of one kind. Beads that bind a target (e.g., an antibody or streptavidin) are rendered colored or fluorescent. Lam reports that several million beads distributed in 10-15 petri dishes can be screened with a low-power dissecting microscope in an afternoon. Positive beads are washed with 8M guanidine hydrochloride to remove the target protein and then sequenced. The 100-200 ⁇ m diameter beads contain 50-200 pmol of peptide, putatively well above their 5 pmol sensitivity limit. Three pentapeptide beads were sequenced daily. The essence of Lam's method is that the identity of positive beads is established by direct sequencing.
  • a target e.g., an antibody or streptavidin
  • Houghten et al. use a different approach to identify peptide sequences that are recognized by an antibody. Using the nomenclature described herein, Houghten et al. screened an X 6 X S X 4P X 3P X 2P X IP library and found that the mixture DVX 4p X 3p X 2p Xi p had greatest potency in their inhibition assay. Houghten then synthesized a DVX 4 X 3p X 2p Xi p library and identified the most potent amino acid in the third position. After three more iterations, they found that DVPDYA binds to the antibody with a Kd of 30 iiM.
  • Antibodies In order to detect binding of a receptor or antibody to a peptide, the antibody must be labeled. Antibodies may also be modified with a detectable label, such as an enzymatic, fluorescent, radioisotopic or affinity label to allow for detection and isolation of the antibody.
  • suitable enzymatic labels include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable escent materials include biotin, umbelliferone, fluorescein, fluorescein isothiocyanate, mine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include a radioactive metal ion, e.g., alpha-emitters such as, for example, 213 Bi, or other radioisotopes such as, for example, iodine ( 131 I, 125
  • Antibodies may also be labeled with Europium.
  • antibodies may be labelled with Europium using the DELFIA Eu-labeling kit (catalog# 1244-302, Perkin Elmer Life Sciences, Boston, Mass.) following manufacturer's instructions.
  • Antibodies may be attached to macrocyclic chelators useful for conjugating radiometal ions, including but not limited to, 111 In, 177 Lu, 90 Y, 166 Ho, 153 Sm, 215 Bi and 225 Ac to polypeptides.
  • the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is 111 In.
  • the radiometal ion associated on with the macrocyclic chelator attached to antibodies polypeptides of the invention is Y.
  • the macrocyclic chelator is l,4,7,10-tetraazacyclododecane-N,N',N",N'"- tetraacetic acid (DOTA).
  • the macrocyclic chelator is a-(5-isothiocyanato- 2-m- ethoxyphenyl)- 1, 4,7, 10-tetraazacyclododecane-l ,4,7,10-tetraacetic acid.
  • the DOTA is attached to the antibody of the invention via a linker molecule. Examples of linker molecules useful for conjugating a macrocyclic chelator such as DOTA to a polypeptide are commonly known in the art-see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90, 1998; Peterson et al., Bioconjug. Chem.
  • the affinity reagents/agents of the invention have various utilities, including use as diagnostic and monitoring assays for proteins of the invention, e.g., detecting their expression in specific cells, tissues, or serum.
  • antibodies may be used in diagnostic and monitoring assays for the proteins of the invention, e.g., detecting their expression in specific cells, tissues, or serum.
  • diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158].
  • the antibodies used in the diagnostic and monitoring assays can be labeled with a detectable moiety.
  • the detectable moiety should be capable of producing, either directly or indirectly, a detectable signal.
  • the detectable moiety may be a radioisotope, such as 3 H, 14 C, 32 P, 35 S, or 125 I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase.
  • a radioisotope such as 3 H, 14 C, 32 P, 35 S, or 125 I
  • a fluorescent or chemiluminescent compound such as fluorescein isothiocyanate, rhodamine, or luciferin
  • an enzyme such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase.
  • Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et
  • the diagnostic and monitoring assays can be utilized to diagnose and/or monitor cancer, heart disease, hematopoietic stem cell transplantation, neurologic disease, autoimmune and chronic inflammatory disease, gynecologic disease and infectious disease.
  • “Diagnosing” can include detection of any type of activity or progression of a disease, for example, determination of whether the disease is present, identifying the stage of the disease, monitoring the response of the disease to therapy, etc.
  • the term "monitoring” is used herein to describe the use of an affinity agent to de useful information about an individual or an individual's health or disease status.
  • nitoring can include, determination of prognosis, risk-stratification, selection of drug therapy, sment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patient's health status over time, selecting patients most likely to benefit from experimental therapies with known molecular mechanisms of action, selecting patients most likely to benefit from approved drugs with known molecular mechanisms where that mechanism may be important in a small subset of a disease for which the medication may not have a label, screening a patient population to help decide on a more invasive/expensive test, for example, a cascade of tests from a non-invasive blood test to a more invasive option such as biopsy, or testing to assess side effects of drugs used to treat another indication.
  • Such diagnostic and monitoring assays can be in the form of a kit.
  • the kit may include reagents for performing the diagnostic assay.
  • an affinity reagent e.g., antibody or peptide
  • imaging contrast or signal emitting source is incorporated into the reagent. This can be done for a variety of technologies as discussed above.
  • isotopes are most commonly used isotopes. Also of potential use are 140, 64Cu 3 62Cu, 1241, 76Br, 82Rb and 68Ga. These isotopes are produced in a cyclotron and available in radiopharmacies (Strijckmans 2001, Gambhir 2002). These isotopes can often be substitute for naturally occurring atoms in affinity reagents. Isotopes that emit gamma rays directly (e.g., 99mTc, 11 Hn, 1231, 1311) are used for SPECT imaging (Rosenthal et al. 1995).
  • Radiolabeling can be achieved by direct ng (incorporation of label materials into molecules) or chelation of a label (Bogdanov et al. 2005). Radiopeptides have been used for tumor imaging with some success (Lamberts et al., 1990). Octreotide has also been labeled with technicium and is used for tumor imaging (Octreoscan, Mid- South Imaging, Memphis). Introduction of label into a molecule may affect biological or binding properties markedly. These properties must be reassessed after labeling.
  • Radiolabeled molecules must also be tested in animals before human testing (Stolz et al., 1998). This will help assess toxicity and tissue distribution and clearance. Clearance of radiopeptides by the kidneys is a key issue which needs improvement. Examples of common methods used to incorporate labels into affinity reagents for PET and SPECT imaging are found in Cumming and Gjedde 1998, Lucignani and Frost 2000, Wagner et al. 1983, Coenen et al. 1987, Kung et al. 1990, Crouzel et al. 1988, Virgolini 2000, Oriuchi and Yang 2001, Lovqvist et al. 2001, Kim 2001.
  • the most common approaches currently in use include the incorporation or labeling of the affinity reagent with Gadolinium or Supermagnetic Iron Oxide containing compounds. These molecules alter local magnetic resonance characteristics which creates a local signal contrast in the area of reagent accumulation.
  • One strategy involves the use of a biotinylated antibody followed by the administration of Gadolinium complexes (e.g., with liopsomes) which are linked to Avidin (Artemov et al. 2003).
  • Another strategy involves the use of enzyme mediated polymerization of paramagnetic substrates into oligomers of higher relaxivity (Weissleder et al. 2002).
  • Scanning using the selected imaging technology using 384 well plates of potential eagent combinations to determine binding characteristics and labeling efficiency may be utilized as a direct approach to evaluation of potential reagents.
  • Tissue or cell arrays can be used to screen eagent combinations.
  • Clonal cell line expressing target on surface in high throughput format could also be used.
  • Animal testing with scanning is used when appropriate models exist. This can be done in vivo or explanted tumor tissue or other explanted tissues may be used to determine binding characteristics.
  • Standard immunohistochemistry or immunofluorescence can be used to test the binding, sensitivity and cell type specificity of the reagent and label combination (Brown et al., 1990; Abbondanzo et al., 1990; Allred et al., 1990, and Sambrook et al. 1989). This can be done using human tissue specimens or animal model tissue specimens in the case of animal reagents.
  • the imaging reagent needs to be produced with materials which provide contrast or can be linked with contrast materials after production.
  • Probes should be biocompatible, ack interference with biological function, generate high signal output and signal-to-noise. PET and SPECT tracers are easier to develop because of need for low concentrations and ease of labeling.
  • Multiplex imaging may prove to be clinically useful. Such an approach could be used to image more than one molecule in a single scan. It could be done in such a way that the >1 target both contribute signal, but are not resolvable ("one color") or may be done using contrast or signal emitting reagents that allow the >1 targets to be distinguished in the image ("two color”). Simultaneous imaging of multiple markers may be useful to overcome variability in the population (e.g., some tumors express one marker and others express another marker). This approach could also provide a means to provide additional contrast by specifically imaging both the diseased and control tissues. Perhaps also this approach would add to the information value of an imaging protocol.
  • PET can only measure two targets by injecting and imaging one and then performing a second injection and scan for the second target after the signal from the first has faded.
  • SPECT can more than one target in a single scan.
  • Other combinations of technologies may be used to ure more than one target simultaneously (combine MRI, CT, Nuclear, Optical).
  • test For any given molecular imaging reagent, clinical utility and efficacy in humans must be demonstrated for specific clinical indications if the test will have an impact on clinical practice. After appropriate safety studies have been performed in primates and then human subjects, patients with the target disease process (or suspected to have it) are recruited along with appropriate control subjects. The performance of the molecular imaging test with respect to disease diagnosis or prognosis is then assessed. The assessment of performance may be related to a gold standard based on the pathological diagnosis of the disease status or other standards such as endoscopic evaluation, other imaging approaches or diagnostic testing. Alternatively or in addition, the test is assessed with respect to its ability to identify patients at risk for events, complications, outcomes or mortality related to the disease process (prognosis).
  • test may also be shown to identify patients with an increased or decreased responsiveness to therapy (therapy broadly or specific medications). Alternatively, testing can be shown to monitor response to therapy.
  • therapies broadly or specific medications.
  • testing can be shown to monitor response to therapy.
  • Various clinical utilities of molecular imaging approaches are discussed and exemplified below in the section on clinical indications for molecular testing.
  • Molecular imaging approaches may be utilized in numerous clinical situations in oncology. Diagnosis of disease may be improved in this way. Cancer marker specific imaging affinity reagents may provide added sensitivity for small tumors vs. standard imaging or clinical monitoring. Also, this approach may be more specific and allow distinction of cancer tissue from normal tissue or benign processes. Clearly, it may also provide a less invasive means of diagnosis compared to invasive procedures such as endoscopy or biopsy. Upon diagnosis of cancer, staging and risk stratification is necessary to plan surgery and guide radiation and chemotherapy usage. Molecular imaging may provide information about the local regional and distant spread of cancer. One possibility is for molecular imaging to be performed before completion of cancer surgery to ensure that there has been complete tumor removal ("molecular imaging margins").
  • the tumor may be treated differently on this basis alone.
  • Multiple markers could be imaged using imaging reagent with differential labeling which can be resolved with a single scan or could have multiple scans done with different individual reagents.
  • response to therapy may be monitored with molecular imaging. This may provide a means for an earlier assessment of response so that the regimen can be altered earlier if not effective. Imaging may also be done after cancer surgery to check for complete excision if the imaging target is cancer specific. This can be difficult with non-molecular imaging because of anatomical changes from surgery and sensitivity limitations.
  • molecular imaging may provide a sensitive way to monitor for recurrence.
  • the primary tumor tissue may be obtained at the time of biopsy or surgery and assessed for the expression of the molecular target. Subsequently the tumor spread or recurrence can be imaged with the appropriate agent that the primary tumor is found to express.
  • Molecular imaging approaches may be extremely valuable in chemotherapeutic drug trials as patient selection tools or urrogate endpoint.
  • Imaging could provide tremendous clinical value for oncologists and patients in those situations described above. These benefits are associated with increased sensitivity and specificity of imaging techniques which could lead to earlier treatment, more appropriate treatment, improved surgical or radiation therapy planning and appropriate cessation or withholding or treatment. These applications may also be associated with significant economic value for the health care system. Early detection of cancer may lead to an increased rate of curative treatment, avoiding the costs of prolonged curative or non-curative therapy. Improvements in staging may help plan more appropriate surgical or radiation therapy which may improve survival or decrease costs of complications. Identification of distant metastasis may obviate the need for unnecessary or fruitless medical or surgical therapy. Imaging may also reduce the need for invasive or expensive diagnostic procedures such as biopsy, endoscopy or bronchoscopy. Earlier assessment of response to chemotherapy could reduce prolonged and costly unnecessary treatment and allow more rapid changes in treatment. A beneficial impact on drug trials could decrease, cost and duration of these expensive trials and increase likelihood of success.
  • Molecular imaging may be useful to diagnose disease in patients at risk, stage disease, monitor response to therapy and remission.
  • Flurodeoxyglucose (FDG) Positron Emission Tomograpy (PET) scanning can reduce need for thoracotomy (van Tinteren et al. 2002).
  • Diatide's Neospect (labeled depreotide) helps assess the need for biopsy with solitary pulmonary nodules. Staging is critical prior to surgery or medical therapy.
  • FDR PET scanning can be useful, but lacks specificity and may be positive with any inflammatory lesion even if not malignant. Scanning may be used to assess local tumor extent (T staging), Nodal spread (N) and Metastasis (M).
  • Lardinois et al used combined PET-CT imaging for non-small cell lung cancer to assess metastatic disease. Patients received FDG- 18F. This approach provided additional information in 40% of patients beyond that of separate PET and CT scans, along with a significant 35% to 40% improvement in diagnostic acy with respect to lung cancer tumor staging.
  • optical techniques may be used.
  • the scan may help distinguish benign from malignant skin lesions. Scanning could also be used to stage and monitor the cancer.
  • Breast cancer occurs close to the surface and is amenable to imaging with most modalities including those with more limited penetration of tissue (ultrasound, optical imaging).
  • Molecular probes could be used to aid in screening and diagnosis.
  • Breast tumors metastasize to axillary lymph nodes and a lymph node dissection is often done for staging.
  • Molecular imaging could aid in this staging process by identifying tumor spread to these regional lymph nodes as well as to distant sites though out the body.
  • Molecular imaging may also be appropriate for monitoring of recurrence in treated patients.
  • Prostate cancer can be assessed with a variety of imaging techniques. Low penetrations techniques such as ultrasound can be used in conjunction with endoscopy. Both CT and MRI have very high false negative results for early prostate cancer which could be improved upon with the addition of a molecular probe using the same or other imaging technologies. Assessment of regional or distant spread could aid in the staging or prostate cancer. This information could guide medical, surgical and radiation therapy. MRI enhanced with lymphotropic monocrystalline iron oxide nanoparticles can be used to detect prostate cancer metastases as small as 2 mm in diameter, n contrast with conventional MRI detection (>8-10 mm).
  • Colon cancer is often diagnosed only after is has grown to a size associated with clinical symptoms (bleeding or obstruction) or is large enough to be easily visible on a standard examination (endoscopy, non-molecular imaging study). Unfortunately, at this stage the cancer is too often associated with aggressive local behavior and distant spread. Earlier diagnosis with the help of specific affinity reagents would help guide earlier resection which is more likely to be curative. Colon cancer cannot be distinguished from benign adenoma using anatomical imaging or visualization using endoscopy. Molecular imaging techniques may provide a non-invasive means to make this distinction. Colon cancer is known to be associated with multiple molecular changes ("hits") on the way from benign adenoma to cancer.
  • This information may be used in the design of molecular imaging protocols.
  • One may image more than one molecule or only one molecule associated with malignant transformation.
  • Colon cancer staging involves evaluation of the region around the primary tumor and the liver.
  • Molecular imaging may improve the accuracy of anatomical imaging in staging. This information can help guide medical therapy and surgical planning. In some cases, limited liver resection can be performed if a solitary metastasis exists. After surgery for colon cancer, anatomical changes (inflammation or scarring) may be seen with conventional anatomical imaging techniques. It is difficult to distinguish these findings from cancer persistence or recurrence and specific molecular probes may help identify malignant cells in this situation.
  • CT scanning does not permit distinction between post-surgical changes and tumor recurrence and cannot determine tumor involvement in normal sized lymph nodes (Goldberg et al., 1998). Stomach
  • Cancer of the stomach may be difficult to distinguish from benign ulceration. Gastric ulceration is very common. Biopsy of ulcer edges is performed, however this technique may be subject to sampling error and a negative result can occur in cases of cancer associated with ulceration. Clinical practice when biopsy is negative for cancer is to treat for gastric ulcer and then to reassess for at a later time for refractory cases. Unfortunately, this may result in a delay in osis and treatment which could be costly to the patient. Molecular imaging could help identify gnancy as an underlying cause of ulceration at the time of first diagnosis for at risk patients.
  • Lymphoma can be associated with bulky disease masses which are largely cancerous cells, but also are composed of inflammatory cells. Upon treatment, malignant cells become necrotic and significant inflammation and clean up of residual disease occurs. Standard imaging techniques cannot distinguish non-malignant from malignant causes of masses in these cases. There is a need to evaluate treatment response after completion of therapy especially when there are residual masses.
  • Head and neck cancers can spread to numerous regional lymph nodes and the surgical approach to these patients involves extensive and disfiguring procedures.
  • Molecular imaging may help identify primary lesions, lymph node involvement and distant metastasis. This information may also help guide radiation therapy.
  • Pancreatic cancer is very difficult to diagnosis at a curable stage. Symptoms may occur due to mass effects in the abdomen or if the tumor happens to obstruct the pancreatic duct, however most cancers are incurable at the time of diagnosis. Molecular imaging could add significantly to the diagnosis of this cancer at an early stage. This approach could also be used to evaluate spread of tumors at the time of diagnosis to help plan surgical therapy. In the absence of evidence of distant spread, curative surgical therapy may be attempted. Otherwise, palliative treatment may be the only option.
  • Ovary cancer is difficult to diagnose at asymptomatic stage with standard CT or MRI. Addition of specific molecular reagents to imaging protocols may add sensitivity for early stage ns which are more amenable to curative therapy. Also, benign masses (adenomas and cysts) ery common in and around the ovaries. Molecular imaging may provide a means to distinguish n and malignant lesions. Ovarian cancer may also be assessed after diagnosis and monitored for recurrence in a sensitive and specific way using molecular imaging approaches. CIS bio International has developed an indium labeled monoclonal antibody to CA 125 which can be used to image ovarian cancers.
  • Hepatocellular carcinoma often occurs in patients with cirrhotic liver disease from hepatis B or C, alcohol or other processes. This presents a difficult diagnostic dilemma as cirrhosis is associated with nodule formation and scarring in the liver tissue which makes detection of a cancer nodule nearly impossible at an early stage using standard anatomical imaging techniques (ultrasound, MRI, CT). Biopsy is not a very helpful modality in this setting either as it is very difficult to know where to sample this very large organ for monitoring for onset of cancer and patients with liver disease often have underlying clotting disorders or platelet abnormalities which create a risk of excessive bleeding.
  • hepatocellular cancer can occur any time over many years in cirrhotic patients which makes monitoring modality selection critical. Hepatocellular carcinoma can be cured by liver lobar resection if the cancer is clearly restricted to one area. In addition, a patient with this cancer could have a transplant if the risk of spread beyond the liver is extremely low. Molecular imaging may help make this determination.
  • Cancers of the central nervous system present significant diagnostic and treatment challenges to physicians and surgeons. Because of their anatomical location, biopsy based diagnosis of brain masses is technically challenging and associated with complications. Molecular imaging may provide a means to make a firm diagnosis of brain cancer (vs. benign mass) and guide planning of surgery, radiation therapy and medical therapy. In addition, surgical therapy can be curative. However it is critically important to know the precise anatomical distribution of the tumor to plan optimal surgery. One reason for this is that removal of brain tissue results in neurological deficits so precision is key to minimize unnecessary brain loss. In addition, it is critical to ensure he entire extent of the tumor is removed at the time of surgery. Given these needs, molecular ng may provide a boost to sensitivity that improves this evaluation.
  • molecular g ng information must be combined with precise anatomical imaging.
  • One possibility is to image the patient during surgery using the molecular probe to assess "margins” and determine if the tumor has been completely removed.
  • Glioblastomas are known to be resistant to many chemotherapeutic agents and often require the use of chemotherapy in a trial and error fashion.
  • Molecular imaging may provide a means for earlier evaluation of treatment response which would decrease costly prolonged futile drug trials.
  • This cancer is treatable with radiation and chemotherapy. Cure is dependent on identification of an appropriate field for radiation and appropriate staging of disease. Molecular imaging could provide a means to stage the disease and also monitor response to therapy and recurrence.
  • Coronary artery disease is an inflammatory disease of the arterial wall. Infiltration of the vessel wall with inflammatory cells, accumulation of lipids and remodeling leads to arterial plaque formation. Atherosclerotic plaques can cause ischemia in tissue served by the diseased artery. This can manifest as angina pectoris, chronic ischemia and cardiac failure, claudication and other signs of peripheral arterial insufficiency. Plaques may suddenly rupture leading to thrombosis and partial or total occlusion of the arterial lumen. In the case of coronary arteries these events lead to unstable angina or myocardial infarction which is a major cause of morbidity and mortality relating to coronary artery disease. Coronary angiography is commonly used to assess the extent and severity W 2
  • Non-invasive imaging techniques can now provide information on the anatomical extent of coronary disease as well as some information on composition.
  • MRI scans can assess degree of lumen occlusion as well as providing some characterization of the cellular and extracellular composition.
  • CT scanning can provide some anatomical information as well as information on calcification of coronary plaques which is know to relate to risk of adverse events.
  • Molecular imaging could be applied to coronary atherosclerosis by identification and targeting of molecules associated with active plaques which are at risk from rupture.
  • An ideal target molecule would be highly expressed specifically in vessels with the highest risk of rupture.
  • Such molecules may represent proteases involved in the remodeling process or genes involved in the inflammatory process. They could be cell surface or secreted.
  • the targeting may also be to a cell type. For example, the relative number of macrophage or lymphocytes may have the highest predictive value.
  • endothelial cells may express molecular which are accessible to circulating affinity reagents.
  • Sensitivity gains could be made by specific contrast accumulation at the site of vulnerable plaques. Information may also be more specific or predictive of future events by imaging molecules which are specific to highest risk lesions. If combined with anatomical imaging cols, this approach would provide information on the extent, severity and specific location of osclerotic plaques as well as the risk of acute events and progression for each lesion. This information could guide intervention with medical therapy, percutaneous interventions and bypass surgery.
  • Gadolinium texaphyrin chelates may accumulate in vulnerable plaques for MR imaging.
  • MMP inhibitors have been developed for vascular lesion imaging (University of Muenster). Gadolinium labeled affinity reagents to components of thrombus have also been explored (Epix, gadolinium labeled fibrin binding peptide).
  • Activated macrophages are the main cellular effectors of inflammation in atherosclerosis and their presence identifies high-risk lesions. Magnetic nanoparticles (eg, iron oxide) accumulate within human atherosclerotic macrophages and are therefore preferentially found in macrophage-rich carotid plaques.
  • Future areas of exploration in this field may include the development of agents that specifically target oxidized low-density lipoprotein, activated macrophages (as opposed to all macrophages or multiple cell types), or endothelial cell markers such as vascular cell adhesion molecule.
  • Detection of apoptotic cells in atherosclerotic lesions may represent another molecular imaging strategy to identify high-risk lesions.
  • Apoptotic cells are able to bind a number of proteins, such as annexin V (Belochine et al. 2004, Toretsky et al. 2004, Blankenberg et al. 2003, Murakami et al. 2004).
  • annexin V Belochine et al. 2004, Toretsky et al. 2004, Blankenberg et al. 2003, Murakami et al. 2004.
  • annexin V Belochine et al. 2004, Toretsky et al. 2004, Blankenberg et al. 2003, Murakami
  • Hematopoietic Stem Cell Transplantation 4 Hematopoietic stem cell transplantation (bone marrow transplant) is performed most monly in the treatment of leukemia. The management of patients after transplant is largely ed on monitoring for the occurrence of graft versus host disease (GVHD) and for recurrence of the cancer for which the procedure was performed. GVHD results from recognition of host tissues as foreign by the donor immune system. This can result in severe complications and is a major cause of death. Molecular imaging reagents could detect T cells as they respond to the graft. This could provide valuable information to guide therapy. Detection of cancer recurrence is a very difficult clinical problem. By the time a recurrent leukemia is detectable in the circulation by standard methods, it is often incurable. Molecular probes specific to cancer cells could provide a means to detect recurrence of leukemia at an earlier stage.
  • GVHD graft versus host disease
  • the brain and spinal cord are difficult to biopsy to make a tissue diagnosis of disease. This is due to accessibility and risk of complications from damage to the organ.
  • Alzheimer's disease is characterized by the formation of amyloid plaques in the brain. There is a characteristic distribution in the frontal lobes. Definitive diagnosis at an early stage is not possible as findings of dementia are not specific and numerous alternative causes must be considered. Even when these have been ruled out, Alzheimer's disease is a diagnosis of exclusion and can only be definitively diagnosed at autopsy. A specific molecular probe would be valuable to make a definitive early diagnosis which would allow early medical therapy. Molecular imaging would also facilitate monitoring of response to therapy. Dojindo Laboratories has developed an MRI reagent for amyloid plaques.
  • Multiple Sclerosis is an autoimmune disease of the central nervous system characterized by inflammation and demyelination leading to chronic neurologic disability.
  • the disease is often characterized by flares and periods of remission.
  • MRI scanning is used to detect plaques acteristic lesions).
  • the disease has already d irreversible damage to the brain. It would be very useful if one could detect plaque formation at an earlier stage.
  • Molecular imaging contrast or signal emitting reagents specific to features of the plaque could provide additional sensitivity for early disease.
  • Parkinson's Disease and Amyotrophic Lateral Sclerosis are additional diseases of the nervous system that could benefit from the emergence of specific and sensitive molecular imaging reagents. Earlier diagnosis could facilitate earlier therapy or the validation of new treatments which could slow progression of disease.
  • Imaging reagents specific to markers of active Crohn's disease could provide a means to overcome current limitations. Active Crohn's lesions could be identified in a specific manner anywhere in the GI tract. These lesions would be differentiated from ulcerative colitis and post-surgical findings. The need to CT scanning or endoscopy +/- biopsy could be reduced. Early diagnosis of disease flare (prior to symptoms) could allow proactive use of therapies which could decrease complications and hospitalizations. This approach would also be of value for surgical planning so that the location of active lesions could be assessed prior to surgery.
  • pancreatic islet cells could be assessed with molecular imaging reagents in nts with type I diabetes or pre-diabetics. In this disease, destruction of these cells leads to loss of insulin production and diabetes. Diabetes becomes clinically apparent only after 90% of islet cells are destroyed by the autoimmune process. Monitoring of islet cell mass with specific imaging reagents would provide a means to follow islet cell destruction and intervene with immunosuppression prior to significant destruction.
  • Allograft rejection is a major complication of transplantation leading to graft loss.
  • Current methods to diagnose and monitor rejection rely on invasive biopsy and blood testing.
  • Molecular imaging could provide a means to assess rejection. It could be used in combination with imaging of graft function so that a single procedure may allow assessment of both rejection and graft function.
  • Endometriosis causes very significant morbidity in young women and can lead to surgery and infertility. A specific diagnosis of this disease is not possible prior to open biopsy. Specific molecular imaging reagents could allow for diagnosis and surgical planning.
  • Infections can occur in any part of the human body. Diagnosis of infection can be difficult to distinguish from other inflammatory processes or from colonization. Molecular imaging could provide a means to make a diagnosis of infection, identify anatomical extent and monitor herapy. Currently available are Leukoscan Fab against granulocytes; Palatin technologies NeutroSpec anti-CD25 for diagnosis of appendicitis; Draximage's labeled Ciprofloxicin.
  • Analyses were performed to identify candidate molecular imaging target peptides from the human genome. Methods were employed to identify a set of proteins with like expression on cell surfaces or secretion from cells.
  • 113,708 records for human proteins were extracted from the Uniprot database (Version number 46). Each record was associated with a Uniprot ID number, an amino acid sequence of the associated protein and Gene Ontology terms (GO terms) associated with the protein. The GO terms represent compiLed information regarding each protein with respect to protein structure and subcellular location. Of these 113,708 peptides, a subset of 7626 were identified which were associated with the GO terms: cell surface, cell septum surface, external side of plasma membrane, extracellular region, extracellular matrix, extracellular space, membrane, external encapsulating structure and cell surface. These proteins are listed in Table 2, which can be found at the end of the specification.
  • a subgroup of 3163 proteins was identified associated with the terms “signal, secreted, extracellular domain, extracellular” and “GPI-anchor” (Group 1 in Tables 2 and 3). These proteins may have an increased likelihood of being accessible outside the cell.
  • Another subgroup of 3117 proteins was identified which was Group 1, less those proteins associated with the terms “mitochondrial” and “nuclear”, which may confer a decreased likelihood of accessibility from outside the cell (Group T).
  • a subgroup of 1973 proteins was identified which was associated with the annotation term "extracellular domain” (Group 3).
  • the SAGE map library (Serial Analysis of Gene Expression, Lash et al. 2000) at the NCBI was analyzed to identify genes specific to Glioblastoma as compared to normal brain tissue. This was done by comparing the frequency of SAGE tags in Glioblastoma tissues (11) to those in normal brain (6).
  • the libraries compared were: Normal brain libraries:
  • Brain 5 pooled Duke glioblastoma multiforme primary tumors, brain glioblastoma multiforme SAGE CGAP non-normalized SAGE library method bulk
  • the identified set of 141 proteins associated with Glioblastoma (Table 4) are candidate targets for molecular imaging reagent development as described.
  • Candidate cell surface or secreted proteins which are highly expressed and specific to hepatic cancer can be identified by the method described in the invention. Proteins must be expressed specifically in the setting of cancer or pre-malignant transformation of hepatic cells versus normal or cirrhotic hepatic cells.
  • Methods for identification of these targets include mining of existing data as described above. These data can take the form of published literature, sequence databases, gene expression databases, or proteomic database. Methods similar to those described in Example 2 can also be used. In addition, data can be generated using animal models of liver cancer, tissue culture or human tissue specimens. Gene expression or proteomic data sets can be generated from these tissues and data from cancerous cells or tissues can be compared to normal liver tissues or control cells or tissues.
  • Identified markers of hepatic cancer which are expressed on the cell surface or secreted such as those present in Table 2 and have expression features as described in the specification are candidates for development of molecular imaging reagents.
  • tissue microarrays which contain hundreds of human tissue samples representing hepatic cancer and control tissues.
  • MAGE-I and Glypican 3 antibodies reactive to human antigen are tested on a tissue microarray consisting of more than 140 cases of hepatocellular carcinoma of various grades (US Biomax, Rockville, MD).
  • the controls on the tissue array are normal liver sections and other metastatic adenocarcinoma as well as intrahepatic cholangiocarcinoma.
  • Tissue samples are fixed in 4% in neutral phosphate buffered formalin for 24 hours. Then the tissue is dehydrated with ethanol and embedded in paraffin. The paraffin embedded tissue is section and mounted onto a positive charge lass slide. Each tissue section is 5 ⁇ m thick and ⁇ 1.0 mm in diameter and ⁇ 200 cores are mounted onto each slide. Among the 200 cases, there are 140 cases hepatocellular carcinoma grade 1-3, 12 cases of intrahepatic cholangiocarcinoma, and 31 metastic adenocarcinoma. The tissue cores are layered with a thin layer of paraffin to prevent oxidation or moisture condensation. Before the slide is used for immunohistochemistry studies, the tissue microarray is de-paraffinized.
  • the array is rinsed with phosphate buffer saline. In some cases, the endogenous peroxidase activity is blocked.
  • the array goes through an antigen retrieval process to expose the antigenic sites.
  • the array is incubated with normal serum to reduce nonspecific binding.
  • the array is incubated with the primary antibody.
  • the primary antibodies are against human antigens for MAGE-I and Glypican 3.
  • the MAGE-I is a monoclonal antibody raised in mouse.
  • the Glypican 3 antibody is polyclonal antibody raised in sheep.
  • the array slide is rinsed with phosphate buffer saline. Then the array is incubated with a biotin- conjugated secondary antibody.
  • the secondary antibody is anti-host of the primary antibody.
  • the secondary antibody is against rabbit, mouse and sheep.
  • the array is incubated with an Avidin/Biotinylated Enzyme Complex (ABC).
  • ABSC Avidin/Biotinylated Enzyme Complex
  • the enzyme is horseradish peroxidase.
  • the array is incubated with diaminobenzidine which is the substrate for the enzyme to produce a nsoluble brown product.
  • the array is stained with hematoxylin to differentiate cell structure in the sections.
  • the array is dehydrated and mounted.
  • An image of the immunostained tissue array russiad through image acquisition software. Image analysis software is used to generate q itative data.
  • One form of the raw data is percentage of positive cells and intensity of positive signal.
  • Another form of the raw data is scoring the signal from a range of + to
  • SPIO superparamagnetic iron oxide
  • SPIO superparamagnetic iron oxide
  • Gadolinium(Gd) based Biotinyl-albumin-GdDTPA reagent was synthesized and then the antibody of interest was covalently conjugated through a EDC/NHS link to albumin.
  • Glypican-3 (H-162) (GPC-3) is a rabbit polyclonal antibody.
  • NCTC normal liver cell line
  • Hepal-6 hepatoma cell line
  • Cells were cultured according to ATCC requirements, then incubated with contrast reagents or controls for Jackpot. After treatment, cells were washed, collected and embedded in 2% agarose in small vials. The vials were imaged on a Bruker Biospec 7.0 Tesla/30 cm horizontal-bore imaging spectrometer.
  • T2 -weighted images were acquired using a 2D multi-slice multi-echo imaging pulse sequence (Bruker) (repetition time (TR) 3sec, 8 echoes, echo times (TEs) 15, 30, 45, 60, 75, 90, 105 and 120 msec, 256 x 256 matrix).
  • TR repetition time
  • TE echo times
  • T 2 values for Hepa 1 -6 and NCTC cells treated with anti-GPC-3-SPIO or control preparations are shown in Table 6.
  • the hepatoma cell line (but not the control cell line) was found to have a significantly lower T2 value when treated with SPIO-anti-GPC-3 compared to control cells treated with SPIO alone.
  • Table 6 T 2 data for Glypican 3 ta ⁇ ; ⁇ eted cell line experiments with SPIO contrast
  • GPC-3 were tested for detection of malignant nodules. Anaesthetised mouse was placed in a MR probe, and liver was localised by MRI. Respiratory gating was used to trigger acquisition of the -encoding steps in the imaging sequence for liver images. Mouse was injected intravenously ontrast agent.
  • the binding specificity of the targeting agents is indicated by the changes in Ti or T 2 and intensity of the signal.
  • SPIO-based reagent the decrease in T 2 and decrease in signal intensity for selected regions indicate binding specificity of this targeting agent.
  • Gd-based reagent the decrease in Ti and increased signal intensity for selected regions indicate binding specificity of this targeting agent.
  • Atherosclerosis is an inflammatory process of arterial walls which can lead to occlusion mitation in blood flow. Atherosclerotic plaques can suddenly rupture leading to complete ion of a blood vessel which leads to myocardial infarction (heart attack) or stroke. It is not ossible to predict which atherosclerotic plaques in which vessels are likely to rupture and lead to cute events. Molecular imaging could enable assessment of both blood vessel anatomy and risk of plaque rupture.
  • Candidate cell surface or secreted proteins which are highly expressed and specific to ctive (at risk) atherosclerotic plaque can be identified by the method described in the invention. Proteins must be specifically expressed in active athrerosclerotic plaque (e.g., with subsequent acute events) versus lower risk atherosclerosis.
  • Methods for identification of these targets include mining of existing data as described above. These data can take the form of published literature, sequence databases, gene expression databases, or proteomic database. Methods similar to those described in Example 2 can also be used. In addition, data can be generated using animal models of atherosclerosis, tissue culture or human tissue specimens. Gene expression or proteomic data sets can be generated from these tissues and comparisons or active vs. low-risk plaque can be used to identify candidate markers.
  • mice Hadjantonakis, A. K. and A. Nagy (2001). "The color of mice: in the light of GFP-variant reporters.” Histochem Cell Biol 115(1): 49-58.
  • ADAM 10 precursor ⁇ EC 342481 (A dismteg ⁇ and metaUoproteinase domain 10) (Mammalian disi ⁇ teg ⁇ n-metalloprotease) (Kuzba ⁇ ian pro'ADA10_HUMAN Y Y Y
  • CCL21 Small inducible cytokine A21 precursor (CCL21) (Beta chemokine exodus-2) (6Ck ⁇ ne) (Secondary lymphoid-tissue chemokine) (SLC) Y
  • CCL22 Small inducible cytokine A22 precursor (CCL22) (Macrophage-de ⁇ ved chemokine) (MDC(1-69)) (Stimulated T cell chemotactic protein 1) (CC CCU2_HUMAN Y
  • CCL24 Small inducible cytokine A24 precursor (CCL24) (Myeloid progenitor inhibitory factor-2) (MPIF-2) (CK-beta-6) (Eosinophil chemotactic CCL24JHUMAN Y
  • CDP-diacylglycerol- inositol 3-phosphat ⁇ dyltransferase (EC 278 11) (Phosphatidyli ⁇ ositol synthase) (Ptdlns synthase) (Pl synthase) CDIPT_HUMAN
  • Adapter-related protein complex 3 beta 1 subunit (Beta3A-adapt ⁇ n) (Adaptor protein complex AP-3 beta-1 subu ⁇ it) (AP-3 complex beta-1 AP3B1_HUMAN
  • ADAMTS-3 precursor (EC 3424 -) (A disintegnn and metaUoproteinase with thrombospondin motifs 3) (ADAM-TS 3) (ADAM-TS3) (Procollagi ATS3_HUMAN Y
  • Amyloid beta A4 precursor protein-binding family B member 1 protein APBB1_HUMAN
  • Beta defensin 2 precursor (BD-2) (hBD-2) (Defensin, beta 2) (Skin- antimicrobial peptide 1) (SAP1) BD02_HUMAN Y
  • Voltage-dependent P/Q-type calcium channel alpha-1 A subunit Voltage- gated calcium channel alpha subunit Cav2 1) (Calcium channel, L CAC1A_HUMAN
  • Claud ⁇ -4 Clostridium perfnngens enterotoxin receptor
  • CPE-R Clostridium perfnngens enterotoxin receptor
  • Chlonde intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (p64 CLCP) (Chlonde channel ABP) (Regulatory nuclear CLIC1_HUMAN
  • Chlonde intracellular channel protein 2 (XAP121) CLIC2_HUMAN
  • ADAM DEC1 precursor (EC 3424 -) (A disintegnn and metalloprotei ⁇ ase domain-like protein decysin 1) (ADAM-like protein decysin 1) ADEC1_HUMAN Y
  • Apolipoprotein L1 precursor (Apolipoprotein L-I) (Apolipoprotei ⁇ L) (ApoL-l) (Apo L) (ApoL) APOL1_HUMAN Y
  • DAP 1 Disks large-associated protein 1 (DAP 1) (Guanylate kinase-asso ⁇ ated protein) (hGKAP) (SAP90/PSD-95-assoc ⁇ ated protein 1) (SAPAP1) DLPI-HUMAN
  • Chemokine binding protein 2 (Chemokine-binding protein D6) (OC chemokine receptor D6) (Chemokine receptor CCR-9) (CC-Chemok ⁇ e CCBP2_HUMAN
  • CXC-R6 CXCR-6 (G protein coupled receptor bonzo) (G-protein coupled receptor STRL33) CXCRe-HUMAN
  • E-NPP 3 Phosphodiesterase l/nucleotlde pyrophosphatase 3
  • CAB4 Voltage-dependent L-type cal ⁇ um channel beta-4 subunit (CAB4) (Calcium channel, voltage-dependent, beta 4 subunit) CACB4_HUMAN
  • CAAX box protein 1 (Cerebral prote ⁇ n-5) (hucep-5) CXXI-HUMAN
  • Cortistatin precursor (UNQ307/PRO350) [Contains Cort ⁇ stati ⁇ -29, Cortistat ⁇ n-17] CORT-HUMAN Y
  • CYR61 protein precursor (Cysteme- ⁇ ch, angiogenic inducer, 61) (Insulin-like growth factor-binding protein 10) (GIG1 protein) CYR61_HUMAN Y
  • Eph ⁇ n type-B receptor 6 precursor (Tyrosi ⁇ e-protem kinase-defective receptor EPH-6) (HEP) EPHB6_HUMAN Y
  • GFR-alpha 2 precursor GFR-alpha 2 precursor (GFR-alpha 2) (Neurtun ⁇ receptor alpha) (NTNR-alpha) (NRTNR-alpha) (TGF beta related GFRA2_HUMAN Y
  • Hyalurona ⁇ synthase 3 (EC 241 212) (Hyaluronate synthase 3) (Hyaluronic acid synthase 3) (HA synthase 3) HAS3_HUMAN
  • HS1-b ⁇ nd ⁇ ng protein HS1-assoc ⁇ ating protein X-1) (HAX-1) HAX1_HUMAN
  • G(I)/G(S)/G(O) gamma-T2 subunit G gamma-C
  • G gamma-8 G-gamma 9
  • GABA(A) receptor Gamma-aminobuty ⁇ c-acid receptor delta subunit precursor (GABA(A) receptor) GBRD-HUMAN Y
  • GABA(A) receptor Gamma-aminobuty ⁇ c-acid receptor pi subunit precursor (GABA(A) receptor) GBRP-HUMAN Y
  • Golgi SNARE protein 64 27 kDa Golgi SNARE protein (Golgi SNAP receptor complex (Membrin) GOSR2_HUMAN
  • G protein coupled receptor 171 G-protein coupled receptor H963 _. GP171_HUMAN
  • Neurop ⁇ l ⁇ n-1 precursor (Vascular endothelial cell growth factor 165 receptor) NRPI-HUMAN
  • Integ ⁇ n beta 1 binding protein 1 (Integnn cytoplasmic domain- associated protein 1) (ICAP-1) ITBP1_HUMAN
  • Ladi ⁇ i ⁇ 1 (120 kDa linear IgA bullous dermatosis kDa linear IgA bullous dermatosis antigen) (Linear IgA disease LAD1_HUMAN
  • Galect ⁇ n-8 Galect ⁇ n-8 (Gal-8) (Prostate carcinoma tumor antigen 1) (PCTA-1) (Po66 carbohydrate-binding protein) (P066-CBP) LEG8_HUMAN
  • Beta-1 3-N-acetylglucosam ⁇ nyltransferase manic f ⁇ nge (EC 241 222) (0-fucosylpeptlde 3-beta-N-acetylglucosam ⁇ nyltransferas ⁇ ) MFNG-HUMAN
  • Natural cytotoxicity tnggenng receptor 3 precursor Natural killer cell p30-related protein (NKp30) (NK-p30) NCTR3_HUMAN
  • LIN-7A LIN-7 homolog A
  • h ⁇ n-7 Mammalian UN-seven protein 1
  • MALS-1 Vertebrate LIN 7 homolog 1
  • Vel ⁇ -1 protein Tax LIN7A_HUMAN
  • Membrane associated progesterone receptor component 2 (Progesterone membrane binding protein) (Steroid receptor protein DG6) PGRC2_HUMAN
  • Lipid phosphate phosphohydrolase 1 (EC 3 1 34) (Phosphatide acid phosphatase 2a) (Phosphatidate phosphohydrolase type 2a) (PAP2a) LPP1_HUMAN
  • OB-RGRP 99 Lepti ⁇ receptor gene-related protein
  • N4BP3_HUMAN N4BP3_HUMAN
  • Potassium channel subfamily K member 1 (Inward rectifying potassium channel protein TWIK-1) (Potassium channel KCNO1) KCNK1JHUMAN
  • Potassium channel subfamily K member 3 (Acid-sensitive potassium channel protein TASK-1) (TWIK-related acid-sensitive K(+) channel 1 ⁇ KCNK3_HUMAN
  • RIM binding protein 2 (RIM-BP2)
  • PLD 2 Phospholipase D2 (EC 31 44) (PLD 2) (Choline phosphatase 2) (Phosphatidylcholine-hydrolyzing phospholipase D2) (PLD1C) (hPLD2) PLD2JHUMAN
  • P2Y10JHUMAN Putative P2Y pu ⁇ noceptor 10 (P2Y10) (P2Y-I ⁇ ke receptor) P2Y10JHUMAN
  • Pro-neuregul ⁇ n-2 precursor Pro-NRG2 [Contains Neuregul ⁇ n-2 (NRG 2) (Neural and thymus-denved activator for ERBB kinases) (NTAK) NRG2_HUMAN
  • Ras-related protein M-Ras Ras-related protein R-Ras3
  • SIRB1_HUMAN Signal-regulatory protein beta-1 precursor
  • 129 Prostaglandin E synthase (EC 53993) (Microsomal glutathione S-transferase 1-l ⁇ ke 1) (MGST1-L1) (p53- ⁇ nduced apoptosis protein 12)
  • Phospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-depende ⁇ t phospholipid scramblase 1) (Erythrocyte phospholipid scramblase) PLS1_HUMAN
  • Glycine receptor beta chain precursor (Glycine receptor 58 kDa subumt) GLRB-HUMAN Y Y Y
  • G-protein coupled receptor 109B G-protein coupled receptor HM74
  • GAL1-R Galanin receptor type 1 (GAL1-R) (GALR1) GALR1_HUMAN Y Y
  • GABA(A) receptor Gamma-aminobuty ⁇ c-acid receptor alpha-2 subunit precursor
  • GABA(A) receptor Gamma ammobuty ⁇ c-acid receptor alpha-4 subunit precursor (GABA(A) receptor) GBRA4_HUMAN Y Y Y
  • GABA(A) receptor Gamma-aminobutync-acid receptor beta-2 subunit precursor
  • Hyaluro ⁇ idase 1 precursor (EC 32135) (Hyal-1) (Hyaluro ⁇ idase PH-20) (Sperm surface protein PH-20) (Sperm adhesion molecule 1) HYAL1_HUMAN Y
  • Glutamate receptor 1 precursor (GIuR-I) (GIuR-A) (GIuR-KI) (Glutamate receptor ionotropic AMPA 1) GRIA1_HUMAN Y Y Y
  • Glutamate receptor 2 precursor (GluR-2) (GIuR B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) GRIA2_HUMAN Y Y Y
  • Glioma pathogenesis-related protein 1 precursor (GIiPR 1) (RTVP-1 protein) GLIP1JHUMAN Y
  • Interferon-alpha/beta receptor beta chain precursor IFN-alpha-REC
  • Jype I interferon receptor IFN-R
  • Interferon-gamma receptor beta chain precursor Interferon-gamma receptor accessory factor-1) (AF-1) (Interfero ⁇ -gamma transducer-1) INGR2_HUMAN Y Y Y
  • Neuron specific protein family member 1 (Brain neuron cytoplasmic protein 1) (D4S234) NSG1_HUMAN Y
  • IL-12R betai lnterleukin 12 receptor beta-1 chain precursor (IL-12R betai) (lnterleuk ⁇ n-12 receptor beta) (IL-12 receptor beta component) I12R1_HUMAN Y Y Y Y
  • G protein-activated inward rectifier potassium channel 1 (G1RK1) (Potassium channel, inwardly rectifying, subfamily J, member 3) IRK3_HUMAN Y Y
  • G protein-activated inward rectifier potassium channel 4 (GIRK4) (Potassium channel, inwardly rectifying subfamily J, member 5) IRK5_HUMAN Y Y
  • G protein-activated inward rectifier potassium channel 2 G protein-activated inward rectifier potassium channel 2 (Gl RK2) (Potassium channel, inwardly rectifying, subfamily J, member 6)
  • IL15_HUMAN Y Y 487 Killer cell immunoglobulin-like receptor 2DL1 precursor (MHC class I NK cell receptor) (Natural killer associated transc ⁇ pt 1) (NKAT-1) KI2L1_HUMAN Y Y Y Y
  • Killer cell immunoglobulm-like receptor 2DL2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 6) (NKAT-6) KI2L2_HUMAN Y Y Y
  • Killer cell immu ⁇ oglobuli ⁇ -like receptor 2DL3 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 2) (NKAT-2) KI2L3_HUMAN Y Y Y
  • Killer cell immu ⁇ oglobulm-like receptor2DS2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 5) (NKAT-5) KI2S2_HUMAN Y Y Y
  • Galect ⁇ n-7 Galect ⁇ n-7 (Gal-7) (HKL-14) (PI7) (p53- ⁇ nduced protein 1) LEG7JHUMAN Y
  • ERGIC-53 protein precursor ER-Golgi intermediate compartment 53 kDa protein
  • Lectin ma ⁇ nose binding 1 Gp58
  • IL-6R-beta lnterleukin 6 signal transducer
  • gp130 gp130
  • Metabotropic glutamate receptor 5 precursor MGR5_HUMAN Y Y Y
  • LIF-R Leukemia inhibitory factor receptor precursor
  • Lamina-associated polypeptide 2 isoform alpha (Thymopoietin isoform alpha) (TP alpha) (Thymopoieti ⁇ -related peptide isoform alpha) (TPRP LAP2AJHUMAN
  • Leptin receptor precursor (LEP-R) (OB receptor) (OB-R) (HuB219) LEPR_HUMAN Y Y Y Y Y
  • Ra reactive factor precursor (EC 3421 -) (Ra-reactive factor senne protease p1O0) (RaRF) MASP1_HUMAN Y
  • Melatonin receptor type 1A (MeHA-R) (MeHa melatonin receptor) MTR1A_HUMAN Y Y
  • Neurogenic locus notch homolog protein 1 precursor (Notch 1) (Translocation-associated notch protein TAN-1) NOTC1_HUMAN Y Y Y
  • NovH Nephroblastoma overexpressed gene protein homolog
  • Tumor necrosis factor ligand superfamily member 9 (4-1BB liga ⁇ d) (4-1BBL) TNFL9_HUMAN Y Y
  • TPO-R Thrombopoietin receptor precursor
  • C-mpl Myeloproliferative leukemia protein
  • CD110 antigen TPOR_HUMAN Y Y
  • Thrombopoietin precursor Megakaryocyte colony stimulating factor
  • Myeloproliferative leukemia virus oncogene ligand C-mpl ligand
  • Vitamin K-depe ⁇ dent gamma-carboxylase (EC 64 --) (Gamma-glutamyl carboxylase) VKGC_HUMAN
  • SREBP-1 Sterol regulatory element binding prote ⁇ n-1 (SREBP-1) (Sterol regulatory element-binding transcnptio ⁇ factor 1)
  • SRBP1_HUMAN Sterol regulatory element binding prote ⁇ n-1 (SREBP-1) (Sterol regulatory element-binding transcnptio ⁇ factor 1)
  • Tumor necrosis factor receptor superfamily member 4 precursor OX40L receptor
  • ACT35 antigen TNR4_HUMAN Y
  • DRP1 Dystrophin-related protein 1
  • V1aR Vasopressin Via receptor
  • V1aR Vasopressin Via receptor
  • AVPR Via V1ARJHUMAN
  • V1bR Vasopressin V1b receptor
  • AVPR V1b Vasopressin V3 receptor
  • AVPR V3 Vasopressin V3 receptor
  • V1BR_HUMAN Vasopressin V1b receptor
  • TrpC1 Short transient receptor potential channel 1 (TrpC1) (TRP-1 protein) TRPC1_HUMAN
  • Chemokine XC receptor 1 (XC chemokine receptor 1) (Lymphotactin receptor) (G-protein coupled receptor 5) XCR1_HUMAN
  • Dopachrome tautomerase precursor (EC 533 12) (DT) (DCT) (Dcpachrome delta-isomerase) (Tyrosmase-related protein 2) (TRP-2) (TRP2) TYRP2_HUMAN Y
  • Cytochrome c-type heme lyase (EC 441 17) (CCHL) (Holocytochrome c-type synthase) CCHL-HUMAN
  • Eotaxin precursor (Small inducible cytokine A11) (CCL11) (Eosinophil chemotactic protein) CCL11_HUMAN Y
  • CCL18J Macrophage inflammatory protein 4
  • MlP-4 Small inducible cytokine A18 precursor
  • CCL23 Small inducible cytokine A23 precursor (CCL23) (Macrophage inflammatory protein 3) (MIP-3) (Myeloid progenitor inhibitory CCL23_HUMAN Y
  • C-C chemokine receptor type 3 (C-C CKR-3) (CC CKR-3) (CCR-3) (CKR3) (Eosinophil eotaxin receptor) CCR3JHUMAN
  • C-C chemokine receptor type 4 (C-C CKR-4) (CC-CKR-4) (CCR-4) (K5-5) CCR4 ⁇ HUMAN
  • C-C chemokine receptor type 6 C-C CKR-6) (CC-CKR-6) (CCR-6) receptor) (GPR-CY4) (GPRCY4) (Chemokine receptor-like 3) (CKR-L3) CCR6J-IUMAN
  • C-C chemokine receptortype 8 C-C CKR-8) (CC-CKR 8) (CCR-8) (GPRCY6) (Chemokine receptor-like 1) (CKR-L1) (TER1) (CMKBRL2) CCR8_HUMAN
  • C-C chemokine receptor type 9 C-C CKR-9) (CC-CKR 9) (CCR-9) (GPR-9-6) CCR9_HUMAN
  • WCH4 (Mercu ⁇ al-msensitive water channel) (MIWC)
  • MIWC Mercu ⁇ al-msensitive water channel
  • BCR-associated protein Bap31 (p28 Bap31) (CDM protein) (6C6-AG tumor associated antigen)
  • Adapter-related protein complex 1 sigma 1B subunit (Sigma-adapti ⁇ 1B) (Adaptor protein complex AP-1 Sigma 1B subunit) (Golgi adaptor HA AP1S2_HUMAN
  • Clath ⁇ coat assembly protein AP17 (Clath ⁇ n coat associated protein AP17) (Plasma membrane adaptor AP 217 kDa protein) (HA2 AP2S1JHUMAN
  • Adenylate cyclase, type VII (EC 46 1 1) (ATP pyrophosphate-lyase 7) (Adenylyl cyclase 7) ADCY7JHUMAN
  • Arfaptn 1 (ADP- ⁇ bosylation factor interacting protein 1) ARFP1_HUMAN
  • Amyloid-like protein 1 precursor (APLP-1) [Contains C30] APLP1JHUMAN Y
  • ATPB 3 Sodium/potassium-transporting ATPase beta-3 chain (Sodium/potassium- dependent ATPase beta-3 subunit) (ATPB 3) AT1B3_HUMAN Y
  • Chlo ⁇ de channel protein CIC-Ka (Chlo ⁇ de channel Ka) (CIC-K1) CLCKA_HUMAN Y Y
  • Chlo ⁇ de channel protein CIC-Kb Chlonde channel Kb (Chlonde channel Kb) (CIC-K2) CLCKBJHUMAN Y Y
  • Chlonde channel protein 2 (ClC-2) CLCN2_HUMAN Y Y
  • Chloride channel protein 5 (CIC-5) CLCN5 HUMAN Y
  • Chloride channel protein 6 (CIC-6) CLCN6J-IUMAN Y
  • Diacylgiycerol kinase, epsilon (EC 271 107) (Diglyce ⁇ de kinase) (DGK-epsilo ⁇ ) (DAG kinase epsilon) DGKEL.HUMAN
  • CXC-R3 CXCR-3) (CKR-L2) (CD183 antigen)
  • CXCR3_HUMAN CX-C chemokine receptortype 3 (CXC-R3) (CXCR-3) (CKR-L2) (CD183 antigen)
  • MUC24JHUMAN 1107 Putative mucin core protein 24 precursor (MULTI-glycosylated core protein 24) (MGC-24) (MUC-24) (CD164 antigen) MUC24JHUMAN
  • IL-9R 1111 lnterleuk ⁇ -9 receptor precursor (IL-9R) IL9R_HUMAN
  • Lysyl oxidase homolog 1 precursor (EC 1 43 -) (Lysyl oxidase-like protein 1) (LOL) LOXL1_HUMAN
  • NKG2-E type Il integral membrane protein (NKG2-E activating NK receptor) (NK cell receptor E) NKG2E_HUMAN
  • Mitochond ⁇ al processing peptidase alpha subunit, mitochond ⁇ al precursor (EC 342464) (Alpha-MPP) (P-55) (HA1523) MPPA_HUMAN
  • MSH-R Melanocyte stimulating hoimone receptor
  • M1-R Melanocyte stimulating hoimone receptor
  • Inositol polyphosphate 5 phosphatase OCRL-1 (EC 31 336) (Lowe's oculocerebrorenal syndrome protein) OCRLJHUMAN
  • HSPG basement membrane-specific heparan sulfate proteoglycan core protein precursor
  • PLC Proliferative coactivator-associated proteoglycan core protein precursor
  • Polycystin 1 precursor (Autosomal dominant polycystic kidney disease protein 1) PKD1_HUMAN
  • PSBG-4 Pregnancy-specific beta-1-glycoprotein 4 precursor (PSBG-4) (PSBG-9) PSG4JHUMAN Y
  • Renal sodium-dependent phosphate transport protein 2 (Sodium/phosphate cotra ⁇ sporter 2) (Na(+)/P ⁇ cotransporter2) (Renal sodium-phospr NPT2JHUMAN
  • Pro- ⁇ euregul ⁇ n-1 precursor Pro-NRG1 [Contains Neuregul ⁇ -1 (Neu differentiation factor) (Hereguli ⁇ ) (HRG) (Breast cancer cell NRG1JHUMAN
  • Rhesus blood group-associated glycoprotein (Rhesus blood group-associated ammonia channel) (Erythrocyte plasma membrane 50 kDa RHAGJHUMAN
  • Proteolipid protein 2 (Intestinal membrane A4 protein) (Differentiation dependent protein A4) (Proteolipid protein 2) PLP2JHUMAN
  • Semenogel ⁇ n-2 precursor Semenogelm II (SGII) SEMG2JHUMAN
  • CXCL9 Small inducible cytokine B9 precursor (CXCL9) (Gamma interferon induced monokine) (MIG) SCYB9 JHUMAN
  • ROSP1 ROD outer segment membrane protein 1
  • Macrophage-stimulating protein receptor precursor (EC 271 112) (MSP receptor) (p185 Ron) (CDW136) (CD136 antigen) RON-HUMAN
  • Tyrosine-protein kinase transmembrane receptor ROR1 precursor (EC 271 112) (Neurotrophic tyrosine kinase, receptor-related 1) ROR1 JHUMAN
  • Tyrosine-protein kinase transmembrane receptor ROR2 precursor (EC 271 112) (Neurotrophic tyrosine kinase, receptor-related 2) ROR2 JHUMAN
  • Trefoil factor 3 precursor (Intestinal trefoil factor) (hP1 B) TFF3 JHUMAN
  • TGF-beta receptor type 111 precursor TGFR-3 (Transforming growth factor beta receptor III) (Betaglycan) TGBR3JHUMAN
  • Antigen peptide transporter 1 (Peptide transporter TAP1) (ATP- binding cassette, sub-family B, member 2) (Peptide transporter PSF1) TAP1 JHUMAN
  • VMAT2JHUMAN Synaptic vesicular amine transporter (Monoamine transporter) (Vesicular amine transporter 2) (VAT2) (Solute earner family 18, VMAT2JHUMAN
  • a ⁇ giopoieti ⁇ 1 receptor precursor (EC 271 112) (Tyrosine-protein kinase receptorTIE-2) (Tyrosine-protein kinase receptor TEK) (P140 T1E2JHUMAN
  • Spectnn beta chain brain 1 (Spect ⁇ , ⁇ o ⁇ -erythroid beta chain (Beta-II spectrin) (Fod ⁇ n beta chain) SPTB2JHUMAN
  • DA transporter Sodium-dependent dopamine transporter (DAT) SC6A3 JHUMAN
  • SCAP Sterol regulatory element binding protein cleavage-activating protein
  • Tumor necrosis factor alpha-induced protein 2 (Pnmary response geneB94 protein) TNAP2_HUMAN
  • LT-beta Lymphotoxin-beta (LT-beta) (Tumor necrosis factor C) (TNF-C) (Tumor necrosis factor ligand superfamily member 3)
  • TNF-C Tumor necrosis factor ligand superfamily member 3
  • Urokinase plasminogen activator surface receptor precursor U-PAR
  • Monocyte activation antigen Mo3 CD87 antigen
  • SREBP-2 Sterol regulatory element binding prote ⁇ n-2 (SREBP-2) (Sterol regulatory element-binding transcnption factor 2) SRBP2_HUMAN
  • Tumor necrosis factor receptor superfamily member 17 (B-cell maturation protein) TNR17JHUMAN
  • Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen 4-1 BB homolog) (T-cell antigen ILA) TNR9_HUMAN Y
  • Tyrosine-protei ⁇ kinase receptor TYR03 precursor (EC271 112) (Tyrosine-protein kinase RSE) (Tyrosine-protei ⁇ kinase SKY) (Tyrosine- TYR03_HUMAN Y
  • Tight junction protein 20-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1) Z01_HUMAN
  • ADAM 15 precursor (EC 3424-) (A disinteg ⁇ n and metalloproteinase domain 15) (Metalloproteinase-like, disintegnn like and cysteine- ADA15JHUMAN Y
  • CD166 antigen precursor Activated leukocyte-cell adhesion molecule
  • ACAM Activated leukocyte-cell adhesion molecule
  • Cyclic-nucleotide-gated cation channel 4 (CNG channel 4) (CNG-4) (CNG4) (Cyclic ⁇ ucleotide-gated cation channel modulatory subunit) CNGB1_HUMAN
  • Dystroglycan precursor (Dystrophin-associated glycoprotein 1) [Contains Alpha-dystroglycan (Alpha-DG), Beta-dystroglycan DAG1_HUMAN Y
  • kinase anchor protein 6 Protein kinase A ancho ⁇ ng protein (PRKA6) (A kinase anchor protein 100 kDa) (AKAP 100) (mAKAP) AKAP6_HUMAN
  • Adapter-related protein complex 3 beta 2 subunit (BetaSB-adaptin) (Adaptor protein complex AP-3 beta-2 subunit) (AP-3 complex beta-2 AP3B2_HUMAN
  • Bone mo ⁇ hogenetic protein receptortype Il precursor (EC 271 37) (BMP type Il receptor) (BMPR-II) BMPR2_HUMAN Y
  • ADAM 9 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 9) (Metalloprotease/disinteg ⁇ /cysteine-nch protein 9) ADAM9_HUMAN Y
  • Activin receptor type HB precursor (EC 271 37) (ACTR-IIB) AVR2B_HUMAN Y
  • Carci ⁇ oembryonic antigen-related cell adhesion molecule 7 precursor (Carcinoembryo ⁇ ic antigen CGM2) CEAM7_HUMAN Y
  • Phakinin (Beaded filament structural protein 2) (Lens fiber cell beaded filament protein CP 49) (CP49) (49 kDa cytoskeletal BFSP2JHUMAN
  • Presynaptic protein SAP97 (Synapse-associated protein 97) (SAP-97) (Discs, large homolog 1) (hDlg) DLG1JHUMAN
  • CLN3 protein (Battenin) (Batten disease protein) CLN3_HUMAN
  • CRF-R 2 Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2) (Corticotropi ⁇ -releasing hormone receptor 2) (CRH-R 2) CRFR2JHUMAN Y Y Y
  • Ectonudeotide pyrophosphatase/phosphodiesterase 2 (E-NPP 2) (Phosphodiesterase l/nudeotide pyrophosphatase 2) (Phosphodiesterase ENPP2_HUMAN Y
  • HERV-R_7q21 2 provirus ancestral Env polyprotein precursor envelope polyprotein
  • envelope polyprotein envelope protein
  • ERV-3 envelope protein ERV-3 envelope protein
  • Cadher ⁇ -17 precursor Liver-intestme-cadhe ⁇ n
  • U-cadhe ⁇ Intestinal peptide-associated transporter HPT-1
  • Chromatin assembly factor 1 subunit B (CAF-1 subunit B) assembly factor I p60 subunit) (CAF I 60 kDa subu ⁇ it) CAF1 BJHUMAN
  • Type-1B angiotensin Il receptor (AT1B) (AT1BR) AG2SJHUMAN
  • Glycerol kinase, testis specific 1 (EC 271 30) (ATP glycerol 3-phosphotransferase) (Glycerohnase) (GK) GKP3 JHUMAN
  • Dihydropy ⁇ midine dehydrogenase [NADP+] precursor (EC 1 31 2) (DPD) (DHPDHase) (Dihydrouracil dehydrogenase) (Dlhydrothymi ⁇ e DPYDJHUMAN
  • EMR1 JHUMAN EGF-like module containing mucin-like hormone receptor-like 1 precursor (Cell surface glycoprotein EMR1) (EMR1 hormone receptor) EMR1 JHUMAN
  • GNRP Guanine nucleotide releasing protein
  • GRB10 adaptor protein Insulin receptor binding protein GRB-IR
  • IL-10R-A nterleukin-10 receptor alpha chain precursor
  • IL-15Ralpha 1269 lnterleuk ⁇ n-15 receptor alpha chain precursor (IL-15Ralpha) (IL-15RA) I15RAJHUMAN
  • IL-16 1270 lnterleuk ⁇ -16 precursor (IL-16) (Lymphocyte chemoattractant factor) (LCF) IL16JHUMAN
  • IL1 receptor-related protein 1271 lnterleuk ⁇ -18 receptor 1 precursor (IL1 receptor-related protein) (IL-1Rrp) IL18RJHUMAN
  • Interleuk ⁇ -18 precursor (IL-18) (I ⁇ terferon-gamma inducing factor) (IFN gamma-inducing factor) (l ⁇ terieuk ⁇ -1 gamma) (IL-"! gamma) IL18JHUMAN
  • Mitogen-activated protein kinase kinase kinase 12 (EC 271 37) (Leucine-zipper protein kinase) (ZPK) M3K12JHUMAN
  • Mitogen-activated protein kinase kinase kinase kinase kinase 2 (EC 271 37) (MAPK/ERK kinase kinase kinase 2) (MEK kinase kinase 2) M4K2JHUMAN
  • Vsicular integral-membrane protein VIP36 precursor (GP36b glycoprotein) (Lectin, ma ⁇ nose-binding 2) LMAN2JHUMAN
  • IL-27B 1280 lnterieuk ⁇ n-27 beta chain precursor (IL-27B) (Epstein-Barr virus induced gene 3 protein) (EBV induced gene 3 protein) IL27BJHUMAN
  • Laminin beta-3 chain precursor (Laminin 5 beta 3) (Lami ⁇ i ⁇ (Kalinin B1 chain) LAMB3JHUMAN
  • Laminin gamma-2 chain precursor (Kalinin/ ⁇ icein/epilignn 100 kDa subunit) (Laminin B2t chain) (Cell scatte ⁇ ng factor 140 kDa subunit) LAMC2JHUMAN
  • Multisy ⁇ thetase complex auxiliary component p43 [Contains Endothelial-monocyte activating polypeptide Il (EMAP-II) (Small MCA1 JHUMAN
  • MAdCAM-1 precursor (hMAdCAM 1)
  • MADCA JHUMAN Mucosal addressi ⁇ cell adhesion molecule-1 precursor
  • Nldogen 2 precursor NlD-2 precursor (Osteonidogen) N1D2JHUMAN
  • Proto-oncogene tyrosi ⁇ e-protein kinase MER precursor (EC 271 112) (C-mer) (Receptor tyrosine kinase MerTK) MERTKJHUMAN
  • Myotubula ⁇ n-related protein 3 (EC 31 348) (FYVE domain-containing dual specificity protein phosphatase 1) (FYVE-DSP1) (Zinc finger FYVI MTM R3JHUMAN
  • Natural killer cells antigen CD94 (NK cell receptor) (Killer lectin-like receptor subfamily D member 1) (KP43) KLRD1 JHUMAN
  • I ⁇ teg ⁇ n alpha-9 precursor (Integ ⁇ alpha-RLC) ITA9_HUMAN Y Y Y
  • Prostaglandin D2 receptor Prostanoid DP receptor
  • PPD receptor Prostaglandin D2 receptor
  • Ecto-ADP- ⁇ bosyltransferase 3 precursor (EC 24231) (NAD(PX+)- arginine ADP-nbosyltransferase 3) (Mo ⁇ o(ADP- ⁇ bosyl)tra ⁇ sferase 3) NAR3_HUMAN
  • Pappalys ⁇ -1 precursor (EC 342479) (Pregnancy-associated plasma protein A) (PAPP-A) (Insulin-like growth factor-dependent IGF binding PAPPA_HUMAN
  • PAF-2 Peroxisome assembly factor-2
  • Peroxi ⁇ 6 Peroxisomal biogenesis factor 6
  • NAD(P) transhydrogenase mitochondrial precursor (EC 1 6 1 2) (Py ⁇ dine nucleotide transhydroge ⁇ ase) (Nicotinamide nucleotide NNTM_HUMAN
  • MFAP-5 Microfibnllar associated protein 5 precursor (MFAP-5) (Microfib ⁇ l- associated glycoprotein 2) (MAGP-2) (MP25) MFAP5_HUMAN Y
  • Polycysti ⁇ 2 (Autosomal dominant polycystic kidney disease type Il protein) (Polycystwin) (R48321) PKD2_HUMAN
  • Oviduct specific glycoprotein precursor (Oviductal glycoprotein) (Oviductin) (Estrogen-dependent oviduct protein) (Mucin 9) OVGP1_HUMAN Y
  • Olfactory receptor 2F1 Olfactory receptor-like protein 0LF3
  • Platelet-activating factor acetylhydrolase precursor (EC 31 1 47) (PAF acetylhydrolase) (PAF 2-acylhydrolase) (LDL-associated PAFA-HUMAN
  • PLD 1 Choline phosphatase 1 (Phosphatidylcholine-hydrolyzing phospholipase D1) (hPLD1) PLD1_HUMAN
  • Olfactory receptor 511 Olfactory receptor-like protein OLF1 OR5I ⁇ J-IUMAN
  • Receptor-type tyrosi ⁇ e-protein phosphatase eta precursor (EC 3 1348) (Protei ⁇ -tyrosine phosphatase eta) (R-PTP-eta) (HPTP eta) (Protein- PTPRJ_HUMAN
  • Rho-GTPase-activating protein 5 (p190-B) RHG05_HUMAN
  • P-select ⁇ glycoprotein ligand 1 precursor PSGL-1) (Selectin P ligand) (CD162 antigen) SELPLJHUMAN
  • Lysosome membrane protein Il (LIMP II) (Scavenger receptor class member 2) (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD SCRB2_HUMAN
  • Red protein (RER protein) IK factor
  • Cytokine IK Cytokine IK
  • Gamma-SG Gamma-sarcoglycan (Gamma-SG) (35 kDa dystrophin-associated glycoprotein) (35DAG) SGCG_HUMAN
  • TNK1_HUMAN Non-receptor tyrosi ⁇ e-protein kinase TNK1 (EC 27 1 112) (CD38 negative kinase 1) TNK1_HUMAN
  • V-ATPase 116-kDa isoform a3 Vacuolar proton translocating ATPase 116 kDa subunit a isoform (V-ATPase 116-kDa isoform a3) (Osteoclastic proton pump 116 kDa VPP3_HUMAN
  • Endothelial cells scavenger receptor precursor (Acetyl LDL receptor) (Scavenger receptor class F member 1) SREC-HUMAN
  • Alpha-1-syntroph ⁇ n (59 kDa dystrophin-associated protein A1 acidic component 1) (Pro-TGF-alpha cytoplasmic domain interacting protein 1) SNTA1_HUMAN
  • Beta-1-sy ⁇ troph ⁇ n 59 kDa dystraphin-associated protein A1, basic component 1 (DAPA1B) (Tax interaction protein 43) (TIP 43) SNTB1_HUMAN
  • Beta-2-sy ⁇ troph ⁇ n (59 kDa dystrophin-associated protein A1, basic component 2) (Sy ⁇ trophin 3) (SNT3) (Sy ⁇ trophin like) (SNTL) SNTB2_HUMAN
  • Tumor differentially expressed protein 1 (Transmembrane protein SBBI99) TDE1JHUMAN
  • TrpC3 Short transient receptor potential channel 3 (TrpC3) (Ht ⁇ -3) (Ht ⁇ 3) TRPC3_HUMAN

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention describes both the identification of disease target molecules and the development of imaging reagents and diagnostic assays specific to those molecules. Described herein are methods and reagents for the identification of molecular targets specific to a disease or disease state, methods of imaging technology which can be used, the development of specific molecular imaging reagents, clinical validation of the imaging reagents, and clinical indications for molecular imaging.

Description

REAGENTS FOR TESTING AND MOLECULAR IMAGING OF LIVER CANCER
CROSS-REFERENCE TO RELATED APPLICATIONS
0001] This application claims the benefit of U.S. Provisional App. Ser. No. 60/714,790, filed September 6, 2005. This application is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
] The methods and reagents described herein generally relate to the identification of molecular targets which are specific to disease and the development of affinity reagents to the argets. The affinity reagent may be utilized as a diagnostic in a diagnostic assay. A contrast or ignal emitting source may be incorporated into the reagent, to generate a target-specific imaging eagent.
BACKGROUND OF THE INVENTION
0003] Medical diagnosis and monitoring utilize a variety of imaging techniques. Standard adiography, fluoroscopy, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Ultrasound are all useful methods in clinical practice. These techniques all have their unique advantages and drawbacks. The clinical utility of all of these techniques could be greatly enhanced by using contrast or signal emitting reagents which are targeted to disease specific molecules. This approach (molecular imaging) could provide added sensitivity for detection of disease or anatomical extent of disease and specificity to help differentiate anatomical findings due to disease from normal or non-diseased tissue. The potential applications of this approach are clear in every medical discipline and disease category.
[0004] Discovery or selection of molecules to target with such an approach can leverage the published literature, gene expression and protein databases, genomics studies, in vitro models, animal models and genomic level screening of candidates using high throughput scanning of thousands of candidate reagent combinations. Development of specific affinity reagents for such molecules can leverage recent advances in antibody development peptide and small molecule design long with methods for incorporation of contrast or signal emitting materials into reagents. When n affinity reagent is developed for a disease specific target, it may subsequently be linked to or abeled with a variety of different contrast/signal reagents for use with a variety of imaging echnologies. In some cases the disease tissue may be obtained from a patient and assessed for the xpression of appropriate markers prior to imaging of the patient. This may be useful in cancer g or monitoring for recurrence where tumor tissue is obtained by biopsy or in surgery. ng may also be targeted to a biological process as opposed to a specific antigen. Examples of would be targeting angiogenesis or macrophage transit into the blood vessel wall.
0005] The field of molecular imaging represents a crossroads of multiple scientific and clinical disciplines. Clinical expertise is needed to assess needs, identify best indications for application of he technology and design clinical trials. Molecular biology, genomics and bioinformatics expertise s needed for identification of disease specific target molecules. The development of labeled affinity reagents requires expertise in chemistry and an understanding of physics. Radiological expertise is needed to develop the specific imaging protocols and technology use. As with early efforts in applications of genomics to diagnostics, it is critical that development and commercial efforts in this area not be driven only by technology concerns. Instead, clinical value should be the primary consideration for focusing these efforts. These efforts should not be wed to a single echnology only, but should utilize the appropriate imaging technology for the specific disease ndication. The imaging technology used must meet certain specifications to be useful for a given clinical indication and molecular marker, but a number of technologies may be useful alone or in combination and efforts to develop reagents should not be restricted to a single technology without consideration of all issues.
[0006] There is currently an opportunity to identify the most relevant target molecules for the clinical indications with highest need and take them downstream in focused development efforts to bring them to clinical use. The significant value associated with this effort is in development of clinically useful reagents and protocols and creation of a pipeline for target identification and evelopment which brings a genomic level approach to this field and brings together the diverse isciplines needed to bring new tools to bear on clinical management for the benefit of patients.
0007] In general the addition of a specific molecular targeting reagent to imaging protocols will be most useful for those diseases where: the anatomical distribution of disease is important (cancer, atherosclerosis, Crohn's), the diagnosis is difficult to make by biopsy or other modalities (early Alzheimer's, Hepatocellular carcinoma, active plaque, Crohn's flare), detection of preclinical e is important (cancer metastasis, recurrence), detection of disease prior to being detectable by ng without molecular specific reagent contrast (cancer, Alzheimer's, prostate cancer) and there s difficulty distinguishing diseased tissue from other causes of abnormal anatomical findings (posturgical changes vs. cancer, quiescent, fixed atherosclerosis vs. inflamed, active plaque).
0008] Molecular imaging approaches may be utilized in numerous clinical situations in oncology. Diagnosis of disease may be improved in this way. Cancer marker specific imaging affinity reagents may provide added sensitivity for small tumors vs. standard imaging or clinical monitoring. Also, this approach may be more specific and allow distinction of cancer tissue from normal tissue or benign processes. Clearly, it may also provide a less invasive means of diagnosis compared to invasive procedures such as endoscopy or biopsy. Upon diagnosis of cancer, staging and risk stratification is necessary to plan surgery and guide radiation and chemotherapy usage. One possibility is for molecular imaging to be performed before completion of cancer surgery to ensure that there has been complete tumor removal ("molecular imaging margins"). Also, if the expression of the molecular target for imaging has prognostic value, the tumor may be treated differently on this basis alone. Imaging may also be done after cancer surgery to check for complete excision if the imaging target is cancer specific. This can be difficult with non-molecular imaging because of anatomical changes from surgery and sensitivity limitations. When a treatment has been successful in inducing remission, molecular imaging may provide a sensitive way to monitor for recurrence. In one scenario for clinical implementation, the primary tumor tissue may be obtained at the time of biopsy or surgery and assessed for the expression of the molecular target. Subsequently the tumor spread or recurrence can be imaged with the appropriate agent that the rimary tumor is found to express. Molecular imaging approaches may be extremely valuable in hemotherapeutic drug trials as patient selection tools or as a surrogate endpoint.
0009] Hepatocellular carcinoma often occurs in patients with cirrhotic liver disease from hepatis B or C, alcohol or other processes. This presents a difficult diagnostic dilemma as cirrhosis s associated with nodule formation and scarring in the liver tissue which makes detection of a ancer nodule nearly impossible at an early stage using standard anatomical imaging techniques ound, MRI, CT). Biopsy is not a very helpful modality in this setting either as it is very ult to know where to sample this very large organ for monitoring for onset of cancer and patients with liver disease often have underlying clotting disorders or platelet abnormalities which create a risk of excessive bleeding. In addition, hepatocellular cancer can occur any time over many years in cirrhotic patients which makes monitoring modality selection critical. Hepatocellular carcinoma can be cured by liver lobar resection if the cancer is clearly restricted to one area. In addition, a patient with this cancer could have a transplant if the risk of spread beyond the liver is extremely low. Molecular imaging may help make this determination.
BRIEF SUMMARY OF THE INVENTION
[0010] Described herein is a target-specific imaging reagent composed of an affinity agent coupled to an imaging agent, where the affinity agent specifically binds to a biological molecule, and where the expression of the biological molecule is predictive of a disease or a disease state. A "disease state" refers to the current status of a disease which may have been previously diagnosed, such prognosis, risk-stratification, assessment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patient's health status over time.
[0011] Also described are imaging agents detectable by at least one of computed tomography, ultrasound, magnetic resonance, nuclear imaging (PET or SPECT), or optical imaging, where the optical imaging is by Diffuses Optical Tomography, Optical Coherence Tomography, Confocal Laser Scanning Microscopy, Fluorescence Correlation Microscopy, Fluorescence Resonance Energy Transfer, or Fluorescence Lifetime Imaging. 0012] Also described are affinity agents which can be used, including antibodies, small molecules, or peptides. Such affinity agents can be used with or without the imaging agent to dentify the biological molecule in body fluids. Such body fluids include blood or serum.
0013] Also described are biological molecules which can be used, including cell surface roteins, secreted proteins, cell surface polysaccharides, RNA, or DNA.
Also described are diseases which can be diagnosed or monitored, including cancer as lung cancer, melanoma, breast cancer, prostate cancer, neuroendocrine, stomach cancer, ymphoma, head and neck cancer, pancreatic cancer, ovarian cancer, liver cancer, cancer of the entral nervous system, or testicular cancer), cardiovascular disease, a condition caused by hematopoietic stem cell transplantation, neurologic disease, autoimmune disease, chronic nflammatory disease, gynecologic disease, or infectious disease.
0015] In certain embodiments of the invention, the disease is hepatocellular carcinoma or liver cancer and the biological molecule used is a hepatocellular carcinoma antigen, such as Glypican-3 or MAGE-I .
0016] Also described is a method of diagnosing or monitoring a disease or disease state ncluding administering to a mammal the target-specific imaging reagent as described, imaging said mammal, and diagnosing a disease or disease state.
0017] Also described is a method of diagnosing and monitoring disease by molecular imaging of at least one protein chosen from proteins 1-7626 depicted in Table 2.
[0018] In this method, the imaging method may be chosen from one of computed tomography, ultrasound, magnetic resonance, nuclear imaging, or optical imaging. The optical imaging may be by Diffuses Optical Tomography, Optical Coherence Tomography, Confocal Laser Scanning Microscopy, Fluorescence Correlation Microscopy, Fluorescence Resonance Energy Transfer, or Fluorescence Lifetime Imaging. 0019] In the methods of the invention, the disease may be chosen from cancer, cardiovascular disease, a condition caused by hematopoietic stem cell transplantation, neurologic disease, utoimmune disease, chronic inflammatory disease, gynecologic disease, or infectious disease. The ancer may be chosen from lung cancer, melanoma, breast cancer, prostate cancer, neuroendocrine, tomach cancer, lymphoma, head and neck cancer, pancreatic cancer, ovarian cancer, liver cancer, ancer of the central nervous system, or testicular cancer.
] In certain embodiments of the methods, the disease is hepatocellular carcinoma or liver r and the protein chosen from Table 2 is a hepatocellular carcinoma antigen, such as Glypican- 3 or MAGE-I.
0021] In another format of the invention, at least two proteins chosen from proteins 1-7626 depicted in Table 2 are imaged. In another format, at least three or more proteins chosen from proteins 1-7626 depicted in Table 2 are imaged.
0022] In another format of the invention, the target-specific affinity agents of the invention may be used in diagnostic assays to identify the biological agents in blood or serum. The diagnostic assay may be in the form of a kit.
[0023] Also described herein is a target-specific imaging reagent, composed of an antibody coupled to an imaging agent detectable by magnetic resonance, where the antibody specifically binds to Glypican-3 or MAGE-I and where expression of Glypican-3 or MAGE-I is predictive of iver cancer. In another aspect, the invention provides methods of diagnosing liver cancer by administering to a mammal the target-specific imaging reagent described above, imaging the mammal using magnetic resonance, and diagnosing liver cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 shows an axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with lighter color indication difference caused by SPIO effect. [0025] Figure 2 is a difference image from Figure 1 with region of interest (ROI) corresponding to the difference regions. Values for T2 are in Figure 3.
[0026] Figure 3 shows T2 values for the ROI in Figure 2.
[0027] Figure 4 shows an axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with darker color indication ence caused by Gd effect.
8] Figure 5 is a difference image from Figure 4 with ROI corresponding to the difference regions. Values for T1 are in Figure 6.
[0029] Figure 6 shows Ti values for the ROI in Figure 5.
[0030] Figure 7 shows a axial slice on the liver: a- before contrast, b- after injection of the contrast, c- 1 hr after injection, d- difference image (before-lhr after) with darker color indication difference caused by Gd effect.
[0031] Figure 8 is a difference image from Figure 7 with ROI corresponding to the difference regions. Values for Ti are in Figure 9.
[0032] Figure 9 shows Ti values for the ROI in Figure 8.
DETAILED DESCRIPTION OF THE INVENTION
Identification of Molecular Targets
[0033] Given the sequencing of the human genome and the extent of annotation of the encoded genes, as well as the emergence of tools which can predict protein localization, there is an opportunity to identify targets for molecular imaging from the human genome sequence. Of particular interest are those genes known or predicted to be expressed as proteins on the cell surface. Such genes can be identified via annotation or protein prediction algorithms. Care should be taken to identify proteins expressed on the cell surface and not simply associated with membranes. The specific amino acid sequence which is extra-cellular can be predicted and specific affinity reagents or these can be developed. Secreted proteins may also be of interest as targets for imaging. Although these proteins may have the potential to diffuse away from the diseased tissue they are ikely to have a high concentration in diseased tissue vs. other surrounding tissues and they may accumulate in the disease tissue by binding to receptors of other molecules. These proteins may also accumulate in blood or serum where they can be detected with the affinity agents. Cell surface polysaccharides are also of interest as targets, but are often not possible to predict from genome nce information. RNA and DNA may also be targets, particularly when the process in on results in apoptosis or necrosis which lead to exposure of these molecular to the ellular environment.
0034] Data may be available or may be generated to help identify and prioritize the most appropriate targets for a given clinical indication. Such data may take the form of gene expression, proteomics, glycomics, cell sorting (fluorescence activated cell sorting), sequence databases or other such information. Information may come from public literature or databases or in vitro studies nvolving diseased tissue, animal models or studies utilizing human subjects.
[0035] The following steps can be taken to identify and prioritize molecular targets for imaging from literature, gene expression or proteomic data sets.
[0036] Identification of disease molecular imaging targets for specific indications:
[0037] • Knowledge-based approaches
[0038] o Search published literature to identify relevant potential target information (gene expression, cellular, protein)
[0039] o Search annotation databases of the human genome to identify genes and gene products associated with the clinical indication. For example, Online Mendelian Inheritance in Man (OMIM, Johns Hopkins University, NCBI).
[0040] • Analysis of genomic data sets relevant to target diseases. 0041] o Identification of molecular targets specific to disease state of interest (expressed in disease and not in relevant control (non-diseased) tissues
0042] o Assessment of level of expression in diseased tissue vs. control specimens (signal to noise)
0043] o Assessment of % of diseased specimens with expression of each gene above control sample level
] o Data used may be derived from gene expression (e.g. microarray, SAGE) or proteomic (e.g. ELISA, protein array, mass spec or other)
[0045] o Data can be generated using tissue samples (disease and control) derived from human specimens or animal models or from cell culture / in vitro experiments.
[0046] o Hierarchical clustering of genes to identify pathways or cell type association, choose candidate markers that cover multiple pathways and cell types
[0047] o Identification of simple combinations of gene markers which may provide added value above the use of a single marker
[0048] • Using candidate markers derived from and prioritized by the above approaches, further characterize
[0049] o Identification of cellular expression of genes of interest from annotation (Pub
Med, NCBI) or from protein structure and localization prediction algorithms
[0050] o Identification of sub-cellular localization of expressed proteins for identified markers
[0051] o Determine known or predicted amino acid sequence of encoded product
[0052] o Identification of predicted extracellular domain of encoded protein (sequence to target for affinity reagent development) 0053] In vitro experiments may be done to identify and prioritize candidate targets for molecular imaging of specific diseases. Cell lines, human or animal model diseased and control issues can be obtained and used for experimentation. Gene expression data can be generated from RNA extracted from these tissues using RNA prepared from whole tissue or from laser capture micro-dissection. Genes can then be identified with appropriate expression patterns as described above. Proteins from such tissues can also be directly analyzed using a variety of approaches such ss spectrometry or protein arrays. Immunohistochemistry or immunofluorescence can be med on fixed of frozen sections of these tissues to evaluate these proteins and their ution. In addition, real-time PCR can be performed on paraffin sections to evaluate gene xpression using newly developed methodologies (Paik et al., 2004). Tissue arrays can also be utilized to help define the expression patterns of markers and the specificity for diseased tissue (see ubb et al. 2003, Tsiambas et al. 2006, Divito et al. 2004).
0054] For studies involving animal models, animals with and without a disease can have issues compared or can compare disease to control tissues within individual animals.
0055] Human tissues can be obtained from biopsies or specimens removed at surgery.
0056] A wide variety of gene expression and genomic data set analytical tools are available and well known which can be applied to data sets to help identify those candidate targets with the most desirable expression features. These include tools which identify individual genes or proteins which are significantly correlated with a disease state as well as clustering tools which can group sets of genes into pathways which have some expression or functional relationship. Examples of such tools can be found in Alizadeh et al. 2000, Golub et al. 1999, Hastie et al. 2000, Perou et al. 2000, Tibshirani et al. 2002, Eisen et al. 1998, Tusher et al. 2001.
[0057] For nucleic acid or peptide sequences which are identified by genomic analysis as having desirable expression features for an imaging target, sequence analysis tools can be applied to predict which of these are secreted or have extracellular domains which may be accessible for targeting. A wide variety of prediction tools exist, some of which can be found in Nielsen et al. 1997, Emanuelsson et al. 2000, Bannai et al. 2002, Horton et al. 1997, Geourjon et al. 2001, Rost et al. 995, Argos et al. 1982, Kyte et al. 1982, Rost et al. 1993, Kneller et al. 1990, Jonassen et al. 1995, 997, Altschul et al. 1991, 1994, 1996.
maging Technology 0058] Development of molecular imaging targets for specific disease states can be done without regards to downstream label or contrast agent for imaging technology. Modalities differ espect to spatial resolution and sensitivity, which are usually mutually exclusive. Suitability maging modality for molecular imaging is judged on the criteria of spatial resolution, mical coverage, reproducibility, potential for quantification, support of image-guided drug elivery and, finally, the ability to image molecular targets.
0059] Computed Tomography (CT) has good spatial resolution. However, there are limitations n imaging with the use of contrast agents and in assessing molecular information. CT scanning xposes the subject to ionizing radiation. The high spatial resolution makes x-ray-based imaging mportant for hybrid systems such as PET-CT (see below).
0060] Ultrasound has a wide range of applications but is restricted to anatomical regions that re closer to a surface which is accessible to the ultrasound probe. Ultrasound does allow the use of microbubbles as a contrast agent and other ultrasound contrast agents have recently been developed hat allow imaging of smaller molecular targets.
0061] Magnetic Resonance (MR) can visualize anatomy with good spatial resolution, is applicable to all body regions and will allow reproducible and quantitative imaging. It can also be used for intravascular and needle image-guided drug delivery, but not for a broad range of drugs due to safety aspects. MR can partly assess molecular information, for example through spectroscopy, but is limited by sensitivity. However, highly sensitive contrast agents have recently been used to allow imaging of molecular targets and gene expression. Since MR allows reproducible quantitative imaging without radiation it has significant potential for molecular imaging. Magnetic Resonance Spectroscopy (MRS) is also available as a method of evaluation of molecular content of tissues. This approach has significant advantages in that no target specific reagent needs to be administered in that molecular discrimination is achieved using specific pulse sequences. The otential drawback of this approach is the technical challenge associated with development and mplementation of molecular specific pulses and sequences. For further information about the use f MRI for molecular imaging see Artemov et al., 2003a and 2003b.
0062] Nuclear Imaging, comprising PET (Huang et al., 1980) and SPECT is a molecular maging technique with excellent sensitivity and whole-body applications with good reproducibility nd quantitation. However, its poor spatial resolution makes it unsuitable for image-guided drug ry, and it requires relatively long scan times. Using nuclear imaging with harmaceutical agents enables drug tracing, including the study of pharmacokinetics in vivo. Recently, PET has produced images of gene expression that show promise for future applications in monitoring of gene therapy.
0063] PET requires isotopes which are generally short lived and thus a cyclotron needs to be within 2 hours of the scanning site. The advantage of this is a short period of exposure to ionizing adiation. PET is more sensitive than SPECT. SPECT tracers are 99Tc or 201 Tl. SPECT is everal-fold inferior to PET with respect to sensitivity and special resolution. Mobile PET units are being developed. There are about 200 PET centers in the US. PET/CT combinations are replacing PET alone. A PET/CT scanner is $2M vs. $1.3M for PET alone.
0064] PET/CT combined scanning allows anatomical and molecular information to be collected on the same piece of equipment which helps combine sensitivity to specific cells or molecules with anatomical information.
[0065] Optical Imaging is a relatively new imaging technique that, because of its lower penetration depth, is currently limited to endoscopic and microscopic applications in humans and animals. Optical imaging may eventually be used to retrieve information from deeper areas. Potential is seen in screening applications where only a yes/no answer is required rather than spatially resolved information. There are a number of specific optical approaches:
[0066] DOT - Diffuses Optical Tomography, which can penetrate several centimetres.
[0067] OCT - Optical Coherence Tomography [0068] CSLM - Confocal Laser Scanning Microscopy
[0069] FCM — Fluorescence Correlation Microscopy
[0070] FRET — Fluorescence Resonance Energy Transfer
[0071] FLIM - Fluorescence Lifetime Imaging
] In general, these imaging approaches can be assessed with respect to anatomical ution, sensitivity, amount of probe needed, difficulty of designing, producing and labelling probe, costs, imaging depth and availability. Some of these features are examined in Table 1. The particular technology selected may differ for specific clinical indications. Detailed descriptions of these technologies and their implementation for clinical use are provided in these references:
Nuclear imaging technology:
[0073] Blasberg et al, 2002, Chatziioannou et al., 2001, Chatziioannou et al., 2002, Chen et al., 2000, Chen et al., 2004, Cherry et al., 2001, Cumming et al., 1998, Del Vecchio et al., 2000, Fischman et al., 1993, Gambhir et al., 2002, Ghambhir et al., in press, Springer- Verlag, Huang et al., 1980. Iyer et al., 2002, Jacobs et al., 2002, Kim et al., 2001, Lamberts et al., 1990, Lardinois et al., 2003, Liang et al., 2002, Lovqvist et al., 2001, Lucignani et al., 2000, McCarthy et al., 2002, Polyakov et al., 2000, Reubi et al., 2000, Rosenthal et al., 1995, Shields et al., 1998, Stolz et al., 1998, Strijckmans et al., 2001, Townsend et al., 2001, Townsend et al., 2001, van Tinteren et al., 2002, Virgolini et al., 2000, and Ziegler et al., 2000.
Optical imaging:
[0074] Bogdanov et al., 2002, Bremer et al., 2001, Bremer et al., 2002, Bremer et al., 2001, Chen et al., 2002, Chen et al., 2004, Contag et al., 1998, Hadjantonakis et al., 2001, Iyer et al., 2002, Kelly et al., 2004, Li et al., 2002, Remington et al., 2002, and Tung et al., 1999. MRI technology: 0075] Artemov et al., 2003a, b, and c, Bhorade et al., 2000, Bogdanov et al., 2005, Castillo et l., 1996, Chatham et al., 2001, Dodd et al., 2001, Flacke et al., 2001, Harisinghani et al., 2003, ackson et al., 2001, Jacobs et al., 2002, Josephson et al., 1999, Kobayashi et al., 2003, Lewin et al., 000, Luypaert et al., 2001, Remsen et al., 1996, Winter et al., 2003, and Wunderbaldinger et al., 002.
1
Figure imgf000016_0001
Development of Specific Molecular Imaging Reagents
[0076] Once appropriate antigens are identified that may be expressed locally in the diseased tissue, an affinity reagent/agent which binds in a specific manner to the target is developed. Humanized monoclonal antibodies may be used and avoid problems with sensitization seen with murine antibodies. Small molecules may also be developed that bind to targets using computational tools and databases. Small molecule design technologies may be employed in this way. Some antibodies may have high molecular weight and limited uptake in target sites along with slow blood clearance resulting in high signal to noise (Fischman et al., 1993). Peptides are readily synthesized via solid phase synthesis and other parallel approaches as well as phage display. They are cheaper and more stable for labeling, less immunogenic, and have better tissue penetration and blood clearance than antibodies. A peptide is identified which binds a specific receptor and then is taken downstream for imaging reagent development.
[0077] The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody multimers and antibody fragments as well as nts (including derivatives) of antibodies, antibody multimers and antibody fragments. mples of molecules which are described by the term "antibody" herein include, but are not limited to: single chain Fvs (scFvs), Fab fragments, Fab' fragments, F(ab')2, disulfide linked Fvs (sdFvs), Fvs, and fragments comprising or alternatively consisting of, either a VL or a VH domain. The term "single chain Fv" or "scFv" as used herein refers to a polypeptide comprising a VL domain of antibody linked to a VH domain of an antibody.
[0078] Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, anti- idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), intracellularly-made antibodies (i.e., intrabodies), and epitope-binding fragments of any of the above. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGb IgG2, IgG3, IgG4, IgAi and IgA2) or subclass of immunoglobulin molecule. Preferably, an antibody of the invention comprises, or alternatively consists of, a VH domain, VH CDR, VL domain, or VL CDR having an amino acid sequence of any one of those referred to in Table 2, or a fragment or variant thereof. In a preferred embodiment, the immunoglobulin is an IgGl isotype. In another preferred embodiment, the immunoglobulin is an IgG4 isotype. Immunoglobulins may have both a heavy and light chain. An array of IgG, IgE, IgM, IgD, IgA, and IgY heavy chains may be paired with a light chain of the kappa or lambda forms.
[0079] Antibodies of the invention may also include multimeric forms of antibodies. For example, antibodies of the invention may take the form of antibody dimers, trimers, or higher-order multimers of monomelic immunoglobulin molecules. Dimers of whole immunoglobulin molecules or of F(ab')2 fragments are tetravalent, whereas dimers of Fab fragments or scFv molecules are bivalent. Individual monomers within an antibody multimer may be identical or different, i.e., they may be heteromeric or homomeric antibody multimers. For example, individual antibodies within a multimer may have the same or different binding specificities.
[0080] Multimerization of antibodies may be accomplished through natural aggregation of odies or through chemical or recombinant linking techniques known in the art. For example, percentage of purified antibody preparations (e.g., purified IgGl molecules) spontaneously form protein aggregates containing antibody homodimers, and other higher-order antibody multimers. Alternatively, antibody homodimers may be formed through chemical linkage techniques known in the art. For example, heterobifunctional crosslinking agents including, but not limited to, SMCC (succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate) and SATA (N- succinimidyl S-acethylthio-acetate) (available, for example, from Pierce Biotechnology, Inc. (Rockford, 111.)) can be used to form antibody multimers. An exemplary protocol for the formation of antibody homodimers is given in Ghetie et al., Proceedings of the National Academy of Sciences USA (1997) 94:7509-7514, which is hereby incorporated by reference in its entirety. Antibody homodimers can be converted to Fab'2 homodimers through digestion with pepsin. Another way to form antibody homodimers is through the use of the autophilic Tl 5 peptide described in Zhao and Kohler, The Journal of Immunology (2002) 25:396-404, which is hereby incorporated by reference in its entirety.
[0081] Alternatively, antibodies can be made to multimerize through recombinant DNA techniques. IgM and IgA naturally form antibody multimers through the interaction with the J chain polypeptide. Non-IgA or non-IgM molecules, such as IgG molecules, can be engineered to contain the J chain interaction domain of IgA or IgM, thereby conferring the ability to form higher order multimers on the non-IgA or non-IgM molecules, (see, for example, Chintalacharuvu et al., (2001) Clinical Immunology 101:21-31. and Frigerio et al., (2000) Plant Physiology 123:1483-94., both of which are hereby incorporated by reference in their entireties.) ScFv dimers can also be formed through recombinant techniques known in the art; an example of the construction of scFv dimers is iven in Goel et al., (2000) Cancer Research 60:6964-6971 which is hereby incorporated by eference in its entirety. Antibody multimers may be purified using any suitable method known in he art, including, but not limited to, size exclusion chromatography.
0082] In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In particular, DNA equences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or e cDNA libraries of lymphoid tissues) or synthetic cDNA libraries. The DNA encoding the nd VL domains are joined together by an scFv linker by PCR and cloned into a phagemid vector (e.g., pCANTAB 6 or pComb 3 HSS). The vector is electroporated in E. coli and the E. coli s infected with helper phage. Phage used in these methods are typically filamentous phage ncluding fd and Ml 3 and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII. Phage expressing an antigen binding domain that binds to an antigen of interest (i.e., a GMAD polypeptide or a fragment thereof) can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Examples of phage display methods that can be used to make the antibodies of the present invention nclude, but are not limited to, those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. mmunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280(1994); PCT application No. PCT/GB91/O1 134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18719; WO 93/1 1236; WO 95/15982; WO 95/20401; WO97/13844; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,717; 5,780,225; 5,658,727; 5,735,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.
[0083] For some uses, such as for in vitro affinity maturation of an antibody of the invention, it may be useful to express the VH and VL domains of one or more scFvs referred to in Table 2 as single chain antibodies or Fab fragments in a phage display library. For example, the cDNAs encoding the VH and VL domains of the scFvs referred to in Table 2 may be expressed in all possible combinations using a phage display library, allowing for the selection of VH/VL combinations that bind a GMAD polypeptide with preferred binding characteristics such as improved affinity or improved off rates. Additionally, VH and VL segments, the CDR regions of the VH and VL domains of the scFvs, may be mutated in vitro. Expression of VH and VL domains with "mutant" CDRs in a phage display library allows for the selection of VH/VL combinations that bind a GMAD polypeptides with preferred binding characteristics such as improved affinity or improved off rates.
4] Methodologies for preparing and screening such libraries are known in the art. There are mercially available kits for generating phage display libraries (e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAP.TM. phage display kit, catalog no. 240612). There are also other methods and reagents that can be used in generating and screening antibody display libraries (see, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. PCT Publication No. WO 92/18619; Dower et al. PCT Publication No. WO 91/17271; Winter et al. PCT Publication No. WO 92/20791; Markland et al. PCT Publication No. WO 92/15679; Breitling et al. PCT Publication No. WO 93/01288; McCafferty et al. PCT Publication No. WO 92/01047; Garrard et al. PCT Publication No. WO 92/09690; Fuchs et al. (1991) Bio/Technology 9:1370- 1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275- 1281; McCafferty et al., Nature (1990) 348:552-554; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J. MoI. Biol. 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) Proc. Natl. Acad. Sci. USA 89:3576-3580; Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) Proc. Natl. Acad. Sci. USA 88:7978-7982.
[0085] Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of Table 2 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, erum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one killed in the art without undue experimentation.
0086] The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies e prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 95 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is ypically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the ymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Table 2, a fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell ines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, mmortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
[0087] Humanized forms of antibodies are chimeric immunoglobulins in which residues from a complementary determining region (CDR) of human antibody are replaced by residues from a CDR of a non-human species such as mouse, rat or rabbit having the desired specificity, affinity and capacity. 0088] An example of a chimeric humanized antibody is a molecule having a human variable egion and a non-human (e.g., murine) immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., J. Immunol. Methods 125:191 -202 (1989); U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Chimeric antibodies comprising one or more CDRs from human species and framework ns from a non-human immunoglobulin molecule (e.g., framework regions from a murine, e or feline immunoglobulin molecule) (or vice versa) can be produced using a variety of ques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska et al., PNAS 91 :969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,352). In a preferred embodiment, chimeric antibodies comprise a human CDR3 having an amino acid sequence of any one of the VH CDR3s or VL CDR3s of a VH or VL domain of one or more of the scFvs and non-human framework regions or human framework regions different from those of the frameworks in the corresponding scFvs. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are dentified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 352:323 (1988), which are incorporated herein by reference in their entireties.)
[0089] Human antibodies can be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. MoI. Biol. 227:381 (1991); Marks et al., J. MoI. Biol. 222:581 (1991)). The techniques of Cole et al. and Boemer et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boemer et al., J. Immunol. 147(l):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 4); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 6 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).
[0090] A number of methods have been devised to generate peptide libraries and methods of using the libraries to identify a peptide sequence that is complementary to a receptor or antibody.
[0091] An early method is the "Merrifield" method, described in Atherton et al., "Solid Phase Peptide Synthesis," IRL Press, (1989), incorporated herein by reference for all purposes. This method has been used to synthesize peptides on a solid support such as pins or rods. The peptides are then screened to determine if they are complementary to a receptor.
[0092] To screen a larger number of polymer sequences, more advanced techniques have been disclosed. For example, Pirrung et al., WO 90/15070, incorporated herein by reference for all purposes, describes a method of synthesizing a large number of polymer sequences on a solid substrate using light directed methods. Dower et al., U.S. application Ser. No. 07/762,522, also incorporated by reference herein for all purposes, describes a method of synthesizing a library of polymers and a method of use thereof. The polymers are synthesized on beads, for example. A first monomer is attached to a pool of beads. Thereafter, the pool of beads is divided, and a second monomer is attached. The process is repeated until a desired, diverse set of polymers is synthesized.
[0093] Houghten et al., "Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery," Nature (1991) 354:84-86, disclose a method of generating peptide libraries that are used for screening peptides for biological activity (see also, Houghton et al., "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," Peptide Research (1992) 5:351-358). Houghten synthesized a peptide combinatorial ibrary (SPCL) composed of some 34x106 hexapeptides and screened it to identify antigenic determinants that are recognized by a monoclonal antibody. Furka et al., "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures," Int. J. Peptide Protein Res. (1991) 37:487- 493, discusses a method of synthesizing multicomponent peptide mixtures. Furka proposed pooling as a general method for the rapid synthesis of milticomponent peptide mixtures and illustrated its application by synthesizing a mixture of 27 tetrapeptides and 180 pentapeptides. Lam et al., "A new of synthetic peptide library for identifying ligand-binding activity," Nature (1991) 354:82-84 pooling to generate a pentapeptide bead library that was screened for binding to a monoclonal ody. Blake et al. "Evaluation of Peptide Libraries: An Interative Strategy To Analyze the Reactivity of Peptide Mixtures With Antibodies," Bioconjugate Chem. (1992) 3:510-513 discusses, the screening of presumed mixtures of 50,625 tetrapeptides and 16,777,216 hexpeptides to select epitopes recognized by specific antibodies.
[0094] Lam's synthetic peptide library consists of a large number of beads, each bead containing peptide molecules of one kind. Beads that bind a target (e.g., an antibody or streptavidin) are rendered colored or fluorescent. Lam reports that several million beads distributed in 10-15 petri dishes can be screened with a low-power dissecting microscope in an afternoon. Positive beads are washed with 8M guanidine hydrochloride to remove the target protein and then sequenced. The 100-200 μm diameter beads contain 50-200 pmol of peptide, putatively well above their 5 pmol sensitivity limit. Three pentapeptide beads were sequenced daily. The essence of Lam's method is that the identity of positive beads is established by direct sequencing.
[0095] Houghten et al. use a different approach to identify peptide sequences that are recognized by an antibody. Using the nomenclature described herein, Houghten et al. screened an X6XSX4PX3PX2PXIP library and found that the mixture DVX4pX3pX2pXip had greatest potency in their inhibition assay. Houghten then synthesized a DVX4X3pX2pXip library and identified the most potent amino acid in the third position. After three more iterations, they found that DVPDYA binds to the antibody with a Kd of 30 iiM. The essence of Houghten's method is recursive retrosynthesis, in which the number of pooled positions decreases by one for each iteration. [0096] In order to detect binding of a receptor or antibody to a peptide, the antibody must be labeled. Antibodies may also be modified with a detectable label, such as an enzymatic, fluorescent, radioisotopic or affinity label to allow for detection and isolation of the antibody.
[0097] Examples of suitable enzymatic labels include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable escent materials include biotin, umbelliferone, fluorescein, fluorescein isothiocyanate, mine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi, or other radioisotopes such as, for example, iodine (131I, 125I, 1231, 121I, carbon (14C), sulfur (35S), tritium (3H), indium (115mIn, 113mIn, 112In, 11 1In), and technetium (99Tc, 99mTc), thallium (201Ti), gallium (68Ga, 67Ga), palladium (103Pd), molybdenum (99Mo), xenon (133Xe), fluorine (18F), 153Sm, 177Lu, 159Gd, 149Pm, 140La, 175Yb, 166Ho, 90Y, 47Sc, 186Re, 142Pr, 105Rh, 97Ru, 68Ge, 57Co, 65Zn, 85Sr, 32P, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn, and 117Tin.
[0098] Antibodies may also be labeled with Europium. For example, antibodies may be labelled with Europium using the DELFIA Eu-labeling kit (catalog# 1244-302, Perkin Elmer Life Sciences, Boston, Mass.) following manufacturer's instructions.
[0099] Antibodies may be attached to macrocyclic chelators useful for conjugating radiometal ions, including but not limited to, 111In, 177Lu, 90Y, 166Ho, 153Sm, 215Bi and 225Ac to polypeptides. In a preferred embodiment, the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is 111In. In another preferred embodiment, the radiometal ion associated on with the macrocyclic chelator attached to antibodies polypeptides of the invention is Y. In specific embodiments, the macrocyclic chelator is l,4,7,10-tetraazacyclododecane-N,N',N",N'"- tetraacetic acid (DOTA). In specific embodiments, the macrocyclic chelator is a-(5-isothiocyanato- 2-m- ethoxyphenyl)- 1, 4,7, 10-tetraazacyclododecane-l ,4,7,10-tetraacetic acid. In other specific embodiments, the DOTA is attached to the antibody of the invention via a linker molecule. Examples of linker molecules useful for conjugating a macrocyclic chelator such as DOTA to a polypeptide are commonly known in the art-see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90, 1998; Peterson et al., Bioconjug. Chem. 10(4):553-7, 1999; and Zimmerman et al, Nucl. Med. Biol. 26(8):943-50, 1999 which are hereby incorporated by reference in their entirety. In addition, U.S. Pat. Nos. 5,652,361 and 5,756,065, which disclose chelating agents that may be gated to antibodies, and methods for making and using them, are hereby incorporated by ence in their entireties. Antibodies can also be labeled with biotin.
Diagnostic and Monitoring Assays
[0100] The affinity reagents/agents of the invention have various utilities, including use as diagnostic and monitoring assays for proteins of the invention, e.g., detecting their expression in specific cells, tissues, or serum.
[0101] For example, antibodies may be used in diagnostic and monitoring assays for the proteins of the invention, e.g., detecting their expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic and monitoring assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as 3H, 14C, 32P, 35S, or 125I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982). [0102] The diagnostic and monitoring assays can be utilized to diagnose and/or monitor cancer, heart disease, hematopoietic stem cell transplantation, neurologic disease, autoimmune and chronic inflammatory disease, gynecologic disease and infectious disease. "Diagnosing" can include detection of any type of activity or progression of a disease, for example, determination of whether the disease is present, identifying the stage of the disease, monitoring the response of the disease to therapy, etc. The term "monitoring" is used herein to describe the use of an affinity agent to de useful information about an individual or an individual's health or disease status. nitoring" can include, determination of prognosis, risk-stratification, selection of drug therapy, sment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patient's health status over time, selecting patients most likely to benefit from experimental therapies with known molecular mechanisms of action, selecting patients most likely to benefit from approved drugs with known molecular mechanisms where that mechanism may be important in a small subset of a disease for which the medication may not have a label, screening a patient population to help decide on a more invasive/expensive test, for example, a cascade of tests from a non-invasive blood test to a more invasive option such as biopsy, or testing to assess side effects of drugs used to treat another indication.
[0103] Such diagnostic and monitoring assays can be in the form of a kit. The kit may include reagents for performing the diagnostic assay.
Development of Imaging Reagent from Target Specific Reagents
[0104] Once an affinity reagent (e.g., antibody or peptide) is available for a molecular imaging target, imaging contrast or signal emitting source is incorporated into the reagent. This can be done for a variety of technologies as discussed above.
[0105] For development of imaging reagents for nuclear techniques (PET and SPECT) an isotope which emits particles is incorporated into or attached to the reagent. For PET, isotopes that emit positrons which collide with electrons to produce two gamma rays. These gamma rays are then detected to generate a signal. Positrons are emitted by 150, 11C, 13N and 18F which are the W
most commonly used isotopes. Also of potential use are 140, 64Cu3 62Cu, 1241, 76Br, 82Rb and 68Ga. These isotopes are produced in a cyclotron and available in radiopharmacies (Strijckmans 2001, Gambhir 2002). These isotopes can often be substitute for naturally occurring atoms in affinity reagents. Isotopes that emit gamma rays directly (e.g., 99mTc, 11 Hn, 1231, 1311) are used for SPECT imaging (Rosenthal et al. 1995).
[0106] Methods for development of signal emitting reagents for nuclear imaging (PET and CT) are well established (Bogdanov et al., 2005). Radiolabeling can be achieved by direct ng (incorporation of label materials into molecules) or chelation of a label (Bogdanov et al. 2005). Radiopeptides have been used for tumor imaging with some success (Lamberts et al., 1990). Octreotide has also been labeled with technicium and is used for tumor imaging (Octreoscan, Mid- South Imaging, Memphis). Introduction of label into a molecule may affect biological or binding properties markedly. These properties must be reassessed after labeling. This may be done in a high throughput manner using cell or tissue preps in 96 or 384 well plates (Reubi et al., 2000). Radiolabeled molecules must also be tested in animals before human testing (Stolz et al., 1998). This will help assess toxicity and tissue distribution and clearance. Clearance of radiopeptides by the kidneys is a key issue which needs improvement. Examples of common methods used to incorporate labels into affinity reagents for PET and SPECT imaging are found in Cumming and Gjedde 1998, Lucignani and Frost 2000, Wagner et al. 1983, Coenen et al. 1987, Kung et al. 1990, Crouzel et al. 1988, Virgolini 2000, Oriuchi and Yang 2001, Lovqvist et al. 2001, Kim 2001.
[0107] For MRI scanning, the most common approaches currently in use include the incorporation or labeling of the affinity reagent with Gadolinium or Supermagnetic Iron Oxide containing compounds. These molecules alter local magnetic resonance characteristics which creates a local signal contrast in the area of reagent accumulation. One strategy involves the use of a biotinylated antibody followed by the administration of Gadolinium complexes (e.g., with liopsomes) which are linked to Avidin (Artemov et al. 2003). Another strategy involves the use of enzyme mediated polymerization of paramagnetic substrates into oligomers of higher relaxivity (Weissleder et al. 2002). 0108] One can develop reagents which activate with binding (Bogdanov et al., 2002). Also one an develop high relaxivity contrast agents (Artemov et al., 2003, Weissleder et al., 2001, Bogdanov t al., 2002). Other magnetic resonance signal amplification probe technologies are available which tilize receptor mediated internalization or enzyme mediated signal amplification. Additional methods for conjugation of iron oxide or Gadolinium compounds to affinity probes are found in Remson et al. 1996, Kang et al. 2002 and Zhao et al. 2001, Flacke et al. 2001, Li et al. 2002, Sipkins 1998, Sipkins et al. 2000, Weissleder 1991, Artemov et al. 2003, Storrs et al. 1995.
] Scanning using the selected imaging technology using 384 well plates of potential eagent combinations to determine binding characteristics and labeling efficiency may be utilized as a direct approach to evaluation of potential reagents. Tissue or cell arrays can be used to screen eagent combinations. Clonal cell line expressing target on surface in high throughput format could also be used. Animal testing with scanning is used when appropriate models exist. This can be done in vivo or explanted tumor tissue or other explanted tissues may be used to determine binding characteristics. Standard immunohistochemistry or immunofluorescence can be used to test the binding, sensitivity and cell type specificity of the reagent and label combination (Brown et al., 1990; Abbondanzo et al., 1990; Allred et al., 1990, and Sambrook et al. 1989). This can be done using human tissue specimens or animal model tissue specimens in the case of animal reagents.
0110] In any case, the imaging reagent needs to be produced with materials which provide contrast or can be linked with contrast materials after production. Probes should be biocompatible, ack interference with biological function, generate high signal output and signal-to-noise. PET and SPECT tracers are easier to develop because of need for low concentrations and ease of labeling.
[0111] "Multiplex imaging" may prove to be clinically useful. Such an approach could be used to image more than one molecule in a single scan. It could be done in such a way that the >1 target both contribute signal, but are not resolvable ("one color") or may be done using contrast or signal emitting reagents that allow the >1 targets to be distinguished in the image ("two color"). Simultaneous imaging of multiple markers may be useful to overcome variability in the population (e.g., some tumors express one marker and others express another marker). This approach could also provide a means to provide additional contrast by specifically imaging both the diseased and control tissues. Perhaps also this approach would add to the information value of an imaging protocol. For example, one could image 2 or 3 markers of tumor progression and the worst prognosis would be associated with the presence of more markers or more advanced markers in the process. PET can only measure two targets by injecting and imaging one and then performing a second injection and scan for the second target after the signal from the first has faded. SPECT can more than one target in a single scan. Other combinations of technologies may be used to ure more than one target simultaneously (combine MRI, CT, Nuclear, Optical).
Clinical Validation of Imaging Reagents
[0112] For any given molecular imaging reagent, clinical utility and efficacy in humans must be demonstrated for specific clinical indications if the test will have an impact on clinical practice. After appropriate safety studies have been performed in primates and then human subjects, patients with the target disease process (or suspected to have it) are recruited along with appropriate control subjects. The performance of the molecular imaging test with respect to disease diagnosis or prognosis is then assessed. The assessment of performance may be related to a gold standard based on the pathological diagnosis of the disease status or other standards such as endoscopic evaluation, other imaging approaches or diagnostic testing. Alternatively or in addition, the test is assessed with respect to its ability to identify patients at risk for events, complications, outcomes or mortality related to the disease process (prognosis). The test may also be shown to identify patients with an increased or decreased responsiveness to therapy (therapy broadly or specific medications). Alternatively, testing can be shown to monitor response to therapy. Various clinical utilities of molecular imaging approaches are discussed and exemplified below in the section on clinical indications for molecular testing.
Clinical Indications for Molecular Imaging
[0113] In general the addition of a specific molecular targeting reagent to imaging protocols will be most useful for those diseases where:
[0114] 1. The anatomical distribution of disease is important (cancer, atherosclerosis, Crohn's) [0115] 2. The diagnosis is difficult to make by biopsy or other modalities (early Alzheimer's, Hepatocellular carcinoma, active plaque, Crohn's flare)
[0116] 3. Detection of preclinical disease is important (cancer metastasis, recurrence)
[0117] 4. Detection of disease prior to being detectable by imaging without molecular specific reagent contrast (cancer, Alzheimer's, prostate cancer)
8] 5. There is difficulty distinguishing diseased tissue from other causes of abnormal mical findings (post-surgical changes vs. cancer, quiescent, fixed atherosclerosis vs. inflamed, active plaque.
Cancer
[0119] Molecular imaging approaches may be utilized in numerous clinical situations in oncology. Diagnosis of disease may be improved in this way. Cancer marker specific imaging affinity reagents may provide added sensitivity for small tumors vs. standard imaging or clinical monitoring. Also, this approach may be more specific and allow distinction of cancer tissue from normal tissue or benign processes. Clearly, it may also provide a less invasive means of diagnosis compared to invasive procedures such as endoscopy or biopsy. Upon diagnosis of cancer, staging and risk stratification is necessary to plan surgery and guide radiation and chemotherapy usage. Molecular imaging may provide information about the local regional and distant spread of cancer. One possibility is for molecular imaging to be performed before completion of cancer surgery to ensure that there has been complete tumor removal ("molecular imaging margins"). Also, if the expression of the molecular target for imaging has prognostic value, the tumor may be treated differently on this basis alone. Multiple markers could be imaged using imaging reagent with differential labeling which can be resolved with a single scan or could have multiple scans done with different individual reagents. Once treatment has begun, response to therapy may be monitored with molecular imaging. This may provide a means for an earlier assessment of response so that the regimen can be altered earlier if not effective. Imaging may also be done after cancer surgery to check for complete excision if the imaging target is cancer specific. This can be difficult with non-molecular imaging because of anatomical changes from surgery and sensitivity limitations. When a treatment has been successful in inducing remission, molecular imaging may provide a sensitive way to monitor for recurrence. In one scenario for clinical implementation, the primary tumor tissue may be obtained at the time of biopsy or surgery and assessed for the expression of the molecular target. Subsequently the tumor spread or recurrence can be imaged with the appropriate agent that the primary tumor is found to express. Molecular imaging approaches may be extremely valuable in chemotherapeutic drug trials as patient selection tools or urrogate endpoint.
Clinical and economic value of molecular imaging for cancer
[0120] Molecular imaging could provide tremendous clinical value for oncologists and patients in those situations described above. These benefits are associated with increased sensitivity and specificity of imaging techniques which could lead to earlier treatment, more appropriate treatment, improved surgical or radiation therapy planning and appropriate cessation or withholding or treatment. These applications may also be associated with significant economic value for the health care system. Early detection of cancer may lead to an increased rate of curative treatment, avoiding the costs of prolonged curative or non-curative therapy. Improvements in staging may help plan more appropriate surgical or radiation therapy which may improve survival or decrease costs of complications. Identification of distant metastasis may obviate the need for unnecessary or fruitless medical or surgical therapy. Imaging may also reduce the need for invasive or expensive diagnostic procedures such as biopsy, endoscopy or bronchoscopy. Earlier assessment of response to chemotherapy could reduce prolonged and costly unnecessary treatment and allow more rapid changes in treatment. A beneficial impact on drug trials could decrease, cost and duration of these expensive trials and increase likelihood of success.
Lung cancer
[0121] Molecular imaging may be useful to diagnose disease in patients at risk, stage disease, monitor response to therapy and remission. Flurodeoxyglucose (FDG) Positron Emission Tomograpy (PET) scanning can reduce need for thoracotomy (van Tinteren et al. 2002). Diatide's Neospect (labeled depreotide) helps assess the need for biopsy with solitary pulmonary nodules. Staging is critical prior to surgery or medical therapy. FDR PET scanning can be useful, but lacks specificity and may be positive with any inflammatory lesion even if not malignant. Scanning may be used to assess local tumor extent (T staging), Nodal spread (N) and Metastasis (M). This can be done for new cancer, cancer under treatment or cancer in remission. Lardinois et al used combined PET-CT imaging for non-small cell lung cancer to assess metastatic disease. Patients received FDG- 18F. This approach provided additional information in 40% of patients beyond that of separate PET and CT scans, along with a significant 35% to 40% improvement in diagnostic acy with respect to lung cancer tumor staging.
Melanoma
[0122] As this cancer is present on the skin, optical techniques may be used. The scan may help distinguish benign from malignant skin lesions. Scanning could also be used to stage and monitor the cancer.
Breast
[0123] Breast cancer occurs close to the surface and is amenable to imaging with most modalities including those with more limited penetration of tissue (ultrasound, optical imaging). Molecular probes could be used to aid in screening and diagnosis. Breast tumors metastasize to axillary lymph nodes and a lymph node dissection is often done for staging. Molecular imaging could aid in this staging process by identifying tumor spread to these regional lymph nodes as well as to distant sites though out the body. Molecular imaging may also be appropriate for monitoring of recurrence in treated patients.
Prostate
[0124] Prostate cancer can be assessed with a variety of imaging techniques. Low penetrations techniques such as ultrasound can be used in conjunction with endoscopy. Both CT and MRI have very high false negative results for early prostate cancer which could be improved upon with the addition of a molecular probe using the same or other imaging technologies. Assessment of regional or distant spread could aid in the staging or prostate cancer. This information could guide medical, surgical and radiation therapy. MRI enhanced with lymphotropic monocrystalline iron oxide nanoparticles can be used to detect prostate cancer metastases as small as 2 mm in diameter, n contrast with conventional MRI detection (>8-10 mm).
Neuroendocrine Tumors
[0125] These cancers often have a distinct molecular phenotype compared to surrounding tissue. They can occur in almost any anatomical location. Molecular techniques could help diagnose, stage d monitor these tumors. One existing reagent targets the somatostatin receptor (Mallinckrodt oScan).
[0126] Colon cancer is often diagnosed only after is has grown to a size associated with clinical symptoms (bleeding or obstruction) or is large enough to be easily visible on a standard examination (endoscopy, non-molecular imaging study). Unfortunately, at this stage the cancer is too often associated with aggressive local behavior and distant spread. Earlier diagnosis with the help of specific affinity reagents would help guide earlier resection which is more likely to be curative. Colon cancer cannot be distinguished from benign adenoma using anatomical imaging or visualization using endoscopy. Molecular imaging techniques may provide a non-invasive means to make this distinction. Colon cancer is known to be associated with multiple molecular changes ("hits") on the way from benign adenoma to cancer. This information may be used in the design of molecular imaging protocols. One may image more than one molecule or only one molecule associated with malignant transformation. Colon cancer staging involves evaluation of the region around the primary tumor and the liver. Molecular imaging may improve the accuracy of anatomical imaging in staging. This information can help guide medical therapy and surgical planning. In some cases, limited liver resection can be performed if a solitary metastasis exists. After surgery for colon cancer, anatomical changes (inflammation or scarring) may be seen with conventional anatomical imaging techniques. It is difficult to distinguish these findings from cancer persistence or recurrence and specific molecular probes may help identify malignant cells in this situation. CT scanning does not permit distinction between post-surgical changes and tumor recurrence and cannot determine tumor involvement in normal sized lymph nodes (Goldberg et al., 1998). Stomach
[0127] Cancer of the stomach may be difficult to distinguish from benign ulceration. Gastric ulceration is very common. Biopsy of ulcer edges is performed, however this technique may be subject to sampling error and a negative result can occur in cases of cancer associated with ulceration. Clinical practice when biopsy is negative for cancer is to treat for gastric ulcer and then to reassess for at a later time for refractory cases. Unfortunately, this may result in a delay in osis and treatment which could be costly to the patient. Molecular imaging could help identify gnancy as an underlying cause of ulceration at the time of first diagnosis for at risk patients.
Lymphoma
[0128] Lymphoma can be associated with bulky disease masses which are largely cancerous cells, but also are composed of inflammatory cells. Upon treatment, malignant cells become necrotic and significant inflammation and clean up of residual disease occurs. Standard imaging techniques cannot distinguish non-malignant from malignant causes of masses in these cases. There is a need to evaluate treatment response after completion of therapy especially when there are residual masses.
Head and Neck
[0129] Head and neck cancers can spread to numerous regional lymph nodes and the surgical approach to these patients involves extensive and disfiguring procedures. Molecular imaging may help identify primary lesions, lymph node involvement and distant metastasis. This information may also help guide radiation therapy.
Pancreas
[0130] Pancreatic cancer is very difficult to diagnosis at a curable stage. Symptoms may occur due to mass effects in the abdomen or if the tumor happens to obstruct the pancreatic duct, however most cancers are incurable at the time of diagnosis. Molecular imaging could add significantly to the diagnosis of this cancer at an early stage. This approach could also be used to evaluate spread of tumors at the time of diagnosis to help plan surgical therapy. In the absence of evidence of distant spread, curative surgical therapy may be attempted. Otherwise, palliative treatment may be the only option.
Ovary
[0131] Ovary cancer is difficult to diagnose at asymptomatic stage with standard CT or MRI. Addition of specific molecular reagents to imaging protocols may add sensitivity for early stage ns which are more amenable to curative therapy. Also, benign masses (adenomas and cysts) ery common in and around the ovaries. Molecular imaging may provide a means to distinguish n and malignant lesions. Ovarian cancer may also be assessed after diagnosis and monitored for recurrence in a sensitive and specific way using molecular imaging approaches. CIS bio International has developed an indium labeled monoclonal antibody to CA 125 which can be used to image ovarian cancers.
Liver
[0132] Hepatocellular carcinoma often occurs in patients with cirrhotic liver disease from hepatis B or C, alcohol or other processes. This presents a difficult diagnostic dilemma as cirrhosis is associated with nodule formation and scarring in the liver tissue which makes detection of a cancer nodule nearly impossible at an early stage using standard anatomical imaging techniques (ultrasound, MRI, CT). Biopsy is not a very helpful modality in this setting either as it is very difficult to know where to sample this very large organ for monitoring for onset of cancer and patients with liver disease often have underlying clotting disorders or platelet abnormalities which create a risk of excessive bleeding. In addition, hepatocellular cancer can occur any time over many years in cirrhotic patients which makes monitoring modality selection critical. Hepatocellular carcinoma can be cured by liver lobar resection if the cancer is clearly restricted to one area. In addition, a patient with this cancer could have a transplant if the risk of spread beyond the liver is extremely low. Molecular imaging may help make this determination.
Central Nervous System — Glioblastoma
[0133] Cancers of the central nervous system present significant diagnostic and treatment challenges to physicians and surgeons. Because of their anatomical location, biopsy based diagnosis of brain masses is technically challenging and associated with complications. Molecular imaging may provide a means to make a firm diagnosis of brain cancer (vs. benign mass) and guide planning of surgery, radiation therapy and medical therapy. In addition, surgical therapy can be curative. However it is critically important to know the precise anatomical distribution of the tumor to plan optimal surgery. One reason for this is that removal of brain tissue results in neurological deficits so precision is key to minimize unnecessary brain loss. In addition, it is critical to ensure he entire extent of the tumor is removed at the time of surgery. Given these needs, molecular ng may provide a boost to sensitivity that improves this evaluation. Clearly, molecular g ng information must be combined with precise anatomical imaging. One possibility is to image the patient during surgery using the molecular probe to assess "margins" and determine if the tumor has been completely removed. Glioblastomas are known to be resistant to many chemotherapeutic agents and often require the use of chemotherapy in a trial and error fashion. Molecular imaging may provide a means for earlier evaluation of treatment response which would decrease costly prolonged futile drug trials.
Testicular cancer
[0134] This cancer is treatable with radiation and chemotherapy. Cure is dependent on identification of an appropriate field for radiation and appropriate staging of disease. Molecular imaging could provide a means to stage the disease and also monitor response to therapy and recurrence.
Cardiovascular disease
[0135] Coronary artery disease is an inflammatory disease of the arterial wall. Infiltration of the vessel wall with inflammatory cells, accumulation of lipids and remodeling leads to arterial plaque formation. Atherosclerotic plaques can cause ischemia in tissue served by the diseased artery. This can manifest as angina pectoris, chronic ischemia and cardiac failure, claudication and other signs of peripheral arterial insufficiency. Plaques may suddenly rupture leading to thrombosis and partial or total occlusion of the arterial lumen. In the case of coronary arteries these events lead to unstable angina or myocardial infarction which is a major cause of morbidity and mortality relating to coronary artery disease. Coronary angiography is commonly used to assess the extent and severity W 2
of coronary artery disease. This technique provides information on the degree of lumen occlusion by atherosclerotic plaque. However, one cannot determine which lesions in the coronary tree are at high risk for rupture and acute events from this information. The risk of rupture is not related to the degree of stenosis as lesions causing 40-50% vessel occlusion are more likely to cause acute events han those with higher degrees of occlusion. It is known that the risk of plaque rupture is related to he degree of inflammation in the lesion as well as the cellular and extracellular composition ues with less collagen and more cholesterol are at higher risk).
] When a patient is found to have coronary artery disease on angiography, it is often unclear how to intervene. When the patient has a recent history of acute coronary events (unstable angina or myocardial infarction) it can sometimes be difficult to identify the culprit vessel. Even more challenging is to identify vessel segments with coronary atherosclerosis which pose a high risk for subsequent plaque rupture. If one could identify these vessel segments, they could be addressed with percutaneous interventions such as angioplasty or stenting. More generally, if one knew that a patient had atherosclerotic lesions at risk for rupture, the patient would be a candidate for the most aggressive medical therapy. This information would be of particular interest in the future when drugs are available for coronary disease that target the underlying inflammatory process.
[0137] Non-invasive imaging techniques can now provide information on the anatomical extent of coronary disease as well as some information on composition. MRI scans can assess degree of lumen occlusion as well as providing some characterization of the cellular and extracellular composition. CT scanning can provide some anatomical information as well as information on calcification of coronary plaques which is know to relate to risk of adverse events.
[0138] Molecular imaging could be applied to coronary atherosclerosis by identification and targeting of molecules associated with active plaques which are at risk from rupture. An ideal target molecule would be highly expressed specifically in vessels with the highest risk of rupture. Such molecules may represent proteases involved in the remodeling process or genes involved in the inflammatory process. They could be cell surface or secreted. The targeting may also be to a cell type. For example, the relative number of macrophage or lymphocytes may have the highest predictive value. Given their exposure to the circulation, endothelial cells may express molecular which are accessible to circulating affinity reagents.
[0139] Molecular imaging approaches could provide a number of advantages over available techniques. Sensitivity gains could be made by specific contrast accumulation at the site of vulnerable plaques. Information may also be more specific or predictive of future events by imaging molecules which are specific to highest risk lesions. If combined with anatomical imaging cols, this approach would provide information on the extent, severity and specific location of osclerotic plaques as well as the risk of acute events and progression for each lesion. This information could guide intervention with medical therapy, percutaneous interventions and bypass surgery.
[0140] Such techniques could be useful in the coronary circulation, carotids or peripheral vessels. It is clear that patients with atherosclerosis in any one arterial bed are at risk for disease in other distributions. Therefore, this approach also may allow evaluation of atherosclerosis throughout the body in a single scan in patients at risk or for pre-surgical planning.
[0141] Molecular imaging of vascular disease has wide applicability.
[0142] Gadolinium texaphyrin chelates may accumulate in vulnerable plaques for MR imaging.
[0143] Reagents to MMP inhibitors have been developed for vascular lesion imaging (University of Muenster). Gadolinium labeled affinity reagents to components of thrombus have also been explored (Epix, gadolinium labeled fibrin binding peptide). Activated macrophages are the main cellular effectors of inflammation in atherosclerosis and their presence identifies high-risk lesions. Magnetic nanoparticles (eg, iron oxide) accumulate within human atherosclerotic macrophages and are therefore preferentially found in macrophage-rich carotid plaques. Future areas of exploration in this field may include the development of agents that specifically target oxidized low-density lipoprotein, activated macrophages (as opposed to all macrophages or multiple cell types), or endothelial cell markers such as vascular cell adhesion molecule. Detection of apoptotic cells in atherosclerotic lesions may represent another molecular imaging strategy to identify high-risk lesions. Apoptotic cells are able to bind a number of proteins, such as annexin V (Belochine et al. 2004, Toretsky et al. 2004, Blankenberg et al. 2003, Murakami et al. 2004). Using radiolabeled annexin A5 investigators have imaged apoptosis in patients with acute myocardial infarction.
Hematopoietic Stem Cell Transplantation 4] Hematopoietic stem cell transplantation (bone marrow transplant) is performed most monly in the treatment of leukemia. The management of patients after transplant is largely ed on monitoring for the occurrence of graft versus host disease (GVHD) and for recurrence of the cancer for which the procedure was performed. GVHD results from recognition of host tissues as foreign by the donor immune system. This can result in severe complications and is a major cause of death. Molecular imaging reagents could detect T cells as they respond to the graft. This could provide valuable information to guide therapy. Detection of cancer recurrence is a very difficult clinical problem. By the time a recurrent leukemia is detectable in the circulation by standard methods, it is often incurable. Molecular probes specific to cancer cells could provide a means to detect recurrence of leukemia at an earlier stage.
Neurologic Disease
[0145] The brain and spinal cord are difficult to biopsy to make a tissue diagnosis of disease. This is due to accessibility and risk of complications from damage to the organ. At the same time, there are a number of neurologic diseases involving specific regions of the brain. In each case, it is extremely difficult to diagnose disease prior to significant neurologic dysfunction. Detection of disease at an earlier stage may allow intervention with medical or other therapies which slows progression of disease prior to significant damage.
[0146] Alzheimer's disease is characterized by the formation of amyloid plaques in the brain. There is a characteristic distribution in the frontal lobes. Definitive diagnosis at an early stage is not possible as findings of dementia are not specific and numerous alternative causes must be considered. Even when these have been ruled out, Alzheimer's disease is a diagnosis of exclusion and can only be definitively diagnosed at autopsy. A specific molecular probe would be valuable to make a definitive early diagnosis which would allow early medical therapy. Molecular imaging would also facilitate monitoring of response to therapy. Dojindo Laboratories has developed an MRI reagent for amyloid plaques.
[0147] Multiple Sclerosis is an autoimmune disease of the central nervous system characterized by inflammation and demyelination leading to chronic neurologic disability. The disease is often characterized by flares and periods of remission. MRI scanning is used to detect plaques acteristic lesions). However, once apparent on a standard MRI scan, the disease has already d irreversible damage to the brain. It would be very useful if one could detect plaque formation at an earlier stage. Molecular imaging contrast or signal emitting reagents specific to features of the plaque could provide additional sensitivity for early disease.
[0148] Parkinson's Disease and Amyotrophic Lateral Sclerosis are additional diseases of the nervous system that could benefit from the emergence of specific and sensitive molecular imaging reagents. Earlier diagnosis could facilitate earlier therapy or the validation of new treatments which could slow progression of disease.
Autoimmune and chronic inflammatory disease
Inflammatory bowel disease: Crohn 's disease and Ulcerative colitis
[0149] These disorders are characterized by inflammation of the gastrointestinal tract. They are currently diagnosed and monitored using clinical evaluation, endoscopy and CT scanning. However, these methods have significant limitations, particularly in the care of patients with Crohn's. Crohn's disease can flare and remit and can occur in any location in the gastrointestinal tract. Endoscopy is limited to accessible regions of the GI tract. Biopsy is needed to make a definitive diagnosis and to distinguish from Ulcerative colitis in many cases. CT scanning can evaluate any portion of the GI tract but is very non-specific. Patients with a history of Crohn's can have findings on CT scanning that represent previous bouts of inflammation or reactions to surgery and these may not be readily distinguished from active disease by a CT image. Imaging reagents specific to markers of active Crohn's disease could provide a means to overcome current limitations. Active Crohn's lesions could be identified in a specific manner anywhere in the GI tract. These lesions would be differentiated from ulcerative colitis and post-surgical findings. The need to CT scanning or endoscopy +/- biopsy could be reduced. Early diagnosis of disease flare (prior to symptoms) could allow proactive use of therapies which could decrease complications and hospitalizations. This approach would also be of value for surgical planning so that the location of active lesions could be assessed prior to surgery.
Autoimmune diabetes 0] The status of pancreatic islet cells could be assessed with molecular imaging reagents in nts with type I diabetes or pre-diabetics. In this disease, destruction of these cells leads to loss of insulin production and diabetes. Diabetes becomes clinically apparent only after 90% of islet cells are destroyed by the autoimmune process. Monitoring of islet cell mass with specific imaging reagents would provide a means to follow islet cell destruction and intervene with immunosuppression prior to significant destruction.
Transplantation
[0151] Allograft rejection is a major complication of transplantation leading to graft loss. Current methods to diagnose and monitor rejection rely on invasive biopsy and blood testing. Molecular imaging could provide a means to assess rejection. It could be used in combination with imaging of graft function so that a single procedure may allow assessment of both rejection and graft function.
Gynecologic disease
[0152] Endometriosis causes very significant morbidity in young women and can lead to surgery and infertility. A specific diagnosis of this disease is not possible prior to open biopsy. Specific molecular imaging reagents could allow for diagnosis and surgical planning.
Infectious disease
[0153] Infections can occur in any part of the human body. Diagnosis of infection can be difficult to distinguish from other inflammatory processes or from colonization. Molecular imaging could provide a means to make a diagnosis of infection, identify anatomical extent and monitor herapy. Currently available are Leukoscan Fab against granulocytes; Palatin technologies NeutroSpec anti-CD25 for diagnosis of appendicitis; Draximage's labeled Ciprofloxicin.
[0154] The following examples illustrate various aspects and embodiments of the disclosed nvention. These examples in no way limit the scope of the claimed invention.
EXAMPLES mple 1: Identification of Molecular Imaging Candidate Target Peptide Sequences from uman Genome
[0155] Analyses were performed to identify candidate molecular imaging target peptides from the human genome. Methods were employed to identify a set of proteins with like expression on cell surfaces or secretion from cells.
[0156] 113,708 records for human proteins were extracted from the Uniprot database (Version number 46). Each record was associated with a Uniprot ID number, an amino acid sequence of the associated protein and Gene Ontology terms (GO terms) associated with the protein. The GO terms represent compiLed information regarding each protein with respect to protein structure and subcellular location. Of these 113,708 peptides, a subset of 7626 were identified which were associated with the GO terms: cell surface, cell septum surface, external side of plasma membrane, extracellular region, extracellular matrix, extracellular space, membrane, external encapsulating structure and cell surface. These proteins are listed in Table 2, which can be found at the end of the specification.
[0157] For each of the 7626 proteins selected (identified as 1-7626), those with annotation terms Signal, Secreted, Extracellular Domain, Integral Membrane, Type I, Type II, Type III, Type IV, Mitochondrial, Golgi, Endoplasmic reticulum, Nuclear, Extracellular, Cytoskeletal, Peroxisomal, GPI-anchor, Microsomal were identified (Tables 2 and 3). These annotation terms confer in some cases increased and in some cases decreased likelihood that the protein is expressed on the cell surface or secreted. In Table 3, the numbers of proteins among the 7626 associated with each term are given. A subgroup of 3163 proteins was identified associated with the terms "signal, secreted, extracellular domain, extracellular" and "GPI-anchor" (Group 1 in Tables 2 and 3). These proteins may have an increased likelihood of being accessible outside the cell. Another subgroup of 3117 proteins was identified which was Group 1, less those proteins associated with the terms "mitochondrial" and "nuclear", which may confer a decreased likelihood of accessibility from outside the cell (Group T). A subgroup of 1973 proteins was identified which was associated with the annotation term "extracellular domain" (Group 3).
e 3
Figure imgf000044_0001
Example 2: Identification of Molecular Imaging Targets for Disease - Brain Cancer
[0158] Given a set of secreted and cell surface candidate proteins for molecular imaging, those specific proteins which may serve as targets for molecular imaging of brain cancer were sought. Specifically, protein targets for Glioblastoma were identified.
[0159] The database Online Mendelian Inheritance in Man (OMIM) was searched with the work "glioblastoma" and the resulting set of genes identified were evaluated and those that were identified as cell surface or secreted were identified. The resulting set of 35 proteins is shown in Table 4.
Table 4
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
[0160] The PubMed database was searched with combinations of key words "glioblastoma", "gene expression" and "protein". Resulting publications were evaluated and those which identified genes or proteins which are cell surface or secreted and were expressed in a specific manner on glioblastomas or expressed in association with glioblastoma prognosis or invasiveness were identified. The resulting set of 52 proteins is shown in Table 4.
[0161] The SAGE map library (Serial Analysis of Gene Expression, Lash et al. 2000) at the NCBI was analyzed to identify genes specific to Glioblastoma as compared to normal brain tissue. This was done by comparing the frequency of SAGE tags in Glioblastoma tissues (11) to those in normal brain (6). The libraries compared were: Normal brain libraries:
1. SAGE_Duke_BB542_normal_cerebellum(58826 tags)
Brain, normal, greater than 95% white matter. Post-mortem delay of 3:15. normal cerebellum bulk CGAP non-normalized SAGE library method bulk
2. SAGE_Duke_thalamus(48548 tags)
Brain, normal thalamus. Post-mortem delay of 3:15 normal bulk thalamus CGAP non-normalized SAGE library method bulk
3. SAGE_NHA(5th)(52261 tags)
Brain, normal human astrocyte cells harvested at passage 5 brain normal SAGE astrocyte CGAP non-normalized SAGE library method cell line 4. SAGE_normal__cerebellum(51280 tags) normal cerebellum normal cerebellum bulk CGAP non -normalized SAGE library method bulk
5. SAGE_normal_pool(6th)(63208 tags)
Brain, normal, pooled, brain normal SAGE CGAP non-normalized SAGE library method bulk
6. SAGE_normaljpediatric_cortex_Hl 571(77968 tags) frontal cortex normal cortex CGAP non-normalized SAGE library method bulk Glioblastoma libraries: GE_glioma_l 150(62675 tags) g a brain glioblastoma multiforme CGAP non-normalized SAGE library method bulk
2. SAGE_Brain_gIioblastoma_B_H833(l 00600 tags) Glioblastoma brain glioblastoma bulk short SAGE adult male
3. SAGE_Brain_glioblastoma_B_R336(102322 tags) Glioblastoma brain glioblastoma bulk short SAGE adult male
4. SAGE_Brain_glioblastoma_B_R70(99099 tags) Glioblastoma brain glioblastoma bulk short SAGE adult
5. SAGE_pooled_GBM(61886 tags)
Brain, 5 pooled Duke glioblastoma multiforme primary tumors, brain glioblastoma multiforme SAGE CGAP non-normalized SAGE library method bulk
6. SAGE_Duke_GBM_Hl 110(70087 tags)
Brain, Duke glioblastoma multiforme primary tumor derived from a 51 yo male brain glioblastoma multiforme SAGE CGAP non-normalized SAGE library method bulk
7. SAGE_Duke_H247_Hypoxia(72031 tags) glioblastoma multiforme brain glioblastoma multiforme SAGE cell line CGAP non-normalized SAGE library method cell line
8. SAGE_DukeJH247_normal(60663 tags) glioblastoma multiforme brain glioblastoma multiforme SAGE cell line CGAP non-normalized SAGE library method cell line
9. SAGE_Duke_H392(57582 tags) Brain, Duke glioblastoma multiforme cell line brain glioblastoma multiforme SAGE CGAP non- normalized SAGE library method cell line
10. SAGE_Duke_H54_EGFRvIII(57400 tags) brain brain glioblastoma multiforme cell line CGAP non-normalized SAGE library method cell line
11. SAGE_Duke_H54_lacZ(67236 tags) brain brain glioblastoma multiforme cell line CGAP non-normalized SAGE library method cell line.
] The genes that were most significantly different between the tissues were identified the SAGE algorithm. Those genes with increased frequency in glioblastoma libraries at a p- value < 0.011 were selected and then a subset which were cell surface or secreted (N = 54) were identified and are listed in Table 4.
[0163] The identified set of 141 proteins associated with Glioblastoma (Table 4) are candidate targets for molecular imaging reagent development as described.
Example 3: Identification of Molecular Imaging Targets for Hepatic Cancer
[0164] Patients with hepatic failure and cirrhosis are at increased risk for the occurrence of hepatocellular carcinoma. Given the nodular nature of the scarring process in cirrhosis, it is difficult to monitor for the occurrence of cancer in the setting of the cirrhotic liver. Molecular imaging could provide valuable clinical tools for monitoring, diagnosis and planning of treatment of hepatic cancer.
[0165] Candidate cell surface or secreted proteins which are highly expressed and specific to hepatic cancer can be identified by the method described in the invention. Proteins must be expressed specifically in the setting of cancer or pre-malignant transformation of hepatic cells versus normal or cirrhotic hepatic cells.
[0166] Methods for identification of these targets include mining of existing data as described above. These data can take the form of published literature, sequence databases, gene expression databases, or proteomic database. Methods similar to those described in Example 2 can also be used. In addition, data can be generated using animal models of liver cancer, tissue culture or human tissue specimens. Gene expression or proteomic data sets can be generated from these tissues and data from cancerous cells or tissues can be compared to normal liver tissues or control cells or tissues.
[0167] Identified markers of hepatic cancer which are expressed on the cell surface or secreted such as those present in Table 2 and have expression features as described in the specification are candidates for development of molecular imaging reagents.
8] Further experiments to identify and prioritize protein targets for molecular imaging of hepatic cancer can utilize tissue microarrays which contain hundreds of human tissue samples representing hepatic cancer and control tissues. In this example MAGE-I and Glypican 3 antibodies reactive to human antigen are tested on a tissue microarray consisting of more than 140 cases of hepatocellular carcinoma of various grades (US Biomax, Rockville, MD). To determine the specificity of protein expression in hepatocelluar carcinoma, the controls on the tissue array are normal liver sections and other metastatic adenocarcinoma as well as intrahepatic cholangiocarcinoma.
[0169] Tissue samples are fixed in 4% in neutral phosphate buffered formalin for 24 hours. Then the tissue is dehydrated with ethanol and embedded in paraffin. The paraffin embedded tissue is section and mounted onto a positive charge lass slide. Each tissue section is 5 υm thick and ~1.0 mm in diameter and ~200 cores are mounted onto each slide. Among the 200 cases, there are 140 cases hepatocellular carcinoma grade 1-3, 12 cases of intrahepatic cholangiocarcinoma, and 31 metastic adenocarcinoma. The tissue cores are layered with a thin layer of paraffin to prevent oxidation or moisture condensation. Before the slide is used for immunohistochemistry studies, the tissue microarray is de-paraffinized. The array is rinsed with phosphate buffer saline. In some cases, the endogenous peroxidase activity is blocked. The array goes through an antigen retrieval process to expose the antigenic sites. The array is incubated with normal serum to reduce nonspecific binding. The array is incubated with the primary antibody. In this case, the primary antibodies are against human antigens for MAGE-I and Glypican 3. The MAGE-I is a monoclonal antibody raised in mouse. The Glypican 3 antibody is polyclonal antibody raised in sheep. The array slide is rinsed with phosphate buffer saline. Then the array is incubated with a biotin- conjugated secondary antibody. The secondary antibody is anti-host of the primary antibody. In his case the secondary antibody is against rabbit, mouse and sheep. The array is incubated with an Avidin/Biotinylated Enzyme Complex (ABC). In this case the enzyme is horseradish peroxidase. The array is incubated with diaminobenzidine which is the substrate for the enzyme to produce a nsoluble brown product. The array is stained with hematoxylin to differentiate cell structure in the sections. The array is dehydrated and mounted. An image of the immunostained tissue array uired through image acquisition software. Image analysis software is used to generate q itative data. One form of the raw data is percentage of positive cells and intensity of positive signal. Another form of the raw data is scoring the signal from a range of + to
Example 4: Development and Validation of Molecular Imaging Reagents and Protocols for Hepatocellular Carcinoma (Glypican 3)
Reagents
[0170] Two types of reagents were developed:
1) T2 effecting: SPIO (superparamagnetic iron oxide) nanoparticles based: Commercially available streptavi din-coated SPIO were conjugated with biotinylated antibody of interest through a streptavidin-biotin link.
2) Tl effecting: Gadolinium(Gd) based: Biotinyl-albumin-GdDTPA reagent was synthesized and then the antibody of interest was covalently conjugated through a EDC/NHS link to albumin. Glypican-3 (H-162) (GPC-3) is a rabbit polyclonal antibody.
Cell Screening
[0171] In vitro cell testing was done on mouse cell lines NCTC (normal liver cell line) and
Hepal-6 (hepatoma cell line) using an antibody to Glypican 3. Cells were cultured according to ATCC requirements, then incubated with contrast reagents or controls for Ihr. After treatment, cells were washed, collected and embedded in 2% agarose in small vials. The vials were imaged on a Bruker Biospec 7.0 Tesla/30 cm horizontal-bore imaging spectrometer. [0172] For SPIO-based reagents, T2 -weighted images were acquired using a 2D multi-slice multi-echo imaging pulse sequence (Bruker) (repetition time (TR) 3sec, 8 echoes, echo times (TEs) 15, 30, 45, 60, 75, 90, 105 and 120 msec, 256 x 256 matrix). For Gd-based reagents, Tl- weighted mages were acquired using a 2D multi-slice multi-echo imaging pulse sequence with variable repetition time (Bruker) (echo time (TE) 15msec, repetition times (TRs) = 200, 400, 800, 1200 and 1600 msec, 256 x 256 matrix). The results were analyzed using Paravision software.
] Ti values for these cell lines with treatment with the Glypican-3 imaging reagents and ol are shown in Table 5. The hepatoma cell line (but not the control cell line) was found to have a significantly lower Tl value when treated with Gd-albumin-anti-GPC3 when compared to control cells treated with Gd-albumin.
Table 5: Ti data for Glypican-3 targeted cell line experiments with gadolinium (Gd) contrast
Figure imgf000053_0002
[0174] T2 values for Hepa 1 -6 and NCTC cells treated with anti-GPC-3-SPIO or control preparations are shown in Table 6. The hepatoma cell line (but not the control cell line) was found to have a significantly lower T2 value when treated with SPIO-anti-GPC-3 compared to control cells treated with SPIO alone.
Table 6: T2 data for Glypican 3 taη; ^eted cell line experiments with SPIO contrast
Figure imgf000053_0001
Figure imgf000054_0001
Animal Experiments 0175] Using a transgenic mouse model (double mutation c-MYC/TGF-α), targeted reagents for
GPC-3 were tested for detection of malignant nodules. Anaesthetised mouse was placed in a MR probe, and liver was localised by MRI. Respiratory gating was used to trigger acquisition of the -encoding steps in the imaging sequence for liver images. Mouse was injected intravenously ontrast agent.
[0176] For the anti-glypican-3 (GPC-3)- biotinyl-albumin-GdDTPA conjugated contrast agents (1 mg antibody/kg), Ti- weighted images were acquired using a 2D rapid acquisition relaxation enhanced pulse sequence (echo time (TE) 15msec, 5 repetition times (TRs): 200, 400, 800, 1200, 1600 msec, 256x256 matrix). For the anti-GPC-3-SPIO contrast agent, T2-weighted images were acquired using a 2D multi-slice multi-echo imaging pulse sequence (Bruker) (repetition time (TR) 3sec, 8 echoes, echo times (TEs) 15, 30, 45, 60, 75, 90, 105 and 120 msec, 256 x 256 matrix). The images were taken before injection, immediately after injection and after lhr. The results were analyzed using Paravision software.
[0177] The binding specificity of the targeting agents is indicated by the changes in Ti or T2 and intensity of the signal. For SPIO-based reagent: the decrease in T2 and decrease in signal intensity for selected regions indicate binding specificity of this targeting agent. For Gd-based reagent: the decrease in Ti and increased signal intensity for selected regions indicate binding specificity of this targeting agent.
[0178] The results of the SPIO-anti-GPC3 experiments are summarized in Figure 1 (axial liver slice), Figure 2 (difference image), and Figure 3 (T2 value for ROI).
[0179] The results of the Gd-albumin-anti-GPC3 experiments are summarized in Figures 4-9. The experiment was repeated twice. The results of Injection #1 are shown in Figure 4 (axial liver lice), Figure 5 (difference image), and Figure 6 (Ti value for ROI). The results of Injection #2 are hown in Figure 7 (axial liver slice), Figure 8 (difference image), and Figure 9 (Ti value for ROI).
0180] Example 5: Identification of Molecular Imaging Targets for Atherosclerosis
0181] Atherosclerosis is an inflammatory process of arterial walls which can lead to occlusion mitation in blood flow. Atherosclerotic plaques can suddenly rupture leading to complete ion of a blood vessel which leads to myocardial infarction (heart attack) or stroke. It is not ossible to predict which atherosclerotic plaques in which vessels are likely to rupture and lead to cute events. Molecular imaging could enable assessment of both blood vessel anatomy and risk of plaque rupture.
0182] Candidate cell surface or secreted proteins which are highly expressed and specific to ctive (at risk) atherosclerotic plaque can be identified by the method described in the invention. Proteins must be specifically expressed in active athrerosclerotic plaque (e.g., with subsequent acute events) versus lower risk atherosclerosis.
0183] Methods for identification of these targets include mining of existing data as described above. These data can take the form of published literature, sequence databases, gene expression databases, or proteomic database. Methods similar to those described in Example 2 can also be used. In addition, data can be generated using animal models of atherosclerosis, tissue culture or human tissue specimens. Gene expression or proteomic data sets can be generated from these tissues and comparisons or active vs. low-risk plaque can be used to identify candidate markers.
[0184] Identified markers of high-risk atherosclerosis which are expressed on the cell surface or secreted such as those present in Table 2 and have expression features as described in the specification are candidates for development of molecular imaging reagents. REFERENCES
Abbondanzo, Medeiros, Cossman, "Molecular genetics and its application to the diagnosis and lassification of hematopoietic neoplasms," Am. J. Pediatr. Hematol. Oncol., 12(4):480-489, 1990.
Alizadeh, A. A. et al. "Distinct types of diffuse large B-cell lymphoma identified by gene xpression profiling" Nature 403 (2000): 503-11.
, Bustamante, Daniel, Gaskill, Cruz, "Immunocytochemical analysis of estrogen receptors in n breast carcinomas. Evaluation of 130 cases and review of the literature regarding oncordance with biochemical assay and clinical relevance," Arch. Surg., 125(1): 107-113, 1990.
Altschul SF. Amino acid substitution matrices from an information theoretic perspective. J MoI Biol. 1991 Jun 5;219(3):555-65.
Altschul SF, Boguski MS, Gish W, Wootton JC. Issues in searching molecular sequence databases. Nat Genet. 1994 Feb;6(2): 119-29.
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST nd PSI-BLAST: a new generation of protein database search programs. Curr Opin Struct Biol. 996 Jun;6(3):353-60.
Argos P, Rao JK, Hargrave PA. Structural prediction of membrane-bound proteins. Eur J Biochem 982 Nov 15;128(2-3):565-575.
Artemov, D. (2003a). "Molecular magnetic resonance imaging with targeted contrast agents." J Cell Biochem 90(3): 518-24.
Artemov, D., N. Mori, et al. (2003b). "Magnetic resonance molecular imaging of the HER-2/neu receptor." Cancer Res 63(11): 2723-7.
Artemov D, Mori N, Okollie B, Bhuj walla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003c Mar;49(3):403-8. Bannai H, Tamada Y, Maruyama O, Nakai K, Miyano S. Extensive feature detection of N-terminal rotein sorting signals. Bioinformatics. 2002 Feb;18(2):298-305.
Belhocine TZ, Tait JF, Vanderheyden JL, Li C, Blankenberg FG. Nuclear medicine in the era of enomics and proteomics: lessons from annexin V. J Proteome Res. 2004 May-Jun;3(3):345-9.
Bendtsen, JD, Henrik Nielsen, Gunnar von Heijne and Søren Brunak. Improved prediction of signal es: SignalP 3.0. J. MoI. Biol., 340:783-795, 2004.
de, R., R. Weissleder, et al. (2000). "Macrocyclic chelators with paramagnetic cations are nternalized into mammalian cells via a HIV-tat derived membrane translocation peptide." Bioconjug Chem 11(3): 301-5.
Blankenberg F, Mari C, Strauss HW. Imaging cell death in vivo. Q JNucl Med. 2003 Dec;47(4):337-48. Review.
Blasberg, R. G. and J. Gelovani (2002). "Molecular-genetic imaging: a nuclear medicine-based perspective." MoI Imaging 1(3): 280-300.
Bogdanov, A., Chen J, Kang, H, Weissleder R (2005). "Molecular Imaging: An Essential Tool in Preclinical Research, Diagnostic Imaging and Therapy." Springer- Verlag.
Bogdanov, A., Jr., L. Matuszewski, et al. (2002). "Oligomerization of paramagnetic substrates result n signal amplification and can be used for MR imaging of molecular targets." MoI Imaging 1(1): 16-23.
Bogdanov A Jr, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. MoI Imaging. 2002 Jan-Mar; 1(1): 16-23.
Bogdanov, A. A., Jr., C. P. Lin, et al. (2002). "Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment," Neoplasia 4(3): 228-36. Bremer, C, S, Bredow, et al. (2001). "Optical imaging of matrix metalloproteinase-2 activity in umors: feasibility study in a mouse model." Radiology 221(2): 523-9.
Bremer, C, C. H. Tung, et al. (2002). "Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes." Radiology 222(3): 814-8.
Bremer, C, C. H. Tung, et al. (2001). "In vivo molecular target assessment of matrix oproteinase inhibition." Nat Med 7(6): 743-8.
n et al., J. Immunol. Meth., 12;130(l):l 11-121, 1990.
Castillo, M., L. Kwock, et al. (1996). "Clinical applications of proton MR spectroscopy." AJNR Am Neuroradiol l7(l): 1-15.
Chatham, J. C. and S. J. Blackband (2001). "Nuclear magnetic resonance spectroscopy and imaging n animal research." liar J 42(3): 189-208.
Chatziioannou, A., Y. C. Tai, et al. (2001). "Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging." Phys Med Biol 46(11): 2899-910.
Chatziioannou, A. F. (2002). "Molecular imaging of small animals with dedicated PET omographs." Eur J Nucl Med MoI Imaging 29(1): 98-114.
Chen, J., C. H. Tung, et al. (2002). "In vivo imaging of proteolytic activity in atherosclerosis." Circulation 105(23): 2766-71.
Chen, W. S., K. E. Luker, et al. (2000). "Effects of MDRl and MDR3 P-glycoproteins, MRPl, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin." Biochem Pharmacol 60(3): 413-26.
Chen, W. T., C. H. Tung, et al. (2004). "Imaging reactive oxygen species in arthritis." MoI Imaging 3(3): 159-62.
Chen, X., M. Tohme, et al. (2004). "Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide." MoI Imaging 3(2): 96-104. herry, S. R. and S. S. Gambhir (2001). "Use of positron emission tomography in animal research." ar J 42(3): 219-32.
hoe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloυghesy TF, Mischel PS. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002 Sep;8(9):2894-901.
n HH, Laufer P, Stocklin G, Wienhard K, Pawlik G, Bocher-Schwarz HG, Heiss WD. Links -(18F)-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with pet. ife Sci. 1987 Jan 5;40(l):81-8.
Contag, P. R., I. N. Olomu, et al. (1998). "Bioluminescent indicators in living mammals." Nat Med (2): 245-7. x
Crouzel, C, Venet, M, Irie, T., Sanz, G., And Boullais, C. 1988 Labeling of Serotonergic ligand with 18F : (18F)Setoperone. J. Label. Compd. Radiopharm. 25: 403.
Cumming, P. and A. Gjedde (1998). "Compartmental analysis of dopa decarboxylation in living rain from dynamic positron emission tomograms." Synapse 29(1): 37-61.
Del Vecchio, S., A. Ciarmiello, et al. (2000). "Scintigraphic detection of multidrug resistance in ancer." Cancer Biother Radiopharm 15(4): 327-37.
Dendy, P. a. H., B. (1999). "Tomographic imaging." Physics for diagnostic radiology: 249-278.
Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. (2004) "Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma." Cancer Res. 64(23): 8773-7,
Dodd, C. H., H. C. Hsu, et al. (2001). "Normal T-cell response and in vivo magneiic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles." J Immunol Methods 256(1-2): 89-105. isen MB, Spellman PT, Brown PO, and D Botstein. Cluster analysis and display of genome-wide xpression patterns. Proceedings National Academy of Sciences, USA, 1998. 95: p. 14863-14868.
manuelsson, Olof, Henrik Nielsen, Søren Brunak and Gunnar von Heijne. Predicting subcellular ocalization of proteins based on their N-terminal amino acid sequence. J. MoI. Biol., 300: 1005- 016, 2000.
amp MM, LaIa P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor ors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 1999 Dec;45(6): 1442-53.
ischman, A. J., J. W. Babich, et al. (1993). "A ticket to ride: peptide radiopharmaceuticals." J Nucl Med 34(12): 2253-63.
lacke, S., S. Fischer, et al. (2001). "Novel MRI contrast agent for molecular imaging of fibrin: mplications for detecting vulnerable plaques." Circulation 104(1 1): 1280-5.
ranc, B. L., S. J. Mandl, et al. (2003). "Breaching biological barriers: protein translocation domains s tools for molecular imaging and therapy." MoI Imaging 2(4): 313-23.
Gambhir, S. S. (2002). "Molecular imaging of cancer with positron emission tomography." Nat Rev Cancer 2(9): 683-93.
Gambhir, S. S., J. R. Barrio, et al. (1999). "Assays for noninvasive imaging of reporter gene expression." Nucl Med Biol 26(5): 481-90.
Ghambhir, S. (in press, Springer- Verlag). "Quantitative assay development for positron emission tomography." Molecular imaging with positron emission tomography.
Geourjon C, Combet C, Blanchet C, Deleage G. Identification of related proteins with weak sequence identity using secondary structure information. Protein Sci 2001 Apr;10(4):788-97.
Figure imgf000061_0001
Ghambhir, S. (in press, Springer- Verlag). "Quantitative assay development for positron emission tomography." Molecular imaging with positron emission tomography.
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group f genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003 Oct 5;63(20):6613-25.
Goldberg, R. M., T. R. Fleming, et al. (1998). "Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group." Ann Intern Med 129(1): 27-35.
Golembieski WA, Rempel SA. cDNA array analysis of SPARC-modulated changes in glioma gene expression. J Neurooncol. 2002 Dec;60(3):213-26.
Golub, T. R. et al. "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring" Science 286 (1999): 531-7.
Hadjantonakis, A. K. and A. Nagy (2001). "The color of mice: in the light of GFP-variant reporters." Histochem Cell Biol 115(1): 49-58.
\
Harisinghani, M. G.? J. Barentsz, et al. (2003). "Noninvasive detection of clinically occult lymph- node metastases in prostate cancer." N Engl J Med 348(25): 2491-9.
Harn HJ, Lee HS, Ho LI, Lee WH, Ding JH. Selective expression of CD44 messenger RNA sp ilice variants in four high grade human brain tumour cell lines. Biochem MoI Biol Int. 1994 / Jul;33(4):743-9.
;
Hastie, T. et al, '"Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns" Genome Biol. 2000;l(2):RESEARCH0003. Epub 2000 Aug 4.
59
ε<M,wo/ozsfi/i3d icsoeo/ioo: OΛV Herschman, H. R., D. C. MacLaren, et al. (2000). "Seeing is believing: non-invasive, quantitative nd repetitive imaging of reporter gene expression in living animals, using positron emission omography." J Neurosci Res 59(6): 699-705.
Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, Sloan A, Coons SW, Berens ME. Gene expression profile of glioblastoma multiforme invasive phenotype points to new herapeutic targets. Neoplasia. 2005 Jan;7(l):7-16.
n P, Nakai K. "Better prediction of protein cellular localization sites with the k nearest eighbors classifier." Proc Int Conf Intell Syst MoI Biol. 1997;5: 147-52.
Huang, S. C, M. E. Phelps, et al. (1980). "Noninvasive determination of local cerebral metabolic ate of glucose in man." Am J Physiol 238(1): E69-82.
yer, M., M. Berenji, et al. (2002). "Noninvasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice." MoI Ther 6(4): 555-62.
ackson, E. (2001). "Principles of magnetic resonance imaging and magnetic resonance pectroscopy." Targeted molecular imaging in oncology: 30-61.
Jacobs, A. H., C. Dittmar, et al. (2002). "Molecular imaging of gliomas." MoI Imaging 1(4): 309-
35.
Jacobs, A. H., A. Winkler, et al. (2002). "Molecular and functional imaging technology for the development of efficient treatment strategies for gliomas." Technol Cancer Res Treat 1(3): 187-204.
Jaffer, F. A. and R. Weissleder (2004). "Seeing within: molecular imaging of the cardiovascular system." Circ Res 94(4): 433-45.
Jaffer, F. A. and R. Weissleder (2005). "Molecular imaging in the clinical arena." Jama 293(7): 855- 62. onassen I. Efficient discovery of conserved patterns using a pattern graph. Comput. Appl. Biosci. 3(5):509-522(1997)
onassen I., Collins J. F. and Higgins D.; Finding flexible patterns in unaligned protein sequences. Protein Science 4(8):1587-1595(1995)
osephson, L., C. H. Tung, et al. (1999). "High-efficiency intracellular magnetic labeling with novel paramagnetic-Tat peptide conjugates." Bioconjug Chem 10(2): 186-91.
AM, Landon TH, Burwick J, Pham TQ, Frantz GD, Cairns B, Quirke P, Peale FV, Hillan KJ. 2003) "Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. " J Pathol. 200(5): 577-88.
Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem. 2002 Jan- Feb;13(l):122-7.
Kelly, K., H. Alencar, et al. (2004). "Detection of invasive colon cancer using a novel, targeted, ibrary-derived fluorescent peptide." Cancer Res 64(17): 6247-51.
Kim, E. (2001). "Radioimmunodetection of cancer." Targeted molecular imaging in oncology, Springer- Verlag: 88-101.
Kneller, D. G., F. E. Cohen and R. Langridge (1990) "Improvements in Protein Secondary Structure Prediction by an Enhanced Neural Network" J. MoI. Biol. (214) 171-182.
Kobayashi, H. and M. W. Brechbiel (2003). "Dendrimer-based macromolecular MRI contrast agents: characteristics and application." MoI Imaging 2(1): 1-10.
Kung HF, Alavi A, Chang W, Kung MP, Keyes JW Jr, Velchik MG, Billings J, Pan S, Noto R5 Rausch, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine- 123-IBZM in humans. J Nucl Med. 1990 May;31(5):573-9. yte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J MoI iol 1982 May 5;157(l):105-132
amberts, S. W., W. H. Bakker, et al. (1990). "Somatostatin-receptor imaging in the localization of ndocrine tumors." N Engl J Med 323(18): 1246-9.
anza, G. M. and S. A. Wickline (2001). "Targeted ultrasonic contrast agents for molecular imaging erapy." Prog Cardiovasc Dis 44(1): 13-31.
ois, D., W. Weder, et al. (2003). "Staging of non-small-cell lung cancer with integrated ositron-emission tomography and computed tomography." N Engl J Med 348(25): 2500-7.
ash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ, Altschul SF. AGEmap: a public gene expression resource. Genome Res. 2000 JuI; 10(7): 1051-60.
ewin, M., N. Carlesso, et al. (2000). "Tat peptide-derivatized magnetic nanoparticles allow in vivo acking and recovery of progenitor cells." Nat Biotechnol 18(4): 410-4.
i, J. J., X. Fang, et al. (2002). "Molecular aptamer beacons for real-time protein recognition." iochem Biophys Res Commun 292(1): 31-40.
i KC, Bednarski MD. Vascular-targeted molecular imaging using functionalized polymerized esicles. J Magn Reson Imaging. 2002 Oct; 16(4): 388-93.
iang, Q., K. Nguyen, et al. (2002). "Monitoring adenoviral DNA delivery, using a mutant herpes simplex virus type 1 thymidine kinase gene as a PET reporter gene." Gene Ther 9(24): 1659-66.
Ligon AH, Pershouse MA, Jasser S, Hong YK, Yung WK, Steck PA. Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. J Neurovirol. 1998 Apr;4(2):217-26.
Ljubimova JY, Khazenzon NM, Chen Z, Neyman YI, Turner L, Riedinger MS, Black KL. Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol. 2001 Feb;18(2):287-95. jubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin LM, Ljubimov V, Black KL. Overexpression of alpha4 chain-containing laminins in human glial tumors entified by gene microarray analysis. Cancer Res. 2001 JuI 15;61(14):5601-10.
ovqvist, A., J. L. Humm, et al. (2001). "PET imaging of (86)Y-labeled anti-Lewis Y monoclonal ntibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels." J Nucl Med 1281-7.
ucignani, G. a. F., HH. (2000). "Neurochemical imaging with emission tomography: Clinical pplications." Diagnostic nuclear medicine, Springer-Verlag: 7-35.
uypaert, R., S. Boujraf, et al. (2001). "Diffusion and perfusion MRI: basic physics." Eur J Radiol 8(1): 19-27.
Mahmood, U. and R. Weissleder (2002). "Some tools for molecular imaging." Acad Radiol 9(6): 29-31.
Marchler-Bauer A, Panchenko AR, Shoemaker BA, Thiessen PA5 Geer LY, and Bryant SH CDD: a atabase of conserved domain alignments with links to domain three-dimensional structure. Nucleic Acids Res. 2002;30:281-3.
Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons W, Watts G, Trent JM, Wei JS, Giese A, Berens ME. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol. 2001 Jun;53(2):161-76.
Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, Ponce F, Coons SW, Giese A, Seiler RW, Berens ME. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res. 2001 Aug;7(8):2480-9. Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ. Differential gene expression profiling in human brain tumors. Physiol Genomics. 2001 Feb 7;5(l):21-33.
Massoud, T. F. and S. S. Gambhir (2003), "Molecular imaging in living subjects: seeing undamental biological processes in a new light." Genes Dev 17(5): 545-80.
rthy, T. J., A. U. Sheriff, et al. (2002). "Radiosynthesis, in vitro validation, and in vivo tion of 18F-labeled COX-I and COX-2 inhibitors." J Nucl Med 43(1): 117-24.
Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau M, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene xpression profiling. Oncogene. 2003 Apr 17;22(15):2361-73.
Mitchell, P. (2001). "Turning the spotlight on cellular imaging." Nat Biotechnol 19(11): 1013-7.
Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, Tait JF, Nishimura S. 18F- abelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med MoI Imaging. 2004 Apr;31(4):469-74. Epub 2003 Dec 10.
Naghavi, M., P. Libby, et al. (2003). "From vulnerable plaque to vulnerable patient: a call for new efinitions and risk assessment strategies: Part II." Circulation 108(15): 1772-8.
Nielsen, Henrik, Jacob Engelbrecht, Søren Brunak and Gunnar von Heijne. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Engineering, 10:1-6, 1997.
Nielsen, H and Anders Krogh. Prediction of signal peptides and signal anchors by a hidden Markov model. Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, California, pp. 122-130, 1998.
Oriuchi, N. a. Y., DJ. (2001). "Antibodies for targeted imaging: properties and radiolabeling." Targeted molecular imaging in oncology, Springer- Verlag: 83-87. Paik, S., S. Shale, et al. (2004). "A multigene assay to predict recurrence of tamoxifen-treated, node- negative breast cancer." N Engl J Med 351(27): 2817-26.
Perou, C. M. et al. "Molecular portraits of human breast tumours" Nature 406 (2000): 747-52.
Polyakov, V., V. Sharma, et al. (2000). "Novel Tat-peptide chelates for direct transduction of echnetium-99m and rhenium into human cells for imaging and radiotherapy." Bioconjug Chem 762-71.
SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R. Identification of necrosis- associated genes in glioblastoma by cDNAmicroarray analysis. Clin Cancer Res. 2004 Jan 1; 10(1 Pt ):212-21.
Remington, S. J. (2002). "Negotiating the speed bumps to fluorescence." Nat Biotechnol 20(1): 28- 9.
Remsen, L. G., C. I. McCormick, et al. (1996). "MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis." AJNR Am J Neuroradiol 17(3): 411-8.
Reubi, J. C, J. C. Schar, et al. (2000). "Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use." Eur J Nucl Med 27(3): 273-82.
Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001 Sep 15;61(18):6885-91.
Rosebrough, S. F. (1996). "Two-step immunological approaches for imaging and therapy." Q J Nucl Med 40(3): 234-51. Rosenthal, M. S., J. Cullom, et al. (1995). "Quantitative SPECT imaging: a review and ecommendations by the Focus Committee of the Society of Nuclear Medicine Computer and nstrumentation Council." J Nucl Med 36(8): 1489-513.
Rost B, Casadio R, Fariselli P, Sander C. "Transmembrane helices predicted at 95% accuracy". rotein Sci 1995 Mar;4(3):521-33.
B, Sander C. Prediction of protein secondary structure at better than 70% accuracy. J MoI Biol JuI 20;232(2):584-99.
allinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray nd tissue chip techniques. Cancer Res. 2000 Dec l;60(23):6617-22.
Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
Shields, A. F., J. R. Grierson, et al. (1998). "Imaging proliferation in vivo with (F-18)FLT and positron emission tomography." Nat Med 4(11): 1334-6.
Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998 May;4(5):623-6.
Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman L. ICAM-I expression in autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol. 2000 Apr 3;104(l):l-9.
Stolz, B., G. Weckbecker, et al. (1998). "The somatostatin receptor-targeted radiotherapeutic (90Y- DOTA-DPhel, Tyr3)octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours." Eur J Nucl Med 25(7): 668-74. trijckmans, K. (2001). "The isochronous cyclotron: principles and recent developments." Comput Med Imaging Graph 25(2): 69-78.
Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a otential serum marker for malignant character in human glioma. Cancer Res. 2002 Aug ;62(15):4364-8.
any, C. M. and B. J. McNeil (2001). "Advances in biomedical imaging." Jama 285(5): 562-7.
rani R, Hastie T, Narasimhan B, and G Chu. Diagnosis of multiple cancer types by shrunken entroids of gene expression. Proc Natl Acad Sci U S A, 2002. 99(10): p. 6567-72.
Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Preparation of F- 18 labeled nnexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol. 2004 Aug;31(6):747-52.
Townsend, D. W. (2001). "A combined PET/CT scanner: the choices." J Nucl Med 42(3): 533-4.
Townsend, D. W. and S. R. Cherry (2001). "Combining anatomy and function: the path to true mage fusion." Eur Radiol 11(10): 1968-74.
Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, Hoelzinger DB, Beaudry C, Coons SW, Berens ME. The human Fn 14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol. 2003 Apr; 162(4): 1313-21.
Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E. (2006) "HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis." JOP 7(3): 283-94.
Tung, C. H., S. Bredow, et al. (1999). "Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging." Bioconjug Chem 10(5): 892-6. usher VG, Tibshirani R, and G Chu. Significance analysis of microarrays applied to the ionizing adiation response. Proceedings National Academy of Sciences, USA5 2001. 98(9): p. 5116-5121.
an Tinteren, H., O. S. Hoekstra, et al. (2002). "Effectiveness of positron emission tomography in he preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial." Lancet 359(9315): 1388-93.
ini, I. (2000). "Peptide imaging." Diagnostic nuclear medicine, Springer- Verlag: 135-158.
er HN Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, inks JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ. Imaging dopamine receptors in the uman brain by positron tomography. Science. 1983 Sep 23;221(4617):1264-6.
Weissleder R. Target-specific superparamagnetic MR contrast agents. Magn Reson Med. 1991 Dec;22(2):209-12; discussion 213-5.
Weissleder, R. (1999). "Molecular imaging: exploring the next frontier." Radiology 212(3): 609-14.
Weissleder, R. (2002). "Scaling down imaging: molecular mapping of cancer in mice." Nat Rev Cancer 2(1): 11-8.
Weissleder, R. and U. Mahmood (2001). "Molecular imaging." Radiology 219(2): 316-33.
Winter, P. M., A. M. Morawski, et al. (2003). "Molecular imaging of angiogenesis in early-stage therosclerosis with alpha(v)beta3-integrin-targeted nanoparticles." Circulation 108(18): 2270-4.
Wunderbaldinger, P., L. Josephson, et al. (2002). "Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles." Bioconjug Chem 13(2): 264-8.
Zerhouni, E. (2003). "Medicine. The NIH Roadmap." Science 302(5642): 63-72.
Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. GHa. 2003 Apr 15 ;42(2): 194-208. Ziegler, S. (2000). "Instrumentation and data acquisition." Diagnostic nuclear medicine, Springer- Verlag: 221-236.
Extracellular Integral
PID Descπption UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1 ADAM 10 precursor {EC 342481) (A dismtegππ and metaUoproteinase domain 10) (Mammalian disiπtegπn-metalloprotease) (Kuzbaπian pro'ADA10_HUMAN Y Y Y
2 Small inducible cytokine A21 precursor (CCL21) (Beta chemokine exodus-2) (6Ckιne) (Secondary lymphoid-tissue chemokine) (SLC) Y
3 Small inducible cytokine A22 precursor (CCL22) (Macrophage-deπved chemokine) (MDC(1-69)) (Stimulated T cell chemotactic protein 1) (CC CCU2_HUMAN Y
4 Small inducible cytokine A24 precursor (CCL24) (Myeloid progenitor inhibitory factor-2) (MPIF-2) (CK-beta-6) (Eosinophil chemotactic CCL24JHUMAN Y
5 CDP-diacylglycerol- inositol 3-phosphatιdyltransferase (EC 278 11) (Phosphatidyliπositol synthase) (Ptdlns synthase) (Pl synthase) CDIPT_HUMAN
6 Aquapoπn 7 (Aquapoπn-7 like) (Aquaponn adipose) (AQPap) AQP7 HUMAN
7 Brain specific aπgiogenesis inhibitor 1 precursor BAII-HUMAN Y
8 Agπn precursor AGRN_HUMAN Y
9 Agouti-related protein precursor AGRP-HUMAN Y
10 Acyl-CoA desaturase (EC 1 14 19 1) (Stearoyl-CoA desaturase) (Fatty acid desaturase) (Delta(9)-desaturase) ACOD-HUMAN
11 ATP-binding cassette sub family D, member4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-lιke) (PXMP1 ABCD4_HUMAN
12 Adapter-related protein complex 3 beta 1 subunit (Beta3A-adaptιn) (Adaptor protein complex AP-3 beta-1 subuπit) (AP-3 complex beta-1 AP3B1_HUMAN
13 Adapter-related protein complex 4 mu 1 subunit (Mu subunit (AP 4 adapter complex mu subunit) (Mu-adaptin-related protein 2) AP4M1_HUMAN
14 ADAMTS-3 precursor (EC 3424 -) (A disintegnn and metaUoproteinase with thrombospondin motifs 3) (ADAM-TS 3) (ADAM-TS3) (Procollagi ATS3_HUMAN Y
15 Bone moφhogenetιc proteιn receptortype lB precursor(EC 271 37) BMR1 B-HUMAN Y
16 Amyloid beta A4 precursor protein-binding family B member 1 protein) APBB1_HUMAN
17 Astrotactin 1 (Fragment) ASTN-HUMAN
18 Beta defensin 2 precursor (BD-2) (hBD-2) (Defensin, beta 2) (Skin- antimicrobial peptide 1) (SAP1) BD02_HUMAN Y
19 BET1 homolog (Golgi vesicular membrane trafficking protein p18) (hBET1) BET1_HUMAN
20 Voltage-dependent P/Q-type calcium channel alpha-1 A subunit (Voltage- gated calcium channel alpha subunit Cav2 1) (Calcium channel, L CAC1A_HUMAN
21 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (EC 3638) (Calcium pump 1) (SERCA1) (SR Ca(2+)-ATPase 1) (Calcιum-transportιιAT2A1_HUMAN
22 Claudιπ-4 (Clostridium perfnngens enterotoxin receptor) (CPE- receptor) (CPE-R) (Williams-Beuren syndrome chromosome region 8 CLD4_HUMAN
23 Claudιπ-S (Transmembrane protein deleted in VCFS) (TMDVCF) CLDS-HUMAN
24 Calmegin precursor CLGN-HUMAN Y
25 Chlonde intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (p64 CLCP) (Chlonde channel ABP) (Regulatory nuclear CLIC1_HUMAN
26 Chlonde intracellular channel protein 2 (XAP121) CLIC2_HUMAN
27 ADAM DEC1 precursor (EC 3424 -) (A disintegnn and metalloproteiπase domain-like protein decysin 1) (ADAM-like protein decysin 1) ADEC1_HUMAN Y
28 Apolipoprotein L1 precursor (Apolipoprotein L-I) (Apolipoproteiπ L) (ApoL-l) (Apo L) (ApoL) APOL1_HUMAN Y
29 SH2 and PH domain containing adapter protein APS (Adapter protein pleckstnn homology and Src homology 2 domains) APS-HUMAN
30 Angιopoιetin-2 precursor (ANG 2) ANGP2_HUMAN Y
31 Delta-like protein 1 precursor (Drosophila Delta homolog 1) (Deltal) (H-Delta-1) (UNQ146/PRO172) DLLI-HUMAN Y
32 Disks large-associated protein 1 (DAP 1) (Guanylate kinase-assoαated protein) (hGKAP) (SAP90/PSD-95-assocιated protein 1) (SAPAP1) DLPI-HUMAN
33 Chemokine binding protein 2 (Chemokine-binding protein D6) (OC chemokine receptor D6) (Chemokine receptor CCR-9) (CC-Chemokιπe CCBP2_HUMAN
34 Butyrophilin subfamily 3 member A1 precursor BT3A1_HUMAN Y
35 Butyrophilin subfamily 3 member A3 precursor BT3A3_HUMAN Y
36 C-X-C chemokine receptor type 6 (CXC-R6) (CXCR-6) (G protein coupled receptor bonzo) (G-protein coupled receptor STRL33) CXCRe-HUMAN
37 Adrenomedullm receptor (AM-R) ADMR J-IUMAN
38 Coatomer epsilon subunit (Epsiloπ coat protein) (Epsiloπ-COP) COPE-HUMAN
39 Ectonudeotide pyrophosphatase/phosphodiesterase 3 (E-NPP 3) (Phosphodiesterase l/nucleotlde pyrophosphatase 3) (Phosphodiesterase ENPP3_HUMAN
40 Voltage-dependent L-type calαum channel beta-4 subunit (CAB4) (Calcium channel, voltage-dependent, beta 4 subunit) CACB4_HUMAN
41 Seπne/threonme-proteiπ kinase DCAMKL1 (EC 271 37) (Doublecortin- like and CAM kinase-like 1) DCAK1_HUMAN
42 CAAX box protein 1 (Cerebral proteιn-5) (hucep-5) CXXI-HUMAN
43 Cortistatin precursor (UNQ307/PRO350) [Contains Cortιstatiπ-29, Cortistatιn-17] CORT-HUMAN Y
44 Fatty-acid amide hydrolase (EC 31 --) (Oleamide hydrolase) (Anandamide amidohydrolase) FAAH-HUMAN
45 CYR61 protein precursor (Cysteme-πch, angiogenic inducer, 61) (Insulin-like growth factor-binding protein 10) (GIG1 protein) CYR61_HUMAN Y
46 Excitatory amino acid transporter 5 (Retinal glutamate transporter) EAA5_HUMAN
47 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondπal precursor (CybS) (Succinate-ubiquinone reductase DHSD-HUMAN
48 Ephπn type-B receptor 6 precursor (Tyrosiπe-protem kinase-defective receptor EPH-6) (HEP) EPHB6_HUMAN Y
49 RGS19 interacting protein 1 (GAIP C-termmus interacting protein GIPC) (RGS-GAlP interacting protein) (Tax interaction protein 2) (TIP-2) GIPC-HUMAN
50 Protein C18orf1 CS001_HUMAN
51 Probable G-proteiπ coupled receptor 25 GPR25-HUMAN
52 Probable G protein coupled receptor 31 GPR31_HUMAN
53 Putative G-protein coupled receptor 40 GPR40JHUMAN
54 Putative G-protein coupled receptor 41 GPR41JHUMAN
55 Dihydroxyacetone phosphate acyltransferase (EC 23 1 42) (DHAP-AT) (DAP-AT) (Glycerone-phosphate O-acyltraπsferase) (Acyl-
56 Guanine nucleotide-bmding protein beta subunit 5 (Transduciπ beta chain 5) (Gbetaδ) GBB5_HUMAN
57 GDNF family receptor alpha 2 precursor (GFR-alpha 2) (Neurtunπ receptor alpha) (NTNR-alpha) (NRTNR-alpha) (TGF beta related GFRA2_HUMAN Y
58 Hyaluronaπ synthase 3 (EC 241 212) (Hyaluronate synthase 3) (Hyaluronic acid synthase 3) (HA synthase 3) HAS3_HUMAN
59 HS1-bιndιng protein (HS1-assocιating protein X-1) (HAX-1) HAX1_HUMAN
60 Fπzzled 9 precursor (Fπzzled-9) (Fz-9) (hFz9) (FzE6) FZD9.HUMAN Y
61 Guanine nucleotide-bmding protein G(I)/G(S)/G(O) gamma-T2 subunit (G gamma-C) (G gamma-8) (G-gamma 9) GBGT2JHUMAN
62 Gamma-aminobutyπc-acid receptor delta subunit precursor (GABA(A) receptor) GBRD-HUMAN Y
63 Gamma-aminobutyπc-acid receptor pi subunit precursor (GABA(A) receptor) GBRP-HUMAN Y
64 27 kDa Golgi SNARE protein (Golgi SNAP receptor complex (Membrin) GOSR2_HUMAN
65 Probable G protein coupled receptor 171 (G-protein coupled receptor H963) _. GP171_HUMAN
Extracellular Integral
PID Description UπiProt ACC Signal Secreted Domain Membrane Type I Type Il Type 111 Type IV Mitochondrial Golgi
66 Penpheral plasma membrane protein CASK (EC 271 -) (hCASK) (Calcium/calmodulm-dependent serine protein kinase) (bn-2 homolog) CSKP_HUMAN
67 lmportin alpha-3 subunit (Karyopheπn alpha-3 subunit) (SRP1-gamma) IMA3_HUMAN
68 lmportin beta-3 (Karyopheπn beta-3) (Ran-binding protein S) (RanBPδ) IMB3_HUMAN
69 Neuropιlιn-1 precursor (Vascular endothelial cell growth factor 165 receptor) NRPI-HUMAN
70 RER1 protein RER-f HUMAN
71 Integπn beta 1 binding protein 1 (Integnn cytoplasmic domain- associated protein 1) (ICAP-1) ITBP1_HUMAN
72 ERC protein 2 ERC2_HUMAN
73 Ladiπiπ 1 (Lad-1) (120 kDa linear IgA bullous dermatosis kDa linear IgA bullous dermatosis antigen) (Linear IgA disease LAD1_HUMAN
74 Matπlιπ-2 precursor(UNQ193/PRO219) MATN2_HUMAN
75 Matnlιπ-3 precursor MATN3JHUMAN
76 Leukocyte cell-deπved chemotaxin 2 precursor (hLECT2) LECT2JHUMAN
77 Galectιn-8 (Gal-8) (Prostate carcinoma tumor antigen 1) (PCTA-1) (Po66 carbohydrate-binding protein) (P066-CBP) LEG8_HUMAN
78 Epiregulin precursor EREG-HUMAN
79 Beta-1 3-N-acetylglucosamιnyltransferase manic fπnge (EC 241 222) (0-fucosylpeptlde 3-beta-N-acetylglucosamιnyltransferasθ) MFNG-HUMAN
80 Laminin alpha-5 chain precursor LAMAS_HUMAN
81 Metabotropic glutamate receptor 8 precursor (mGIuRβ) MGR8_HUMAN
82 Microsomal glutathione S-traπsferase 3 (EC 25 1 18) (Microsomal GST-3) (Microsomal GST-III) MGST3_HUMAN
83 Natural cytotoxicity tnggenng receptor 3 precursor (Natural killer cell p30-related protein) (NKp30) (NK-p30) NCTR3_HUMAN
84 Muscle, skeletal receptor tyrosine protein kinase precursor (EC 271 112) (Muscle-specific tyrosine protein kinase receptor) MUSK-HUMAN
85 Protein KIAA0286 K0286_HUMAN
86 LIN-7 homolog A (LIN-7A) (hϋn-7) (Mammalian UN-seven protein 1) (MALS-1) (Vertebrate LIN 7 homolog 1) (Velι-1 protein) (Tax LIN7A_HUMAN
87 Senne palmitoyltransferase 1 (EC 23 1 50) (Long chain base biosynthesis protein 1) (LCB 1) (Seπne-palmitoyl-CoA transferase 1) LCB1_HUMAN
88 Mannan binding lectin senne protease 2 precursor (EC 3421 -) (Mannose-binding protein associated senne protease 2) (MASP-2) (MBL- MASP2_HUMAN
89 Phosphatιdylιnosιtol-4-phosphate 3-kιnase C2 domain-containing beta polypeptide (EC 271 154) (Phosphomositide 3-Kϊnase-C2-beta) P3C2B_HUMAN
90 Leukocyte specific transcript 1 protein (B144 protein) LSTI-HUMAN
91 Membrane associated progesterone receptor component 1 (mPR) PGRC1_HUMAN
92 Membrane associated progesterone receptor component 2 (Progesterone membrane binding protein) (Steroid receptor protein DG6) PGRC2_HUMAN
93 Niemaπn-Pick C1 protein precursor NPC1_HUMAN
94 Lipid phosphate phosphohydrolase 1 (EC 3 1 34) (Phosphatide acid phosphatase 2a) (Phosphatidate phosphohydrolase type 2a) (PAP2a) LPP1_HUMAN
95 ϋpid phosphate phosphohydrolase 3 (EC 3 1 34) (Phosphatide acid phosphatase 2b) (Phosphatidate phosphohydrolase type 2b) (PAP2b) LPP3_HUMAN
96 Heparan sulfate glucosamine 3 O-sulfotransferase 1 precursor (EC 28223) (Heparan sulfate D-gIucosamιny[ 3-0 sulfαtraπεferase 1) OSTI-HUMAN
97 cGMP-dependent 3',5'-cycllc phosphodiesterase (EC 3 1417) (Cyclic GMP stimulated phosphodiesterase) (CGS-PDE) (cGSPDE) PDE2A_HUMAN
98 Proteinase activated receptor 3 precursor (PAR-3) (Thrombin receptor- like 2) (Coagulation factor Il receptor-like 2) PAR3_HUMAN
99 Leptiπ receptor gene-related protein (OB-R gene related protein) (OB-RGRP) OBRG_HUMAN
100 Peroxisome assembly protein 12 (Peroxιn-12) (Peroxisome assembly factor-3) (PAF-3) PEX12_HUMAN
101 Netnn-2 like protein precursor NET2_HUMAN
102 Visual pigment like receptor peropsin OPSX_HUMAN
103 Nedd4-bιndιng protein 3 (N4BP3) N4BP3_HUMAN
104 Nephrocystin 1 (Juvenile πephroπophthisis 1 protein) NPH1_HUMAN
105 Sodium-dependent phosphate transport protein 3 (Sodium/phosphate cotransporter 3) (Na(+)/Pl cotransporter 3) NPT3JHUMAN
106 Sodium-dependent phosphate transport protein 4 (Sodium/phosphate cotransporter 4) (Na(+)/PI cotransporter 4) NPT4JHUMAN
107 Potassium channel subfamily K member 1 (Inward rectifying potassium channel protein TWIK-1) (Potassium channel KCNO1) KCNK1JHUMAN
108 Potassium channel subfamily K member 3 (Acid-sensitive potassium channel protein TASK-1) (TWIK-related acid-sensitive K(+) channel 1} KCNK3_HUMAN
109 PDZ domain containing protein 3 (PDZ domain containing protein (Activated in prostate cancer protein) PDZK3 HUMAN
110 Prostaglandin E2 receptor, EP3 subtype (Prostanoid EP3 receptor) (PGE receptor, EP3 subtype) (PGE2-R) PE2R3JHUMAN
111 Podocalyxin-like protein 1 precursor PODXL_HUMAN
112 RIM binding protein 2 (RIM-BP2) RIMB2_HUMAN
113 1 acyl-sn-glycerol-3 phosphate acyltransferase beta (EC 231 51) (1-AGP acyltraπsferase 2) (1-AGPAT 2) (Lysophosphatidic acid PLCB_HUMAN
114 Phospholipase D2 (EC 31 44) (PLD 2) (Choline phosphatase 2) (Phosphatidylcholine-hydrolyzing phospholipase D2) (PLD1C) (hPLD2) PLD2JHUMAN
115 Olfactory receptor 7A17 OR7AH_HUMAN
116 Receptor-binding cancer antigen expressed on SiSo cells (Cancer associated surface antigen RCAS1) (Estrogen receptor-binding fragment-
117 Receptor-type tyrosine-protein phosphatase T precursor (EC 3 1 348) (R-PTP-T) (RPTP-rho)
118 Ubiquiπol-cytochrome c reductase complex 64 kDa protein (EC 1 1022) (Complex III subunit Xl) UCR11JHUMAN
119 Putative P2Y puπnoceptor 10 (P2Y10) (P2Y-Iιke receptor) P2Y10JHUMAN
120 RING finger protein 103 (Zinc finger protein 103 homolog) (KF-1) (hKF-1) RN103_HUMAN
121 Semaphoπn3E precursor SEM3E_HUMAN
122 RιbonucleaseT2 precursor (EC 3 1 27 -) (Ribonuclease 6) RNT2_HUMAN
123 Phospholemman precursor (FXYD domain-containing ion transport regulator 1) PLM-HUMAN
124 Procollagen lysine 2-oxoglutarate 5-dιoxygenase 2 precursor (EC 1 14 11 4) (Lysyl hydroxylase 2) (LH2) PLOD2JHUMAN
125 Sodium/πudeoside cotransporter 1 {Na(+ynuc!eosιde cotransporter 1) (Sodium-coupled nucleoside transporter 1) (Concentrative nucleoside S28A1_HUMAN
126 Pro-neuregulιn-2 precursor (Pro-NRG2) [Contains Neuregulιn-2 (NRG 2) (Neural and thymus-denved activator for ERBB kinases) (NTAK) NRG2_HUMAN
127 Ras-related protein M-Ras (Ras-related protein R-Ras3) RASM_HUMAN
128 Signal-regulatory protein beta-1 precursor (SIRP-beta-1) SIRB1_HUMAN
129 Prostaglandin E synthase (EC 53993) (Microsomal glutathione S-transferase 1-lιke 1) (MGST1-L1) (p53-ιnduced apoptosis protein 12)
130 Phospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-dependeπt phospholipid scramblase 1) (Erythrocyte phospholipid scramblase) PLS1_HUMAN
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000077_0001
Figure imgf000078_0001
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type 1 Type Il Type IH Type IV Mitochondrial Golgi
456 Neuropeptides B/W receptor type 1 (G protein coupled receptor 7) GPR7_HUMAN Y Y
457 Neuropeptides B/W receptor type 2 (G-protein coupled receptor 8) GPR8_HUMAN Y Y
458 Platelet glycoprotein V precursor (GPV) (CD42D) GPV.HUMAN Y Y Y
459 Complement factor H-related protein 2 precursor (FHR-2) (H factor-like protein 2) (H factor-like 3) (DDESK59) FHR2_HUMAN Y Y
460 Glycine receptor beta chain precursor (Glycine receptor 58 kDa subumt) GLRB-HUMAN Y Y Y
461 Radiation-mducible immediate-early gene IEX-1 (Immediate early protein GLY96) (Immediate early response 3 protein) (PACAP-responsive IEX1_HUMAN Y Y
462 Probable G-protein coupled receptor 109B (G-protein coupled receptor HM74) G109BJHUMAN Y Y
463 Galanin receptor type 1 (GAL1-R) (GALR1) GALR1_HUMAN Y Y
464 Gamma-aminobutyπc-acid receptor alpha-2 subunit precursor (GABA(A) receptor) GBRA2_HUMAN Y Y Y
465 Gamma ammobutyπc-acid receptor alpha-4 subunit precursor (GABA(A) receptor) GBRA4_HUMAN Y Y Y
466 Gamma-aminobutync-acid receptor beta-2 subunit precursor (GABA(A) receptor) GBRB2_HUMAN Y Y Y
467 Glucagon receptor precursor (GL-R) GLR_HUMAN Y Y Y
468 Hyaluroπidase 1 precursor (EC 32135) (Hyal-1) (Hyaluroπidase PH-20) (Sperm surface protein PH-20) (Sperm adhesion molecule 1) HYAL1_HUMAN Y
469 Glutamate receptor 1 precursor (GIuR-I) (GIuR-A) (GIuR-KI) (Glutamate receptor ionotropic AMPA 1) GRIA1_HUMAN Y Y Y
470 Glutamate receptor 2 precursor (GluR-2) (GIuR B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) GRIA2_HUMAN Y Y Y
471 Glutamate receptor 3 precursor (Glutamate receptor ionotropic, AMPA 3) GRIA3_HUMAN Y Y Y
472 Glutamate receptor 4 precursor (GluR-4) (GluR4) (GIuR-D) (Glutamate receptor ionotropic AMPA 4) GRIA4_HUMAN Y Y Y
473 Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GluR-5) (GluRδ) (Excitatory amino acid receptor 3) (EAA3) GRIK1_HUMAN Y Y Y
474 Glioma pathogenesis-related protein 1 precursor (GIiPR 1) (RTVP-1 protein) GLIP1JHUMAN Y
475 Interferon-alpha/beta receptor beta chain precursor (IFN-alpha-REC) (Jype I interferon receptor) (IFN-R) (Interferon alpha/beta INAR2_HUMAN Y Y Y
476 Interferon-gamma receptor beta chain precursor (Interferon-gamma receptor accessory factor-1) (AF-1) (Interferoπ-gamma transducer-1) INGR2_HUMAN Y Y Y
477 Interferon-alpha induced 115 kDa protein (p27) (ISG12(a) protein) INI7_HUMAN Y
478 Neuron specific protein family member 1 (Brain neuron cytoplasmic protein 1) (D4S234) NSG1_HUMAN Y
479 Nuclear pore glycoprotein p62 (62 kDa nucleoponπ) NUP62_HUMAN
480 lnterleukin 12 receptor beta-1 chain precursor (IL-12R betai) (lnterleukιn-12 receptor beta) (IL-12 receptor beta component) I12R1_HUMAN Y Y Y
481 ATP-sensitive inward rectifier potassium channel 1 (Potassium channel, inwardly rectifying, subfamily J, member 1) (ATP-regulated potassturr IRK1_HUMAN Y Y
482 G protein-activated inward rectifier potassium channel 1 (G1RK1) (Potassium channel, inwardly rectifying, subfamily J, member 3) IRK3_HUMAN Y Y
483 Inward rectifier potassium channel 4 (Potassium channel, inwardly rectifying, subfamily J, member 4) (Inward rectifier K(+) channel IRK4_HUMAN Y Y
484 G protein-activated inward rectifier potassium channel 4 (GIRK4) (Potassium channel, inwardly rectifying subfamily J, member 5) IRK5_HUMAN Y Y
485 G protein-activated inward rectifier potassium channel 2 (Gl RK2) (Potassium channel, inwardly rectifying, subfamily J, member 6) IRK6_HUMAN Y Y 486 lnterieukιn-15 precursor (IL-15) IL15_HUMAN Y Y 487 Killer cell immunoglobulin-like receptor 2DL1 precursor (MHC class I NK cell receptor) (Natural killer associated transcπpt 1) (NKAT-1) KI2L1_HUMAN Y Y Y
488 Killer cell immunoglobulm-like receptor 2DL2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 6) (NKAT-6) KI2L2_HUMAN Y Y Y
489 Killer cell immuπoglobuliπ-like receptor 2DL3 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 2) (NKAT-2) KI2L3_HUMAN Y Y Y
490 Killer cell immuπoglobulm-like receptor2DS2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 5) (NKAT-5) KI2S2_HUMAN Y Y Y
491 Killer cell immunoglobulm-like receptor2DS4 precursor (MHC class I NK cell receptor) (Natural killer associated transcπpt 8) (NKAT-8) KI2S4JHUMAN Y Y Y
492 Killer cell immunoglobuliπ-like receptor 3DL1 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 3) (NKAT-3) KI3L1_HUMAN Y Y Y
493 Killer cell immunoglobuliπ-llke receptor 3DL2 precursor (MHC class I NK cell receptor) (Natural killer associated transcπpt 4) (NKAT-4) KI3L2JHUMAN Y Y Y
494 Matπn3 MATR3JHUMAN
495 Galectιn-7 (Gal-7) (HKL-14) (PI7) (p53-ιnduced protein 1) LEG7JHUMAN Y
496 Platelet-activating factor acetylhydrolase IB alpha subunit (PAF acetylhydrolase 45 kDa subunit) (PAF-AH 45 kDa subunit) (PAF-AH LIS1_HUMAN
497 ERGIC-53 protein precursor (ER-Golgi intermediate compartment 53 kDa protein) (Lectin maπnose binding 1) (Gp58) (Intracellular maππose LMAN1_HUMAN Y Y
498 lnterieukιn-6 receptor beta chain precursor (IL-6R-beta) (lnterleukin 6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin M IL6RB__HUMAN Y Y Y Y
499 Mpv17 protein MPV17JHUMAN Y
500 Metabotropic glutamate receptor 5 precursor (mGluRδ) MGR5_HUMAN Y Y Y
501 Melanocortin-3 receptor (MC3-R) MC3R_HUMAN Y Y
502 Probable G-protein coupled receptor 12 GPR12_HUMAN Y Y
503 Cell surface glycoprotein MUC18 precursor (Melanoma-associated antigen MUC18) (Melanoma associated antigen A32) (S-endo 1 eπdotheli. MUC18_HUMAN Y Y Y
504 Melanoma-associated antigen 1 (MAGE-1 antigen) (Antigen MZ2-E) MAGA1 JiUMAN
505 Leukemia inhibitory factor receptor precursor (LIF-R) LlFR_HUMAN Y Y Y Y
506 ϋgatin (Hepatocellular carcinoma associated antigen 56) LIGA-HUMAN
507 Lamina-associated polypeptide 2 isoform alpha (Thymopoietin isoform alpha) (TP alpha) (Thymopoietiπ-related peptide isoform alpha) (TPRP LAP2AJHUMAN
508 Lamina-associaled polypeptide 2 isoforms beta/gamma (Thymopoietin, isoforms beta/gamma) (TP beta/gamma) (Thymopoietin related peptic LAP2B_HUMAN Y
509 Leptin receptor precursor (LEP-R) (OB receptor) (OB-R) (HuB219) LEPR_HUMAN Y Y Y Y
510 Interferon delta-1 precursor IFND-T.HUMAN Y Y
511 Complement-activating component of Ra reactive factor precursor (EC 3421 -) (Ra-reactive factor senne protease p1O0) (RaRF) MASP1_HUMAN Y
512 Melatonin receptor type 1A (MeHA-R) (MeHa melatonin receptor) MTR1A_HUMAN Y Y
513 Melatonin receptortype iB fMel-IB-RMMeHbmelatonin receptor) MTR1B_HUMAN Y Y
514 Integπn alpha-E precursor (Mucosal lymphocyte-1 antigen) (HML-1 antigen) (CD103 antigen) (Integπn alpha-IEL) ITAE_HUMAN Y Y Y
515 Choline phosphate cytidylyltransferase A (EC 27715) (Phosphorylcholine transferase A) (CTP phosphocholine PCY1A_HUMAN
516 Potassium voltage-gated channel subfamily C member 1 (Voltage-gated potassium channel subunit Kv31) (Kv4) (NGK2) KCNC1_HUMAN Y
517 Phosphatιdylιnosιtol N-acetylglucosamιnyltransferase suDunιtA (EC24 1 198) (GIcNAc-PI synthesis protein) (Phosphatidylinositol- PIGAJHUMAN Y
518 Neurogenic locus notch homolog protein 1 precursor (Notch 1) (Translocation-associated notch protein TAN-1) NOTC1_HUMAN Y Y Y
519 NOV protein homolog precursor (NovH) (Nephroblastoma overexpressed gene protein homolog) NOV-HUMAN Y Y
520 Dolichyl-diphosphooligosacchaπde-protein glycosyltraπsferase 48 kDa subunit precursor (EC 24 1 119) (Oligosaccharyl transferase 48 kDa OST48_HUMAN Y Y
Figure imgf000080_0001
Extracellular Integra!
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type il Type Ut Type IV Mitochondrial Golgi
586 Tumor necrosis factor ligand superfamily member 9 (4-1BB ligaπd) (4-1BBL) TNFL9_HUMAN Y Y
587 Thrombopoietin receptor precursor (TPO-R) (Myeloproliferative leukemia protein) (C-mpl) (CD110 antigen) TPOR_HUMAN Y Y
588 Thrombopoietin precursor (Megakaryocyte colony stimulating factor) (Myeloproliferative leukemia virus oncogene ligand) (C-mpl ligand) TPO_HUMAN Y Y
589 Vitamin K-depeπdent gamma-carboxylase (EC 64 --) (Gamma-glutamyl carboxylase) VKGC_HUMAN
590 Sterol regulatory element binding proteιn-1 (SREBP-1) (Sterol regulatory element-binding transcnptioπ factor 1) SRBP1_HUMAN
591 Signal recognition particle 9 kDa protein (SRP9) SRP09JHUMAN
592 Tumor necrosis factor receptor superfamily member 4 precursor (OX40L receptor) (ACT35 antigen) (TAX-transcπptioπally activated TNR4_HUMAN Y
593 Utrophiπ (Dystrophin-related protein 1) (DRP1) (DRP) UTROJHUMAN
594 Vasopressin Via receptor (V1aR) (Vascular/hepatic type arginiπe vasopressin receptor) (Antidiuretic hormone receptor 1a) (AVPR Via) V1ARJHUMAN
595 Vasopressin V1b receptor (V1bR) (AVPR V1b) (Vasopressin V3 receptor) (AVPR V3) (Antidiuretic hormone receptor 1b) V1BR_HUMAN
596 Wnt-5a protein precursor WNT5AJHUMAN Y
597 Short transient receptor potential channel 1 (TrpC1) (TRP-1 protein) TRPC1_HUMAN
598 Lymphotactin precursor (XCL1) (Cytokine SCM-1) (ATAC) (Lymphotaxiπ) (SCM-1-alpha) (Small inducible cytokine C1) (XC chemokine hgaπd XCL1_HUMAN Y
599 Chemokine XC receptor 1 (XC chemokine receptor 1) (Lymphotactin receptor) (G-protein coupled receptor 5) XCR1_HUMAN
600 Dopachrome tautomerase precursor (EC 533 12) (DT) (DCT) (Dcpachrome delta-isomerase) (Tyrosmase-related protein 2) (TRP-2) (TRP2) TYRP2_HUMAN Y
601 Cytochrome c-type heme lyase (EC 441 17) (CCHL) (Holocytochrome c-type synthase) CCHL-HUMAN
602 Eotaxin precursor (Small inducible cytokine A11) (CCL11) (Eosinophil chemotactic protein) CCL11_HUMAN Y
603 Small inducible cytokine A18 precursor (CCL18J (Macrophage inflammatory protein 4) (MlP-4) (Pulmonary and activation-regulated CCL18_HUMAN Y
604 Small inducible cytokine A23 precursor (CCL23) (Macrophage inflammatory protein 3) (MIP-3) (Myeloid progenitor inhibitory CCL23_HUMAN Y
605 5-hydroxytryptamιne 6 receptor (5-HT-6) (Serotonin receptorβ) 5HT6R_HUMAN
606 C-C chemokine receptor type 3 (C-C CKR-3) (CC CKR-3) (CCR-3) (CKR3) (Eosinophil eotaxin receptor) CCR3JHUMAN
607 C-C chemokine receptor type 4 (C-C CKR-4) (CC-CKR-4) (CCR-4) (K5-5) CCR4~HUMAN
608 C-C chemokine receptor type 6 (C-C CKR-6) (CC-CKR-6) (CCR-6) receptor) (GPR-CY4) (GPRCY4) (Chemokine receptor-like 3) (CKR-L3) CCR6J-IUMAN
609 C-C chemokine receptortype 8 (C-C CKR-8) (CC-CKR 8) (CCR-8) (GPRCY6) (Chemokine receptor-like 1) (CKR-L1) (TER1) (CMKBRL2) CCR8_HUMAN
610 C-C chemokine receptor type 9 (C-C CKR-9) (CC-CKR 9) (CCR-9) (GPR-9-6) CCR9_HUMAN
611 Collagen alpha 4(IV) chain precursor CO4A4_HUMAN Y
612 Aquaponn 4 (WCH4) (Mercuπal-msensitive water channel) (MIWC) AQP4_HUMAN
613 Aquaponn 5 AQP5JHUMAN
614 B-cell receptor-assoαated protein 31 (BCR-associated protein Bap31) (p28 Bap31) (CDM protein) (6C6-AG tumor associated antigen) BAP31_HUMAN
615 Annexiπ A11 (Anπexin Xl) (Calcyclin assoαated aπnexin 50) (CAP-50) (56 kDa autoantigen) ANX11_HUMAN
616 Cartilage oligomeπc matrix protein precursor (COMP) COMP_HUMAN Y
617 Sodium/potasstum-transpαrtiπg ATPase gamma chain (Sodium pump gamma chain) (Na+/K+ ATPase gamma subunit) (FXYD domain-contaii ATNG-HUMAN
618 Potassium-transporting ATPase beta chain (Proton pump beta chain) (Gastπc H+/K+ ATPase beta subunit) ATP4BJHUMAN
619 ATP synthase epsilon chain, mitochondπal (EC 36314) ATP5E_HUMAN
620 Adapter-related protein complex 1 sigma 1B subunit (Sigma-adaptiπ 1B) (Adaptor protein complex AP-1 Sigma 1B subunit) (Golgi adaptor HA AP1S2_HUMAN
621 Clathππ coat assembly protein AP17 (Clathπn coat associated protein AP17) (Plasma membrane adaptor AP 217 kDa protein) (HA2 AP2S1JHUMAN
622 Adapter-related protein complex 3 mu 2 subunit (Clathrin coat protein AP47 homolog 2) (Clafhπn coat associated protein AP47 AP3M2JHUMAN
623 Caveolιn-2 CAV2_HUMAN
624 Caveolιn-3 (M-caveolin) CAV3_HUMAN
625 ATP synthase f chain, mιtochondπal (EC 36314) ATPK_HUMAN
626 Adenylate cyclase, type VII (EC 46 1 1) (ATP pyrophosphate-lyase 7) (Adenylyl cyclase 7) ADCY7JHUMAN
627 Arfaptn 1 (ADP-πbosylation factor interacting protein 1) ARFP1_HUMAN
628 Fatty aldehyde dehydrogenase (EC 1 21 3) (Aldehyde dehydrogenase, microsomal) (Aldehyde dehydrogenase family 3 member A2) AL3A2JHUMAN
629 ATP synthase e chain, mitochondπa[ (EC 36314) ATP5I_HUMAN
630 Potassium-transporting ATPase alpha chain 2 (EC 36310) (Proton pump) (Non gastπc H(+)/K(+) ATPase alpha subunit) AT12A_HUMAN
631 Amyloid-like protein 1 precursor (APLP) (APLP-1) [Contains C30] APLP1JHUMAN Y
632 Breast cancer type 2 susceptibility protein BRCA2_HUMAN
633 Dihydropyndme-sensitive L-type, calcium channel alpha-2/delta subunits precursor CAC2D_HUMAN Y Y
634 Sodium/potassium-transporting ATPase alpha 2 chain precursor (EC 3639) (Sodium pump 2) (Na+/K+ ATPase 2) AT1A2_HUMAN Y
635 Sodium/potassium-transporting ATPase beta-3 chain (Sodium/potassium- dependent ATPase beta-3 subunit) (ATPB 3) AT1B3_HUMAN Y
636 Chloπde channel protein CIC-Ka (Chloπde channel Ka) (CIC-K1) CLCKA_HUMAN Y Y
637 Chloπde channel protein CIC-Kb (Chlonde channel Kb) (CIC-K2) CLCKBJHUMAN Y Y
638 Chlonde channel protein 2 (ClC-2) CLCN2_HUMAN Y Y
639 Chloride channel protein 4 (CIC-4) CLCN4_HUMAN Y
640 Chloride channel protein 5 (CIC-5) CLCN5 HUMAN Y
641 Chloride channel protein 6 (CIC-6) CLCN6J-IUMAN Y
642 Chlonde channel protein 7 (ClC 7) CLCN7JHUMAN Y
643 Claudιn-15 CLD15_HUMAN Y
644 Claudin 6 (Skullin 2) (UNQ757/PRO1488) CLD6_HUMAN Y
645 Clathnπ heavy chain 2 (CLH-22) CLH2JHUMAN
646 Diacylgiycerol kinase, epsilon (EC 271 107) (Diglyceπde kinase) (DGK-epsiloπ) (DAG kinase epsilon) DGKEL.HUMAN
647 Bax ιnhibιtor-1 (BI-1) (Testis enhanced gene transcript) BI1_HUMAN
648 Dynamιn2 (EC 3655) DYN2 HUMAN
649 C-X-C chemokine receptortype 3 (CXC-R3) (CXCR-3) (CKR-L2) (CD183 antigen) CXCR3_HUMAN
650 Coatomer alpha subunit (Alpha-coat protein) (Alpha-COP) (HEPCOP) (HEP- COP) [Contains Xeπin (Xenopsin related peptide) Proxenin] COPAJHUMAN
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Extracellular Integral
PlD Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1106 Lamiπ B2 LAM2JHUMAN
1107 Putative mucin core protein 24 precursor (MULTI-glycosylated core protein 24) (MGC-24) (MUC-24) (CD164 antigen) MUC24JHUMAN
1108 Mucin 2 precursor (Intestinal mucin 2) MUC2 JHUMAN
1109 Mucin 3A (Intestinal mucin 3A) (Fragments) MUC3A_HUMAN
1110 Protein KIAA0195 K0195JHUMAN
1111 lnterleukιπ-9 receptor precursor (IL-9R) IL9R_HUMAN
1112 lnterleukιn-1 receptor-like 1 precursor (ST2 protein) ILRL1_HUMAN
1113 Nomn precursor (Nome disease protein) NDP_HUMAN
1114 Large neutral ammo acids transporter small subunit 1 (L-type acid transporter 1) (4F2 light chain) (4F2 LC) (4F2LC) LAT1_HUMAN
1115 Induced myeloid leukemia cell differentiation protein Mcl-1 MCL1 JHUMAN
1116 Interferon-induced transmembrane protein 2 (Interferon-inducible protein 1-8D) 1FM2JHUMAN
1117 Interferon induced transmembrane protein 3 (Interferon-inducible protein 1-8U) 1FM3_HUMAN
1118 Lysyl oxidase homolog 1 precursor (EC 1 43 -) (Lysyl oxidase-like protein 1) (LOL) LOXL1_HUMAN
1119 Phosphate carrier protein, mitochondπal precursor (PTP) (OK/SW- cl 48) MPCP_HUMAN
1120 Protein kinase C, delta type (EC 271 -) (nPKC-delta) KPCD_HUMAN
1121 NKG2-E type Il integral membrane protein (NKG2-E activating NK receptor) (NK cell receptor E) NKG2E_HUMAN
1122 Potassium voltage-gated channel subfamily C member 4 (Voltage-gated potassium channel subunit Kv34) (KSHIIIC) KCNC4JHUMAN
1123 Potassium voltage-gated channel subfamily H member 2 (Voltage-gated potassium channel subunit Kv11 1) (Ether-a-go-go related gene KCNH2_HUMAN
1124 Pancreatitis-associated protein 1 precursor (Regenerating islet- derived protein 3 alpha) PAP1_HUMAN
1125 Mitochondπal processing peptidase alpha subunit, mitochondπal precursor (EC 342464) (Alpha-MPP) (P-55) (HA1523) MPPA_HUMAN
1126 Phosphatldylinositol-glycaπ biosynthesis, class F protein (PIG-F) PIGF_HUMAN
1127 Neurogenic locus notch homolog protein 2 precursor (Notch 2) NOTC2JHUMAN
1128 CDC42 effector protein 1 (Serum protein MSE55) MSE55_HUMAN
1129 Melanocyte stimulating hoimone receptor (MSH-R) (Melanotropin receptor) (Melanocortin-1 receptor) (MC1-R) MSHR_HUMAN
1130 Basic salivary proline-nch protein 3 precursor (Parotid salivary glycoprotein G1) (Proline-nch protein G1) PRB3_HUMAN
1131 GIutamate [NMDA] receptor subunit zeta 1 precursor (N-methyl-D- aspartate receptor subunit NR1) NMDZ1JHUMAN
1132 Penpheral myelin protein 22 (PMP-22) PMP22 JHUMAN
1133 Inositol polyphosphate 5 phosphatase OCRL-1 (EC 31 336) (Lowe's oculocerebrorenal syndrome protein) OCRLJHUMAN
1134 Protein kinase C, zeta type (EC 271 37) (nPKC-zeta) KPCZ_HUMAN
1135 Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor) PTHR1_HUMAN
1136 Basement membrane-specific heparan sulfate proteoglycan core protein precursor (HSPG) (Periecaπ) (PLC) PGBM_HUMAN
1137 Polycystin 1 precursor (Autosomal dominant polycystic kidney disease protein 1) PKD1_HUMAN
1138 Pregnancy-specific beta-1-glycoprotein 4 precursor (PSBG-4) (PSBG-9) PSG4JHUMAN Y
1139 Pregnancy-specific beta-1-glycoproteιπ 6 precursor (PSBG 6) PSG6_HUMAN Y
1140 Pregnancy-specific beta 1-glycoprotein 9 precursor (PSBG-9) (Pregnancy specific glycoprotein 9) (Pregnancy-specific beta-1 PSG9_HUMAN Y
1141 Protocadheπn 1 precursor (Protocadheπn 42) (PC42) (Cadherin-like protein 1) PCDH1_HUMAN
1142 Renal sodium-dependent phosphate transport protein 2 (Sodium/phosphate cotraπsporter 2) (Na(+)/Pι cotransporter2) (Renal sodium-phospr NPT2JHUMAN
1143 P protein (Melanocyte-specific transporter protein) (Pink-eyed dilution protein homolog) PJHUMAN
1144 1-phosphatιdyIιnosιtol-4.5-bιsphosphate phosphodiesterase beta 3 (EC 3 1 4 11) (Phosphoinositide phospholipase C) (PLC-beta-3) PLCB3JHUMAN
1145 Sodium channel beta 1 subunit precursor SCN1BJHUMAN
1146 Pro-πeuregulιn-1 precursor (Pro-NRG1) [Contains Neuregulιπ-1 (Neu differentiation factor) (Hereguliπ) (HRG) (Breast cancer cell NRG1JHUMAN
1147 Regulator of G-protein signaling 1 (RGS1) (Early response protein 1R20) (B-cell activation protein BL34) RGS1JHUMAN
1148 Rhesus blood group-associated glycoprotein (Rhesus blood group- associated ammonia channel) (Erythrocyte plasma membrane 50 kDa RHAGJHUMAN
1149 Blood group Rh(D) polypeptide (Rhesus D antigen) (RHXIII) (Rh polypeptide 2) (RhPII) RHDJHUMAN
1150 Dihydroorotate dehydrogenase, mitochondπal precursor (EC 1 331) (Dihydroorotate oxidase) (DHOdehaεe) PYRDJHUMAN
1151 Procollagen-lysine 2-oxogIutarate 5-dιoxygeπase 1 precursor (EC 1 1411 4) (Lysyl hydroxylase 1) (LH1) PLOD1 JHUMAN
1152 Proteolipid protein 2 (Intestinal membrane A4 protein) (Differentiation dependent protein A4) (Proteolipid protein 2) PLP2JHUMAN
1153 Sodium channel protein type VIl alpha subunit (Putative voltage-gated sodium channel alpha subunit Nax) (Sodium channel protein, cardiac SCN7AJHUMAN
1154 Semenogelιn-2 precursor (Semenogelm II) (SGII) SEMG2JHUMAN
1155 Small inducible cytokine B9 precursor (CXCL9) (Gamma interferon induced monokine) (MIG) SCYB9 JHUMAN
1156 Neutral and basic ammo acid transport protein rBAT (B(O,+)-type acid transport protein) (NBAT) (D2H) SLC31 JHUMAN
1157 ROD outer segment membrane protein 1 (ROSP1) ROM1JHUMAN
1158 Macrophage-stimulating protein receptor precursor (EC 271 112) (MSP receptor) (p185 Ron) (CDW136) (CD136 antigen) RON-HUMAN
1159 Tyrosine-protein kinase transmembrane receptor ROR1 precursor (EC 271 112) (Neurotrophic tyrosine kinase, receptor-related 1) ROR1 JHUMAN
1160 Tyrosine-protein kinase transmembrane receptor ROR2 precursor (EC 271 112) (Neurotrophic tyrosine kinase, receptor-related 2) ROR2 JHUMAN
1161 Trefoil factor 3 precursor (Intestinal trefoil factor) (hP1 B) TFF3 JHUMAN
1162 TGF-beta receptor type 111 precursor (TGFR-3) (Transforming growth factor beta receptor III) (Betaglycan) TGBR3JHUMAN
1163 Antigen peptide transporter 1 (APT1) (Peptide transporter TAP1) (ATP- binding cassette, sub-family B, member 2) (Peptide transporter PSF1) TAP1 JHUMAN
1164 Synaptic vesicular amine transporter (Monoamine transporter) (Vesicular amine transporter 2) (VAT2) (Solute earner family 18, VMAT2JHUMAN
1165 Testιcaπ-1 precursor (SPOCK protein) TIC1JHUMAN
1166 Aπgiopoietiπ 1 receptor precursor (EC 271 112) (Tyrosine-protein kinase receptorTIE-2) (Tyrosine-protein kinase receptor TEK) (P140 T1E2JHUMAN
1167 Sperm-associated antigen 11 precursor (EP2 protein) (Sperm antigen HE2) SPA11JHUMAN
1168 Spectnn beta chain, brain 1 (Spectππ, πoπ-erythroid beta chain (Beta-II spectrin) (Fodπn beta chain) SPTB2JHUMAN
1169 Vigilin (High density lipoprotein-binding protein) (HDL-binding protein) VIGLNJHUMAN
1170 Sodium-dependent dopamine transporter (DA transporter) (DAT) SC6A3 JHUMAN
Extracellular Integral
PID Description UπiProtACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1171 Sterol regulatory element binding protein cleavage-activating protein (SREBP cleavage-activating protein) (SCAP) SCAP-HUMAN Y
1172 Tumor necrosis factor, alpha-induced protein 2 (Pnmary response geneB94 protein) TNAP2_HUMAN
1173 Lymphotoxin-beta (LT-beta) (Tumor necrosis factor C) (TNF-C) (Tumor necrosis factor ligand superfamily member 3) TNFC_HUMAN
1174 CMP-N-acetylneurammate-beta-galactosamide-alpha^ 3 sialyltransferase (EC 24994) (Beta-galactoside alpha-23-sιalyltransferase) (Alpha SIA4A_HUMAN
1175 CMP-N-acetylπeuramιnate-beta galactosamιde-alpha-2,3-sιalyltransferass (EC 2499 -) (Beta-galactoside alpha 2,3-sιalyltransferase) (Alpha SIA4C_HUMAN
1176 Very low-density lipoprotein receptor precursor (VLDL receptor) VLDLR_HUMAN Y
1177 Urokinase plasminogen activator surface receptor precursor (uPAR) (U-PAR) (Monocyte activation antigen Mo3) (CD87 antigen) UPAR_HUMAN Y
1178 Sterol regulatory element binding proteιn-2 (SREBP-2) (Sterol regulatory element-binding transcnption factor 2) SRBP2_HUMAN
1179 Tumor necrosis factor receptor superfamily member 17 (B-cell maturation protein) TNR17JHUMAN
1180 Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen 4-1 BB homolog) (T-cell antigen ILA) TNR9_HUMAN Y
1181 CMP-N-acetylπeuramιnate-beta-1,4-ga[actosιde a|pha-23-sιalyltransferase (EC 24996) (N-acetyllactosaminide SIAT6_HUMAN
1182 B-lymphocyte antigen precursor (B-lymphocyte surface antigen) (721 P) (Protein XE7) XE7_HUMAN Y
1183 Very very hypothetical protein CMAR YYY5JHUMAN
1184 Tyrosine-proteiπ kinase receptor TYR03 precursor (EC271 112) (Tyrosine-protein kinase RSE) (Tyrosine-proteiπ kinase SKY) (Tyrosine- TYR03_HUMAN Y
1185 Tight junction protein 20-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1) Z01_HUMAN
1186 Zona pellucida sperm-binding protein 2 precursor (Zona pellucida glycoprotein ZP2) (Zona pellucida protein A) ZP2_HUMAN Y
1187 Putative tumor suppressor (Hyaluronoglucosaminidase 1 isoform 1) Q12794_HUMAN
1188 TB1 protein (Fragment) Q04197_HUMAN
1189 Oncogene tyrosine protein kinase receptor (Fragment) Q04227_HUMAN
1190 GTP binding protein (Fragment) Q06976_HUMAN
1191 lnterleukιπ-1 homologue (Fragment) Q08124J-1UMAN
1192 Leukemia virus receptor 1
1193 Titin, heart isoform N2-B (EC 271 -) (Connectin) Q10466_HUMAN
1194 Nonspecific cross-reacting antigen Q03715_HUMAN
1195 High sulfur keratin (Keratin associated protein 1 1) (Keratin associated protein 1 1A) Q07627_HUMAN
1196 High sulfur keratin Q07628_HUMAN
1197 M130 antigen precursor (CD163 protein) Q07898_HUMAN Y
1198 M130 antigen extracellular vanant precursor Q07901_HUMAN Y
1199 P63 protein (Cytoskeleton-associated protein 4) Q07065~HUMAN
1200 Leukemia virus receptor 2 (Solute earner family 20 member Q08357_HUMAN
1201 ADAM 15 precursor (EC 3424-) (A disintegπn and metalloproteinase domain 15) (Metalloproteinase-like, disintegnn like and cysteine- ADA15JHUMAN Y
1202 5-hydroxytiyptamιne 4 receptor (5-HT-4) (Serotonin receptor 4) (5-HT4) 5HT4R_HUMAN
1203 CD166 antigen precursor (Activated leukocyte-cell adhesion molecule) (ALCAM) CD166_HUMAN Y
1204 Cyclic-nucleotide-gated cation channel 4 (CNG channel 4) (CNG-4) (CNG4) (Cyclic πucleotide-gated cation channel modulatory subunit) CNGB1_HUMAN
1205 Contactin i precursor (Neural cell surface protein F3) (Glycoprotein gp135) CNTN1JHUMAN Y
1206 Collagen alpha 6(IV) chain precursor CO4A6JHUMAN Y
1207 Collagen alpha 2(IX) chain precursor CO9A2_HUMAN Y
1208 Collagen alpha 3(IX) chain precursor CO9A3 J-IUMAN Y
1209 Aquaporιn 6 (Aquapoπn-2llke) (hKID) AQP6_HUMAN
1210 Putative Bcl-2 homologous antagonist/killer 2 (Apoptosis regulator BAK-2) BAK2_HUMAN
1211 BMP and activin membrane-bound inhibitor homolog precursor (Putative transmembrane protein NMA) (Noπ-metastatic gene A protein) BAMBI_HUMAN Y
1212 Dystroglycan precursor (Dystrophin-associated glycoprotein 1) [Contains Alpha-dystroglycan (Alpha-DG), Beta-dystroglycan DAG1_HUMAN Y
1213 A kinase anchor protein 6 (Protein kinase A anchoπng protein (PRKA6) (A kinase anchor protein 100 kDa) (AKAP 100) (mAKAP) AKAP6_HUMAN
1214 Adapter-related protein complex 3 beta 2 subunit (BetaSB-adaptin) (Adaptor protein complex AP-3 beta-2 subunit) (AP-3 complex beta-2 AP3B2_HUMAN
1215 Bone moφhogenetic protein receptortype Il precursor (EC 271 37) (BMP type Il receptor) (BMPR-II) BMPR2_HUMAN Y
1216 BCLΣ/adeπovirus EIB ig-kDa proteiπ-iπteracting protein 1 BNIP1JHUMAN
1217 BCLΣ/adenovirus EIB IΘ-kDa protein-interacting protein 3 BNIP3_HUMAN
1218 ADAM 9 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 9) (Metalloprotease/disintegππ/cysteine-nch protein 9) ADAM9_HUMAN Y
1219 Activin receptor type HB precursor (EC 271 37) (ACTR-IIB) AVR2B_HUMAN Y
1220 BENE protein BENEJHUMAN
1221 Carciπoembryonic antigen-related cell adhesion molecule 7 precursor (Carcinoembryoπic antigen CGM2) CEAM7_HUMAN Y
1222 Voltage-dependent L-type calcium channel alpha-1C subunit (Voltage- gated calcium channel alpha subunit Cav1 2) (Calcium channel, L CAC1C_HUMAN
1223 Voltage-dependent L-type calcium channel alpha-1S subunit (Voltage- gated calcium channel alpha subunit Cav1 1) (Calcium channel, L CAC1S_HUMAN
1224 Sodium/potassium-transporting ATPase alpha-4 chain (EC 3639) (Sodium pump 4) (Na+/K+ ATPase 4) AT1A4JHUMAN
1225 Filensin (Beaded filament structural protein 1) (Lens fiber cell beaded-filament structural protein CP 115) (CP115) (Lens intermediate BFSP1_HUMAN
1226 Phakinin (Beaded filament structural protein 2) (Lens fiber cell beaded filament protein CP 49) (CP49) (49 kDa cytoskeletal BFSP2JHUMAN
1227 Apolipoprotein F precursor (Apo-F) APOF_HUMAN Y
1228 Presynaptic protein SAP97 (Synapse-associated protein 97) (SAP-97) (Discs, large homolog 1) (hDlg) DLG1JHUMAN
1229 DGCR6 protein (DiGeorge syndrome cπtical region 6) DGCR6_HUMAN
1230 Butyrophiliπ subfamily 1 member A1 precursor (BT) BT1A1_TlUMAN Y
1231 CLN3 protein (Battenin) (Batten disease protein) CLN3_HUMAN
1232 Bcl-2 interacting killer (Apoptosis inducer NBK) (BP4) (BIP1) BIK_HUMAN
1233 Double C2-llke domain containing protein alpha (Doc2 alpha) (Doc2) DOC2A_HUMAN
1234 Double C2-lιke domain containing protein beta (Doc2 beta) DOC2B_HUMAN
1235 Chitotπosidase 1 precursor (EC 321 14) (Chitiπase 1) CHIT1_HUMAN Y
Extracellular Integral
PID Description UπiProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondπal Golgi
1236 Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2) (Corticotropiπ-releasing hormone receptor 2) (CRH-R 2) CRFR2JHUMAN Y Y Y
1237 Ectonudeotide pyrophosphatase/phosphodiesterase 2 (E-NPP 2) (Phosphodiesterase l/nudeotide pyrophosphatase 2) (Phosphodiesterase ENPP2_HUMAN Y
1238 HERV-R_7q21 2 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (ERV3 envelope protein) (ERV-3 envelope protein) (HEF ENR1 J-IUMAN Y
1239 Dentin matπx acidic phosphoprotein 1 precursor (Dentin matπx proteιn-1) (DMP-1) DMP1_HUMAN Y
1240 Dedicator of cytokinesis protein 1 (180 KDa protein downstream (DOCK180) DOCK1JHUMAN
1241 Cadherιπ-17 precursor (Liver-intestme-cadheπn) (U-cadheππ) (Intestinal peptide-associated transporter HPT-1) CAD17JHUMAN
1242 Cadheππ-18 precursor (Cadhenn-14) CAD18_HUMAN
1243 Chromatin assembly factor 1 subunit B (CAF-1 subunit B) assembly factor I p60 subunit) (CAF I 60 kDa subuπit) CAF1 BJHUMAN
1244 Flotilltn-2 (Epidermal surface antigen) (ESA) FLOT2 JHUMAN
1245 Desmogleιn-2 precursor (HDGC) DSG2 JHUMAN
1246 Follistatin-related protein 1 precursor (Follistatiπ-like 1) FSTL1 JHUMAN
1247 Protoheme IX famesyltransferase, mitochondπal precursor (EC 251 -) (Heme O synthase) COX10JHUMAN
1248 Type-1B angiotensin Il receptor (AT1B) (AT1BR) AG2SJHUMAN
1249 Maπnosyl-oligosacchande glucosidase (EC 32 1 106) (Processing A glucosidase !) GCS1 JHUMAN
1250 Growth-arrest-speαtϊc protein 6 precursor (GAS-6) GAS6 JHUMAN
1251 Transcription elongation factor B polypeptide s (RNA polymerase Il transcription factor SIII suburntAI) (SIH p110) (Eloπgin A) ELOA1JHUMAN
1252 Glycerol kinase, tests specιfic2 (EC 271 30) (ATP glycerol 3-phosphotraπsferase) (Glycerokiπase) (GK) GKP2 JHUMAN
1253 Glycerol kinase, testis specific 1 (EC 271 30) (ATP glycerol 3-phosphotransferase) (Glycerohnase) (GK) GKP3 JHUMAN
1254 Guanine πucleotide-biπding protein, alpha-13 subunit (G alpha 13) GNA13JHUMAN
1255 Dihydropyπmidine dehydrogenase [NADP+] precursor (EC 1 31 2) (DPD) (DHPDHase) (Dihydrouracil dehydrogenase) (Dlhydrothymiπe DPYDJHUMAN
1256 Dynactin subunit 2 (Dynactin complex 50 kDa subunit) (50 associated polypeptide) (p50 dynamitin) (DCTN-50) DCTN2JHUMAN
1257 EGF-like module containing mucin-like hormone receptor-like 1 precursor (Cell surface glycoprotein EMR1) (EMR1 hormone receptor) EMR1 JHUMAN
1258 Probable P2Y puπnoceptor GPR17 (P2Y-lιke receptor) (R12) GPR17JHUMAN
1259 Probable G-protem coupled receptor 18 GPR18JHUMAN
1260 Guanine nucleotide releasing protein (GNRP) (Ras-specific nucleotide exchange factor CDC25) (Ras-specific guanine nucleotide-releasing GNRPJH UMAN
1261 Flbroleukin precursor (Fibnnogen like protein 2) (pT49) FGL2JHUMAN
1262 Growth factor receptor-bound protein 10 (GRB10 adaptor protein) (Insulin receptor binding protein GRB-IR) GRB10JHUMAN
1263 Fnzzled 2 precursor (Frιzzled-2) (Fz-2) (hFz2) (FzE2) FZD2 JHUMAN
1264 Fnzzled 5 precursor (Fnzzled 5) (Fz-5) (hFz5) (FzE5) FZD5JHUMAN
1265 Glutamate receptor, ionotropic kainate 2 precursor (Glutamate receptor 6) (GluR-6) (GluR6) (Excitatory ammo acid receptor 4) (EAA4) GRIK2JHUMAN
1266 Glutamate receptor, ionotropic kainate 3 precursor (Glutamate receptor 7) (GluR-7) (GluR7) (Excitatory amino acid receptor 5) (EAA5) GRIK3JHUMAN
1267 Ileal sodium/bile acid cotransporter (Ileal Na(+)/bι!e acid cotransporter) (Na(+) dependent ileal bile acid transporter) (Ileal NTCP2JHUMAN
1268 !nterleukin-10 receptor alpha chain precursor (IL-10R-A) (IL-10R1) I10R1JHUMAN
1269 lnterleukιn-15 receptor alpha chain precursor (IL-15Ralpha) (IL-15RA) I15RAJHUMAN
1270 lnterleukιπ-16 precursor (IL-16) (Lymphocyte chemoattractant factor) (LCF) IL16JHUMAN
1271 lnterleukιπ-18 receptor 1 precursor (IL1 receptor-related protein) (IL-1Rrp) IL18RJHUMAN
1272 Interleukιπ-18 precursor (IL-18) (Iπterferon-gamma inducing factor) (IFN gamma-inducing factor) (lπterieukιπ-1 gamma) (IL-"! gamma) IL18JHUMAN
1273 Leucine-πch repeat-containing protein 32 precursor (GARP protein) (Garpin) (Glycoprotein A repetitions predominant) LRC32JHUMAN
1274 Low-density lipoprotein receptor related protein 8 precursor (Apolipoprotein E receptor 2) LRP8JHUMAN
1275 Mitogen-activated protein kinase kinase kinase 12 (EC 271 37) (Leucine-zipper protein kinase) (ZPK) M3K12JHUMAN
1276 Mitogen-activated protein kinase kinase kinase kinase 2 (EC 271 37) (MAPK/ERK kinase kinase kinase 2) (MEK kinase kinase 2) M4K2JHUMAN
1277 Neuronal membrane glycoprotein M6-b (M6b) GPM6BJHUMAN
1278 Vesicular integral-membrane protein VIP36 precursor (GP36b glycoprotein) (Lectin, maπnose-binding 2) LMAN2JHUMAN
1279 lnterleukιn-24 precursor (Suppression of tumoπgenicity 16 protein) (Melanoma differentiation-associated protein 7) (MDA-7) ΪL24JHUMAN
1280 lnterieukιn-27 beta chain precursor (IL-27B) (Epstein-Barr virus induced gene 3 protein) (EBV induced gene 3 protein) IL27BJHUMAN
1281 Voltage-gated potassium channel beta-2 subunit (K(+) channel beta-2 subunit) (Kv-beta 2) (HKvbeta2) KCAB2JHUMAN
1282 Laminin beta-3 chain precursor (Laminin 5 beta 3) (Lamiπiπ (Kalinin B1 chain) LAMB3JHUMAN
1283 Laminin gamma-2 chain precursor (Kalinin/πicein/epilignn 100 kDa subunit) (Laminin B2t chain) (Cell scatteπng factor 140 kDa subunit) LAMC2JHUMAN
1284 Metabotropic glutamate receptor 1 precursor (mGluRI) MGR1 JHUMAN
1285 Metabotropic glutamate receptor 2 precursor (mGluR2) MGR2JHUMAN
1286 Multisyπthetase complex auxiliary component p43 [Contains Endothelial-monocyte activating polypeptide Il (EMAP-II) (Small MCA1 JHUMAN
1287 Noggin precursor NOGGJHUMAN
1288 Mucosal addressiπ cell adhesion molecule-1 precursor (MAdCAM-1) (hMAdCAM 1) MADCA JHUMAN
1289 Protein KIAA0133 K0133JHUMAN
1290 Protein KIAA0152 precursor K0152 JHUMAN
1291 Nldogen 2 precursor (NlD-2) (Osteonidogen) N1D2JHUMAN
1292 Proto-oncogene tyrosiπe-protein kinase MER precursor (EC 271 112) (C-mer) (Receptor tyrosine kinase MerTK) MERTKJHUMAN
1293 LAP4 protein (Scribble homolog protein) (hScπb) LAP4JHUMAN
1294 Lysosomai-associated multitransmembrane protein (Retiπoic acid- inducible E3 protein) (HA1520) LAPM5JHUMAN
1295 Myotubulaπn-related protein 3 (EC 31 348) (FYVE domain-containing dual specificity protein phosphatase 1) (FYVE-DSP1) (Zinc finger FYVI MTM R3JHUMAN
1296 17 kDa membrane associated protein (DD96 protein) MAP17JHUMAN
1297 Natural killer cells antigen CD94 (NK cell receptor) (Killer lectin-like receptor subfamily D member 1) (KP43) KLRD1 JHUMAN
1298 Melatoniπ-related receptor (H9) MTR1LJHUMAN
1299 Metaxiπ 1 MTX1JHUMAN
1300 Integnπ alpha-7 precursor (UNQ406/PRO768) ITA7JHUMAN
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1301 Iπtegπn alpha-9 precursor (Integππ alpha-RLC) ITA9_HUMAN Y Y Y
1302 Inlegπn alpha-D precursor (Leukointegπn alpha D) (CD11d) (ADB2) ITADJHUMAN Y
1303 Prostaglandin D2 receptor (Prostanoid DP receptor) (PGD receptor) PD2R_HUMAN
1304 Ecto-ADP-πbosyltransferase 3 precursor (EC 24231) (NAD(PX+)- arginine ADP-nbosyltransferase 3) (Moπo(ADP-πbosyl)traπsferase 3) NAR3_HUMAN
1305 Potassium voltage-gated channel subfamily C member 3 (Voltage-gated potassium channel subunit Kv33) (KSHIIID) KCNC3_HUMAN
1306 Pappalysιπ-1 precursor (EC 342479) (Pregnancy-associated plasma protein A) (PAPP-A) (Insulin-like growth factor-dependent IGF binding PAPPA_HUMAN
1307 MAGUK p55 subfamily member2 (MPP2 protein) (Discs, large MPP2_HUMAN
1308 MAGUK p55 subfamily member 3 (MPP3 protein) (Discs, large MPP3_HUMAN
1309 Glutamate [NMDA] receptor subunit epsilon 1 precursor (N methyl D-aspartate receptor subtype 2A) (NR2A) (NMDAR2A) (hNR2A) NMDE1_HUMAN
1310 Glutamate [NMDA] receptor subunit epsilon 2 precursor (N-methyl D-aspartate receptor subtype 2B) (NR2B) (NMDAR2B) (N-methyl-D- NMDE2_HUMAN
1311 cGMP-jnhibited 3',5' cyclic phosphodiesterase B (EC 31 417) (Cyclic GMP inhibited phosphodiesterase B) (CGI-PDE B) (CGIPDE1) (CGIP1) PDE3B_HUMAN
1312 Peroxisome assembly factor-2 (PAF-2) (Peroxisomal-type ATPase 1) (Peroxiπ 6) (Peroxisomal biogenesis factor 6) PEX6JHUMAN
1313 NAD(P) transhydrogenase, mitochondrial precursor (EC 1 6 1 2) (Pyπdine nucleotide transhydrogeπase) (Nicotinamide nucleotide NNTM_HUMAN
1314 Nuclear body protein SP140 (Nuclear autoantigeπ Sp-140) (Speckled 140 kDa) (LYSpIOO protein) (Lymphoid-restncted homolog of SpIOO) LY10_HUMAN
1315 Lymphocyte antigen Ly-6D precursor (E48 antigen) LY6DJHUMAN Y
1316 Microfibnllar associated protein 5 precursor (MFAP-5) (Microfibπl- associated glycoprotein 2) (MAGP-2) (MP25) MFAP5_HUMAN Y
1317 Polycystiπ 2 (Autosomal dominant polycystic kidney disease type Il protein) (Polycystwin) (R48321) PKD2_HUMAN
1318 Plakophilin 1 (Band-6-proteιn) (B6P) PKP1_HUMAN
1319 Mesothelin precursor (CAK1 antigen) MSLN_HUMAN Y
1320 Nociceptin precursor (Oφhamn FQ) (PPNOC) PNOC-HUMAN Y
1321 Pregnancy-specific beta-1-glycoprotein 7 precursor (PSBG-7) PSG7_HUMAN Y
1322 Tyrosme-proteiπ kmase-like 7 precursor (Colon carcinoma kιnase-4) (CCK-4) PTK7_HUMAN Y
1323 Oviduct specific glycoprotein precursor (Oviductal glycoprotein) (Oviductin) (Estrogen-dependent oviduct protein) (Mucin 9) OVGP1_HUMAN Y
1324 Olfactory receptor 2F1 (Olfactory receptor-like protein 0LF3) OR2F1_HUMAN
1325 Platelet-activating factor acetylhydrolase precursor (EC 31 1 47) (PAF acetylhydrolase) (PAF 2-acylhydrolase) (LDL-associated PAFA-HUMAN
1326 PL6 protein (Placental protein 6) PL6_HUMAN
1327 Phospholipase D1 (EC 31 44) (PLD 1) (Choline phosphatase 1) (Phosphatidylcholine-hydrolyzing phospholipase D1) (hPLD1) PLD1_HUMAN
1328 Olfactory receptor 511 (Olfactory receptor-like protein OLF1) OR5IΪJ-IUMAN
1329 Receptor-type tyrosiπe-protein phosphatase eta precursor (EC 3 1348) (Proteiπ-tyrosine phosphatase eta) (R-PTP-eta) (HPTP eta) (Protein- PTPRJ_HUMAN
1330 Receptor-type tyrosine-proteiπ phosphatase S precursor (EC 31 348) (R-PTP-S) (Protein tyrosine phosphatase Sigma) (R PTP sigma) PTPRS_HUMAN
1331 Ras and Rab interactor 1 (Ras interaction/interference protein 1) inhibitor JC99) RIN1JHUMAN
1332 Rho-GTPase-activating protein 5 (p190-B) RHG05_HUMAN
1333 P-selectιπ glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand) (CD162 antigen) SELPLJHUMAN
1334 Semaphonn 3B precursor (Semaphoπn V) (Sema V) (Sema A(V)) SEM3B_HUMAN
1335 Semaphoπn 3F precursor (Semaphonn IV) (Sema IV) (Sema IHZf=) SEM3F_HUMAN
1336 Patched protein homolog 1 (PTC1) (PTC) PTC1_HUMAN
1337 43 kDa receptor-associated protein of the synapse (RAPsyn) (Acetylcholine receptor-associated 43 kDa protein) (43 kDa RAPSN_HUMAN
1338 Lysosome membrane protein Il (LIMP II) (Scavenger receptor class member 2) (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD SCRB2_HUMAN
1339 Red protein (RER protein) (IK factor) (Cytokine IK) RED-HUMAN
1340 Stromal interaction molecule 1 precursor STIM1_HUMAN
1341 Phosphatidylmositol-bindiπg dathπn assembly protein (Clathπn assembly lymphoid myeloid leukemia protein) PICAL^HUMAN
1342 Semaphonn 5A precursor (Semaphonn F) (Sema F) SEM5A_HUMAN
1343 Seprase (EC 3421 -) (Fibroblast activation protein alpha) (Integral membrane seπne protease) (170-kDa melanoma membrane-bound SEPR_HUMAN
1344 Signaling lymphocytic activation molecule precursor (IPO-3) (CD150 antigen) (CDw150) SLAF1_HUMAN
1345 Syntaxιπ-3 STX3JHUMAN
1346 Syntaxιn 4 STX4JHUMAN
1347 Syntaxιπ-5 STX5J-IUMAN
1348 Secreted phosphoprotein 24 precursor (Spp-24) (Secreted phosphoprotein 2) SPP24_HUMAN
1349 Sarcoma amplified sequence SAS_HUMAN
1350 Gamma-sarcoglycan (Gamma-SG) (35 kDa dystrophin-associated glycoprotein) (35DAG) SGCG_HUMAN
1351 Sperm-associated antigen 8 (Sperm membrane protein 1) (SMP-1) (HSD-1) (Sperm membrane protein BS-84) SPAG8_HUMAN
1352 Spectrin alpha chain, brain (Spectrin, non erythroid alpha chain) (Alpha-ll spectnn) (Fodrin alpha chain) SPTA2JHUMAN
1353 Tumor necrosis factor, alpha-induced protein 1 , endothelial (B12 protein) TNAP1_HUMAN
1354 Non-receptor tyrosiπe-protein kinase TNK1 (EC 27 1 112) (CD38 negative kinase 1) TNK1_HUMAN
1355 Vacuolar proton translocating ATPase 116 kDa subunit a isoform (V-ATPase 116-kDa isoform a3) (Osteoclastic proton pump 116 kDa VPP3_HUMAN
1356 Trophimπ (MAGE-D3 antigen)
1357 Src substrate cortactiπ (Amplaxin) (Oncogene EMS1) SRC8_HUMAN
1358 Endothelial cells scavenger receptor precursor (Acetyl LDL receptor) (Scavenger receptor class F member 1) SREC-HUMAN
1359 Tπadin TRDN^HUMAN
1360 Urea transporter, erythrocyte UT1_HUMAN Y
1361 Hypothetical protein KIAA0143 (Fragment) Y0143_HUMAN Y
1362 Solute earner family 12, member 1 (Bumetanide-sensitive sodium- (potassιum)-chlonde cotransporter 2) (Kidney-specific Na-K-Cl S12A1_HUMAN Y
1363 Solute earner family 13, member 2 (Renal sodium/dicarboxylate cotransporter) (Na(+)/dιcarboxylate cotransporter 1) (NaDC-1) S13A2_HUMAN Y
1364 Alpha-1-syntrophιn (59 kDa dystrophin-associated protein A1 acidic component 1) (Pro-TGF-alpha cytoplasmic domain interacting protein 1) SNTA1_HUMAN
1365 Beta-1-syπtrophιn (59 kDa dystraphin-associated protein A1, basic component 1) (DAPA1B) (Tax interaction protein 43) (TIP 43) SNTB1_HUMAN
Extracellular Integral
P[D Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1366 Beta-2-syπtrophιn (59 kDa dystrophin-associated protein A1, basic component 2) (Syπtrophin 3) (SNT3) (Syπtrophin like) (SNTL) SNTB2_HUMAN
1367 Tumor differentially expressed protein 1 (Transmembrane protein SBBI99) TDE1JHUMAN
1368 Short transient receptor potential channel 3 (TrpC3) (Htφ-3) (Htφ3) TRPC3_HUMAN
1369 Tumor suppressor candidate 3 (N33 protein) TUSC3 J-IUMAN
1370 Zona pellucida sperm-binding protein 4 precursor (Zona pellucida sperm-binding protein B) ZP4_HUMAN
1371 HPMSR3 Q13401_HUMAN
1372 HPMSR6 Q13670 JHUMAN
1373 Lymphαd-restπcted membrane protein Q12912JHUMAN
1374 180 kDa transmembrane PLA2 receptor Q13018_HUMAN
1375 Soluble PLA2 receptor Q13019_HUMAN
1376 Glycophoπn Eπk I-IV precursor Q13030_HUMAN
1377 GABA/πoradrenaline transporter Q13032_HUMAN
1378 Transmembrane protein precursor Q13086JHUMAN
1379 Peroxisomal targeting signal import receptor (Fragment) Q13335JHUMAN
1380 UDP-glucuronosyltransferase Q13460_HUMAN
1381 Anion exchange protein 3 (Fragment) Q13717_HUMAN
1382 Alt ankyπn (Vanant22) Q13768JHUMAN
1383 Peπpheral benzodiazepine receptor Q13850 JHUMAN
1384 Mucin (Fragment) Q14394_HUMAN
1385 Mucin (Fragment) Q14395_HUMAN
1386 Liver beta-subumt signal transducing proteins Gs/Gι (beta-G) Q14396JHUMAN
1387 Glycophonn Mz U-IV (Fragment) Q14420 JHUMAN
1388 Interleukιn 2 Q13169 JHUMAN
1389 Estrogen regulated LIV-1 protein Q13433 JHUMAN
1390 Aπthracycline resistance associated protein Q13798JHUMAN
1391 Choπoπic somatomammotropin CS-5 Q14406JHUMAN
1392 HNKR-PIa protein Q12918JHUMAN
1393 Bone morphogeny protein type II receptor Q13161 JHUMAN
1394 AP0A4 protein (Fragment) Q13784 JHUMAN
1395 Collagen (Fragment) Q13992 JHUMAN
1396 D collagen (Fragment) Q13993 JHUMAN
1397 COL1A2 protein (Fragment) Q13998 JHUMAN
1398 Hypothetical protein (Fragment) Q14089JHUMAN
1399 Putative T1/ST2 receptor binding protein (Interleukin 1 receptor-like 1 ligand,) Q13445 JHUMAN
1400 5T4 oπcofoetal antigen precursor (5T4 oncofetal trophoblast glycoprotein precursor) Q13641 JHUMAN
1401 Neutral ammo acid transporter B(O) (ATB(O)) (Sodium-dependent neutral amino acid transporter type 2) (RD114/sιmιaπ type D retrovirus AAATJHUMAN
1402 CD226 antigen precursor (DNAX accessory molecule-1) (DNAM-1) CD226JHUMAN
1403 Cyclic-nucleotide-gated olfactory channel (Cyclic-nucleotide-gated cation channel 2) (CNG channel 2) (CNG 2) (CNG2) (Fragment) CNGA2JHUMAN
1404 Cyclic-nucleotide-gated cation channel alpha 3 (CNG channel alpha 3) (CNG-3) (CNG3) (Cyclic nucleotide gated channel alpha 3) (Cone CNGA3 JHUMAN
1405 ARL-6 interacting protein-1 (Aιp-1) AR6P1JHUMAN
1406 Voltage-dependent R-type calcium channel alpha-IE subunit (Voltage- gated calcium channel alpha subunit Cav23) (Calcium channel, L CAC1EJHUMAN
1407 Transforming growth factor-beta induced protein IG-H3 precursor (Beta IG-H3) (Kerato-epitheliπ) (RGD-containing collagen associated proteir BGH3JHUMAN
1408 Channel associated protein of synapse-110 (Chapsyn-110) (Discs, large homolog 2) DLG2JHUMAN
1409 Neuronal acetylcholine receptor protein alpha-2 chain precursor ACHA2JHUMAN
1410 Neuronal acetylcholine receptor protein alpha-6 chain precursor ACHA6JHUMAN
1411 Carboxypeptldase B2 precursor (EC 341720) (Carboxypeptidase U) (Thrombin-activatable fibπnolysis inhibitor) (TAFI) (Plasma CBPB2 JHUMAN
1412 Adiponectiπ precursor (Adipocyte, C1q and collagen domain containing protein) (30 kDa adipocyte complement related protein) (ACRP30) ADIPOJHUMAN
1413 24-dehydrocholesterol reductase precursor (EC 1 3 1 -) (3-beta- hydroxysterol delta-24-reductase) (Seladιn-1) (Diminuto/dwarfi DHC24JHUMAN
1414 Adhesion regulating molecule 1 precursor (110 kDa cell membrane glycoprotein) (Gp110) ADRM1 JHUMAN
1415 Desmocollιn-3 precursor (Desmocolliπ 4) (HT-CP) DSC3_HUMAN
1416 Conserved oligomeπc Golgi complex component 2 (Low density lipoprotein receptor defect C-complementjng protein) COG2JHUMAN
1417 Electron transfer flavoproteiπ-ubiquinone oxidoreductase, mitochoπdπal precursor (EC 1 551) (ETF-QO) (ETF-ubiqumone ETFDJHUMAN
1418 Tumor-associated hydroquinone oxidase (tNOX) (Cytosolic ovarian carcinoma antigen 1) (APK1 antigen) [Includes Hydroquinone [NADH] COVA1 JHUMAN
1419 3-beta-hydroxystero<d-delta(8),de!ta(7)-ιsomerase (EC 5335) (Cholestenol delta-isomerase) (Delta8-delta7 sterol isomerase) (D8-D7 EBPJHUMAN
1420 Epididymal secretory protein E3 alpha precursor (HE3 alpha) EP3AJHUMAN
1421 Ephπn type-A receptor 7 precursor (EC 271 112) (Tyrosine-protein kinase receptor EHK-3) (Eph homology kιnase-3) (Receptor protein- EPHA7JHUMAN
1422 Collagen alpha 1(XIX) chain precursor (Collagen alpha 1(Y) chain) COJA1 JHUMAN
1423 Chitinase 3-lιke protein 2 precursor (YKL-39) (Chondrocyte protein 39) CH3L2JHUMAN
1424 Ephπn-B3 precursor (EPH-related receptor tyrosine kinase ligand 8) (LERK-8) (EPH-related receptor transmembrane ligand ELK L3) EFNB3JHUMAN
1425 Early endosome antigen 1 (Endosome associated protein p162) (Zinc finger FYVE domain containing protein 2) EEA1 JHUMAN
1426 Probable G-proteιπ coupled receptor 19 (GPR-NGA) GPR19JHUMAN
1427 Exostosιπ-1 (EC 24 1 224) (EC 2.41 225) (Glucuronosyl-N- acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl proteoglycan EXT1 JHUMAN
1428 Golgi autoantjgeπ, golgiπ subfamily B member 1 (Giantin) (Macrogolgin) (Golgi complex-associated protein 372 kDa) (GCP372) GOGB1JHUMAN
1429 FXYD domain-containing ion transport regulator 3 precursor (Chlonde conductance inducer protein Mat-Θ) (Mammary tumor 8 kDa protein) FXYD3JHUMAN
1430 Polypeptide N-acetylgalactosamiπyltransferase 3 (EC 24 1 41) (Protein-UDP acetylgalactosaminyltransferase 3) (UDP- GALT3 JHUMAN
Figure imgf000094_0001
Extracellular Integral PlD Description UniProtACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
1496 RaIA binding protein 1 (RaIBPI) (RaI interacting protein 1) RaI interacting protein) (Dinitrophenyl S glutathione ATPase) (DNP-SG RBP1_HUMAN
1497 Cop-coated vesicle membrane protein p24 precursor (p24A) P24_HUMAN Y Y
1498 Olfactory receptor 4D1 (Olfactory receptor TPCR16) 0R4D1_HUMAN Y Y
1499 Olfactory receptor 7A5 (Olfactory receptor TPCR92) OR7A5_HUMAN Y Y
1500 Olfactory receptor 8B8 (Olfactory receptor TPCR85) (Olfactory-like receptor JCG8) OR8B8JHUMAN Y Y
1501 Olfactory receptor 8G1 (Olfactory receptor TPCR25) (Fragment) 0R8G1_HUMAN Y Y
1502 Olfactory receptor 8G2 (Olfactory receptor TPCR120) (Fragment) OR8G2_HUMAN Y Y
1503 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF-2) (Tyrosine kinase activator protein 1) (TKA-1) (SRY interacting protein 1) NHRF2JHUMAN
1504 Receptor-type tyrosine-protein phosphatase kappa precursor (EC 3 1 348) (Proteiπ-tyrosine phosphatase kappa) (R-PTP-kappa) PTPRK_HUMAN Y Y Y
1505 Receptor-type tyrosine-protein phosphatase R precursor (EC 3 1 348) (Proteiπ-tyrosine phosphatase PCPTP1) (NC-PTPCOMI) (Ch-IPTPaS PTPRR-HUMAN Y Y Y
1506 Proline-πch protein 4 precursor (Lacrimal proline-πch protein) (Nasopharyngeal carcinoma-associated proline πch protein 4) PROL4_HUMAN Y Y
1507 Phosphoglucomutase-like protein S (Phosphoglucomutase related protein) (PGM-RP) (Aciculin) PGM5_HUMAN
1508 GTP-binding protein Rheb (Ras homolog enπched in brain) RHEB_HUMAN
1509 P2Y puππoceptor6 (P2Y6) P2RY6_HUMAN Y Y
1510 P2Y puππoceptor 14 (P2Y14) (UDP-glucose receptor) (G-protein coupled receptor 105) P2Y14_HUMAN Y Y
1511 Advanced glycosylate end product-specific receptor precursor (Receptor for advanced glycosylation end products) RAGE_HUMAN Y Y Y Y
1512 Semaphonn 3A precursor (Semaphonn 111) (Sema III) SEM3A_HUMAN Y Y
1513 Plectin 1 (PLTN) (PCN) (Hemidesmosoma! protein 1) (HD1) PLEC1 JHUMAN
1514 Oligopeptide transporter, kidney isoform (Peptide transporter 2) (Kidney H(+)/peptide cotraπsporter) (Solute carrier family 15, member S15A2_HUMAN Y
1515 Equilibrative nucleoside transporter 2 (Equilibrative nitrobenzylmercaptopunne πboside-insensitive nucleoside transporter) S29A2_HUMAN Y
1516 Microsomal signal peptidase 25 kDa subunit (EC 34 - -) (SPase subunit) (SPC25) SPC25~HUMAN Y
1517 Protein tyrosine phosphatase receptortype C-associated protein (PTPRC-associated protein) (CD45-assocιated protein) (CD45-AP) PTCA_HUMAN
1518 Ras GTPase-activatng protein 3 (GAP1(IP4BP)) (Ins P4-bιndιng protein) RASA3JHUMAN
1519 Sodium channel protein type V alpha subunit (Voltage-gated sodium channel alpha subunit Nav1 5) (Sodium channel protein cardiac muscle SCN5A_HUMAN Y
1520 Sodium channel protein type IX alpha subunit (Voltage-gated sodium channel alpha subunit Nav1 7) (Neuroendocnne sodium channel) (hNE-ISCN9A_HUMAN Y
1521 ]-plastin (Intestine-specific plastn) PLSl HUMAN
1522 Sodium/hydrogen exchangers (Na(+)/H(+) exchanger 5) (NHE-5) SL9E5_HUMAN Y
1523 Sarcospan (K-ras oncogeπe-associated protein) (Kirsten ras associated protein) SSPN-HUMAN Y Y
1524 Toll-like receptor 1 precursor (Toll/iπterleukιn-1 receptor-like) (TIL) TLR1_HUMAN Y Y Y
1525 Syntaxιn-1B1 (Syntaxιn 1B) - STX1B_HUMAN Y 1526 Tubulin-specific chaperone C (Tubulin-folding cofactor C) (CFC) TBCCjlUMAN 1527 Vacuolar ATP synthase subunit S1 precursor(EC 36314) (V-ATPase subunit) (V-ATPase S1 accessory protein) (V-ATPase Ac45 subunit) VAS1_HUMAN Y Y
1528 Sphingosylphosphorylcholiπe receptor (Ovanan cancer G-protein coupled receptor 1) (OGR-1) (G-protein coupled receptor 68) (GPR12A) SPR1_HUMAN Y Y
1529 SPARC-like protein 1 precursor (High endothelial venule protein) (Hevin) (MAST 9) SPRL1_HUMAN Y Y
1530 Protein transport protein Sec23A (SEC23-related protein A) SC23A_HUMAN Y
1531 Protein transport protein Sec23B (SEC23 related protein B) SC23B_HUMAN Y
1532 Mothers against decapentaplegic homolog 1 (SMAD 1) (Mothers against DPP homolog 1) (Mad-related protein 1) (Transforming growth factor SMAD1_HUMAN
1533 Sperm surface protein Sp17 (Sperm autoantigenic protein 17) (Sperm protein 17) (Sp17-1) SP17_HUMAN
1534 Surfeit locus protein 1 SURF1_HUMAN Y
1535 Neuregulιπ-1, sensory and motor neuron denved factor isoform SMDF-HUMAN Y
1536 WAP four-dtsulfide core domain protein 2 precursor (Major epididymis- specific protein E4) (Epididymal secretory protein E4) (Putative WFDC2_HUMAN Y Y
1537 Serum paraoxonase/arylesterase 2 (EC 3 1 1 2) (EC 3 1 8 1) (PON 2) (Serum aryldialkylphosphatase 2) (A esterase 2) (Aromatic esterase Z) PON2_HUMAN Y
1538 Serum paraoxonase/lactonase 3 (EC 31 1 -) PON3JHUMAN Y
1539 Translocation associated membrane protein 1 TRAM1_HUMAN
1540 Translocation associated membrane protein 2 TRAM2JHUMAN Y
1541 Urea transporter, kidney UT2_HUMAN Y
1542 Ryanodine receptor 3 (Brain-type ryanodine receptor) (RyR3) (RYR-3) (Brain ryanodine receptor-calcium release channel) RYR3_HUMAN Y
1543 Peπostin precursor (PN) (Osteoblast-specific factor 2) (OSF-2) POSTN_HUMAN Y Y
1544 Sorting nexiπ 17 SNX17.JiUMAN
1545 Mitochondnal import receptor subunit TOM20 homolog (Mitochondnal 20 kDa outer membrane protein) (Outer mitochondnal membrane recep TOM20_HUMAN Y Y
1546 Vesicle-associated membrane protein 3 (VAMP-3) (Synaptobrevin 3) (Cellubreviπ) (CEB) VAM3_HUMAN Y
1547 Zyxin (Zyxiπ 2) ZYX_HUMAN
1548 Mucin (Fragment) Q14851_HUMAN
1549 K222 protein (Fragment) Q14867_HUMAN
1550 Effector cell protease receptor 1 (Fragment) Q14868_HUMAN
1551 Mucin (Fragment) Q14879 JHUMAN
1552 Intestinal mucin (Fragment) Q14883_HUMAN
1553 Intestinal mucin (Fragment) Q14884_HUMAN
1554 Myelin protein zero Q14902JHUMAN
1555 Notch 3 protein (Fragment) Q14962_HUMAN
1556 Leukocyte platelet-activating factor receptor Q1496δlHUMAN Y
1557 KIAA0062 protein (Fragment) Q15043JHUMAN
1558 Pregnancy-specific beta-1 glycoprotein (Fragment) Q151O6_HUMAN
1559 Polycystic kidney disease-associated protein Q15142_HUMAN
1560 1TGA2B protein (Fragment) Q15150JHUMAN
Figure imgf000096_0001
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondπal Golgi
1626 Duffy antigen/chemokine receptor (Fy glycoprotein) (GpFy) (Glycoprotein D) (Plasmodium vivax receptor) (CD234 antigen)
1627 2-hydroxyacylsphιngosιne 1-beta-galactosyltransferase precursor (EC 24145) (UDP-galactose-ceramide galactosyltransferase) (Ceramide CGT-HUMAN
1628 Cardιotrophin-1 (CT-1) CTF1_HUMAN
1629 Carbonic anhydrase IX precursor (EC 42 1 1) (Carbonate dehydratase IX) (CA-IX) (CAIX) (Membrane antigen MN) (P54/58N) (Renal cell CAH9JHUMAN
1630 Cytochrome P45051A1 (EC 1 14 1370) (CYPLI) (P450LI) (Sterol 14-alpha demethylase) (Lanosteral 14-alpha demethylase) (LDM) (P450-14CP51AJHUMAN
1631 Extracellular matrix protein 1 precursor (Secretory component p85) ECMI-HUMAN
1632 Hereditary hemochromatosis protein precursor (HLA H) HFE-HUMAN
1633 Mitochondπal inner membrane protein (Mltofilin) (p87/89) (Proliferation-inducing gene 4 protein) IMMT-HUMAN
1634 NADH ubiquinone oxldoreductase 13 kDa-B subunit (EC 1 653) (EC 1 6993) (Complex 1-13Kd-B) (CI-13Kd-B) (Complex I subunit B13) NUFM-HUMAN
1635 BDNF/NT-3 growth factors receptor precursor (EC 271 112) (Neurotrophic tyrosine kinase receptor type 2) (TrkB tyrosine kinase) NTRK2_HUMAN
1636 lnlerleukin 17 precursor (IL-17) (IL-17A) (Cytotoxic T lymphocyte- associated antigen 8) (CTLA-8) IL17_HUMAN
1637 Alpha-maπnosidase Il (EC 32 1 114) (Mannosyl-oligosacchande 1,3-1 ,6-alpha-mannosldase) (MAN II) (Golgl alpha-mannosidase II) MA2A1JHUMAN
1638 Calcium-activated potassium channel beta subunit 1 (Calcium-activated potassium channel, subfamily M1 beta subunit 1) (Maxi K KCMB1_HUMAN
1639 Laminin alpha-3 chain precursor (Epilignn 170 kDa subunit) (E170) (Nicein alpha subunit) LAMA3_HUMAN
1640 Mepnn A alpha subunit precursor (EC 34.2418) (Endopeptιdase-2) (N-benzoyl L-tyrosyl-P-amino-benzoic acid hydrolase alpha subunit) MEP1A_HUMAN
1641 Mepnn A beta-subuπit precursor (EC 342418) (Endopeptidase 2) (N-benzoyl L-tyrosyl-P-amino-benzoicacid hydrolase beta εubunit) MEP1B_HUMAN
1642 Melanoma deπved growth regulatory protein precursor (Melanoma inhibitory activity) MIA-HUMAN
1643 Myelin oligodendrocyte glycoprotein precursor MOG-HUMAN
1644 Melanoma antigen recognized by T-cells 1 (MART-1) (Melan-A protein) (Antigen SK29-AA) (Antigen LB39-AA) MAR1JHUMAN
1645 Protein NKG7 (Natural killer cell protein 7) (G-CSF-induced gene protein) (Protein G1G-1) NKG7_HUMAN
1646 Leukotnene C4 synthase (EC 441.20) (Leukotnene-C(4) synthase) (LTC4 synthase) LTC4S_HUMAN
1647 Occludin OCLN-HUMAN
1648 Lymphocyte antigen Ly-6E precursor (Retinoic acid induced gene E protein) (RIG-E) (Thymic shared antigen-1) (TSA-1) (Stem cell antigen LY6E HUMAN
1649 Pregnancy specific beta-1-glycoproteιn 3 precursor (PSBG 3) (Carcinoembryonic antigen SG5) PSG3JHUMAN
1650 Prostasinprecursor(EC3421 -) PRSS8_HUMAN
1651 Proprotein convertase subtihsin/kexin type 7 precursor (EC 3421 -) (Proprotein convertase PC7) (Subtilisin/kexin-like protease PC7) PCSK7_HUMAN
1652 Protein phosphatase 1, regulatory subunit 3A (Protein phosphatase 1 glycogen-associated regulatory subunit) (Protein phosphatase type-1 PPR3A_HUMAN
1653 Receptor-type tyrosine-proteiπ phosphatase like N precursor (R PTP-N) (PTP lA-2) (Islet cell antigen 512) (ICA 512) (Islet PTPRN_HUMAN
1654 Receptor-type tyrosine-protein phosphatase O precursor (EC 3 1 348) (Glomerular epithelial protein 1) (Protein tyrosine phosphatase U2)
1655 Retculon 1 (Neuroendocnne-specific protein) RTNI-HUMAN
1656 Receptor-transporting protein 2 RTP2_HUMAN
1657 Retinal pigment epithelium-specific 65 kDa protein RPE65_HUMAN
1658 Pantophysin (Synaptophysiπ-like protein) SYPL-HUMAN
1659 Prostacyclin synthase (EC S 3994) (Prostaglandin I2 synthase) 1650 Syntaxm-1A (Neuron-specific antigen HPC-1) STX1AJHUMAN
1661 Alpha-sarcoglycaπ precursor (Alpha-SG) (Adhalm) (50 kDa dystrophin- associated glycoprotein) (50DAG) (Dystroglycan 2) SGCA-HUMAN
1662 Beta sarcoglycaπ (Beta-SG) (43 kDa dystrophin associated glycoprotein) (43DAG) (A3b) SGCB-HUMAN
1663 Vacuolar ATP synthase subunit F (EC 36314) (V-ATPase F (Vacuolar proton pump F subunit) (V-ATPase 14 kDa subunit) VATF-HUMAN
1664 Tafazziπ TAZ-HUMAN
1665 CMP-N-acetylneuramiπate-beta-galactosamide-alpha^ 3 sialyUransferase (EC 2499 -) (Beta-galactoside alpha-2,3-sιalyltransferase) (Alpha SIA4B_ HUMAN
1666 Vesicular acetylcholine transporter (VAChT) (Solute earner family 18 member3)
1667 Apolipoprotein (A) related gene C (OTTHUMP00000017S41) Q16609_HUMAN
1668 HLA-DPB1 precursor (MHC class Il antigen) (HLA DPB1 protein) (Major histocompatibility complex, class II, DP beta 1) Q30174JHUMAN
1669 DMA protein (HLA-DMA protein) (Major histocompatibility complex class II, DM alpha,) (OTTHUMP00000D62997) (OTTHUMP00000029670) Q31604_HUMAN
1670 lnterleukm 3 receptor, alpha (Low affinity) (Fragment) Q5HYQ8_HUMAN
1671 G protein-coupled receptor 64 Q5JPQ5JHUMAN
1672 G protein coupled receptor 64 Q5JPQ6_HUMAN
1673 Zinc finger, DHHC domain containing 9 (Fragment) Q5JSW4_HUMAN
1674 G protein coupled receptor 112 (Fragment) Q5JVK3_HUMAN
1675 OTTHUMP00000030530 (Fragment)
1676 Na+/Ca2+ exchanger 3 Q5K3P7_HUMAN
1677 NADPH oxidase 4 Q5K3RδlHUMAN
1678 OTTHUMP00000038657 (Fragment) 0.5HYTO-HUMAN
1679 Testis-expressed transmembrane-4 protein splice vaπant b Q5J8X3_HUMAN
1680 Testis-expressed transmembrane-4 protein Q5J8X5_HUMAN
1681 W1SP1I Q5JBS6JHUMAN
1682 Protein A-2 Q16538_HUMAN
1683 SLC10A5 Q5PT55_HUMAN
1684 Alkaline ceramidase 2 Q5QJU3_HUMAN
1685 ϋgaπd-deleted cytotoxic T lymphocyte associated antigen Q5S005_HUMAN
1686 VDAC4 protein (Fragment) Q36732_HUMAN
1687 CCR5 chemokine receptor Q5QIN9_HUMAN Y
1688 KPG_013 protein Q5KU14 HUMAN Y
1689 KPG_012 protein Q5KU15JHUMAN Y
1690 G-protein coupled receptor Q5KU19_HUMAN Y
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Extracellular Integral
PID Descnption UπiProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondπal Golgi
3966 Two-pore calcium channel protein 2 (Two pore segment channel Q8NHX9_HUMAN
3967 KIAA1189 protein, isoform b Q8TAM6_HUMAN
3968 Intercellular adhesion molecule 5, Q8TAM9JHUMAN
3969 MBTPS1 protein Q8TAN4JHUMAN
3970 Seven transmembrane helix receptor Q8NH25_HUMAN Y
3971 Macrophage inflammatory proteιπ-1b2 Q8NHW4_HUMAN
3972 Multidrug resistance-associated protein 7 Q8NHX7_HUMAN Y Y
3973 Hypothetical protein DKFZp727E151 Q8TCS5_HUMAN
3974 Amino acid transporter Q8TCU3_HUMAN
3975 Similar to CG4995 gene product Q8TAV9_HUMAN
3976 ASPH protein Q8TB28JHUMAN
3977 Hypothetical protein Q8TB48_HUMAN
3978 Putative nuclear protein ORF1-FL49 Q8TBA5_HUMAN
3979 KIAA1613 protein Q8TBB6_HUMAN
3980 SH3KBP1 binding protein 1 Q8TBC3JHUMAN
3981 Hypothetical protein Q8TBC9_HUMAN
3982 Similar to mouse C030019l05Rιk protein Q8TBE3_HUMAN
3983 TMEM22 protein Q8TBE7JHUMAN
3984 Plasticity related gene 3 (Lipid phosphate phosphatase-related protein type 1) (OTTHUMP00000021800) Q8TBJ4_HUMAN
3985 ST6GALNAC1 protein Q8TBJ6_HUMAN
3986 ATP6V0A2 protein Q8TBM3_HUMAN
3987 Solute earner family 6, member 15, isoform 2 Q8TBM6_HUMAN
3988 Mitochondπal earner family protein (Hypothetical protein MCFP) Q8TBP6_HUMAN
3989 NCK interacting protein with SH3 domain, isoform 2 Q8TC10_HUMAN
3990 SEC61A2 protein Q8TC24_HUMAN
3991 Solute earner family 30 (Zinc transporter), member4 Q8TC39JHUMAN
3992 Solute earner family 26, member8, isoform b Q8TC65 HUMAN
3993 Solute earner family 6 (Neurotransmitter transporter GABA) member 13 Q8TCC2_HUMAN
3994 Solute earner family 22 member 8 Q8TCC7_HUMAN
3995 Hypothetical protein Q8TCD0JHUMAN
3996 Hypothetical protein DKFZp564M1682 Q8TCQ1_HUMAN
3997 Voltage-dependent calcium channel gamma-8 subunit (Neuronal voltage- gated calcium channel gamma 8 subuπit) CCG8JHUMAN Y
3998 Connector enhancer of kinase suppressor of ras 2 (Connector of KSR2) (CNK2) CNKR2JHUMAN
3999 Aquaponn 3 AQP3JHUMAN Y Y
4000 Acid sphιngomye!ιnase-lιke phosphodiesterase 3a precursor (EC 31 4 -) (ASM-like phosphodiesterase 3a) ASM3A_HUMAN Y Y
4001 ADAMTS-14 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondiπ motifs 14) (ADAM-TS 14) (ADAM-TS14) ATS14_HUMAN Y Y
4002 ADAMTS-15 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospoπdin motifs 15) (ADAM-TS 15) (ADAM-TS15) ATS15JHUMAN Y Y
4003 ADAMTS-16 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondiπ motifs 16) (ADAM-TS 16) (ADAM-TS16) ATS16JHUMAN Y Y
4004 ADAMTS-17 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 17) (ADAM-TS 17) (ADAM-TS17) ATS17JHUMAN Y Y
4005 ADAMTS-18 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 18) (ADAM-TS 18) (ADAM-TS18) ATS18_HUMAN Y Y
4006 ADAMTS-19 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 19) (ADAM-TS 19) (ADAM-TS19) ATS19_HUMAN Y Y
4007 Brain-type organic cation transporter (Solute earner family 22, member 17) BOCT_HUMAN Y
4008 Ataxin-2-lιke protein (Ataxιn-2 domain protein) (Ataxιn-2 related protein) ATX2L_HUMAN
4009 Gamma secretaεe εubunit APH-1B (APH-Ib) (Aph 1beta) (Presenilin stabilization factor-like) (UNQ688/PRO1328) APHIB~HUMAN Y
4010 C-type lectin superfamily member2 (Activation-induced C-type lectin) (IFN-alpha2b-ιnducιπg related protein 1) CLEC2_HUMAN Y Y
4011 C-type lectin superfamily member 7 (Blood dendntic cell antigen protein) (BDCA-2) (Dendπtic lectin) (UNQ9361/PRO34150) CLEC7_HUMAN Y Y
4012 C-type lectin superfamily member 8 (C-type lectin-like receptor 6) (CLEC-6) CLEC8_HUMAN Y Y
4013 Discs, large homolog 5 (Placenta and prostate DLG) (Discs protein P-dlg) DLG5_HUMAN
4014 Barttin BSND_HUMAN Y Y
4015 Butyrophilin subfamily 2 member A2 precursor BT2A£1HUMAN Y Y Y
4016 Cytochrome c oxidase polypeptide Vllb2, mitochoπdπal precursor (EC 1 931) CX7B2JHUMAN Y
4017 Potential phospholipid-transporting ATPase IM (EC 3631) (ATPase class I type 8B member 4) AT8B4_HUMAN Y Y
4018 Conserved oligomeπc Golgi complex component 1 COG1JHUMAN , Y
4019 Chondroitin beta-1,4-N acetylgalactosamiπyltransferase 1 (EC 24 1 174) (beta4GalNAcT-1) (UNQ656/PRO1287) CGAT1JHUMAN Y Y
4020 Protein C20orf75 precursor CT075_HUMAN Y Y Y
4021 Engulfment and cell motility protein 1 (CED 12 homolog) ELMO1_HUMAN
4022 GTPase, IMAP family member 1 (Immunity-associated protein 1) (hlMAPI) GIMA1_HUMAN Y Y
4023 Cationic ammo acid transporter 3 (CAT-3) (Solute earner family member 3) (Cationic amino acid transporter y+) CTR3_HUMAN Y Y
4024 Carnitine 0-palmitoyltransferase I, mitochondπal muscle isoform (EC 23 1 21) (CPT I) (CPTI-M) (Carnitine palmitoyltransferase 1B) CPTiI_HUMAN Y
4025 Probable G-proteιn coupled receptor 119 GP119JHUMAN Y Y
4026 Probable G-protein coupled receptor 151 (G-protein coupled receptor PGR7) (GPCR-2037) GP151JHUMAN Y Y
4027 Probable G-protein coupled receptor 152 (G-protein coupled receptor PGR5) GP152_HUMAN Y Y
4028 Protein FAM3C precursor (Protein GS3786) F FAAMM33CC__HHUUMMAANN Y
4029 HERV-K_19p13 11 provims ancestral Env polyprotein precursor (Envelope polyprotein) (HERV-K113 envelope protein) (EnvKδ protein) [Cont ENK5_HUMAN Y
4030 HERV-K_8p231 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (HERV-K115 envelope protein) (EnvKβ protein) [Contair ENK6_HUMAN Y
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Extracellular Integral
PID Descπption UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
4811 Calponιn-2 (Calponin H2, smooth muscle) (Neutral calponin) CLP2_HUMAN
4812 Calsyntenιn-3 precursor CSTN3_HUMAN Y Y
4813 Multiple EGF-like-domain protein 8 precursor (Vascular endothelial- statin 2) (VE-εtatin 2) (NG3) (UNQ8752/PRO29920) EGFL8~HUMAN Y Y
4814 Cytochrome P4502S1 (EC 1 1414 1) (CYPIIS1) (UNQ891/PRO1906) CP2S1_HUMAN
4815 Collagen alpha 1(XII) chain precursor COCA1_HUMAN Y
4816 Cytohesiπ 2 (ARF nucteotide-biπding site opener) (ARNO protein) (ARF exchange factor) CYH2_HUMAN
4817 Galactosylceramide sulfotransferase (EC 282 11) (GalCer sulfotransferase) (Cerebroside sulfotransferase) G3ST1_HUMAN
4818 Galactose-3-O-sulfotransferase 4 (EC 282 -) (Galbeta1-3GalNAc 3 -sulfotransferase) (Beta-galactose-3-O-sulfotransferase 4) (PP8968) G3ST4_HUMAN
4819 Dimethylaniline monooxygenase [N-oxιde-forming] 2 (EC 1 14138) (Pulmonary flavin-containing moπooxygeπase 2) (FMO 2) (Dimethylaniliπi FM02_HUMAN
4820 Protein C20orf165 CT165JHUMAN
4821 Protein cTAGE-2 CTGE2_HUMAN
4822 Glutamate decarboxylase 1 (EC 41 1 15) (Glutamate decarboxylase, 67 kDa isoform) (GAD 67) (67 kDa glutamic acid decarboxylase) DCEI-HUMAN
4823 Glycosyl-phosphatidyliπositol-anchored molecule-like protein precursor GML_HUMAN Y
4824 Sphingosine 1-phosphate receptor Edg-3 (S1 P receptor Edg-3) (Endothelial differentiation G-pratem coupled receptor 3) EDG3_HUMAN
4825 Growth/differentiation factor 15 precursor (GDF-15) (Placental bone morphogeny protein) (Placental TGF-beta) (Macrophage inhibitory GDF15_HUMAN Y
4826 Probable G-protein coupled receptor 20 GPR20_HUMAN Y
4827 Probable G-protein coupled receptor 21 GPR21_HUMAN Y
4828 Probable G-protein coupled receptor 22 GPR22_HUMAN Y
4829 Probable G-pratem coupled receptor 86 (P2Y puππoceptor 13) (P2Y13) (FKSG77 protein) GPR86_HUMAN Y
4830 Granulocyte colony stimulating factor receptor precursor (G-CSF-R) (CD114 antigen) CSF3R_HUMAN Y Y
4831 Golgi reassembly stacking protein 1 (Golgi reassembly stacking protein of 65 kDa) (GRASP65) (Golgi peripheral membrane protein p65) GR65_HUMAN
4832 Gamma-aminobutyπc-acid receptor gamma-3 subunit precursor (GABA(A) receptor) GBRG3_HUMAN Y Y
4833 Hephaestin precursor (EC 1 ---) (UNQ2562/PRO6242) HEPH_HUMAN Y Y
4834 Nuclear pore complex protein Nup88 (Nucleoporin Nup88) (88 kDa pore complex protein) NUP88__HUMAN
4835 lnterleukιn-12 receptor beta-2 chain precursor (IL-12 receptor beta-2) (IL-12R-beta2) I12R2_HUMAN Y Y
4836 ATP-sensιtιve inward rectifier potassium channel 15 (Potassium channel, inwardly rectifying, subfamily J, member 15) (Inward IRK15_HUMAN Y
4837 Cell surface A33 antigen precursor (Glycoprotein A33) GPA33_HUMAN Y Y
4838 Leucine zipper putative tumor suppressor 2 (Protein LAPSER1) LZTS2_HUMAN
4839 Killer cell immunoglobuliπ-like receptor 2DL4 precursor (MHC class I NK cell receptor KIR103AS) (Killer cell inhibitory receptor 103AS) KI2L4_HUMAN Y
4840 Glycoprotein hormone alpha 2 precursor (Thyrostimuliπ alpha subunit) GPHA2JHUMAN Y
4841 Potassium channel tetramensation domain containing protein 14 KCD14_HUMAN
4842 Calcium and integnn binding protein 1 (Calmynn) (DNA-PKcs interacting protein) (Kinase interacting protein) (KIP) (CIB) (SNK KIP1_HUMAN
4843 Microsomal glutathione S-transferase 2 (EC 251 18) (Microsomal GST-2) (Microsomal GST-II) MGST2_HUMAN
4844 Mucin 4 (Tracheobronchial mucin) (Fragment) MUC4_HUMAN
4845 Junctophιlιn2 (Junctophllιn type 2) (JP-2) JPH2JHUMAN
4846 Hyaluronan and proteoglycan link protein 3 precursor (UNQ238/PRO271) HPLN3_HUMAN Y
4847 LAP2 protein (Erbb2 interacting protein) (Erbm) (Deπsιn-180-lιke protein) LAP2JHUMAN
4848 Melanin-concentrating hormone receptor 1 (MCH receptor 1) (MCHR-1) (MCH-R1) (MCH1R) (MCH-1R) (MCHR) (G-protein coupled receptor MCHR1_HUMAN
4849 Myeloiα associated differentiation marker (SB135) (UNQ553/PRO1110) MYADM_HUMAN
4850 Myeloid differentiation pπmary response protein MyD88 MYD88JHUMAN
4851 Protein kinase C-bιπdιng protein NELL2 precursor (NEL-like protein 2) (Nel-related protein 2) NELL2_HUMAN Y
4852 Osteomodulin precursor (Osteoadheπn) (OSAD) (Keratan sulfate proteoglycan osteomodulm) (KSPG osteomodulm) (UNQ190/PRO216) OMDJHUMAN Y
4853 Hepann-biπding EGF-like growth factor precursor (HB-EGF) (HBEGF) (Diphteπa toxin receptor) (DT-R) HBEGF_HUMAN Y
4854 Pannexin 1 (UNQ2529/PRO6028) PANX1_HUMAN
4855 Pannexin 2 PANX2_HUMAN
4856 Protease associated domain-containing protein of 21 kDa precursor (hPAP21) (UNQ833/PRO1760) PAP21_HUMAN Y
4857 Olfactory receptor 52E6 O52E6_HUMAN
4858 M-pfiase phosphoprotein 9 (Fragment) MPP9_HUMAN
4859 Phosphatidylmositol N-acetylglucosaminyltransferase subunit Q (EC 241 198) (Phosphatidyliπositol-glycan biosynthesis class Q PIGQJHUMAN
4860 GPl transamidase component PIG-S (Phosphatidylinositol-glycan biosynthesis, class S protein) (UNQ1873/PRO4316) PlGS-HUMAN
4861 Neurogenic locus notch homolog protein 4 precursor (Notch 4) (hNotch4) NOTC4_HUMAN Y
4862 Proteinase activated receptor 4 precursor (PAR-4) (Thrombin receptor- like 3) (Coagulation factor Il receptor like 3) PAR4_HUMAN Y
4863 Matrix metalloproteιπase-19 precursor (EC 3424 -) (MMP-19) (Matrix metalloproteinase RASI) (MMP-18) MMP19_HUMAN Y
4864 Protein phosphatase 1 regulatory inhibitor subunit 16B (TGF-beta- inhibited membrane-associated protein) (hTIMAP) (CAAX box protein PP16B_HUMAN
4865 Noelin precursor (Neuronal olfactomedm related ER localized protein) (Olfactomediπ 1) NOE1_HUMAN Y
4866 Myocilin precursor (Trabecular meshwork-iπduced glucocorticoid response protein) MYOC_HUMAN Y
4867 Mitochondπal 2-oxodιcarboxylate earner ODC_HUMAN
4868 Plakophllin 2 PKP2_HUMAN
4869 Plakophllin 4 (p0071) PKP4_HUMAN
4870 Membrane-associated tyrosine and threonine-specific cdc2-ιnhιbitory kinase (EC 271 37) (Myt1 kinase) PMYT1_HUMAN
4871 UPF0338 protein NG5 NG5JHUMAN
4872 Potassium channel subfamily K member 16 (TWIK-related alkaline pH activated K(+) channel 1) (2P domain potassium channel Talk-1) KCNKG_HUMAN
4873 Potassium channel subfamily K member 17 (TWIK-related alkaline pH activated K(+) channel 2) (2P domain potassium channel Talk-2) KCNKHJ-IUMAN
4874 Potassium voltage-gated channel subfamily S member 3 (Voltage-gated potassium channel subunit Kv93) (Delayed-rectifier K(+) channel alp KCNS3_HUMAN
4875 1-acyI sn-glyceroi 3-phosphate acyltransferase alpha (EC 231 51) (1-AGP acyltransferase 1) (1-AGPAT 1) (Lysophosphatidic acid PLCA_HUMAN
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
5396 Aladin (Adracalin) (GL003) AAAS-HUMAN
5397 CD209 antigen (Dendrite cell-specific ICAM-3-grabbιng nonmtegπn 1) (DC-SIGN1) (DC-SIGN) CD209_HUMAN
5398 Hypothetical protein C14orf132 CN132JHUMAN
5399 Cyclic-nucleotide-gated cation channel beta 3 (CNG channel beta 3) (Cyclic nucleotide gated channel beta 3) (Cone photoreceptor cGMP- CNGB3JHUMAN
5400 Carbohydrate sulfotransferase 11 (EC 2825) (Chondroitin 4-0- sulfotransferase 1) (Choπdroitin 4-sulfotransferase 1) (C4ST) (C4ST-1) CHSTB_HUMAN
5401 Cartiohydrate sulfotransferase 12 (EC 2825) (Chondroitin 4-0- sulfotransferase 2) (Choπdroitin 4-sulfotransferase 2) (C4ST2) CHSTC_HUMAN
5402 Cartilage acidic protein 1 precursor (Chondrocyte expressed protein 68 kDa) (CEP-68) (ASPIC) CRAC1 JHUMAN Y
5403 ATP-biπding cassette, sub-family B, member 6, mitochondπal precursor (Mitochoπdπal ABC transporter 3) (Mt-ABC transporters) (ABC ABCB6_HUMAN
5404 ATP-binding cassette, sub-family B, member 9 precursor (ATP binding cassette transporter 9) (ABC transporter 9 protein) (TAP-like protein) ABCB9JHUMAN Y
5405 Ameloblastin precursor AMBN_HUMAN Y
5406 Complement component C1q receptor precursor (Complement component 1 q subcomponent receptor 1) (CIqRp) (CIqR(P)) (C1q/MBL/SP/C1QR1 JHUMAN Y
5407 Protein C11orf15 precursor (UNQ712/PRO1375) CK015_HUMAN Y
5408 Adipocyte plasma membrane-associated protein (BSCv protein) (UNQ1869/PRO4305) APMAPJHUMAN
5409 Cadhenπ EGF LAG seven-pass G-type receptor2 precursor (Epidermal growth factor-like 2) (Multiple epidermal growth factor-like domains CELR2JHUMAN Y
5410 Probable cation transporting ATPase 13A1 (EC 363-) (CGI-152) AT131 JHUMAN
5411 Probable cation-transporting ATPase 13A2 (EC 363-) AT132 J-IUMAN
5412 Progressive ankylosis protein homolog (ANK) (UNQ241/PRO274) ANKHJHUMAN
5413 Mitochondπal deoxynucleotide carrier (Mitochoπdπal uncoupling protein 1) DNCJHUMAN
5414 Delta-like protein 4 precursor (Drosophila Delta homolog 4) (UNO.1895/PRO4341) DLL4 JHUMAN Y
5415 Apoptosis regulator BcI B (Bcl-2-lιke 10 protein) (Anti-apoptotic protein NrH) B2L10JHUMAN
5416 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (EC 241 135) (Beta-1,3-glucuroπyltransferase 2) B3GA2JHUMAN
5417 Protein C6orf149 (CGI-203) CF149 JHUMAN
5418 DnaJ homolog subfamily C member4 (Multiple endocπne neoplasia candidate protein number 18) (DnaJ-like protein HSPF2) DNJC4JHUMAN
5419 Endothelial cell-specific molecule 1 precursor (ESM-1 secretory protein) (ESM-1) ESM1JHUMAN Y
5420 Chromatin modifying protein 1 (Charged multivesicular body protein 1) (CHMP1) CHMP1 JHUMAN
5421 Cadheπn-20 precursor CAD20JHUMAN Y
5422 Cytochrome P45026B1 (EC 1 14--) (P45026A2) (P450 retinoic inactivating 2) (P450RAI-2) (Retiπoic-acid metabolizing cytochrome) CP26BJHUMAN
5423 Cytokine receptor-like factor 2 precursor (Cytokine receptor-like 2) (CRL2) (IL-XR) (Thymic stromal lymphopoietiπ protein receptor) CRLF2 JHUMAN Y
5424 Band 41-llke protein 4A (NBL4 protein) E41LA JHUMAN
5425 HEF-like protein CT032JHUMAN
5426 Protein C20orf54 CT054 JHUMAN
5427 Cutaneous T-cell lymphoma-associated antigen 1 (cTAGE-1 protein) CTGE1JHUMAN
5428 Cytochrome P4503A43 (EC 1 14141) CP343JHUMAN
5429 Cytochrome P4504F11 (EC 1 14 14 1) (CYPIVF11) CP4FBJHUMAN
5430 Cytochrome P4504F12 (EC 1 14 14 1) (CYPIVF12) (UNQ568/PRO1129) CP4FCJHUMAN
5431 Tumor necrosis factor receptor superfamily member Fn14 precursor (Fibroblast growth factor-inducible immediate-early response protein FN14JHUMAN Y
5432 Lysophosphatidic acid receptor Edg 4 (LPA receptor 2) (LPA-2) EDG4JHUMAN
5433 EGF, latrophiliπ and seven transmembrane domain containing protein 1 precursor (EGF-TM7-latrophilιn-related protein) (ETL protein) ELTD1 JHUMAN Y
5434 Growth/differentiation factor 3 precursor (GDF-3) (UNQ222/PRO248) GDF3JHUMAN Y
5435 Fibroblast growth factor-20 (FGF-20) FGF20JHUMAN
5436 Fibroblast growth factor-22 precursor (FGF-22) (UNQ2500/PRO5800) FGF22JHUMAN Y
5437 HERV-K_3q123 provirus ancestral Gag polyprotein (Gag polyprotein) (HERV-K(II) Gag protein) [Contains Matnx protein, Capsid protein GAK8 JHUMAN
5438 Fnzzled 3 precursor (Fπzzled-3) (Fz-3) (hFz3) FZD3 JHUMAN Y
5439 Polypeptide N acerylgalactosaminyltransferase 9 (EC 241 41) (Protem-UDP acetylgalactosamiπyltransferase 9) (UDP- GALT9JHUMAN
5440 HERV-H_2q243 proviius ancestral Env polyprotein precursor (Envelope polyprotein) (Env protein HERV-H/p62) (Env protein HERV-H19) (HEENH1 JHUMAN Y
5441 HERV-H_3q26 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (Env protein HERV-H/p60) (HERV-H/env60) [Contains ENH2JHUMAN Y
5442 HERV-H~2q241 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (Env protein HERV-H/p59) (HERV-H/env59) [Contains ENH3JHUMAN Y
5443 Neurexin 3-beta precursor (Neurexin Ill-beta) NRX3BJHUMAN Y Y
5444 Inward rectifier potassium channel 16 (Potassium channel, inwardly rectifying, subfamily J, member 16) (Inward rectifier K(+) channel IRK16JHUMAN Y
5445 X-linked interleukιn-1 receptor accessory protein-like 2 precursor (IL1RAPL 2 related protein) (lnterleukιn-1 receptor 9) (IL-1R9) (IL-1 IRPL2 JHUMAN Y Y
5446 G-protein coupled receptor family C group 5 member C (Retinoic acid induced gene 3 protein) (RAIG-3) GPC5CJHUMAN Y Y
5447 lnterleukιn-1 receptor accessory protein precursor (IL-1 receptor accessory protein) (IL-IRAcP) IL1APJHUMAN Y Y
5448 Integral membrane protein 2C (Transmembrane protein BRI3) (Cerebral protein-14) (hucep-14) (NPD018) ITM2CJHUMAN
5449 Manπosyl-oligosacchaπde 1,2 alpha-mannosidase IC (EC 321 113) (Processing alpha-1 ,2-maππosιdase IC) (Alpha-1,2-maππosιdase IC) MA1C1JHUMAN
5450 Leucine-nch repeat containing G protein coupled receptor 6 LGR6JHUMAN
5451 Relaxin receptor 1 (Leuαπe-πch repeat-containing G-protein coupled receptor 7) LGR7JHUMAN
5452 Iπterieukin 21 receptor precursor (IL-21R) (Novel interleukin receptor) (UNQ3121/PR010273) IL21RJHUMAN Y
5453 Interleukin 26 precursor (AK155 protein) IL26JHUMAN Y
5454 Calcium activated potassium channel beta subunit 3 (Calcium-activated potassium channel, subfamily M, beta subunit 3) (Maxi K KCMB3JHUMAN
5455 Seππe protease inhibitor Kazal-type 5 precursor (Lympho-epithelial Kazal-type related inhibitor) (LEKTI) [Contains- Hemofiltrate peptide ISK5JHUMAN Y
5456 Mucin 5B precursor (Mucin 5 subtype B1 tracheobronchial) (High molecular weight salivary mucin MG1) (Sublingual gland mucin) MUC5BJHUMAN Y
5457 Mucin and cadheπn-Iike protein precursor (Mu protocadhenn) (UNQ2781/PRO7168) MUCDLJHUMAN Y
5458 Junctophilin 1 (Junctophllm type 1) (JP-1) JPH1JHUMAN
5459 Protein KIAA1173 K1173 JHUMAN
5460 lπterleukin-1 receptor-like 2 precursor (IL-1Rrp2) (lπterleukιn-1 receptor related protein 2) (IL1R-rp2) ILRL2 JHUMAN Y
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type HI Type IV Mitochondrial Golgi
5461 Matrix extracellular phosphoglycoprotein precursor (Osteoblast/osteocyte factor 45) (OF45) MEPE-HUMAN
5462 Protein MANBAL MANBLJHUMAN
5463 Leucine-πch repeat-containing protein 4 precursor (Brain tumor associated protein LRRC4) (NAG14) (UNQ554/PRO1111) LRRC4_HUMAN Y
5464 Leukotπeπe B4 receptor 2 (LXB4-R2) (Seven transmembrane receptor BLTR2) (Leukotπene B4 receptor BLT2) (LTB4 receptor JULF2) LT4R2_HUMAN
5465 Neural proliferation differentiation and control protein 1 precursor (NPDC-1 protein) NPDCΪJ-IUMAN Y
5466 Partitioning defective-6 homolog alpha (PAR-6 alpha) (PAR 6A) (PAR-6) (PAR6C) (Tax interaction protein 40) (TIP-40) PAR6A~HUMAN
5467 Matrix metalloproteιnase-25 precursor (EC 3424 -) (MMP-25) (Membrane-type matπx metalloproteinase 6) (MT-MMP 6) (Membrane-type-6 MMP25_HUMAN Y
5468 Matπx metalloproteιnase-26 precursor (EC 3424 -) (MMP-26) (Matnlysιn-2) (Endometase) MMP26 J-IUMAN Y
5469 Prolactin regulatory element-binding protein (Mammalian guanine nucleotide exchange factor mSec12) PREBJHUMAN
5470 T-Iymphocyte surface antigen Ly-9 precursor (Lymphocyte antigen 9) (Cell-surface molecule Ly-9) (CD229 antigen) LY9_HUMAN Y
5471 Sodium/potassium/calcium exchanger 3 precursor (Na(+)/K(+)/Ca(2+)- exchange protein 3) NCKX3_HUMAN Y
5472 Protocadhenn 12 precursor (Vascular cadheππ 2) (Vascular endothelial cadhenπ-2) (VE-cadherιn-2) (VE-cad-2) (UNQ395/PRO731) PCD12_HUMAN Y Y
5473 Protocadhenn 18 precursor PCD18JHUMAN Y Y
5474 Protocadhenn 9 precursor PCDH9JHUMAN Y Y
5475 Otofertin (FeM like protein 2) OTOF_HUMAN
5476 Potassium channel subfamily K member 9 (Acid-sensitive potassium channel protein TASK-3) (TWIK-related acid-sensitive K(+) channel 3) KCNK9_HUMAN Y
5477 Potassium channel subfamily K member 12 (Tandem pore domain inhibited potassium channel 2) (THIK-2) KCNKCJHUMAN Y
5478 Potassium voltage-gated channel subfamily KQT member 5 (Voltage-gated potassium channel subunit Kv75) (Potassium channel alpha subu KCNQ5JHUMAN Y
5479 Olfactory receptor 2S2 OR2S1 JHUMAN Y
5480 Peroxisomal membrane protein 2 (22 kDa peroxisomal membrane protein) PXMP2J-IUMAN Y
5481 Podocin PODO_HUMAN Y
5482 Netπn-G1 ligand precursor (NGL-1) (UNQ292/PRO331) NGL1_HUMAN Y
5483 Prokineticin 2 precursor (PK2) (Protein Bv8 homolog) PROK2_HUMAN Y
5484 FMRFamide-related peptides precursor [Contains Neuropeptide NPSF (Neuropeptide RFRP-1), Neuropeptide RFRP 2, Neuropeptide NPVF RFRP_HUMAN Y
5485 Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Fooceπ) (Neuroeπdocππe-specific protein) (NSP) (Neuroendocπne specific RTN4_HUMAN
5486 Semaphoπn 4B precursor (UNQ749/PRO1480) SEM4B_HUMAN Y
5487 Pleckstnπ homology domain-containing protein family A member 1 (Tandem PH domain containing protein 1) (JAPP-I) PLEA1_HUMAN
5488 Pleckstπn homology domain-containing protein family A member2 (Tandem PH domain containing protein 2) (TAPP-2) (Fragment) PLEA2_HUMAN
5489 Pleckstπn homology domain-containing protein family A member 3 (Phosphomositol 4-phosphate adaptor proteιn-1) (FAPP-1) PLEA3_HUMAN
5490 Sialin (Solute earner family 17 member 5) (Sodium/sialic acid cotransporter) (AST) (Membrane glycoprotein HP59) S17A5_HUMAN
5491 Solute earner family 35 member C2 (Ovaπaπ cancer overexpressed 1 protein) (CGI-15) S35C2_HUMAN
5492 Solute earner family 40, member 1 (Ferroportin 1) (Iron regulated transporter 1) (MSTP079) S40A1 JHUMAN
5493 Roundabout homolog 2 precursor ROBO2JHUMAN Y
5494 Solute earner organic anion transporter family, member 1B3 (Solute earner family 21 , member 8) (Organic anion transporter 8) SO1 B3_HUMAN
5495 Sodium- and chloπde-depeπdent transporter XTRP3 (Solute earner family 6 member 20) (Neurotransmitter transporter rB21 A homolog) S6A20_HUMAN
5496 Resistiπ precursor (Cysteiπe-nch secreted protein F1ZZ3) (Adipose tissue-specific secretory factor) (ADSF) (C/EBP-epsilon regulated RSN-HUMAN Y
5497 PRKCA-bmdiπg protein (Protein kinase C-alpha binding protein) (Protein interacting with C kinase 1) PICK1_HUMAN
5498 Sentπn specific protease 2 (EC 3 A 22 -) (Seπtnn/SUMO specific protease SENP2) (SMT3-specιfic isopeptidase 2) (Smt3ιp2) (Axam2) SENP2_HUMAN
5499 Glycerol-3-phosphate acyltransferase, mitochondnal precursor (EC 23 1 15) (GPAT) PLSB_HUMAN
5500 Protein Pluπc precursor (Palate lung and nasal epithelium clone protein) (Lung specific X protein) (Nasopharyngeal carcinoma-related PLUNC__HUMAN Y
5501 Synaptotagmin like protein 2 (Exophilm 4) SYTL2_HUMAN
5502 Transient receptor potential cation channel subfamily M member 3 transient receptor potential channel 3) (LTrpC3) (Melastatin 2) TRPM3J-1UMAN
5503 Spondιn-1 precursor (F-spondin) (Vascular smooth muscle cell growth promoting factor) SPON1_HUMAN Y
5504 Toll-like receptor 8 precursor (UNQ249/PRO286) TLR8_HUMAN Y
5505 Toll-like receptor 9 precursor (UNQ5798/PRO19605) TLR9_HUMAN Y
5506 Transmembrane protein 16B TM16B_HUMAN
5507 Transmembrane 9 superfamily protein member 3 precursor (SM-11044 binding protein) (EP70-P-ιso) (UNQ245/PRO282) TM9S3_HUMAN Y
5508 Transmembrane protein 8 precursor (M83 protein) TMEM8_HUMAN Y
5509 Sperm-associated antigen 4 protein (Outer dense fiber-associated protein SPAG4) SPAG4JHUMAN
5510 Transient receptor potential cation channel subfamily V member 4 (TrpV4) (osm-9-lιke TRP channel 4) (OTRPC4) (Vanilloid receptor-like TRPV4_HUMAN
5511 Vezatiπ VEZAJHUMAN
5512 Spectπn beta chain, brain 4 (Spectrin, non erythroid beta chain (Beta-V spectπn) (BSPECV) SPTN5JHUMAN
5513 Vacuolar proton translocating ATPase 116 kDa subunit a isoform (V-ATPase 116-kDa isoform a4) (Vacuolar proton translocating ATPase VPP4_HUMAN
5514 WAP four-disulfide core domain protein 1 precursor (Prostate stromal protein ps20) (ps20 growth inhibitor) WFDC1_HUMAN Y
5515 Popeye domain containing protein 2 (Popeye protein 2) POPD2_HUMAN
5516 Popeye domain containing protein 3 (Popeye protein 3) POPD3_HUMAN
5517 Tπggeππg receptor expressed on myeloid cells 1 precursor (Tπggeππg receptor expressed on monocytes 1) (TREM-1) TREM1_HUMAN Y
5518 Short transient receptor potential channel 7 (TrpC7) (TRP7 protein) TRPC7_HUMAN
5519 ZιnctransporterZIP2 (Etl-1) (6A1) (hZ!P2) ZIP2_HUMAN
5520 Tuftelin TUFT1_HUMAN
5521 Zinc finger DHHC domain containing protein 4 (Zinc finger (DC1) (UNQ57B7/PRO19576) ZDHC4_HUMAN
5522 Z-proteιn (CGI-119) (S1R protein) ZPROJHUMAN
5523 Hypothetical protein ORF4 precursor Q9NQC5_HUMAN Y
5524 Islet-specific gIucose-6-phosphatase catalytic subuπit-related protein Q9NQR9_HUMAN
5525 Putative anion transporter 1 Q9NQU1JHUMAN
i
Figure imgf000157_0001
Extracellular Integral
PlD Description UniProtACC Signal Secreted Domain Membrane Type I Type U Type III Type IV Mitochondria! Golgi
5591 CD164 antigen, siatomuαn (OTTHUMP00000016956) Q9NR26_HUMAN
5592 HTGN29 (Keratinocytes associated transmembrane protein 2) (Chromosome 5 open reading frame 15) Q9NRG2JHUMAN
5593 Membrane-associated guanylate kinase MAGI3 Q9HBC4_HUMAN
5594 Small inducible cytokine A28 precursor (CCL28) (Mucosae-assoαated epithelial chemokme) (MEC) (CCK1 protein) CCL28_HUMAN Y Y
5595 Asc-type ammo acid transporter 1 (Asc-1) AAA1_HUMAN Y
5596 Cysteinyl leukotnene receptor2 (CysLTR2) (PSEC0146) (HG57) (HPN321) (hGPCR21) CLTR2JHUMAN Y Y
5597 Protein C14orf101 CN101_HUMAN Y
5598 Carbohydrate sulfotransferase 7 (EC 282 17) (EC 282-) (Chondroitin 6-sulfotransferase 2) (C6ST-2) (N-acetylg!ucosamιne 6-0- CHST7_HUMAN
5599 ATP-binding cassette, sub-family B, member 8 mitochoπdπal precursor (Mitochondrial ATP-bindmg cassette 1) (M-ABC1) ABCB8 HUMAN Y
5600 ATP-binding cassette, sub-family B, member 10, mitochondrial precursor (ATP-bιπdιπg cassette transporter 10) (ABC transporter 10 protein) ABCBAJHUMAN Y
5601 Putative ATP-binding cassette transporter C13 (Protein PRED6) ABCCD_HUMAN
5602 Androgen induced protein 1 (A1G-1) (CGI-103) AIG1_HUMAN Y
5603 Adipocyte-deπved leucine aminopeptidase precursor (EC 3411 -) (A-LAP) (ARTS-1) (Ammopeptdase PILS) (Puromycin-insensitive leucyl- ARTS1_HUMAN Y Y
5604 Cytokine like protein C17 precursor (UNQ1942/PRO4425) C17_HUMAN Y Y
5605 Abl-interactor2 (Abelsoπ iπteractor2) (Abi 2) (AbI binding protein 3) (AblBP3) (Arg binding protein 1) (ArgBPI) ABI2_HUMAN
5606 Chemokine-Iike factor super family member 6 CKLF6_HUMAN Y
5607 Alkaline phytoceramidase (EC 351 -) (aPHC) (Alkaline ceramidase) (Alkaline dihydroceramidase SB89) APHC_HUMAN Y
5608 Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingo homolog 2) (hFmι2) CELR1_HUMAN Y Y Y
5609 C-type lectin superfamily member 5 (Myeloid DAP12-associatιng lectin) (MDL-1) CLEC5JHUMAN Y
5610 DnaJ homolog subfamily B member12 DNJBC_HUMAN
5611 Delta like protein 3 precursor (Drosophila Delta homolog 3) DLL3_HUMAN Y Y
5612 Beta-1,3-galactosyltransferase 7 (EC 241 -) (Beta-1,3-GalTase 7) (Beta3Gal-T7) (b3Gal-T7) (UDP-galactose beta N acetylglucosamine B3GT7_HUMAN
5613 Protein C3orf4 (Membrane protein GENX-3745) (HSPC174) (UNQ2511/PRO6000) CC004JHUMAN Y
5614 Chloπde intracellular channel protein 5 CLIC5JHUMAN
5615 Ceroid lipofuscinosis neuronal protein 6 (CLN6 protein) CLN6_HUMAN Y
5616 Cadheππ EGF LAG seven-pass G-type receptor 3 precursor (Flamingo homolog 1) (hFmil) (Multiple epidermal growth factor-like domains 2) CELR3_HUMAN Y Y Y
5617 Gap junction beta 4 protein (Coπnexin 303) (Cx303) CXB4_HUMAN Y Y
5618 Putative HIF-prolyl hydroxylase PH-4 (EC 1 1411 -) (Hypoxia-inducible factor prolyl 4-hydroxylase) EGLX_HUMAN
5619 Protein FAM18B (NPD008) (CGI-148) FA18B_HUMAN Y
5620 Potential phospholipid-transporting ATPase IB (EC 363 1) (ATPase class I type 8A member 2) (ML-1) AT8A2_HUMAN Y Y
5621 Eukaryobc translation initiation factor 2-alpha kinase 3 precursor (EC 27 1 -) (PRKR-like endoplasmic reticulum kinase) (Pancreatic E2AK3J-IUMAN Y
5622 Leucine-rich repeat transmembrane protein FLRT1 precursor (Fibroπectin-like domain-containing leucine-nch transmembrane protein FLRT1_HUMAN Y Y
5623 Leucine-nch repeat transmembrane protein FLRT3 precursor (Fibroπectin-like domain-containing leucine-nch transmembrane protein FLRT3JHUMAN Y Y
5624 Adiponutrin (iPLA2-epsi!on) [Includes Tπacylglycerol lipase (EC 3 1 1 3), Acylglycerol O-acyltransferase (EC 231 -)] ADPN_HUMAN
5625 Protein C20orf46 CT046_HUMAN Y
5626 Protein C20orf141 CT141 HUMAN
5627 Cytochrome P45039A1 (EC 1 1413 -) (Oxysterol 7-alpha hydroxylase) (hCYP39A1) CP39/T.HUMAN
5628 Elongation of very long chain fatty acids protein 2 ELOV2_HUMAN Y
5629 Dermal papilla deπved protein 7 DER7_HUMAN Y
5630 EMlLIN 3 precursor (EMILIN-5) (Elastin microfibπl interface-located protein 5) (Elastin microfibnl iπterfacer 5) EMIL3_HUMAN Y
5631 Enamelm precursor ENAM_HUMAN Y Y
5632 Probable G-protein coupled receptor 27 (Super conserved receptor expressed in brain 1) GPR27_HUMAN Y Y
5633 Probable G-protein coupled receptor 83 precursor GPR83_HUMAN Y Y Y
5634 Synaptic glycoprotein SC2 GPSN2_HUMAN Y
5635 Fibroblast growth factor-21 precursor (FGF-21) (UNQ3115/PRO10196) FGF21JHUMAN Y Y
5636 HERV-W_3q2632 provims ancestral Gag polyprotein (Gag polyprotein) [Contains Matrix protein (Gag P15), Capsid protein (Core shell GAW2_HUMAN
5637 ADP-πbosylation factor binding protein GGA3 (Golgi-localized, gamma ear-containing, ARF-binding protein 3) GGA3JHUMAN
5638 Probable polypeptide N-acelylgalactosaminyltransferase 8 (EC 2,4141) (Proteiπ-UDP acetylgalactosaminyltraπsferase 8) (UDP- GALT8J-IUMAN
5639 Probable G-proteiπ coupled receptor 173 (Super conserved receptor expressed in brain 3) GP173_HUMAN Y Y
5640 Protocadheπn Fat 2 precursor (hFat2) (Multiple epidermal growth factor-like domains 1) FAT2JHUMAN Y Y
5641 D1 dopamine receptor-interacting protein calcyon D1IP_HUMAN Y
5642 Hypothetical HERV-K_16p33 provirus ancestral Eπv polyprotein (Envelope polyprotein) [Contains Surface protein (SU), Transmembrane ENK14_HUMAN
5643 Solute earner family 2, facilitated glucose transporter, member 8 (Glucose transporter type 8) (Glucose transporter type X1) GTR8_HUMAN Y Y
5644 Solute earner family 2, facilitated glucose transporter, member 9 (Glucose transporter type 9) GTR9_HUMAN Y Y
5645 Interleukin-17B receptor precursor (IL-17B receptor) (IL-17 receptor homolog 1) (IL-17Rh1) (IL17RM) (Cytokine receptor CRL4) I17R2_HUMAN Y Y Y
5546 X-linked ιnterieukιn-1 receptor accessory protein like 1 precursor (IL1 RAPL-1) (Olιgophrenιn-4) (Three immunoglobulin domain-containing IRPL1JHUMAN Y Y
5647 G protein coupled receptor family C group 5 member B (Retinoic add induced gene 2 protein) (RAIG-2) (A-69G12 1) GPC5B_HUMAN Y Y Y
5648 G-protein coupled receptor family C group 5 member D GPC5D!HUMAN Y Y
5649 lnterteukin 1 family member 7 precursor (IL-1F7) (lnterleukιn-1 zeta) (IL-1 zeta) (FIL1 zeta) (lnterteukιn-1 homolog 4) (IL-1H4) IL1F7_HUMAN Y
5650 lnterieukin 1 family member8 (IL-1F8) (lnterleukin-1 eta) (IL-1 (FIL1 eta) (lnterteukιn-1 homolog 2) (IL-1H2) IL1F8_HUMAN Y
5651 lnterieukin 1 family memberθ (IL-1F9) (lπterleukιn-1 homolog 1) (IL-1H1) (lnterieukιπ-1 epsilon) (IL-1 epsilon) (IL-1 related protein IL1F9_HUMAN Y
5652 WD repeat protein HUSSY-07 HUS7_HUMAN
5653 Low density lipoprotein receptor-related protein 1B precursor (Low- density lipoprotein receptor-related protein-deleted in tumor) (LRP- LRP1B_HUMAN Y Y
5654 Membrane-spanning 4-domaιπs subfamily A member 12 M4A12_HUMAN Y
5655 lnterleukιn-20 precursor (IL-20) (Four alpha helix cytokine ZCYTO10) (UNQ852/PRO1801) IL20_HUMAN Y Y
Figure imgf000159_0001
Figure imgf000160_0001
Extracellular Integral
PlD Descπption ~ - UniProtACC Signal Secreted Domain Membrane Type I Type Il Type HI Type IV Mitochondπal Golgi
5786 Hypothetical protein FLJ20730 (Solute camerfamily 35 member A5) (SLC35A5) Q9NWM9JHUMAN
5787 Long chain polyunsaturated fatty acid elongation enzyme (Hypothetical protein FLJ9O408) (Hypothetical protein DKFZp586B1824) (Homolog (Q9NYP7JHUMAN
5788 Eπdoglycan Q9NZ53 J-IUMAN
5789 Membrane interacting protein of RGS16 Q9NZC3_HUMAN
5790 Apoptosis regulator Q9NZS9_HUMAN
5791 Hypothetical protein DKFZp761 K0511 Q9NTK6JHUMAN
5792 Hypothetical protein FLJ20668 Q9NWR0_HUMAN
5793 Hypothetical protein FLJ20445 (Ring finger protein 153) Q9NX47JHUMAN Y
5794 Protein AD-013 (xθ∞8) AD13_HUMAN
5795 ADAM 22 precursor (A disintegπn and metaHoproteinase domain 22) (Metalloprotemase-like, disiπtegπn-like and cysteine-nch protein ADA22 HUMAN Y Y
5796 HLA class I histocompatibility antigen Cw 5 alpha chain precursor (MHC class I antigen Cw*5) 1C05JHUMAN Y Y
5797 HLA class Il histocompatibility antigen DRB1-9 beta chain precursor (MHC class I antigen DRB1*9) (DR 9) (DR9) 2B19JHUMAN Y Y
5798 CMRF35-H antigen precursor (CMRF35-H9) (CMRF-35-H9) (Inhibitory receptor protein 60) (IRp60) (IRC1/IRC2) (NK inhibitory receptor) CM35H JHUMAN Y Y
5799 Contactin 3 precursor (Brain deπved immunoglobulin superfamily protein 1) (BIG 1) (Plasmacytoma associated neuronal glycoprotein) CNTN3_HUMAN Y
5800 Contactin associated protein-like 2 precursor (Cell recognition molecule Caspr2) CNTP2 JHUMAN Y Y
5801 Potassium/sodium hyperpolaπzation-activated cyclic nucleotide-gated channel 3 HCN3_HUMAN Y
5802 B-cell receptor-associated protein 29 (BCR-assoαated protein Bap29) BAP29JHUMAN Y
5803 Protein C9orf7 (UNQ3071/PRO9903) CI007 JHUMAN Y
5804 ATP-binding cassette, sub-family D, member2 (Adrenoleukodystrophy related protein) (hALDR) (Adrenoleukodystrophy-Iike 1) ABCD2_HUMAN Y
5805 ATP-binding cassette, sub-family F member 2 (Iron inhibited ABC transporter 2) (HUSSY-18) ABCF2_HUMAN
5806 ADAMTS-1 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 1) (ADAM-TS 1) (ADAM-TS1) (METH-1) ATS1_HUMAN Y Y
5807 Gamma adducin (Adducin like protein 70) ADDGJHUMAN
5808 ATP synthase g chain, mitochondπal (EC 36314) (ATPase subunit ATP5 LJ-IUMAN
5809 Cingulin ClNG JHUMAN
5810 C5a anaphylatoxin chemotactic receptor C5L2 C5ARLJHUMAN Y Y
5811 Potential phosphollpld-transporting ATPase VD (EC 3631 ) (ATPVD) AT10DJHUMAN Y Y
5812 ADAMTS-9 precursor (EC 3424 -) (A disintegπn and metalloproteinase with thrombospondin motifs 9) (ADAM-TS 9) (ADAM-TS9) ATS9JHUMAN Y Y
5813 Chemokine-llke factor (C32) (HSPC224) (UNQ410/PRO772) CKLF_HUMAN Y Y
5814 Ankyπn repeat and FYVE domain protein 1 (Ankyπn repeats zinc finger motif) ANFY1JHUMAN
5815 Voltage-dependent T-type calcium channel alpha 11 subunit (Voltage- gated calcium channel alpha subunit Cav33) (Ca(v)33) CAC1 IJHUMAN Y Y
5816 Choπdroitin sulfate glucuronyltransferase (EC 241 226) (N acetylgalactosaminyl-proteoglycan 3 beta-glucuronosyltraπsferase) CHGUT HUMAN
5817 DnaJ homolog subfamily C member 5B (Beta cysteine stπng (Beta-CSP) DNJ5BJHUMAN
5818 Disks large-associated protein 2 (DAP 2) (SAP90/PSD 95-assocιated protein 2) (SAPAP2) (PSD-95/SAP90 binding protein 2) (Fragment) DLP2 JHUMAN
5819 Neuronal acetylcholine receptor protein, alpha-9 chain precursor ACHA9 JHUMAN Y Y Y
5820 Galactosylgalactosylxylosylprotein 3-beta glucuronosyltraπsferase 1 (EC 241 135) (Beta-1,3-glucuronyltransferase 1) B3GA1JHUMAN
5821 Beta-1,4-galactosyltraπsferase 6 (EC 24 1 -) (Beta 1 4-GalTase 6) (Beta4Gal-T6) (b4Gal-T6) (UDP-galaclose beta-N-acetylglucosamine B4GT6 JHUMAN
5822 Beta-1,4-galactosyltransferase 7 (EC 24 1 -) (Beta 1,4-GaITase T) (Beta4Gal-T7) (b4Gal-T7) (UDP galactose beta-N-acetylglucosamine B4GT7JHUMAN
5823 Carboxypeptidase B2 precursor (EC 34 1720) (Carboxypeptidase U) (Thrombin-activatable fibnnolysis inhibitor) (TAFI) (Plasma CBPB2JHUMAN Y Y
5824 B-cell stimulating factor-3 precursor (BSF-3) (Novel πeuratrophιn-1) (NNT-1) (Cardiotrophin-like cytokine) BSF3 HUMAN Y Y
5825 CLN8 protein CLN8JHUMAN Y
5826 Coatomer gamma-2 subunit (Gamma-2 coat protein) (Gamma-2 COP) COPG2 JHUMAN
5827 Coatomer zeta-2 subunit (Zeta-2 coat protein) (Zeta-2 COP) COPZ2 JHUMAN
5828 Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage- gated calcium channel gamma-4 subunit) CCG4JHUMAN Y
5829 Voltage-dependent calcium channel gamma-5 subunit (Neuronal voltage- gated calcium channel gamma 5 subunit) CCG5~HUMAN Y
5830 Multiple EGF-like-dσmaiπ protein 7 precursor (Multiple epidermal growth factor-like-domaiπ protein 7) (Vascular endothelial statin) EGFL7.HUMAN Y Y
5831 7-dehydrocholesterσl reductase (EC 1 3 1 21) (7 DHC reductase) (Sterol delta-7-reductase) (Putative sterol reductase SR-2) DHCR7JHUMAN Y
5832 Dolichol-phosphate maπnosyltransferase subunit 3 (Dolichol-phosphate mannose synthase subunit 3) (Dolichyl-phosphate beta-D- DPM3JHUMAN Y
5833 Dentin sialophosphoprotein precursor [Contains Dentin phosphoprotein (Dentin phosphophoryn) (DPP), Dentin sialoproteiπ (DSP)] DSPPJHUMAN Y Y
5834 Hypothetical protein CYorf14 (PRO28349) CY014JHUMAN
5835 Epidermal growth factor receptor substrate 15 like 1 (Eps15-related protein) (Eps15R) EP15RJHUMAN
5836 GTPase, IMAP family member 2 (Immunity-associated protein 2) (hlMAP2) GIMA2JHUMAN
5837 Ena/vasodilator stimulated phosphoproteiπ-like protein (Ena/VASP-like protein) EVLJHUMAN
5838 Fetuin-B precursor (IRL685) (16G2) FETUBJHUMAN Y Y
5839 Mitochondπal dicarboxylate earner DICJHUMAN Y
5840 Dickkopf related proteιn-2 precursor (Dkk-2) (Dickkopf 2) (hDkk-2) (UNQ682/PRO1316) DKK2 JHUMAN Y Y
5841 Dickkopf related proteιn-3 precursor (Dkk-3) (Dickkopf-3) (hDkk-3) (UNQ258/PRO295) DKK3JHUMAN Y Y
5842 Lysophosphatidic aαd receptor Edg-7 (LPA receptor^) (LPA-3) EDG7JHUMAN
5843 EGF-like module containing mucin-like hormone receptor-like 2 precursor (EGF-like module EMR2) EMR2 JHUMAN
5844 Gamma-aminobutyπc acid type B receptor subunit 1 precursor (GABA-B receptor 1) (GABA-B-R1) (Gb1) GABRT HUMAN
5845 Exostosin-like 2 (EC 241 223) (Glucuranyl-galactosyl proteoglycan 4-alpha-N-acetylglucosamιπyltransferase) (Alpha-1,4-N- EXTL2JHUMAN
5846 Dickkopf related proteιn-4 precursor (Dkk-4) (Dιckkopf-4) (hDkk-4) DKK4JHUMAN
5847 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-12 subunit GBG12JHUMAN
5848 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-13 subunit GBG13JHUMAN
5849 Ghreliπ precursor (Growth hormone secretagogue) (Growth hormone releasing peptide) (Motlin related peptide) (M46 protein) GHRLJHUMAN
5850 Prostaglandin F2 receptor negative regulator precursor (Prostaglandin F2-alpha receptor regulatory protein) (Prostaglandin F2-alpha receptor FPRPJHUMAN
Figure imgf000162_0001
Figure imgf000163_0001
Extracelluiar Integral
PlD Descnption UniProtACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
5981 PDZ domain containing guanine nucleotide exchange factor I Q9UHV4_HUMAN
5982 HSPC222 (JTB protein) (Jumping translocation breakpoint) Q9P0Q4_HUMAN
5983 HSPC202 (Adoplιn-1) (ORMDL1) (Hypothetical protein FLJ90275) (Hypothetical protein FU90S79) (Hypothetical protein DKFZp686G141) Q9P0S3_HUMAN
5984 Differentiation-associated Na-dependent inorganic phosphate cotransporter (Differentiation-associated Na-dependent inorganic Q9P2U8_HUMAN
5985 OTTHUMP00000018017 (Major histocompatibility complex, class II, DR alpha,) (OTTHUMP00000029406) (OTTHUMP00000029839) Q9TP70_HUMAN 59B6 Rh type C glycoprotein (Tumor-related protein DRC2) (Rhesus blood group, C glycoprotein) Q9UBD6_HUMAN
5987 Transmembrane adapter protein KAP10 (Membrane protein DAP10) (Hypothetical protein DKFZp586C1522) (DNAX-activatioπ protein 10) Q9UBK5_HUMAN
5988 MMP-23 (MIFR/Femalysin) (Metalloprotease isoform A) (Matrix metalloproteinase 23B) (MIFR-1) Q9UBR9_HUMAN
5989 BK65A62 (Novel Sushi domain (SCR repeat) containing protein similar to Mucins) (Sushi domain containing 2) Q9UGT4_HUMAN
5990 ProSAAS precursor (Proprotein convertase subtilisiπ/kexiπ type 1 inhibitor.) Q9UHG2_HUMAN
5991 Neuronal potassium channel alpha subunit (Potassium channel Kv8 1) Q9UHJ4_HUMAN
5992 A6(l V) collagen (Fragment) Q9UEH6_HUMAN
5993 Hypothetical protein DKFZp586O1922 Q9UFT3_HUMAN
5994 ADAM 21 precursor (EC 3424 -) (A dismtegππ and metalloproteinase domain 21) ADA21JHUMAN
5995 ADAM 28 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 28) (Metalloproteinase-like dismtegπn-like and cysteine- ADA28_HUMAN
5996 ADAM 29 precursor (A disintegnn and metalloproteinase domain 29) ADA29WHUMAN
5997 Alpha-i^-N-acetylglucosaminyltransferase (EC 241 -) (AIpha4GπT) A4GCT_HUMAN
5998 Calcium-binding mitochondπal earner protein Aralar2 (Mitochondπal aspartate glutamate earner 2) (Solute earner family 25 member CMC2JHUMAN
5999 Contactin β precursor (Neural recognition molecule NB-3) (hNB 3) CNTN6_HUMAN 600D Potassium/sodium hyperpolaπzation activated cyclic nucleotide-gated channel 2 (Brain cyclic nucleotide gated channel 2) (BCNG 2) HCN2_HUMAN
6001 Acetylcholinesterase collagenic tail peptide precursor (AChE Q subunit) (Acetylcholinesterase-associated collagen) COLQ_HUMAN
6002 ATP-binding cassette, sub-family G, member 2 (Placenta-specific ATP- binding cassette transporter) (Breast cancer resistance protein) ABCG2_HUMAN
6003 Autocrine motility factor receptor, isoform 2 (EC 632.-) (AMF receptor) (gp78) AMFR2_HUMAN
6004 Adapter-related protein complex 4 epsilon 1 subunit (Epsilon subunit of AP-4) (AP-4 adapter complex epsiloπ subunit) AP4E1_HUMAN
6005 ADAMTS-5 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondiπ motifs 5) (ADAM-TS 5) (ADAM-TS5) (Aggrecan ATS5_HUMAN Y
6006 ADAMTS-6 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 6) (ADAM-TS 6) (ADAM TS6) ATS6_HUMAN Υ
6007 Brain specific membrane-anchored protein precursor BMAP_HUMAN
6008 ADAM 30 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 30) (UNQ2509/PRO5997) ADA30_HUMAN
6009 Loπg-chain-fatty-acid-CoA ligase 5 (EC 62 1 3) (Long chain acyl CoA synthetase 5) (LACS 5) (UNQ633/PRO1250) ACSL5_HUMAN
6010 Loπg-chain-farty-acid-CoA ligaseθ (EC 62.1 3) (Long-chain acyl CoA synthetase 6) (LACS 6) ACSL6_HUMAN
6011 ADAMTS-7 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 7) (ADAM-TS 7) (ADAM-TS7) ATS7_HUMAN
6012 ADAMTS-8 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) ATS8_HUMAN
6013 X/potassium-transporting ATPase beta-m chain (X K ATPase beta-m subunit) AT1B4_HUMAN
6014 ALK tyrosine kinase receptor precursor (EC 271 112) (Anaplastic lymphoma kinase) (CD246 antigen) ALK-HUMAN
6015 C-type lectin superfamily member 6 (Dendritic cell immunoreceptor) (Lectin-like immunoreceptor) (C-type lectin DDB27) (HDCGC13P) CLEC6_HUMAN
6016 C-type lectin superfamily member 9 (Macrophage-inducible C-type lectin) (UNQ218/PRO244) CLEC9_HUMAN
6017 Angiopoietiπ-related protein 2 precursor (Aπgiopoietin like 2) (UNQ170/PRO196) ANGL2_HUMAN
6018 130-kDa phosphatidylinositol 4,5-bιphosphate-dependent ARF1 GTPase- activating protein (PIP2-dependent ARF1 GAP) (ADP πbosylation fε DDEF1JHUMAN
6019 Bassoon protein (Zinc-finger protein 231) BSN_HUMAN
6020 Gap junction alpha 9 protein (Connexm 36) (Cx36) CXA9_HUMAN
6021 Cysteine-πch hydrophobic domain 2 protein (BrX-like translocated in leukemia) CHIC2_HUMAN
6022 Coronιπ-2B (Coronin-like protein C) (ClipinC) (Protein FC96) COR2B_HUMAN
6023 ATP-dependent RNA helicase DDX19 (DEAD-box protein 18) (DEAD-box RNA helicase DEAD5) DDX19_HUMAN
6024 Ectonucleoside tπphosphate diphosphohydrolase 4 (EC 361 6) (NTPDase4) (Uπdme-diphosphatase) (UDPase) (Lysosomal apyrase-like ENP4_HUMAN
6025 Ectonucleotide pyrophosphatase/phosphodiesterase 5 precursor (EC 31 — ) (E-NPP5) (NPP-5) (UNQ550/PRO1107) ENPP5_HUMAN
6026 DCC-interacting protein 13 alpha (Dιp13 alpha) (Adapter protein containing PH domain, PTB domain and leucine zipper motif DP13A_HUMAN
6027 Cadheππ-22 precursor CAD22_HUMAN
6028 Cadheππ-7 precursor CADH7_HUMAN
6029 Cadheπn-9 precursor CADH9JHUMAN
6030 Drebπn-like protein (SH3 domain-containing protein 7) (Drebrin F) (Cervical SH3P7) (HPK1-interactιng protein of 55 kDa) (HIP-55) DBNL-HUMAN
6031 Feline leukemia virus subgroup C receptor-related protein 2 (Calcium- chelate transporter) (CCT) FLVC2_HUMAN
6032 Conserved oligomenc Golgi complex component 5 (13S Golgl transport complex 90 kDa subunit) (GTC 90) (Golgi transport complex 1) COG5_HUMAN
6033 HERV-W_7q21 2 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (HERV-7q Envelope protein) (HERV-W envelope proten ENW1_HUMAN
6034 Protein C20orf103 precursor CT103_HUMAN
6035 Protein C20ort155 (GCD10 protein homolog) CT155_HUMAN
6036 Carbonic anhydraseXIV precursor (EC 42.1 1) (Carbonate dehydratase XIV) (CA-XIV) (UNQ690/PRO1335) CAH14_HUMAN
6037 Cytochrome P4508B1 (EC 1 14--) (CYPVIIIB1) (Sterol 12-alpha- hydroxylase) (7alpha-hydroxy-4-cholesten-3-one 12 alpha-hydroxylase) CP8B1_HUMAN
6038 Endothelial protein C receptor precursor (Endothelial cell protein C receptor) (Activated protein C receptor) (APC receptor) (CD201 EPCR_HUMAN
6039 Collagen alpha 1(XVII) chain (Bullous pemphigoid antigen 2) (180 bullous pemphigoid antigen 2) COHA1_HUMAN
6040 Seπne protease DESC1 precursor (EC 3421 -) (UNQ742/PRO1461) [Contains Senne protease DESC1 non catalytic chain, Seπne protease DESC1_HUMAN
6041 Tumor necrosis factor receptor superfamily member EDAR precursor (Anhidrotic ectodysplasin receptor 1) (Ectodysplasin-A receptor) EDAR_HUMAN
6042 Growth/differentiation factor 2 precursor (GDF-2) (Bone morphogenetic protein 9) (BMP-9) GDF2_HUMAN
6043 Probable G-protein coupled receptor 34 GPR34_HUMAN
6044 Dickkopf-llke protein 1 precursor (Soggy-1 protein) (SGY-1) (UNQ735/PRO1429) DKKL1_HUMAN
6045 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-8 subunit (Gamma-9) GBG8_HUMAN
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Extracellular Integral
PlD Description UniProtACC Signal Secreted Domain Membrane Type I Type Il Type 111 Type IV Mltochondnal Golgi
6241 Neurexin 3-alpha precursor (Neurexin Ill-alpha) NRX3A_HUMAN Y Y Y
6242 Neuron specific protein family member2 (Protein p19) (HMP19) NSG2_HUMAN
6243 Netπn GI precursor (Lamιπet-1) (UNQ571/PRO1133) NTNG1JHUMAN
6244 Glypιcaπ-6 precursor (UNQ369/PRO705) GPC6_HUMAN
6245 Glutamate receptor-interacting protein 1 (GRIP1 protein) GRIP1JHUMAN
6246 Leucine zipper putative tumor suppressor 1 (F37/esophageal cancer- related gene-coding leucine zipper motif) (Fez1)
6247 Hypoxia-inducible gene protein 2. HIG2_HUMAN
6248 Integral membrane protein 2B (Transmembrane protein BRI) [Contains ABπ/ADan amyloid peptide] ITM2B_HUMAN
6249 Low-density lipoprotein receptor-related protein 12 precursor (Suppressor of tumoπgenicity protein 7) LRP12_HUMAN
6250 Calcium-activated potassium channel beta subuπit 2 (Calcium-activated potassium channel, subfamily M, beta subunit 2) (Maxi K KCMB2_HUMAN
6251 Mps one binder kinase activator-like 3 (Mob1 homolog 3) Il mMOB1) (CGI-95/CGI95-ιso) (Preimplantation protein 3) (2C4D) MOB3_HUMAN
6252 Junctional adhesion molecule 1 precursor (JAM) (Platelet adhesion molecule 1) (PAM-1) (Platelet F11 receptor) (UNQ264/PRO301) JAM1_HUMAN
6253 Kallikrein 4 precursor (EC 3421 -) (Prostase) (Kallikrein-like protein 1) (KLK-L1) (Enamel matrix senne proteinase 1) KLK4_HUMAN
6254 Kallikrein 5 precursor (EC 34.21 -) (Stratum comeum tryptic enzyme) (Kallikrein like protein 2) (KLK-L2) (UNQ570/PRO1132) KLK5_HUMAN
6255 Inner nuclear membrane protein Man1 (LEM domain containing protein MAN1_HUMAN
6256 Lysyl oxidase homolog 2 precursor (EC 1 43 -) (Lysyl oxidase-hke protein 2) (Lysyl oxidase related protein 2) (Lysyl oxidase-related LOXL2_HUMAN
6257 Stem cell growth factor precursor (Lymphocyte secreted C-type lectin) (p47) (C-type lectin superfamily member 3) LSLCL_HUMAN
6258 MIR interacting saposin-Iike protein precursor (Transmembrane protein 4) (Putative secreted protein ZSIG9) (UNQ1943/PRO4426) MΞAP_HUMAN
6259 Microtubule-associated seπne/fhreoπiπe-proteiπ kinase 1 (EC 271 37) (Syntrophin associated senne/threonine-protein kinase) MAST1JHUMAN
6260 Mltochondnal ornithine transporter 1 (Solute earner family 25, member 15) (SP1855) ORNT1_HUMAN
6261 N-acetylated-alpha-linked acidic dipeptidase Il (EC 341721) (NAALADase II) NLD2_HUMAN
6262 Olfactory receptor 10H1 O10H1_HUMAN
6263 Olfactory receptor 51B2 (HOR5'beta3) ~ O51B2JHUMAN
6264 Olfactory receptor 51B4 (HOR5'beta1) O51B4~HUMAN
6265 N-acetylglucosamiπyl-phosphatidylinosito! de-N-acetylase (EC 351 89) (Phosphatidylinositol-glycan biosynthesis, class L protein) (PIG-L) PIGL_HUMAN
6266 NADPH oxidase homolog 1 (NOX-1) (NOH-1) (NADH/NADPH mitogenic oxidase subunit P65 MOX) (Mitogeπic oxidase 1) (M0X1) NOX1_HUMAN
6267 Heparan sulfate glucosamine 3-0-sulfotransferase 2 (EC 28229) (Heparan sulfate D-glucosaminyl 3-0-sulfotransferase 2) (Heparan OST2JHUMAN
6268 Heparan sulfate glucosamine 3-0-sulfotransferase 3A1 (EC 2 S 230) (Heparan sulfate D glucosaminyl 3-0-sulfotransferase 3A1) (Heparan OST3A_HUMAN
6269 Heparan sulfate glucosamine 3-0 sulfotraπsferase 3B1 (EC 28230) (Heparan sulfate D glucosaminyl 3-0-sulfotransferase 3B1) (Heparan OST3B_HUMAN Y
6270 Heparan sulfate glucosamine 3-O-sulfotransferase 4 (EC 28223) (Heparan sulfate D glucosaminyl 3-0-sulfotransferase 4) (Heparan OST4_HUMAN Y
6271 Proton-associated sugar transporter A (PAST-A) (Deleted in neuroblastoma 5 protein) (DNb-5) PASTAJHUMAN
6272 Matπx metalloproteιnase-24 precursor (EC 3424 -) (MMP-24) (Membrane type matrix metalloproteinase 5) (MT-MMP 5) (Membrane-type-5 MMP24JHUMAN
6273 Peroxisomal membrane protein PEX16 (Peroxιπ-16) (Peroxisomal biogenesis factor 16) PEX16_HUMAN
6274 Olfactory receptor 1 A2 (Olfactory receptor 17-6) (OR17-6) OR1 A2_HUMAN
6275 Nck-associated protein 1 (NAP 1) (p125Nap1) (Membrane-associated protein HEM-2) NCKP1_HUMAN
6276 Plakophllin 3 PKP3_HUMAN
6277 Nuclear envelope pore membrane protein POM 121 (Pore membrane of 121 kDa) (P145) PO121_HUMAN
6278 Protocadheπn alpha 1 precursor (PCDH-alpha1) PCDA1JHUMAN Y Y Y
6279 Protocadhenπ alpha 2 precursor (PCDH-alpha2) PCDA2_HUMAN Y Y Y
6280 Protocadhenn alpha 3 precursor (PCDH-alpha3) PCDA3_HUMAN Y Y Y
6281 Protocadheπn alpha 5 precursor (PCDH-alpha5) PCDA5_HUMAN Y Y Y
6282 Protocadhenn alpha 8 precursor (PCDH-alpha8) PCDA8_HUMAN Y Y Y
6283 Protocadheπn alpha 9 precursor (PCDH-alpha9) PCDA9_HUMAN Y Y Y
6284 Protocadhenn alpha 10 precursor (PCDH-alpha10) PCDAA_HUMAN Y Y Y
6285 Protocadhenn alpha H precursortPCDH-alphaH) PCDAB_HUMAN Y Y Y
6286 Protocadhenn alpha 13 precursor (PCDH-alpha13) PCDAD_HUMAN Y Y Y
6287 Protocadhenn beta 1 precursor (PCDH-beta1) PCDB1_HUMAN Y Y Y
6288 Protocadheπn beta 2 precursor (PCDH-beta2) PCDB2_HUMAN Y Y Y
6289 Protocadheπn beta 3 precursor (PCDH-beta3) PCDB3_HUMAN Y Y Y
6290 Protocadheπn beta 4 precursor (PCDH beta4) PCDB4_HUMAN Y Y Y
6291 Protocadheπn beta 5 precursor (PCDH-beta5) PCDB5_HUMAN Y Y Y
6292 Protocadheπn beta 6 precursor (PCDH-beta6) PCDB6_HUMAN Y Y Y
6293 Protocadhenn beta 7 precursor (PCDH-beta7) PCDB7_HUMAN Y Y Y
6294 Protocadhenn beta 9 precursor (PCDH-beta9) (Protocadhenn 3H) PCDB9_HUMAN Y Y Y
6295 Protocadhenn beta 11 precursor (PCDH-beta11) PCDBB_HUMAN Y Y Y
6296 Protocadheπn beta 12 precursor (PCDH beta12) PCDBC_HUMAN Y Y Y
6297 Protocadheπn beta 13 precursor (PCDH-beta13) (UNQ332/PRO531) PCDBD_HUMAN Y Y Y
6298 Protocadheπn beta 14 precursor (PCDH-beta14) PCDBEJHUMAN Y Y Y
6299 Protocadhenn beta 15 precursor (PCDH-beta15) PCDBF_HUMAN Y Y Y
6300 Protocadhenn alpha C2 precursor (PCDH-alpha-C2) PCDC2JHUMAN Y Y Y
6301 Protocadheπn gamma A1 precursor (PCDH-gamma-A1) PCDG1_HUMAN Y Y Y
6302 Protocadheπn gamma A2 precursor (PCDH-gamma-A2) PCDG2_HUMAN Y Y Y
6303 Protocadheπn gamma A3 precursor (PCDH-gamma-A3) PCDG3_HUMAN Y Y Y
6304 Protocadheπn gamma A4 precursor (PCDH-gamma-A4) PCDG4_HUMAN Y Y Y
6305 Protocadheπn gamma A5 precursor (PCDH-gamma-A5) PCDG5_HUMAN Y Y Y
Figure imgf000169_0001
Figure imgf000170_0001
Extracellular Integral
PlD Descnption UπiProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
6436 Protein BAT5 (HLA-B-associated transcript 5) (NG26 protein) (G5 protein) (PP199) BAT5_HUMAN
6437 Complement C1r subcomponent precursor (EC 3421 41) (Complement component 1, r subcomponent) C1R_HUMAN
6438 Adapter related protein complex 2 alpha 1 subunit (Alpha-adaptin A) (Adaptor protein complex AP-2 alpha 1 subumt) (Clathnn assembly AP2A1_jHUMAN
6439 Adapter-related protein complex 2 alpha 2 subunit (Alpha adaptin C) (Adaptor protein complex AP 2 alpha-2 subunit) (Clathnn assembly AP2A2JHUMAN
6440 ADAMTS-2 precursor (EC 3424 14) (A disintegnn and metalloproteinase with thrombospondin motifs 2) (ADAM-TS 2) (ADAM-TS2) (Procolla ATS2_HUMAN
6441 Bone morphogenetic protein 10 precursor (BMP-10) BMP10_HUMAN
6442 Bone moφhogenetic protein 15 precursor (BMP-15) (Growth/differentiation factor 9B) (GDF-9B) BMP15_HUMAN
6443 Adenylate cyclase, type V (EC 461 1) (ATP pyrophosphate-lyase 5) (Adenylyl cyclase 5) (Fragment) ADCY5_HUMAN
6444 Amyloid beta A4 precursor protein binding family A member 3 specific X11L2 protein) (Neuronal Munc18-1-ιnteractιng protein 3) APBA3_HUMAN
6445 ATP synthase a chain (EC 36314) (ATPase protein 6) ATP6_HUMAN
6446 Long chaiπ-fatty-acid-CoA ligase 3 (EC 62 1 3) (Long-chain acyl-CoA synthetase 3) (LACS 3) ACSL3_HUMAN
6447 Potential phospholipid-transporting ATPase VB (EC 3631) AT10B_HUMAN
6448 Voltage-dependent T-type calcium channel alpha-1H subunit (Voltage- gated calcium channel alpha subunit Cav32) (Low-voltage-activated CAC1H_HUMAN
6449 Claudιn-14 (UNQ777/PRO1571) CLD14_HUMAN
6450 C!audιn-1 (Senescence-associated epithelial membrane protein) (UNQ481/PRO944) CLD1_HUMAN
6451 Claudιπ-7 (CLDN-7) CLD7_HUMAN
6452 Claudιn-9 CLD9_HUMAN
6453 Chloπde intracellular channel protein 3 CLlC3_HUMAN
6454 Apohpoproteιn-L3 (Apolipoprotein L-III) (ApoL-lll) (TNF-inducible protein CG12-1) (CG12_1) APOL3JHUMAN
6455 Apolipoprotein M (Apo M) (ApoM) (NG20 protein) (G3a protein) (HSPC336) APOM_HUMAN
6456 Galactosylgalactosylxylosylproteiπ 3-beta glucuronosyltransferase 3 (EC 241 135) (Beta-1,3-glucuronyltransferase 3) B3GA3_HUMAN
6457 Beta-1 ,3-galactosyItransferase 4 (EC 241 62) (Beta-1 ,3-GalTase 4) (Beta3Gal-T4) (b3Gal-T4) (Ganglioside galactosyltransferase) (UDP- B3GT4_HUMAN
6458 Ceruloplasmin precursor (EC 1 1631) (Ferroxidase) CERU HUMAN
6459 Complement factor B precursor (EC 3421 47) (C3/C5 coπvertase) (Properdin factor B) (Glycine-rich beta glycoprotein) (GBG) (PBF2) CFABJUMAN
6460 Cytochrome b CYB-HUMAN
6461 Brain protein I3 (pRGR2) BI3JHUMAN
6462 Gapjunction beta-5 protein (Connexin 31 1) (Cx31 1) CXB5_HUMAN
6463 Gap junction beta 6 protein (Connexin 30) (Cx30) CXB6_HUMAN
6464 Ca[syntenιn-1 precursor CSTN1_HUMAN
6465 Epidermal growth factor receptor precursor (EC 271 112) (Receptor tyrosine-proteiπ kinase ErbB-1) EGFR-HUMAN
6466 Coagulation factor X precursor (EC 3421 6) (Stuart factor) (Stuart- Prower factor) FA10_HUMAN
6467 Coagulation factor XII precursor (EC 3421 38) (Hagemaπ factor) (HAF) FA12_HUMAN
6468 Dolichol phosphate-maπnose biosynthesis regulatory protein (MyO26 protein) DPM2_HUMAN
6469 Down syndrome cπtical region protein 2 (Leucine-nch protein C21-LRP) DSCR2_HUMAN
6470 Follistatin related protein 3 precursor (Follistatin-like 3) (Follistatin-related gene protein) (UNQ674/PRO1308) FSTL3_HUMAN
6471 Coagulation factor VIII precursor (Procoagulaπt component) (Antihemophilic factor) (AHF) FA8_HUMAN
6472 Coagulation factor IX precursor (EC 3421 22) (Chnstmas factor) (Plasma thromboplastin component) (PTC) FA9_HUMAN
6473 Endothelin-coπverting enzyme-like 1 (EC 3424 -) (Xce protein) (UNQ2431/PRO4991) ECEL1_HUMAN
6474 Protein C8orE (UNQ2441/PRO9924/PRO5003) CH002_HUMAN
6475 Cytochrome b5 CYB5_HUMAN
6476 Cytochrome c oxidase subunit 1 (EC 1 931) (Cytochrome c polypeptide I) COX1JHUMAN
6477 Extracellular matrix protein 2 precursor (Matrix glycoprotein SC1/ECM2) ECM∑IHUMAN
6478 Dickkopf related proteιn-1 precursor (Dkk-1) (Dlckkopf-1) (hDkk-1) (SK) (UNQ492/PRO1008) DKK1JHUMAN
6479 Guanine nudeotide-binding protein, alpha-14 subuπit (G-protem alpha subunit 14) GNA14_HUMAN
6480 Glucagoπ-like peptide 2 receptor precursor (GLP-2 receptor) (GLP-2-R) (GLP-2R) GLP2R_HUMAN
6481 Sphingosine 1-phosphate receptor Edg-5 (S1 P receptor Edg-5) (Endothelial differentiation G-protem coupled receptor 5) EDG5_HUMAN
6482 Sphingosine 1-phosphate receptor Edg-6 (S1 P receptor Edg 6) (Endothelial differentiation G-proteιπ coupled receptor 6) EDG6_HUMAN
6483 D glucuronyl C5-epιmerase (EC 5 1 3 -) (Hepann/heparan sulfate glucuronic acid C5 epimerase) GLCEJHUMAN
6484 Cytochrome c oxidase subunit 2 (EC 1 931) (Cytochrome c polypeptide II) COX2_HUMAN
6485 Coagulation factor XIII A chain precursor (EC 23213) (Coagulation factor XIIIa) (Protein-glutamme gamma-glutamyltransferase A chain) F13AJHUMAN
6486 Geπethoπm 1 (GENX-3414) GET1_HUMAN
6487 Haptoglobin-related protein precursor HPTR_HUMAN
6488 Haptoglobin precursor HPT_HUMAN
6489 Gamma amiπobutyπc acid receptor associated protein (GABA(A) receptor- associated protein) (MM46) (HT004) GBRAP_HUMAN
6490 28 kDa Golgi SNARE protein (Golgi SNAP receptor complex kDa cis Golgi SNARE p28) (GOS-28) GOSR1_HUMAN
6491 lmportin 13 (Imp13) (Raπ-bindmg protein 13) (RanBP13) (Karyopheπn 13) (Kap13) IPO13_HUMAN
6492 lmportin 7 (Imp7) (Ran-binding protein 7) (RanBP7) IPO7_HUMAN
6493 Neurotensin receptor type 2 (NT-R-2) (Levocabastine-sensitive neurotensin receptor) (NTR2 receptor) NTR2_HUMAN
6494 Solute earner family 2, facilitated glucose transporter, member 10 (Glucose transporter type 10) GTR10JHUMAN
6495 lnterieukin-18 binding protein precursor (IL-18BP) I18BP_HUMAN
6496 EGF-containing Jbulin-like extracellular matrix protein 2 precursor (Fιbulιn-4) (FIBL-4) (UPH1 protein) (UNQ200/PRO226) FBLN4_HUMAN
6497 Lecithin retinol acyltraπsferase (EC 231 135) (Phosphatidylcholine- retinol O-acyltraπsferase) LRAT_HUMAN
6498 Leucine-nch repeats and immunoglobuliπ-like domains protein 2 precursor (LlG-2) LRIG2_HUMAN
6499 Matnlιn-4 precursor MATN4_HUMAN
6500 Transmembrane GTPase MFN2 (EC 365 -) (Mitotan 2) MFN2_HUMAN
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
, Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type 111 Type IV Mitochondria] GoIc
6696 Plasma retinol-bindiπg protein precursor (PRBP) (RBP) (PRO2222) [Contains Plasma retinol-bindmg proteιn(1-182), Plasma retinol- RETBP_HUMAN
6697 Insulin-like growth factor Il precursor (IGF-II) (Somatomedin A) (PP1446) IGF2_HUMAN
6698 Immunoglobulin J chain • IGJ_HUMAN
6699 Glucagon precursor (Contains Glicentin, Glicentiπ related polypeptide (GRPP), Oxyntomodulm (OXY) (OXM), Glucagon, Glucagon like peptιdGLUC_HUMAN
6700 Unne glycopeptide GLUR-HUMAN
6701 Erythropoietin precursor (Epoetin) EPO_HUMAN
6702 lnterleukin-1 alpha precursor (IL-1 alpha) (Hematopoιetιπ-1) IL1AJHUMAN
6703 lnterleukιn-1 beta precursor (IL-1 beta) (Cataboliπ) IL1BJHUMAN
6704 HLA class Il histocompatibility antigen, DQ(1) alpha chain precursor (DC-4 alpha chain) HA21 JHUMAN
6705 HLA class Il histocompatibility antigen, DQ(3) alpha chain precursor (DC-alpha) (HLA-DCA) (HLA-DQA1O5011) (HLA-DQA1*0502) HA23_HUMAN
6706 HLA class Il histocompatibility antigen, DQ(5) alpha chain precursor (DC-1 alpha chain) HA25JHUMAN
6707 HLA class Il histocompatibility antigen, DQ(6) alpha chain precursor (DX alpha chain) (HLA-DQA1) HA26 JHUMAN 670B lnterIeukιn-2 receptor alpha chain precursor (IL-2 receptor alpha subunit) (IL-2-RA) (IL2-RA) (p55) (TAC antigen) (CD25 antigen) IL2RA_HUMAN
6709 Lamm A/C (70 kDa lamin) LAMAJHUMAN
6710 Ig heavy chain V-I region EU HV1AJHUMAN
6711 Ig heavy chain V-I region HG3 precursor HV1BJHUMAN
6712 Ig heavy chain V-I region ND precursor (Fragments) HV1C_HUMAN
6713 Ig heavy chain V-I region WOL HV1D_HUMAN
6714 Ig heavy chain V-I region SIE HV1 EJ-IUMAN
6715 Ig heavy chain V-Il region OU HV2A JHUMAN
6716 Ig heavy chain V-Il region COR HV2BJHUMAN
6717 Ig heavy chain V-II region DAW HV2C JHUMAN
6718 Ig heavy chain V-Il region MCE HV2D JHUMAN
6719 Ig heavy chain V-Il region HE HV2EJHUMAN
6720 Ig heavy chain V-Il region WAH HV2F JHUMAN
6721 Ig heavy chain V-Il region NEWM HV2GJHUMAN
6722 Ig heavy chain V III region TRO HV3A JHUMAN
6723 Ig heavy chain V-III region WEA HV3BJHUMAN
6724 Ig heavy chain V-III region VH26 precursor HV3CJHUMAN
6725 Ig heavy chain V-III region TIL HV3DJHUMAN
6726 Ig heavy chain V-III region BRO HV3EJHUMAN
6727 Ig heavy chain V-III region BUT HV3FJHUMAN
6728 Ig heavy chain V III region CAM HV3GJHUMAN
6729 Ig heavy chain V-III region GA HV3HJHUMAN
6730 Ig heavy chain V-III region NIE HV3IJHUMAN
6731 Ig heavy chain V-III region HIL HV3JJHUMAN
6732 Ig heavy chain V-III region KOL HV3KJHUMAN
6733 Ig heavy chain V-III region BUR HV3LJHUMAN
6734 Ig heavy chain V-III region POM HV3MJHUMAN
6735 Ig heavy chain V-III region LAY HV3NJHUMAN
6736 Ig heavy chain V-IlI region WAS HV3OJHUMAN
6737 Ig heavy chain V-III region TEI HV3PJHUMAN
6738 Ig heavy chain V-III region ZAP HV3Q JHUMAN
6739 Ig heavy chain V-III region TUR HV3R JHUMAN
6740 Ig heavy chain V-Hl region JON HV3SJHUMAN
6741 Ig heavy chain V-III region GAL HV3TJHUMAN
6742 Ig heavy chain V-Ml region DOB HV3U JHUMAN
6743 Interferon alpha-10 precursor (Interferon alpha-C) (LeIF C) (Interferon alpha-6L) IFN10JHUMAN Y
6744 Interferon alpha 14 precursor (Interferon alpha-H) (LeIF H) (Interferon lambda 2 H) IFN14JHUMAN Y
6745 Interferon alpha 17 precursor (Interferon alpha-]') (Interferon alpha-TJ (Interferon alpha-88) IFN17JHUMAN Y
6746 Interferon alpha-21 precursor (Interferon alpha-F) (LeIF F) IFN21 JHUMAN Y
6747 Interferon alpha-1/13 precursor (Interferon alpha-D) (LeIF D) IFNA 1 JHUMAN Y
6748 Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A) IFNA2JHUMAN Y
6749 Interferon alpha-5 precursor (Interferon alpha-G) (LeIF G) (Interferon alpha-61) IFNA5JHUMAN Y
6750 Interferon alpha-7 precursor (Interferon alpha-J1) (IFN-alpha-J1) (Interferon alpha-J) (LeIF J) IFNA7JHUMAN Y
6751 Interferon beta precursor (IFN-beta) (Fibroblast interferon) IFNBJHUMAN Y
6752 Lutropin beta chain precursor (Luteinizing hormone beta subunit) (LSH- beta) (LSH-B) (LH-B) LSHBJHUMAN Y
6753 Kiπmogεn precursor (Alpha-2-thιol proteinase inhibitor) [Contains Bradykinin (Kallidiπ I), Lysyl bradykiπin (Kallidin H)] KNGJHUMAN Y
6754 Ig kappa chain V-I region AG KV1 AJHUMAN
6755 Ig kappa chain V-I region AU KV1 BJHUMAN
6756 Ig kappa Cham V-I region Bl KV1 CJHUMAN
6757 Ig kappa chain V-I region CAR KV1 DJHUMAN
6758 Ig kappa chain V-I region DEE KV1EJHUMAN
6759 Ig kappa chain V-I region EU KV1FJHUMAN
6760 Ig kappa chain V-I region GaI KV1GJHUMAN
Extracellular Integral
PlD Description UniProtACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
6761 Ig kappa chain V-I region Hau KV1 HJHUMAN
6762 Ig kappa chain V-I region HK101 precursor (Fragment) KV1 LHUMAN Y
6763 Ig kappa chain V-I region HK102 precursor (Fragment) KVUJHUMAN Y
6764 Ig kappa chain V-I region Ka KV1K HUMAN
6765 Ig kappa chain V-I region Kue KV1L_HUMAN
6766 Ig kappa chain V-! region Lay KV1MJHUMAN
6767 Ig kappa chain V-I region OU KVINJHUMAN
6768 Ig kappa chain V-I region Rei KV1OJHUMAN
6769 Ig kappa chain V-I region Roy KV1P_HUMAN
6770 Ig kappa chain V-I region Sew KV1QJHUMAN
6771 Ig kappa chain V-I region WEA KV1 RJHUMAN
6772 Ig kappa chain V-I region Wes KV1SJHUMAN
6773 Ig kappa chain V-I region Mev KV1TJHUMAN
6774 Ig kappa chain V-I region Ni KV1 UJHUMAN
6775 Interferon gamma precursor (IFN-gamma) (Immune interferon) IFNGJHUMAN Y
6776 Polymeπc-immunoglobulm receptor precursor (PoIy-Ig receptor) (PlGR) [Contains Secretory component] PIGRJHUMAN Y
6777 Platelet denved growth factor B chain precursor (PDGF B-chain) (Platelet-deπved growth factor beta polypeptide) (PDGF-2) (c-sis) PDGFBJHUMAN
6778 Oxytocin neurophysiπ 1 precursor (OT-NPl) [Contains Oxytocin (Ocytocin), Neurophysin 1] NEU1JHUMAN Y
6779 Vasopressiπ-neurophysin 2-copeptιn precursor (AVP-NPII) [Contains Arg-vasopressin, Neurophysin 2 (Neurophysin-ll), Copeptin] NEU2 HUMAN Y
6780 Neuropeptide Y precursor [Contains Neuropeptide Y (Neuropeptide tyrosine) (NPY), C-flankiπg peptide of NPY (CPON)] NEUYJHUMAN Y
6781 Ig lambda chain V-I region VOR LV1AJHUMAN
6782 Ig lambda chain V-I region HA LV1 BJHUMAN
6783 Ig lambda chain V-I region NEW LV1CJHUMAN
6784 Ig lambda chain V-I region NIG-64 LV1 DJHUMAN
6785 Ig lambda chain V-I region NEWM LV1EJHUMAN
6786 Ig lambda chain V-Il region TOG LV2AJHUMAN
6787 Ig lambda chain V-H region NEI LV2BJHUMAN
6788 Ig lambda chain V-Il region BOH LV2CJHUMAN
6789 Ig lambda chain V-Il region TRO LV2DJHUMAN
6790 Ig lambda chain V-Il region BUR LV2EJHUMAN
6791 Ig lambda chain V-Il region MGC LV2FJHUMAN
6792 Ig lambda chain V-II region BO LV2GJHUMAN
6793 Ig lambda chain V-II region VIL LV2H JIUMAN
6794 Ig lambda chain V-Il region WIN LV2IJHUMAN
6795 Ig lambda chain V-Il region NIG-58 LV2JJHUMAN
6796 Ig lambda chain V-IIl region SH LV3A JHUMAN
6797 Ig lambda chain V-IV region Bau LV4A JHUMAN
6798 Ig lambda chain V-IV region X LV4BJHUMAN
6799 Ig lambda chain V-IV region HiI LV4CJHUMAN
6800 Ig lambda chain V-IV region Kern LV4DJHUMAN
6801 Ig lambda chain V-V region DEL LV5A HUMAN
6802 Ig lambda chain V-Vl region AR LV6A JHUMAN
6803 Ig lambda chain V-VI region NIG-48 LV6BJHUMAN
6804 Ig lambda chain V-VII region MOT LV7A JHUMAN
6805 Parathyro d hormone precursor (Parathynn) (PTH) (Parathormone) PTHYJHUMAN Y
6806 Prolactin precursor (PRL) PRLJHUMAN Y
6807 Pancreatic hormone precursor (Pancreatic polypeptide) (PP) PAHOJHUMAN Y
6808 Beta-neoendorphiπ-dyπorphin precursor (Proenkephalin B) (Preprodynorphin) [Contains Beta-πeoendorphin, Dynorphin Leu- PDYNJHUMAN Y
6809 Transforming protein p21/H-Ras-1 (c-H ras) RASHJHUMAN
6810 Serum amyloid A protein precursor (SAA) [Contains Amyloid protein (Amyloid fibπl protein AA), Serum amyloid protein A(2-104) Serum SAAJHUMAN Y
6811 Somatoliberin precursor (Growth hormone releasing factor) (GRF) (Growth hormone-releasing hormone) (GHRH) (Somatocnmn) (Sermorelin) SLIBJHUMAN Y Y
6812 Serum amyloid P-component precursor (SAP) (95S a!pha-1-glycoproteιn) [Contains Serum amyloid P-component(1-203)] SAMPJHUMAN Y Y
6813 Growth hormone vaπant precursor (GH-V) (Placenta specific growth hormone) (Growth hormone 2) S0M2JHUMAN Y Y
6814 Somatotropin precursor (Growth hormone) (GH) (GH-N) (Pituitary growth hormone) (Growth hormone 1) S0MAJ1UMAN Y Y
6815 Thyroglobulin precursor THYGJHUMAN Y Y
6816 Thyrotropin beta chain precursor (Thyroid-stimulating hormone beta subunit) (TSH-beta) (TSH-B) (Thyrotropin alfa) TSHBJHUMAN Y Y"
6817 T-cell receptor alpha chain C region TCAJHUMAN
6818 T-cell receptor beta chain C region TCBJHUMAN
6819 Spectrin alpha chain, erythrocyte (Erythroid alpha-spectnn) SPTA1JHUMAN
6820 Vasoactive intestinal peptide precursor (VIP) VlPJHUMAN
6821 Transforming growth factor alpha precursor (TGF-alpha) (EGF like TGF) (ETGF) (TGF type 1) TGFAJHUMAN
6822 Tumor necrosis factor precursor (TNF-alpha) (Tumor necrosis factor hgand superfamily member 2) (TNF-a) (Cachectjn) TNFAJHUMAN
6823 Lymphotoxm-alpha precursor (LT-alpha) (TNF-beta) (Tumor necrosis factor ligand superfamily member 1) TNFBJHUMAN
6824 Metalloprotemase inhibitor 1 precursor (TIMP-1) (Erythroid potentiating activity) (EPA) (Tissue inhibitor of metalloprotemases) TIMP1JHUMAN
6825 T-cell receptor alpha chain V region PY14 precursor TVA3 "HUMAN
Figure imgf000177_0001
Figure imgf000178_0001
Extracellular Integral
PlD Description UniProt ACC Signal Secreted Domain Membrane Type ! Type Il Type III Type IV Mitochondrial Golgi
6956 Thyroid peroxidase precursor (EC 1 11 1 8) (TPO) PERT-HUMAN Y Y Y
6957 Basic salivary proline πch protein 2 (Salivary proline-πch protein) (Coπ1 glycoprotein) [Contains Basic peptide P-F] (Fragment) PRB2JHUMAN
6958 Osteocalcin precursor (Gamma-carboxygfutamic acid-containing protein) (Bone GIa protein) (BGP) OSTC-HUMAN
6959 MAS proto-oncogene MAS-HUMAN
6960 Vitamin K-dependent protein S precursor PROS-HUMAN
6961 Platelet-denved growth factor A chain precursor (PDGF A-chain) (Platelet-deπved growth factor alpha polypeptide) (PDGF-1) PDGFA_HUMAN
6962 Protein disulfide-isomerase precursor (EC 534 1) (PDI) (Prolyl 4-hydroxyfase beta subunit) (Cellular thyroid hormone binding protein) PD1A1JHUMAN
6963 Blue-sensitive opsin (BOP) (Blue cone photoreceptor pigment) OPSB_HUMAN
6964 Interstitial collagenase precursor (EC 34247) (Matπx metalloproteιnase-1) (MMP-1) (Fibroblast collagenase) MMP1_HUMAN
6965 Ig lambda chain V region 4A precursor LVOA-HUMAN
6966 Ig lambda chain V-I region WAH LV1F_HUMAN
6967 Ig lambda chain V-I region BL2 precursor LV1GJHUMAN
6968 Ig lambda chain V-I region MEM LV1 HJHUMAN
6969 Ig lambda chain V-I region EPS LVII-HUMAN
6970 Ig lambda chain V-Il region NIG-84 LV2K_HUMAN
6971 Ig lambda chain V-IV region MOL LV4EJHUMAN
6972 Ig lambda chain V-Vl region WLT LV6DJHUMAN
6973 Ig lambda chain V-Vl region EB4 precursor LV6E_HUMAN
6974 Basic salivary prolme-πch protein 1 precursor (Salivary proline-πch protein) [Contains Basic peptide IB-6, Peptide P-H] PRPI-HUMAN
6975 Basic prolme-πch peptide IB-1 PRP5_HUMAN
6976 Salivary acidic proline-πch phosphoproteiπ 1/2 precursor (PRP-1/PRP-3) (PRP-2/PRP-4) (PIF F/PIF-S) (Protein A/protein C) PRPC-HUMAN
6977 Basic prolme-πch peptide P-E (IB-9) PRPE-HUMAN
6978 Alkaline phosphatase, placental type precursor (EC 3 1 31) (PLAP-1) (Regan isozyme) PPBI-HUMAN
6979 Alkaline phosphatase, tissue-nonspecific isozyme precursor (EC 3 1 31) (AP-TNAP) (Liver/bone/kidney isozyme) (TNSALP) PPBT-HUMAN
6980 Green-sensitive opsin (Green cone photoreceptor pigment) OPSG-HUMAN
6981 Red-sensitive opsin (Red cone photoreceptor pigment) OPSR-HUMAN
6982 Dohchyl-dlphosphooligosacchaπde-proteiπ glycosyltransferase 67 kDa subunit precursor (EC 241 119) (Ribophoππ I) (RPN-I) RIBI-HUMAN
6983 Dolichyl diphosphooligosacchaπde-protein glycosyltransferase 63 kDa subunit precursor (EC 24 1 119) (Ribophonn II) (RPN-II) (RIBIIR) RIB2JHUMAN
6984 Vitamin K-depeπdent protein C precursor (EC 3421 69) (Autoprothrombiπ UA) (Anticoagulant protein C) (Blood coagulation PROC-HUMAN
6985 Plasminogen activator inhibitor 1 precursor (PAI-1) (Endothelial plasminogen activator inhibitor) (PAI) PAII-HUMAN
6986 Proline-πch protein 3 precursor (Proline-nch peptide P-B) [Contains Peptide P-A, Peptide D1 A] PROL3_HUMAN
6987 NADH-ubiquinone oxidoreductase chain 3 (EC 1653) (NADH dehydrogenase subunit 3) NU3M_HUMAN
6988 NADH-ubiquinone oxidoreductase chain 4L (EC 1 653) (NADH dehydrogenase subunit 4L) NU4LM_HUMAN
6989 NADH-ubiquinone oxidoreductase chain 4 (EC 1 653) (NADH dehydrogenase subunit 4) NU4MJHUMAN
6990 RAF proto-oncogene senne/threonme-protein kinase (EC 271 37) (Raf-1) (C-RAF) (cRaf) RAF1 JHUMAN
6991 Platelet factor 4 precursor (PF-4) (CXCL4) (Oncostatin A) (Iroplact) PLF4JHUMAN
6992 Semeπogelιn-1 precursor (Semenogelin I) (SGI) [Contains Alpha- inhlbιn-92, Alpha ιnhιbιn-31 Seminal basic protein] SEMG1_HUMAN
6993 Tetranectin precursor (TN) (Plasminogen-kπngle 4 binding protein) TETN-HUMAN
6994 Platelet basic protein precursor (PBP) (Small inducible cytokine B7) (CXCL7) (Leukocyte denved growth factor) (LDGF) (Macrophage-denved SCYB7JHUMAN
6995 Small inducible cytokine B10 precursor (CXCL10) (10 kDa interferon- gamma induced protein) (Gamma-IP10) (IP-10) [Contains CXCL10(1-7
6996 Prorelaxiπ H1 precursor RELI-HUMAN
6997 Prorelaxin H2 precursor REL2_HUMAN
6998 Proactivator polypeptide precursor [Contains Saposin A (Protein A), Saposin B (Sphmgolipid activator protein 1) (SAP-1) (Cerebroside SAP-HUMAN
6999 Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondπal precursor (EC 1 1022) (Mitochondrial hinge protein) (Cytochrome CUCRH_HUMAN
7000 Ubiquitin cross-reactive protein precursor (Interferon induced 17 kDa protein) (Iπterferon-iπduced 15 kDa protein) UCRP-HUMAN
7001 UDP-glucuronosyltraπsferase 2B4 precursor (EC 24 1 17) (UDPGT) (Hyodeoxycholic acid) (HLUG25) (UDPGTh-1) UDB4JHUMAN
7002 Thy-1 membrane glycoprotein precursor (Thy-1 antigen) (CDw90) (CD90 antigen) THYI-HUMAN
7003 Transfernn receptor protein 1 (TfR1) (TR) (TfR) (Trfr) (CD71 (T9) (p90) TFRI-HUMAN
7004 Trypsin I precursor (EC 3421 4) (Cationic trypsmogeπ) TRYI-HUMAN
7005 T-cell receptor gamma chain C region PT-gamma 1/2 TCC-HUMAN
7006 Uromodulin precursor (Tamm Horsfall Uπnary glycoprotein) (THP) UROMJHUMAN Y
7007 Secretograπιn-1 precursor (Secretograπin I) (SgI) (Chromogranin B) (CgB) [Contains GAWK peptide, CCB peptide] SCG1 JHUMAN Y
7008 Sex hormone-binding globulin precursor (SHBG) (Sex steroid binding protein) (SBP) (Testis specific androgen binding protein) (ABP) SHBG-HUMAN Y
7009 Transthyretin precursor (Prealbumin) (TBPA) (TTR) (ATTR) TTHY-HUMAN Y
7010 Thrombomodulin precursor (TM) (Fetomodulin) (CD141 antigen) TRBM-HUMAN Y
7011 Statheππ precursor STAT JHUMAN Y
7012 Thyroxine binding globulin precursor (T4-bιndιng globulin) THBG-HUMAN Y
7013 Vitamin D-binding protein precursor (DBP) (Group-specific component) (Gc-globulin) (VDB) VTDB-HUMAN Y
7014 Vitronectin precursor (Serum spreading factor) (S-protein) (V75) [Contains Vitronectin V65 subunit Vitronectin V10 subunit, VTNC-HUMAN Y
7015 Wnt-1 proto-oncogene protein precursor WNTI-HUMAN Y
7016 S-100 calcium-binding protein beta subunit (S-100 protein, beta chain) S100B_HUMAN
7017 Calcyclin (Prolactin receptor associated protein) (PRA) (Growth factor-iπducible protein 2A9) (S100 calcium-binding protein A6) (MLN S10A6JHUMAN
7018 Calgranulin A (Migration inhibitory factor-related protein 8) (MRP-8) (Cystic fibrosis antigen) (CFAG) (P8) (Leukocyte L1 complex light S10A8JHUMAN
7019 Calgranulin B (Migration inhibitory factor-related protein 14) (MRP-14) (P14) (Leukocyte L1 complex heavy chain) (S100 calcium- S10A9JHUMAN
7020 Serotransferππ precursor (Transfemπ) (Siderophilin) (Beta-1-metal binding globulin) (PRO1400) TRFE-HUMAN
Extracellular Integral
PID Descπption UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondnal Golgi
7021 Lactotransfemn precursor (Lactoferπn) [Contains Kafiocιn-1, Lactoferroxiπ A, Lactoferroxin B, Lactoferroxin C] TRFL_HUMAN Y
7022 Von Willebrand factor precursor (vWF) [Contains Von Willebraπd antigen H] VWF_HUMAN Y
7023 T-cell receptor alpha chain V region HPB-MLT precursor (Fragment) TVA1_HUMAN Y
7024 T-cell receptor alpha chain V region CTL-L17 precursor TVA2_HUMAN Y
7025 T-cell receptor beta chain V region CTL-L17 precursor TVB2_HUMAN Y
7026 T-cell receptor gamma chain V region PT-gamma-1/2 precursor TVCJHUMAN Y
7027 Alpha 2A adrenergic receptor (Alpha-2A adrenoceptor) (Alpha-2A adrenoreceptor) (Alpha-2AAR subtype C10) ADA2A_HUMAN
7028 HLA class I histocompatibility antigen, A-11 alpha chain precursor (MHC class I antigen A"11) 1 A11_HUMAN Y
7029 Small inducible cytokine A2 precursor (CCL2) (Monocyte chemotactic protein 1) (MCP-1) (Monocyte chemoattractant protem-1) (Monocyte CCL2JHUMAN Y
7030 Small inducible cytokine A3 precursor (CCL3) (Macrophage inflammatory protein 1-alpha) (MIP-1-alpha) (Tonsillar lymphocyte LD78 alpha CCL3_HUMAN Y
7031 Small inducible cytokine A4 precursor (CCL4) (Macrophage inflammatory protein 1-beta) (MIP-1 beta) (MIP-1-beta(1-69)) (T-cell activation CCL4_HUMAN Y
7032 Small inducible cytokine A5 precursor (CCL5) (T-cell specific RANTES protein) (SIS-delta) (T cell-specific protein P228) (TCP228) CCL5 JHUMAN Y
7033 HLA class I histocompatibility antigen, A-32 alpha chain precursor (MHC class I antigen A"32) 1 A32_HUMAN Y
7034 HLA class I histocompatibility antigen, A-69 alpha chain (MHC antigen A"69) (Aw 69) (A-28) (Fragment) 1 A69JHUMAN
7035 HLA class I histocompatibility antigen, B-58 alpha chain precursor (MHC class I antigen B*58) (Bw-58) 1 B58_HUMAN Y
7036 HLA class Il histocompatibility antigen, DRB1-4 beta chain precursor (MHC class I antigen DRB1M) (DR-4) (DR4) 2B14JHUMAN Y
7037 HLA class Il histocompatibility antigen, DRB1-7 beta chain precursor (MHC class I antigen DRB1*7) (DR-7) (DR7) 2B17_HUMAN Y
7038 HLA class Il histocompatibility antigen, DO beta chain precursor class Il antigen DOB) 2DOB_HUMAN Y
7039 Proteiπ 4 1 (Band 41) (P41) (EPB41) (4 1R) 41_HUMAN
7040 4F2 cell-surface antigen heavy chain (4F2hc) (Lymphocyte activation antigen 4F2 large subunit) (4F2 heavy chain antigen) (CD98 4F2_HUMAN
7041 5-hydroxytryptamιne 1 A receptor (5-HT-1 A) (Serotonin receptor 1A) (5-HT1 A) (G-21) 5HT1 AJHUMAN
7042 Alpha-2 antiplasmin precursor (Alpha-2-plasmιn inhibitor) (Alpha-2-PI) (Alpha 2 AP) A2AP_HUMAN
7043 Monocyte differentiation antigen CD14 precursor (Myeloid cell-specific leucine-πch glycoprotein) CD14JHUMAN
7044 Clusteπn precursor (Complement-associated protein SP-4040) (Complement cytolysis inhibitor) (CLI) (NA1/NA2) (Apolipoprotein J) CLUS-HUMAN
7045 Chromogranin A precursor (CgA) (Pituitary secretory protein I) (SP-I) [Contains Vasostatιn-1 (Vasostatin I), Vasostatin 2 (Vasostatin II), CMGA_HUMAN
7046 B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1) (Leu-16) (Bp35) CD20_HUMAN
7047 T-cell-specific surface glycoprotein CD28 precursor (TP44) CD28 JHUMAN
7048 Leukocyte antigen CD37 CD37JHUMAN
7049 T cell surface glycoprotein CD3 gamma chain precursor (T-cell receptor T3 gamma chain) CD3G JHUMAN
7050 Leukocyte common antigen precursor (EC 31 348) (L-CA) (CD45 antigen) (T200) CD45 JHUMAN
7051 B-lymphocyte activation marker BLAST-1 precursor (BCM1 surface antigen) (Leucocyte antigen MEM-102) (TCT 1) (Antigen CD48) CD48JHUMAN
7052 2',ϊ cyclic-nudeotide 3-phosphodιesterase (EC 31 437) (CNP) (CNPaεe) CN37 JHUMAN
7053 CD63 antigen (Melanoma-associated antigen ME491) (Lysosome-assoαated membrane glycoprotein 3) (LAMP-3) (Ocular melanoma-associε CD63JHUMAN
7054 B-cell antigen receptor complex associated protein alpha-chain precursor (lg-alpha) (MB-1 membrane glycoprotein) (Surface-IgM- CD79AJHUMAN
7055 T-cell antigen CD7 precursor (GP40) (T-cell leukemia antigen) (TP41) (Leu-9) CD7 JHUMAN
7056 T-cell surface glycoprotein CD8 beta chain precursor (Antigen CD8B) CD8BJHUMAN
7057 Collagen alpha 2(I) chain precursor CO1A2 JHUMAN
7058 Collagen alpha 2(IV) chain precursor CO4A2_HUMAN
7059 Collagen alpha 1(Vl) chain precursor CO6A1 J-IUMAN
7060 Collagen alpha 2(Vl) chain precursor CO6A2 JHUMAN
7061 Collagen alpha 3(Vl) chain precursor CO6A3 JHUMAN
7062 Complement component C6 precursor . CO6JHUMAN
7063 Complement component C7 precursor CO7JHUMAN
7064 Cytochrome c oxidase polypeptide Via liver, mitochondnal precursor (EC 1 931) CX6A1 JHUMAN
7065 Muscaπnic acetylcholine receptor M4 ACM4 JHUMAN
7066 Muscaπnic acetylcholine receptor M5 ACM5JHUMAN
7067 Cytochrome c oxidase subunit IV isoform 1 , mitochondnal precursor (EC 1 931) (COX IV-1) (Cytochrome c oxidase polypeptide IV) COX41 JHUMAN
7068 Cytochrome c oxidase polypeptide Vb, mitochondnal precursor (EC 1 931) COX5BJHUMAN
7069 Cytochrome c oxidase polypeptide VIc precursor (EC 1 931) COX6CJHUMAN
7070 Complement decay accelerating factor precursor (CD55 antigen) DAFJHUMAN
7071 Calcitonin gene-related peptide Il precursor (CGRP-II) (Beta-type CGRP) CALCBJHUMAN
7072 Complement C1s subcomponent precursor (EC 3421 42) (C1 esterase) C1SJHUMAN
7073 Bone morphogenetic protein 1 precursor (EC 342419) (BMP-1) (Procollagen C-proteinase) (PCP) (Mammalian tolloid protein) (mTld) BMP1 J-IUMAN
7074 Bone morphogenetic protein 2 precursor (BMP-2) (BMP-2A) BMP2 JHUMAN
7075 Apoptosis regulator Bcl-2 BCL2 JHUMAN
7076 Clathnn light chain A (Lea) CLCA JHUMAN
7077 Clathnn light chain B (Lcb) CLCB JHUMAN
7078 Apolipoproteiπfa) precursor (EC 3421 -) (Apo(a)) (Lp(a)) APOAJHUMAN
7079 Carcinoembryonic antigen-related cell adhesion molecule 1 precursor (Biliary glycoprotein 1) (BGP-1) (Antigen CD66) (CD66a antigen) CEAM1 JHUMAN
7080 Sodium/potassium transporting ATPase alpha-3 chain (EC 3639) (Sodium pump 3) (Na+/K+ ATPaεe 3) (Alpha(lll)) AT1 A3 JHUMAN
7081 Angiotensin-convertmg enzyme, somatic isoform precursor (EC 3415 1) (ACE) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD143 antigen) ACEJHUMAN
7082 Acetylcholine receptor protein, beta chain precursor ACHBJHUMAN
7083 Cytochrome c oxidase polypeptide Vlll-liver/heart, mitochondnal precursor (EC 1 931) (Cytochrome c oxidase subunit 8-2) COX82JHUMAN
7084 Cytochrome P450 19A1 (Aromatase) (EC 1 14141) (CYPXIX) (Estrogen synthetase) (P-450AROM) CP19A JHUMAN
7085 Gap junction bεta-1 protein (Connexiπ 32) (Cx32) (GAP junction liver protein) CXB1JHUMAN
Extracellular Integral
PID Descπption UniProtACC Signal Secreted Domain Membrane Type I Type Il Type III Type IV Mitochondrial Golgi
7086 Versican core protein precursor (Large fibroblast proteoglycan) (Chondroitin sulfate proteoglycan core protein 2) (PG-M) (Glial CSPG2_HUMAN
7087 Muscaπnic acetylcholine receptor M1
7088 Muscaππic acetylcholine receptor M2 ACM∑IHUMAN
7089 Collagen alpha 1(Xf) chain precursor COBATJ-IUMAN
7090 Collagen alpha 2(Xl) chain precursor COBA2_HUMAN
7091 Dystrophin DMD_HUMAN
7092 Dopamine beta-monooxygenase precursor (EC 1 14 17 1) (Dopamine beta- hydroxylase) (DBH) DOPO_HUMAN
7093 Epithelial cadheππ precursor (E-cadhenn) (Uvomorulin) (Cadheπn-1) (CAM 120/80) CADH1_HUMAN
7094 Cytochrome P450 XXI (EC 1 1499 10) (Steroid 21-hydroxylase) (21-OHase) (P450-C21) (P-450c21) (P450-C21B) CP21A_HUMAN
7095 Cytochrome P4502A6 (EC 1 1414 1) (CYPIIA6) (Coumaπn 7-hydroxylase) (IIA3) (CYP2A3) (P450(l)) CP2A6_HUMAN
7096 Cytochrome P4502C8 (EC 1 14 14 1) (CYPIIC8) (P450 form 1) MP-12/MP-20) (P450 IIC2) (S-mephenytoιπ 4-hydroxylase) CP2C8 HUMAN
7097 Cytochrome P4502C9 (EC 1 141380) ((R)-lιmonene 6-moπooxygeπase) (EC 1 141348) ((S) limoneπe 6-moπooxygenase) (EC 1 141349) CP2C9_HUMAN
7098 Cytochrome P4502D6 (EC 1 14141) (CYPIID6) (P450-DB1) (Debnsoquine 4-hydroxylase) CP2D6JHUMAN
7099 Beta-1 adrenergic receptor (Beta-1 adrenoceptor) (Beta-1 adrenoreceptor) ADRB1_HUMAN
7100 ADP1ATP earner protein, heart/skeletal muscle isoform T1 (ADP/ATP translocase 1) (Adenine nucleotide translocator 1) (ANT 1) (Solute ADTI-HUMAN
7101 ADP1ATP earner protein, liver isoform T2 (ADP/ATP translocase 3) (Adenine nucleotide translocator 3) (ANT 3) (Solute earner family ADT3_HUMAN
7102 Cytochrome c1, heme protein, mitochondπal precursor (Cytochrome c-1) CY1_HUMAN
7103 Cytochrome b-245 light chain (p22 phagocyte B-cytochrome) (Neutrophil cytochrome B, 22 kDa polypeptide) (p22-phox) (p22phox) (Cytochroi CY24A HUMAN
7104 High affinity immunoglobulin epsilon receptor alpha-subunit precursor (FcERI) (IgE Fc receptor, alpha subuπit) (Fc-epsilon Rl-alpha) FCERA_HUMAN
7105 Low affinity immunoglobulin gamma Fc region receptor ll-a precursor (Fc-gamma Rll-a) (FcRII-a) (IgG Fc receptor ll-a) (Fc-gamma RIIa) FCG2A_HUMAN
7106 Low affinity immunoglobulin gamma Fc region receptor IH-A precursor (IgG Fc receptor III-2) (Fc-gamma Rlll-alpha) (Fc-gamma RIIIa) FCG3A_HUMAN
7107 High affinity immunoglobulin gamma Fc receptor I precursor (Fc-gamma Rl) (FcRI) (IgG Fc receptor I) (CD64 antigen) FCGR1 J-IUMAN
7108 Neutrophil defensin 4 precursor (HNP-4) (HP^l) (Defensin alpha 4) DEF4_HUMAN
7109 Coagulation factor V precursor (Activated protein C cofactor) FA5_HUMAN
7110 Coagulation factor VII precursor (EC 342121) (Serum prothrombin conversion accelerator) (SPCA) (Proconvertin) (Eptacog alfa) FA7_HUMAN
7111 Complement factor H precursor (H factor 1) CFAHJHUMAN
7112 Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP- dependent chloπde channel) CFTRJUMAN
7113 Cytochrome P4S04B1 (EC 1 14 14 1) (CYPIVB1) (P450-HP) CP4B1_HUMAN
7114 Elastase 2B precursor (EC 3421 71) ELA2BJHUMAN Y
7115 Elastase HIB precursor (EC 3421 70) (Protease E) ELA3B_HUMAN Y
7116 Gamma-interferoπ inducible lysosomal thiol reductase precursor (Gamma- interferon-inducible protein IP-30) GILT-HUMAN Y
7117 Gastπc inhibitory polypeptide precursor (GlP) (Glucose-dependent insulinotropic polypeptide) GIP_HUMAN Y
7118 Eosinophil cationic protein precursor (EC 3 1 27 -) (ECP) (Ribonuclease 3) (RNase 3) ECP-HUMAN Y
7119 Eosinophil granule major basic protein precursor (MBP) (EMBP) (Pregnancy associated major basic protein) (Proteoglycan 2, bone EMBP-HUMAN Y
7120 Macrophage colony stimulating factor-1 precursor (CSF-1) (MCSF) (M-CSF) CSF1_HUMAN Y
7121 Granulocyte colony-stimulating factor precursor (G-CSF) (Pluπpoietin) (Filgrastim) (Lenograstim) CSF3_HUMAN Y
7122 Funn precursor (EC 342175) (Paired basic amino acid residue cleaving enzyme) (PACE) (Dibasic processing enzyme) Y
7123 Hepaπn-bindmg growth factor 2 precursor (HBGF-2) (Basic fibroblast growth factor) (BFGF) (Prostatropin) FGF2_HUMAN
7124 lNT-2 proto-oncogene protein precursor (Fibroblast growth factor-3) (FGF-3) (HBGF-3) FGF3JHUMAN Y
7125 Fibroblast growth factor-4 precursor (FGF-4) (Hepaπn secretory transforming protein) (HST-1) (HST) (Transforming protein KS3) FGF4_HUMAN Y
7126 Fibroblast growth factor-5 precursor (FGF-5) (HBGF-5) (Smag-82) FGF5JHUMAN Y
7127 Fibroblast growth factor-6 precursor (FGF-6) (HBGF-6) (HST-2) FGFe-HUMAN Y
7128 Basic fibroblast growth factor receptor 1 precursor (EC 271 112) (FGFR-1) (bFGF-R) (Fras-like tyrosine kιnase-2) (c-fgr) Y
7129 HLA class I histocompatibility antigen E alpha chain precursor class I antigen E) HLAE-HUMAN Y
7130 HLA class Il histocompatibility antigen. DR-W53 beta chain precursor HB2KJHUMAN Y
7131 Insulin-like growth factor I receptor precursor (EC 271 112) (CD221 antigen) IGF1R_HUMAN Y
7132 Granzyme A precursor (EC 3421 78) (Cytotoxic T-lymphocyte proteinase 1) (Hanukkah factor) (H factor) (HF) (Granzyme 1) (CTL GRAA-HUMAN Y
7133 Granzyme B precursor (EC 3421 79) (T-cell seπne protease 1-3E) (Cytotoxic T-lymphocyte proteinase 2) (Lymphocyte protease) (SECT) GRAB-HUMAN Y
7134 Growth hormone receptor precursor (GH receptor) (Somatotropin receptor) [Contains Growth hormone binding protein (GH binding GHR-HUMAN Y
7135 Platelet glycoprotein Ib beta chain precursor (GP-Ib beta) (GPIbB) (GPIb beta) (CD42B-beta) (CD42C) GP1 BB-HUMAN Y
7136 lnterphotoreceptor retinoid-binding protein precursor (IRBP) (Interstitial retinol-biπding protein) IRBP-HUMAN Y
7137 HERV-K_5q333 provirus ancestral Eπv polyprotein (Envelope polyprotem) (HERV-K10 envelope protein) (HERV-K107 envelope protein) ENK10JHUMAN
7138 Inhibiπ beta A chain precursor (Activin beta-A chain) (Erythroid differentiation protein) (EDF)
7139 Iπhibiπ beta B chain precursor (Activin beta B chain) INHBB_HUMAN
7140 Interferon-induced protein 6-16 precursor (lfi-6-16) INI2JHUMAN
7141 Proto-oncogene tyroεiπe-protein kinase receptor ret precursor (EC 271 112) (C-ret) RET-HUMAN
7142 Integπn alpha-M precursor (Cell surface glycoprotein MAC-1 alpha subunit) (CR-3 alpha chain) (CD11 b) (Leukocyte adhesion receptor MO1) ITAM-HUMAN
7143 Solute earner family 2, facilitated glucose transporter, member 1 (Glucose transporter type 1, erythrocyte/brain) (HepG2 glucose GTRI-HUMAN Y
7144 Solute earner family 2, facilitated glucose transporter, member 2 (Glucose transporter type 2, liver) GTR2JHUMAN Y
7145 Solute camerfamily 2, facilitated glucose transporter, member 3 (Glucose transporter type 3, brain) GTR3_HUMAN Y
7146 Islet amyloid polypeptide precursor (Diabetes-associated peptide) (DAP) (Amylin) (Insulinoma amyloid peptide) IAPP-HUMAN Y
7147 Growth regulated protein alpha precursor (CXCL1) (Melanoma growth stimulatory activity) (MGSA) (Neutrophil-activating protein 3) (NAP-3) GROA-HUMAN Y
7148 Insulin-like growth factor binding protein 1 precursor (IGFBP-1) (1BP-1) (IGF-binding protein 1) (Placenta! protein 12) (PP12) IBPI-HUMAN Y
7149 Intercellular adhesion molecule-2 precursor (lCAM-2) (CD102 antigen) ICAM2_HUMAN Y
7150 lnterleukιπ-3 precursor (IL-3) (Multipotential colony-stimulating factor) (Hematopoietic growth factor) (P-cell stimulating factor) IL3 HUMAN Y
Figure imgf000182_0001
Figure imgf000183_0001
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type 11 Type III Type IV Mitochondrial Golgi
7281 Carboxypeptidase N catalytic chain precursor (EC 34173) (Lysine carboxypeptidase) (Argiπine carboxypeptidase) (Kiπmase 1) (Serum CBPN-HUMAN Y Y
7282 D(2) dopamine receptor (Dopamine D2 receptor) DRD2_HUMAN Y Y
7283 Cytochrome c oxidase polypeptide Vlla-liver/heart, mitochondπal precursor (EC 1 931) (Cytochrome c oxidase subuπit VIIa-L) (VIIaL) CX7A2 HUMAN Y
7284 Gapjuπction a!pha-1 protein (Conπexin 43) (Cx43) (Gap junction heart protein) CXAI-HUMAN Y Y
7285 Eπdogliπ precursor (CD105 antigen) EGLN-HUMAN Y Y Y
7286 Muscaπnic acetylcholine receptor M3 ACM3JHUMAN Y Y
7287 Endoplasmin precursor (94 kDa glucose-regulated protein) (GRP94) (gp9β homolog) (Tumor rejection antigen 1) ENPL-HUMAN Y Y
7288 Neural-cadheππ precursor (N cadheπn) (Cadheπn-2) CADH2 HUMAN Y Y Y
7289 Cytochrome P4502A7 (EC 1 14 14 1) (CYPIIA7) (P450-IIA4) CP2A7 TlUMAN
7290 Cytochrome P4502B6 (EC 1 14 14 1) (CYPIIBβ) (P450 IIB1) CP2Bβ_HUMAN
7291 Beta-3 adrenergic receptor (Beta 3 adrenoceptor) (Beta-3 adrenoreceptor) ADRB3JHUMAN Y Y
7292 Cysteine-πch secretory proteιn-2 precursor (CRlSP-2) (Testis-specific protein TPX-1) CRIS2_HUMAN Y Y
7293 Follistatiπ precursor (FS) (Activin-binding protein) FST-HUMAN Y Y
7294 Cytotoxic T-lymphocyte protein 4 precursor (Cytotoxic T-lymphocyte- associated antigen 4) (CTLA-4) (CD152 antigen) CTLA4_HUMAN Y Y Y
7295 Cytochrome P4503A5 (EC 1 14141) (CYPHIA5) (P450-PCN3) (HLp2) CP3A5_HUMAN
7296 Erythrocyte membrane protein band 42 (Erythrocyte protein 42) (P42) EPB42JHUMAN
7297 Elafiπ precursor (Elastase-speciflc inhibitor) (ESl) (Skin-denved antileukoproteinase) (SKALP) (WAP four-disulfide core domain protein ELAF_HUMAN Y Y
7298 Elastiπ precursor (Tropoelastin) ELN_HUMAN Y
7299 Desmoplakin (DP) (250/210 kDa paraneoplastic pemphigus antigen) DESP-HUMAN
7300 Chymotrypsinogen Bprecursor(EC3421 1) CTRB1_HUMAN Y
7301 5-Iιpoxygeπase activating protein (FLAP) (MK-886-bιnding protein) FLAP-HUMAN Y
7302 Glycophonn E precursor GLPEJHUMAN Y Y Y
7303 Folate receptor alpha precursor (FR-alpha) (Folate receptor 1) (Folate receptor, adult) (Adult folate-binding protein) (FBP) (Ovaπan tumor- FOLR1JHUMAN Y
7304 Folate receptor beta precursor (FR-beta) (Folate receptor 2) (Folate receptor, fetal/placental) (Placental folate-binding protein) (FBP) FOLR2_HUMAN Y Y
7305 Ephnn-A1 precursor (EPH related receptor tyrosine kinase ligand 1) (LERK-1) (Immediate early response protein B61) (Tumor necrosis Y
7306 Eπdothelin 2 precursor (ET-2) (Preproendothelιn-2) (PPET2) EDN2_HUMAN Y Y
7307 Endothelιn-3 precursor (ET-3) (Preproeπdothelιn-3) (PPET3) EDN3_HUMAN Y Y
7308 Grave's disease earner protein (GDC) (Grave's disease autoantigen) (GDA) (Mitochondria! solute earner protein homolog) GDC-HUMAN Y Y
7309 Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor (GM CSF-R-alpha) (GMR) (CDw116) (CD116 antigen) CSF2R_HUMAN Y Y Y
7310 Ezπn (p81) (Cytovillin) (ViIIm 2) EZRI_HUMAN 7311 Galactoside 2-alpha L fucosyltransferase 1 (EC241 69) (GDP-L- fucose beta-D-galactosιde 2-alpha-L fucosyltransferase 1) FUT1_HUMAN Y Y 7312 Galactoside 3(4)-L-fucosyltransferase (EC 241 65) (Blood group Lewis alpha-4 fucosyltransferase) (Lewis FT) (Fucosyltransferase 3) (FUCT FUT3_HUMAN Y Y 7313 Hexokιnase, type l (EC 2.7 1 1) (HK I) (Braιnform HXK1_HUMAN Y
7314 Guanine nucleotide-biπding protein G(t), alpha-2 subunit (Transducin alpha-2 chain) GNAT2_HUMAN
7315 Guanine nucleotide-binding protein G(Z), alpha subunit (G(X) alpha chain) (Gz-alpha) GNAZJHUMAN
7316 Guanine nudeotide-bindmg protein G(I)/G(S)/G(T) beta subunit 3 (Transducin beta chain 3) GBB3_HUMAN
7317 HLA class I histocompatibility antigen alpha chain G precursor antigen) HLAGJ-IUMAN Y Y Y
7318 Histatin 3 precursor (Histidine πch protein 3) (PB) (Basic histidme- nch protein) [Contains Histatin 3, Histatin 4, Histatin 5, HIS3_HUMAN Y
7319 Gamma-glutamyltranspeptidase 1 precursor (EC 2322) (Gamma- glutamyltransferase 1) (CD224 antigen) [Contains Gamma- GGTI-HUMAN Y Y
7320 Gamma-aminobutyπc-aαd receptor alpha-1 subunit precursor (GABA(A) receptor) Y Y Y
7321 Gamma-ammobutyπc-aαd receptor beta-1 subunit precursor (GABA(A) receptor) GBRB1_HUMAN Y Y Y
7322 Gamma-aminobutyπc-acid receptor gamma-2 subunit precursor (GABA(A) receptor) GBRG2_HUMAN Y Y Y
7323 Ig kappa chain V-III region HAH precursor KV3L_HUMAN Y
7324 Ig kappa chain V-III region HIC precursor KV3MJHUMAN Y
7325 Interferoπ-alpha/beta receptoralpha chain precursor (IFN-alpha-REC) INAR1_HUMAN Y Y Y
7326 lnterferon-gammareceptoralphachaιn precursor(IFN-gamma R1) (CD119antigen) (CDw119) INGR1_HUMAN Y Y Y
7327 Insulin receptor-related protein precursor (EC 271 112) (IRR) (IR-related receptor) INSRRJ-iUMAN Y Y Y
7328 Iπtegnn alpha-L precursor (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function associated molecule 1, alpha ITAL-HUMAN Y Y Y
7329 Integπn alpha-X precursor (Leukocyte adhesion glycoprotein p150,95 alpha chain) (Leukocyte adhesion receptor p150,95) (CDHc) (Leu M5) ITAX-HUMAN Y Y Y
7330 lntegnn beta 4 precursor (GP150) (CD104 antigen) 1TB4_HUMAN Y Y Y
7331 Integπn beta-5 precursor 1TB5JHUMAN Y Y Y
7332 Integπn beta-6 precursor ITB6_HUMAN Y Y Y
7333 Inter-alpha-trypsin inhibitor heavy chain H1 precursor (ITl heavy chain H1) (Inter-alpha-inhibitor heavy chain 1) (Inter-alpha-trypsin ITIH1 JHUMAN Y
7334 Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-iπhibitor heavy chain 2) (Inter-alpha-trypsin 1T1H2_HUMAN Y
7335 Immunoglobulin lambda-like polypeptide 1 precursor (Immunoglobulin- related 141 protein) (Immunoglobulin omega polypeptide) (Lambda 5) 1GLL1_HUMAN Y
7336 Solute earner family 2, facilitated glucose transporter, member4 (Glucose transporter type 4, insulin responsive) GTR4_HUMAN Y Y
7337 Erythropoietin receptor precursor (EPO-R) EPOR-HUMAN Y Y Y Y
7338 Histatin 1 precursor (Histidine-πch protein 1) (Post-PB protein) (PPB) [Contains Histatin 2] HISI-HUMAN Y
7339 Leukosialin precursor (Leucocyte sialoglyeoprotein) (Sialophoπn) (CD43 antigen) (Galactoglycoprotein) (GALGP) LEUK-HUMAN Y Y Y
7340 Lymphocyte function-associated antigen 3 precursor (Ag3) (Antigen CD58) (Surface glycoprotein LFA-3) LFA3_HUMAN Y Y Y
7341 lnterleukin-11 precursor(IL-11) (Adipogenesis inhibitoryfactor) (AGIF) (Oprelvekin) IL11JHUMAN Y Y
7342 Interleukιn-1 receptor, type I precursor (IL-1R-1) (IL-1R-alpha) (P80) (Antgen CD121a) IL1R1_HUMAN Y Y Y
7343 lnterleukιn-1 receptor antagonist protein precursor (IL-1ra) (IRAP) (ILI inhibitor) (1L-1RN) (1CIL-1RA) IL1RA_HUMAN Y Y
7344 Insulin-like growth factor binding protein 2 precursor (IGFBP-2) (lBP-2) (IGF-binding protein 2) IBP2_HUMAN Y Y
7345 Insulin-like growth factor binding protein 3 precursor (IGFBP-3) (IBP-3) (IGF-binding protein 3) IBP3__HUMAN Y Y
Figure imgf000185_0001
Extracellular Integral
PID Description UniProt ACC Signal Secreted Domain Membrane Type I Type Il Type HI Type IV Mitochondrial Golgi
7411 Tryptase beta-2 precursor (EC 34.21 59) (Tryptase 2) (Tryptase II) TRYB2_HUMAN Y Y
7412 Sucrase-isomaltase, intestinal [Contains Sucrase (EC 32 1 48), Isomaltase (EC 32 1 10)] SUISJΪUMAN
7413 Vinculin (Metavinculin) VINCJHUMAN
7414 Vascular cell adhesion protein 1 precursor (V-CAM 1) (CD106 (INCAM-100) VCAM1JHUMAN
7415 Vascular endothelial growth factor receptor 1 precursor (EC 271 112) (VEGFR-1) (Vascular permeability factor receptor) (Tyrosine-protein VGFR1_HUMAN
7416 Transcobalamin Il precursor (TCII) (TC II) TCO2_HUMAN
7417 Synapsιn-1 (Syπapsiπ I) (Brain protein 4 1) * SYN1JHUMAN
7418 Thyrotropin receptor precursor (TSH-R) (Thyroid stimulating hormone receptor) TSHRJHUMAN
7419 Tumor necrosis factor receptor superfamily member 1A precursor (p60) (TNF-R1) (TNF-RI) (p55) (CD120a) [Contains Tumor necrosis factor TNR1AJHUMAN
7420 Tumor necrosis factor receptor superfamily member 1 B precursor (Tumor necrosis factor receptor 2) (TNF-R2) (Tumor necrosis factor receptαTNRIBJHUMAN
7421 Metalloproteinase inhibitor 2 precursor (TIMP-2) (Tissue inhibitor of metalloproteιnases-2) (CSC-21 K) TIMP2JHUMAN
7422 CMP-N-acetylneuraminate-beta-galactosamide-alpha 2,6-sιalyltraπsferase (EC 2499 1) (Beta-galactoside alpha-2,6-sιalyltransferase) (Alpha SIAT1 HUMAN
7423 Very very hypothetical B-cell growth factor (BCGF-12 kDa) YYY3 JHUMAN
7424 Thymidine phosphorylase precursor (EC 242.4) (TdRPase) (TP) (Platelet-derived endothelial cell growth factor) (PD-ECGF) TYPH_HUMAN
7425 Tyrosinase precursor (EC 1 14 18 1) (Monopheπol monooxygenase) (Tumor rejection antigen AB) (SK29 AB) (LB24-AB) TYRO-HUMAN Y
7426 S,6-dιhydroxyιπdole-2-carboxylιc acid oxidase precursor (EC 1 1418 -) (DHlCA oxidase) (Tyrosinase-related protein 1) (TRP-1) (TRP1) (TRP)TYRPI JHUMAN Y
7427 Activin receptor type Il precursor (EC 271 37) (ACTR-II) (ACTRlIA) ACVR2JHUMAN Y Y
7428 Alpha-ID adrenergic receptor (Alpha 1D-adrenoceptor) (Alpha 1D-adrenoreceptor) (Alpha-1 A adrenergic receptor) (Alpha adrenergic ADA1D_HUMAN Y Y
7429 Small inducible cytokine A1 precursor (CCL1) (T lymphocyte-secreted protein I-309) CCL1 JHUMAN
7430 HLA class Il histocompatibility antigen DM alpha chain precursor class Il antigen DMA) 2DMAJHUMAN Y
7431 HLA class II histocompatibility antigen, DM beta chain precursor class Il antigen DMB) 2DMBJHUMAN Y
7432 3 beta-hydroxysteroid dehydrogeπase/delta 5->4-ιsomerase type Il (3Beta-HSD II) [Includes 3-beta-hydroxy-delta(5)-steroιd 3BHS2_HUMAN
7433 5-hydroxytryptamιne 1B receptor (5-HT-1B) (Serotonin receptor 1B) (5-HT1B) (S HT-1D-beta) (Serotonin 1D beta receptor) (S12) 5HT1BJHUMAN Y Y
7434 5-hydroxytryptamιne 1D receptor (5-HT-1D) (Serotonin receptor 1D) (5-HT-1D-alpha) 5HT1DJHUMAN Y Y
7435 5-hydroxytryptamιne 1 E receptor (5-HT-1 E) (Serotonin receptor 1E) (5 HT1E) (S31) SHT1E_HUMAN Y Y
7436 S-hydroxytryptamine 2A receptor (5-HT-2A) (Serotonin receptor 2A) (5-HT-2) 5HT2A_HUMAN Y Y
7437 6-hydroxytryptamιπe 2C receptor (5-HT 2C) (Serotonin receptor 2C) (5-HT2C) (5-HTR2C) (5HT-1C) 5HT2C_HUMAN Y Y
7438 Adenosine A2a receptor AA2AR~HUMAN Y Y
7439 Adenosine A2b receptor AA2BR JHUMAN Y Y
7440 Arylacetamide deacetylase (EC 31 1 -) (AADAC) AAAD _HUMAN
7441 T-cell surface glycoprotein CD1b precursor (CD1b antigen) CD1 BJHUMAN Y Y Y
7442 T-cell surface glycoprotein CD1c precursor (CD1c antigen) CD1C_HUMAN Y Y Y
7443 Signal transducer CD24 precursor CD24_HUMAN Y
7444 Hematopoietic progenitor cell antigen CD34 precursor CD34JHUMAN Y Y Y
7445 ADP-nbosyl cyclase 1 (EC 3225) (Cyclic ADP-nbose hydrolase 1) (cADPr hydrolase 1) (Lymphocyte differentiation antigen CD38) (T10) CD38 JHUMAN Y
7446 Cannabiπoid receptor 1 (CB1) (CB-R) (CANN6) CNR1_HUMAN Y Y
7447 B-cell differentiation antigen CD72 (Lyb 2) CD72_HUMAN Y
7448 CD82 antigen (Inducible membrane protein R2) (C33 antigen) (IA4) (Metastasis suppressor Kangai 1) (Suppressor of tumoπgenicιty-6) CD82JHUMAN Y Y
7449 CD9 antigen (p24) (Leukocyte antigen M1C3) (Motility-related protein) (MRP-1) CD9_HUMAN Y Y
7450 Ciliary neurotrophic factor receptor alpha precursor (CNTFR alpha) CNTFRJHUMAN Y
7451 Ciliary neurotrophic factor (CNTF) CNTFJ-IUMAN
7452 Collagen alpha 5(IV) chain precursor CO4A5 JHUMAN Y
7453 Collagen alpha 3(V) chain precursor CO5A3 JHUMAN Y
7454 Collagen alpha 1 (VIII) chain precursor (Endothelial collagen) C08A1 JHUMAN Y
7455 Collagen alpha 2(VIII) chain precursor (Endothelial collagen) CO8A2_HUMAN Y
7456 Annexin A13 (Annexin XIII) (Annexin, intestine-specrSc) (ISA) ANX13_HUMAN
7457 Cytochrome c oxidase polypeptide VIIb, mitochondrial precursor (EC 1 931) COX7B_HUMAN
7458 ATP-binding cassette, sub-family D, member 3 (70 kDa peroxisomal membrane protein) (PMP70) ABCD3_HUMAN
7459 Autocπne motility factor receptor precursor, isoform 1 (AMF receptor) AMFR1_HUMAN Y
7460 A-kinase anchor protein 5 (A-kinase anchor protein 79 kDa) (cAMP-dependent protein kinase regulatory subunit H high affinity AKAP5_HUMAN
7461 Acyloxyacyl hydrolase precursor (EC 31 1 77) AOAH JHUMAN Y
7462 Amine oxidase [flavin-containing] A (EC 1 434) (Monoamine oxidase type A) (MAO A) AOFA_HUMAN
7463 Amine oxidase [flavin-containing] B (EC 1 434) (Monoamine oxidase type B) (MAO-B) AOFBJHUMAN
7464 Cathepsιn S precursor(EC 342227) CATS J-IUMAN Y
7465 Calnexin precursor (Major histocompatibility complex class I antigen- binding protein p88) (p90) (IP90) CALXJHUMAN Y
7466 C5a aπaphylatoxiπ chemotactic receptor (C5a-R) (C5aR) (CD88 antigen) C5AR_HUMAN
7467 Cerebellin precursor (Precerebelliπ) Y
7468 Carboxypeptidase N 83 kDa chain precursor (Carboxypeptidase N regulatory subunit) (Carboxypeptidase N polypeptide 2) CBP8J-IUMAN Y
7469 C-type natnuretic peptide precursor [Contains CNP-22, CNP-29, CNP-53] ANFCJHUMAN Y
7470 ATP synthase alpha chain, mitochondπal precursor (EC 36314) ATPA HUMAN
7471 Acetylcholinesterase precursor (EC 3 1 1 7J (AChE) ACESJiUMAN Y
7472 Plasma membrane calcium-transporting ATPase 4 (EC 3638) (PMCA4) (Plasma membrane calcium pump isoform 4) (Plasma membrane Ci AT2B4JHUMAN
7473 ATP synthase B chain, mitochondπal precursor (EC 36314) AT5F1 JHUMAN
7474 Angiotensin-converting enzyme, testis-specific isoform precursor (EC 34151) (ACE-T) (Dipeptidyl carboxypeptidase I) (Kininase II) ACETJHUMAN Y
7475 D(1A) dopamine receptor DRD1 JHUMAN
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Endoplasmic Extra- Cyto- Peroxi- GPl- Micro- Group Group Grou
P[D Description UniProt ACC reticulum Nuclear cellular skeletal somai anchor somal 1 2 3
131 Small inducible cytokine B11 precursor (CXCL11) (Interferon-inducible T-cell alpha chemoattractaπt) (I-TAC) (Interferoπ-gamma-inducible SCYBBJHUMAN
132 Transmembrane 4 superfamily member 5 (Tetraspan transmembrane protein L6H) T4S5_HUMAN
133 Transmembrane 4 superfamily member 7 (Novel antigen 2) (NAG-2) (Tetraspanin 4) (Tspan-4) T4S7_HUMAN
134 Sarcohpiπ SARCOJHUMAN
135 Toll like receptor 4 precursor (hToll) TLR4_HUMAN
136 Plexin B2 precursor (MM1) PLXB2 JHUMAN
137 Syntenιn-1 (Syndecan binding protein 1) (Melanoma differentiation- associated protein 9) (MDA-9) (Scaffold protein Pbp1) (Pro-TGF-alpha SDCB1_HUMAN
138 Syπtaxιn-16 (Syn16) STX16J1UMAN
139 Secreted fnzzled-related protein 1 precursor (sFRP-1) (Fπzzled- related protein 1) (FRP-1) (Secreted apoptosis-related protein 2) SFRP1JHUMAN
140 Ubiquinol-cytochrome c reductase complex ubiquinoπe-binding protein QP-C (EC 1 1022) (Ubiquinol-cytochrome c reductase complex 95 klUCRQJHUMAN
141 Syπaptotagmιn-5 (Syπaptotagmm V) (SytV) SYT5JHUMAN
142 Transmembrane gamma-carboxyglutamic acid protein 1 precursor (Proline- πch GIa protein 1) (Prolme-πch gamma-carboxyglutamic acid protTMG1_HUMAN
143 Transmembrane gamma carboxyglutamic acid protein 2 precursor (Proline- rich GIa protein 2) (Proline-rich gamma-carboxyglutamic acid protTMG2_HUMAN
144 Transmembrane protein 24 (DLNB23 protein) TMM24_HUMAN
145 Secreted fnzzled-related protein 4 precursor (sFRP-4) (Fπzzled protein, human endometπum) (FrpHE) SFRP4_HUMAN
146 Secreted fnzzled-related protein 5 precursor (sFRP-5) (Secreted apoptosis related protein 3) (SARP-3) (Fπzzled related protein 1b) SFRP5_HUMAN
147 Spectnn beta chain, brain 2 (Spectπn, non-erythroid beta chain (Beta-Ill spectrin) SPTN2_HUMAN
148 Secretory earner-associated membrane protein 1 (Secretory earner membrane protein 1) SCAM1 JHUMAN
149 Secretory camer-associated membrane protein 2 (Secretory earner membrane protein 2) SCAM2JHUMAN
150 Secretory camer-associated membrane protein 3 (Secretory earner membrane protein 3) SCAM3JHUMAN
151 Surfeit locus protein 4 SURF4JHUMAN
152 Tumor necrosis factor ligand superfamily member 11 (Receptor activator of nuclear factor kappa B ligand) (RANKL) (TNF-related activation- TNF11_HUMAN
153 Tumor necrosis factor receptor superfamily member 10A precursor (Death receptor 4) (TNF-related apoptosis inducing ligand receptor 1) (TRTR10A_HUMAN
154 Tumor necrosis factor receptor superfamily member 10B precursor (Death receptor 5) (TNF-related apoptosis-inducing ligand receptor 2) (TRTR10B_HUMAN
155 Tumor necrosis factor receptor superfamily member 10C precursor (Decoy receptor 1) (DcR1) (Decoy TRAIL receptor without death domain) TR10CJHUMAN
156 Tumor necrosis factor receptor superfamily member 11B precursor (Osteoprotegenn) (Osteoclastogenesis inhibitory factor) TR11B_HUMAN
157 Tumor necrosis factor receptor superfamily member 13B (Transmembrane activator and CAML interactor) TR13BJHUMAN
158 Wπt-10b protein precursor (Wnt-12) WN10B_HUMAN
159 Very-long-chain acyl-CoA synthetase (EC 621 -) (Very-long chain- fatty-acid-CoA ligase) VLCSJHUMAN
160 Uroplakιπ-1a (Uroplakin Ia) (UPIa) (UPKa) UPK1A_HUMAN
161 Uroplakιn-2 precursor (UP 2) (Uroplakin II) (UPII) UPK2_HUMAN
162 Synapsιn-3 (Synapsin III) SYN3_HUMAN
163 Mitochondπal import inner membrane translocase subunιtTιm23 TIM23_HUMAN
164 Transportin 2 (Karyopheππ beta-2b) TNPO2 JHUMAN
165 Wnt-7a protein precursor WNT7AJHUMAN
166 Wnt-9a protein precursor (Wnt-14) WNT9A_HUMAN
167 Wht-9b protein precursor (Wht-15) (Wnt-14b) (UNQ6973/PRO21956) WNT9B_HUMAN
168 Syntaphilm SNPH_HUMAN
169 Testis-specrflc XK related protein Y XKRY JHUMAN
170 Zinc transporter 4 (ZnT-4) (Solute earner family 30, member ZNT4_HUMAN
171 WUGSC DJ515N1 2 protein O00318 JHUMAN
172 Receptor protein tyrosine phosphatase hPTP J precursor O00197JHUMAN
173 Mucin MUC5B (Fragment) O00446_HUMAN
174 130 kD Golgi-localized phosphoprotein O00461 JHUMAN
175 Latent TGF-beta binding proteιn-4 OO0508 JHUMAN
176 Endogenous retrovirus H D1 leader region/integrase-deπved ORF1, ORF2, and putative envelope protein (Endogenous retrovirus H O00627JHUMAN
177 PH-seπsιng regulatory factor of peptide transporter O14496J-IUMAN
178 Placental growth hormone 2OkDa isoform precursor O14643JHUMAN
179 Ran binding protein 2 (Fragment) O14715JHUMAN
180 Putative neurotransmitter receptor 014804 JHUMAN
181 Chloπde channel protein 3 (Chlonde channel 3) O14918_HUMAN
182 KIAA0358 protein (Fragment) O15065_HUMAN
183 KIAA0364 protein (Fragment) O15070 J-IUMAN
184 Myelin transcnption factor 2 O15150JHUMAN
185 Sodium bicarbonate cotransporter O15153_HUMAN
186 Cadheπn (Fragment) O15200_HUMAN
187 Cadheπn (Fragment) O15202_HUMAN
188 Prostaglandin EP3 receptor subtype isoform (Prostaglandin E receptor 3) (Subtype EP3) O00325_HUMAN
189 Insulin receptor substrate 4 014654 J-IUMAN
190 Placental growth hormone isoform hGH-V3 precursor O14644_HUMAN
191 Carboxypeptidase Z precursor O00520JHUMAN
192 Neural cell adhesion molecule 000533 JHUMAN
193 Neural cell adhesion molecule (Fragment) 000557 JHUMAN
194 CDO O14631JHUMAN
195 Acetyl-coenzyme A transporter (SLC33A1 protein) O00400 JHUMAN
Endoplasmic Extra- Cyto- Peroxi- GPl- Micro- Group Group Grou
PID Description UniProtACC reticulum Nuclear cellular skeletal soma! anchor somal 1 2 3
196 Cci6 (Chemokine (C-C motif) receptor like 2) (Chemokine receptor X) (Chemokine receptor like 2) O00421_HUMAN
197 WUGSC H_LUCA122 protein (Cytochrome b-561 domain containing 2) (Putative tumor suppressor protein) O14569_HUMAN
198 CRM1 protein (XPO1 protein) 014980 J-IUMAN
199 MLD (Degenerative spermatocyte homolog 1, lipid desaturase) (Migration-inducing gene 15 protein) (Sphmgolipid delta 4 desaturase O15121_HUMAN
200 Organic cation transporter (Solute earner family 22 member 2, a)
201 Alpha-1A adrenergic receptor (Alpha 1A-adrenoceptor) (Alpha 1A-adrenoreceptor) (Alpha 1C adrenergic receptor) (Alpha adrenergic ADA1A_HUMAN
202 Alpha-IB adrenergic receptor (Alpha 1 B-adrenoceptor) (Alpha 1B-adrenoreceptor) ADA1BJHUMAN
203 14-3-3 protein Sigma (StratiRn) (Epithelial cell marker protein 1) 1433S_J|UMAN
204 HLA class I histocompatibility antigen, A-1 alpha chain precursor class I antigen A*1) 1A01JHUMAN
205 Cholecystokinin type A receptor (CCK-A receptor) (CCK-AR) (Cholecystokιnιn-1 receptor) (CCK1-R) CCKAR_HUMAN
206 HLA class I histocompatibility antigen, A-23 alpha chain precursor (MHC class antigen A*23) (A-9) 1A23_HUMAN
207 HLA class I histocompatibility antigen, A-29 alpha chain precursor (MHC class antigen A*29) (Aw-19) 1A29_HUMAN
208 HLA class I histocompatibility antigen, A-34 alpha chain precursor (MHC class antigen A*34) (Aw-34) (A-10) 1A34_HUMAN
209 HLA class I histocompatibility antigen, A-36 alpha chain precursor (MHC class antigen A*36) (Aw-36) 1A36JHUMAN
210 HLA class I histocompatibility antigen, A-43 alpha chain precursor (MHC class antigen A*43) (Aw-43) 1A43_HUMAN
211 HLA class I histocompatibility antigen, A-74 alpha chain precursor (MHC class antigen A*74) (Aw-74) (Aw-19) 1A74J-1UMAN
212 HLA class I histocompatibility antigen, B-8 alpha chain precursor class I antigei B*8) 1B08_HUMAN
213 HLA class I histocompatibility antigen B-13 alpha chain precursor (MHC class antigen B"13) 1B13JHUMAN
214 HLA class I histocompatibility antigen, B-14 alpha chain precursor (MHC class antigen B*14) 1B14_HUMAN
215 HLA class I histocompatibility antigen, B-18 alpha chain precursor (MHC class I antigen B*18) 1B18_HUMAN
216 HLA class I histocompatibility antigen, B-35 alpha chain precursor (MHC class antigen B*35) 1B35JHUMAN
217 HLA class I histocompatibility antigen, B-39 alpha chain precursor (MHC class antigen B*39) 1B39_HUMAN
218 HLA class I histocompatibility antigen, B-41 alpha chain precursor (MHC class antigen B*41) (Bw-41) 1B41 JHUMAN
219 HLA class I histocompatibility antigen, B-42 alpha chain precursor (MHC class antigen B*42) 1B42_HUMAN
220 HLA class I histocompatibility antigen, B-44 alpha chain precursor (MHC class antigen BM4) (Bw-44) 1B44_HUMAN
221 HLA class I histocompatibility antigen B-45 alpha chain precursor (MHC class antigen B*45) (Bw-45) 1B45_HUMAN
222 HLA class I histocompatibility antigen, B-47 alpha chain precursor (MHC class antigen B*47) (Bw-47) 1B47_HUMAN
223 HLA class I histocompatibility antigen, B-48 alpha chain precursor (MHC class antigen B*48) (Bw-4δ) 1B48_HUMAN
224 HLA class I histocompatibility antigen, B-49 alpha chain precursor (MHC class antigen B*49) (B-21) 1B49_HUMAN
225 HLA class I histocompatibility antigen, B-50 alpha chain precursor (MHC class antigen B*50) (Bw-50) (B-21) 1B50_HUMAN
228 HLA class I histocompatibility antigen, B-52 alpha chain precursor (MHC class I antigen B*52) (Bw-52) (B 5) 1B52_HUMAN
227 HLA class I histocompatibility antigen, B-53 alpha chain precursor (MHC class I antigen B*53) (Bw-53) 1B53_HUMAN
228 HLA class I histocompatibility antigen, B-54 alpha chain precursor (MHC class I antigen B*54) (Bw-54) (Bw 22) 1B54_HUMAN
229 HLA class I histocompatibility antigen, B-55 alpha chain precursor (MHC class I antigen B*55) (Bw-55) (B-12) 1B55_HUMAN
230 HLA class I histocompatibility antigen, B-56 alpha chain precursor (MHC class I antigen B'56) (Bw 56) (Bw-22) 1B56JHUMAN
231 HLA class I histocompatibility antigen, B-78 alpha chain precursor (MHC class I antigen B*78) 1B78_HUMAN
232 HLA class I histocompatibility antigen, Cw-1 alpha chain precursor (MHC class I antigen Cw*1) 1C01_HUMAN
233 HLA class I histocompatibility antigen, Cw 2 alpha chain precursor (MHC class I antigen Cw*2) 1C02JHUMAN
234 HLA class I histocompatibility antigen, Cw-4 alpha chain precursor (MHC class I antigen Cw"4) 1C04JHUMAN
235 HLA class I histocompatibility antigen, Cw-8 alpha chain precursor (MHC class I antigen Cw*8) 1C08_HUMAN
236 HLA class I histocompatibility antigen, Cw-12 alpha chain precursor (MHC class I antigen Cw'12) 1C12_HUMAN
237 Seπne/threomπe protein phosphatase 2A, 65 kDa regulatory subunit A, alpha isoform (PP2A, subunit A, PR65-a!pha isoform) (PP2A, subunit 2AAAJHUMAN
238 Seπne/threonme protein phosphatase 2A, 65 kDa regulatory subunit A, betaisofonm (PP2A. subunit A, PR65-beta isoform) (PP2A subunit 2AAB_HUMAN
239 5-hydroxytryptamine 1F receptor (5-HT-1F) (Serotonin receptor 1F) 5HT1FJHUMAN
240 5-hydroxytryptamιne 7 receptor (5-HT-7) (Serotonin receptor 7) (5-HT-X) (5HT7) SHT7R_HUMAN
241 C-C chemokine receptortype 1 (C C CKR-1) (CC-CKR-1) (CCR-1) (Macrophage inflammatory protein-1 alpha receptor) (MIP-1alpha-R) CCRI-HUMAN
242 C-C chemokine receptor type 7 precursor (C-C CKR-7) (CC-CKR-7) (MIP-3 beta receptor) (EBV-induced G-protein coupled receptor 1) CCR7JHUMAN
243 Adenosine A1 receptor AA1R_HUMAN
244 Adenosine A3 receptor (UNQ1931/PRO4406) AA3R_HUMAN
245 CAMPATH-1 antigen precursor (CD52 antigen) (CDW52) (Cambπdge pathology 1 antigen) (Epididymal secretory protein ES) CD52_HUMAN
246 cGMP-gated cation channel alpha 1 (CNG channel alpha 1) (Cyclic nucleotide gated channel alpha 1) (Cyclic nucleotide gated CNGA1_HUMAN
247 Macrosialm precursor (CD68 antigen) (GP110) CD68_HUMAN
248 T-cell differentiation antigen CD6 precursor (TiZ) (TP120) CD6_HUMAN
249 T lymphocyte activation antigen CD80 precursor (Activation B7-1 antigen) (CTLA-4 counter-receptor B7 1) (B7) (BB1) CD80JHUMAN
250 Cannabinoid receptor 2 (CB2) (CB 2) (CX5) CNR2J1UMAN
251 Aquaporin-CHIP (Water channel protein for red blood cells and proximal tubule) (Aquapoπn 1) (AQP-1) (Unne water channel) AQP1 J-IUMAN
252 Insulin-like growth factor binding protein complex acid labile chain precursor (ALS) ALS_HUMAN
253 ATP synthase delta chain, mitochondπal precursor (EC 36314) ATPD-HUMAN
254 Calcitonin receptor precursor (CT-R) CALCR_HUMAN
255 Beta-arrestin 2 (Arrestiπ, beta 2) ARRB2JHUMAN
256 ATP-bmdiπg cassette, sub family D, member 1 (Adrenoleukodystrophy protein) (ALDP) ABCD1_HUMAN
257 ATP synthase gamma chain, mitochondπal precursor (EC 363 14) ATPGJ-tUMAN
258 B2 bradykinin receptor (BK-2 receptor) (B2R) BKRB2_HUMAN
259 Basigin precursor (CD147 antigen) (Leukocyte activation antigen M6) (Collagenase stimulatory factor) (Extracellular matrix BASI_HUMAN
260 Peπpheral-type benzodiazepine receptor (PBR) (PKBS) (Mitochoπdπal benzodiazepine receptor) BZRP_HUMAN
Figure imgf000194_0001
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Grou
PlD Description UniProtACC reticulum Nuclear cellular skeletal somal anchor soma! 1 2 3
326 Intercellular adhesion molecule-3 precursor (ICAM-3) (ICAM-R) (CDw50) (CD50 antigen) ICAM3_HUMAN
327 Mannosyl oligosacchaπde 1 ,2-alpha-manπosιdase IA (EC 32 1 113) (Processing alpha-1 2-ππaπnosιdase IA) (Alpha-1 2-mannosidase IA) MA1A1_HUMAN
328 Gastπn-releasiπg peptide receptor (GRP-R) (GRP-prefemng bombesin receptor) GRPR-HUMAN
329 ER lumen protein retaining receptor 2 (KDEL receptor 2) endoplasmic reticulum protein retention receptor 2) (ERD2-lιke protein ERD22JHUMAN
330 Cytokine receptor common gamma chain precursor (Gamma-C) (lnterleukιn-2 receptor gamma chain) (IL-2R gamma chain) (P64) (CD132 IL2RGJHUMAN
331 Cytokine receptor common beta chain precursor (CDw131 antigen) (GM CSBIL-3/1L 5 receptor common beta-chain) 1L3RB_HUMAN
332 Melaπocortin-4 receptor (MC4-R) MC4RJHUMAN
333 Melanocortιπ-S receptor (MCS-R) (MC-2) MCSRIHUMAN
334 ES1 protein homolog, mitochondnal precursor (Protein KNP-I) (GT335 protein) ES1JHUMAN
335 Mynstoylated alanine-πch C-kinase substrate (MARCKS) (Protein kinase C substrate, 80 kDa protein, light chain) (PKCSL) (80K-L MACS_HUMAN
336 Lens fiber major iπtπnsic protein (MIP26) (MP26) (Aquapoπn O) MIPJHUMAN
337 Merlin (Moesin-ezπn-radixiπ like protein) (Schwannomm) (Schwannomerliπ) (Neurofibromin 2) MERL.HUMAN
338 Interferon alpha-8 precursor (Interferon alpha-B2) (Interferon alpha-B) (LeIF B) IFNA8_HUMAN
339 Multidrug resistance-associated protein 1 (ATP-binding cassette, sub- family C, member 1) MRP1_HUMAN
340 Moπocarboxylate transporter 8 (MCT 8) (X-linked PEST-containing transporter) (MCT 7) MOT8_HUMAN
341 Dual specificity mitogen-activated protein kinase kinase 2 (EC 271 -) (MAP kinase kinase 2) (MAPKK 2) (ERK MP2K2_HUMAN
342 Mas-related G-protein coupled receptor MRG (MAS-R) (MAS1-lιke) MAS1L_HUMAN
343 NK-tumor recognition protein (Natural-killer cells cyclophilin-related protein) (NK-TR protein) NKTR_HUMAN
344 Olfactory receptor 10J1 (Olfactory receptor-like protein HGMP07J) O10J1_HUMAN
345 Rod cGMP-specific 3',5'-CyClIC phosphodiesterase beta-subunit (EC 31 417) (GMP-PDE beta) PDE6B_HUMAN
346 Mu-type opioid receptor (M0R-1) OPRM HUMAN
347 2'-5'-olιgoadenylate synthetase 2 (EC 277 -) ((2-5')o)ιgo(A) synthetase 2) (2-5A synthetase 2) (p69 OAS / p71 OAS2_HUMAN
348 Prohibitiπ PHB-HUMAN 349 Neurotensin/neuromedin N precursor [Contains Large neuromedin N (NmN-125), Neuromedin N (NmN) (NN), Neurotensin (NT), Tail peptide NEUT_HUMAN
350 Olfactory receptor 1D2 (Olfactory receptor-like protein HGMP07E) (Olfactory receptor 17-4) (OR17-4) 0R1 D2_HUMAN 351 Sodium/calcium exchanger 1 precursor (Na(+)/Ca(2+)-exchaπge protein 1) NAC1_HUMAN 352 Prostaglandin G/H synthase 2 precursor (EC 1 14991) (Cydooxygenase-2) (COX-2) (Prostaglandin-endoperoxide synthase 2) PGH2_HUMAN 353 Olfactory receptor 1 E1 (Olfactory receptor-like protein HGMP07I) (Olfactory receptor 17 2/17-32) (OR17-2) (OR17-32) (Olfactory receptor OR1 E1_HUMAN 354 Prostaglandin E2 receptor EP1 subtype (Prostanoid EP1 receptor) (PGE receptor EP1 subtype) PE2R1 HUMAN 355 Prostaglandin E2 receptor, EP4 subtype (Prostanoid EP4 receptor) (PGE receptor, EP4 subtype) PE2R4_HUMAN 35S Pigment epithelium-deπved factor precursor (PEDF) (EPC-1) PEDF-HUMAN 357 Oxytocin receptor (OT-R) OXYR_HUMAN 358 Sodium channel protein type I alpha subunit (Voltage-gated sodium channel alpha subunit Nav1 1) (Sodium channel protein, brain I SCN1A_HUMAN 359 Sodium channel protein type IV alpha subunit (Voltage-gated sodium channel alpha subunit Nav1 4) (Sodium channel protein, skeletal muscle SCN4A_HUMAN 360 Radixin RADI_HUMAN 361 3-oxo-5-alpha steroid 4-dehydrogenase 2 (EC 1 3995) (Steroid 5-alpha-reductase 2) (SR type 2) (5 alpha-SR2) S5A2JHUMAN 362 Sterol O-acyltransferase 1 (EC 23 126) (Cholesterol acyltransferase 1) (Acyl coenzyme A cholesterol acyltraπsferase 1) (ACAT-1) SOAT1JHUMAN 363 Serum amyloid A-4 protein precursor (Constitutively expressed serum amyloid A protein) (C-SAA) SAA4__HUMAN 364 Transmembrane 4 superfamily member 1 (Tumor-associated antigen L6) (Membrane component surface marker 1) (M3S1) T4S1_HUMAN 365 Syndecan-2 precursor (Fibroglycan) (Heparan sulfate proteoglycan core protein) (HSPG) (SYND2) SDC2_HUMAN 366 Syndecan-4 precursor (Amphiglycan) (SYND4) (Ryudocan core protein) SDC4_HUMAN 367 Epimcrphin (Syntaxin 2) STX2_HUMAN 368 UDP-glucuronosyltransferase 1-2 precursor, microsomal (EC 241 17) (UDP-glucuronosyltransferase 1A2) (UDPGT) (UGT1*2) (UGT1-02) (UUD12_HUMAN Y 369 UDP-glucuronosyltransferase 1-3 precursor, microsomal (EC 241 17) (UDP-glucuronosyltransferase 1A3) (UDPGT) (UGT1*3) (UGT1-03) (UUD13J-IUMAN Y 370 UDP-glucuronosyltransferase 1-5 precursor, microsomal (EC 241 17) (UDP-glucuronosyltransferase 1A5) (UDPGT) (UGT1-5) (UGT1-05) (UUD15_HUMAN Y 371 UDP-glucuronosyltransferase 2B10 precursor (EC 241 17) (UDPGT) UDB10_HUMAN Y 372 Somatostatin receptor type 1 (SS1R) (SRIF-2) SSR1JHUMAN 373 Somatostatin receptor type 2 (SS2R) (SRIF-1) SSR2JHUMAN 374 Somatostatn receptor type 3 (SS3R) (SSR-28) SSR3_HUMAN 375 Somatostatin receptor type 4 (SS4R) 376 Somatostatin receptor type 5 (SS5R) SSR5JHUMAN 377 Sodium/glucose cotransporter 2 (Na(+)/gIucose cotraπsporter 2) (Low affinity sodium-glucose cotransporter) SC5A2_HUMAN 378 Tyrosine-protem kinase receptor UFO precursor (EC 27 1 112) (AXL oncogene) UFO_HUMAN 379 Trypsin 111 precursor (EC 34214) (Brain trypsmogeπ) (Mesotrypsinogen) (Trypsin IV) TRY3_HUMAN 380 Pulmonary surfactant associated protein D precursor (SP-D) (PSP-D) SFTPD_HUMAN 381 Ubiquinol-cytochrome-c reductase complex core protein I, mitochondnal precursor (EC 1 1022) UQCR1_J-1UMAN 382 Tyrosine-protem kinase receptor Tie-1 precursor (EC 271 112) TIE1_HUMAN 383 Vacuolar ATP synthase subunit E (EC 363 14) (V-ATPase E (Vacuolar proton pump E subunit) (V-ATPase 31 kDa subunit) VATE-HUMAN 384 Vasoactive intestinal polypeptide receptor 1 precursor (VIP-R-1) (Pituitary adenylate cyclase activating polypeptide type Il receptor) V1PR1_HUMAN 385 Sodium- and chloπde-dependent GABA transporter 1 SC6A1_HUMAN 386 Sodium-dependent serotonin transporter (5HT transporter) (SHTT) SC6A4_HUMAN 387 Sodium- and chloπde-depeπdent tauπne transporter SC6A6_HUMAN 388 TGF-beta receptor type I precursor (EC 271 37) (TGFR-1) (TGF-beta type I receptor) (Seπne/threonine-protem kinase receptor R4) (SKR4) TGFR1_HUMAN Tumor necrosis factor ligand superfamily memberδ (CD40 ligand) (CD4Q L) (TNF-related activation protein) (TRAP) (T cell antigen Gp39) TNFL5JHUMAN
Tumor necrosis factor ligand superfamily member7 (CD27 ligand) (CD27-L) (CD70 antigen) TNFL7_HUMAN
Figure imgf000196_0001
Endoplasmic Extra- Cyto- Peroxi- GPl- Micro- Group Group Grou
PID Description UπiProtACC reticulum Nuclear cellular skeletal soma! anchor somal 1 2 3
456 Neuropeptides B/W receptor type 1 (G protein coupled receptor 7) GPR7_HUMAN
457 Neuropeptides B/W receptor type 2 (G-protein coupled receptor 8) GPR8 HUMAN
458 Platelet glycoprotein V precursor (GPV) (CD42D) GPV-HUMAN
459 Complement factor H-related protein 2 precursor (FHR-2) (H factor-like protein 2) (H factor-like 3) (DDESK59) FHR2_HUMAN
460 Glycine receptor beta chain precursor (Glycine receptor 58 kDa subunit) GLRBJHUMAN
461 Radiation-iπducible immediate early gene IEX-1 (Immediate early protein GLY96) (Immediate early response 3 protein) (PACAP-respoπsive IEXI-HUMAN
462 Probable G-protein coupled receptor 109B (G-proteιπ coupled receptor HM74) G109B_HUMAN
463 Galanin receptortype 1 (GAL1 R) (GALR1) GALR1_HUMAN
464 Gamma-aminobutyπc-acid receptor alpha 2 subunit precursor (GABA(A) receptor) GBRA2_HUMAN
465 Gamma-amiπobutyπc-acid receptor alpha-4 subunit precursor (GABA(A) receptor) GBRA4_HUMAN
466 Gamma-aminobutyπc-acid receptor beta-2 subunit precursor (GABA(A) receptor) GBRB2__HUMAN
467 Glucagon receptor precursor (GL-R) GLR_HUMAN
468 Hyaluronidase 1 precursor (EC 3.2135) (Hyal-1) (Hyaluroπidase PH-20) (Sperm surface protein PH-20) (Sperm adhesion molecule 1) HYAL1_HUMAN
469 GIutamate receptor 1 precursor (GluR-1) (GIuR A) (GIuR-KI) (Glutamate receptor ionotropic, AMPA 1) GRIA1_HUMAN
470 Glutamate receptor 2 precursor (GluR-2) (GIuR-B) (GIUR-K2) (Glutamate receptor ionotropic, AMPA 2) GRIA2JHUMAN
471 Glutamate receptor 3 precursor (GluR-3) (GIuR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) GRIA3_HUMAN
472 Glutamate receptor4 precursor (GluR-4) (GluR4) (GIuR-D) (Glutamate receptor ionotropic, AMPA 4) GRIA4JHUMAN
473 Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GluR-5) (GluR5) (Excitatory amino acid receptor 3) (EAA3) GRIK1_HUMAN
474 Glioma pathogenesis-related protein 1 precursor (GIiPR 1) (RTVP-1 protein) GLIP1_HUMAN
475 Iπterferoπ-alpha/beta receptor beta chain precursor (IFN-alpha-REC) (Type I interferon receptor) (IFN R) (Interferon alpha/beta INAR2_HUMAN
476 Interferon-gamma receptor beta chain precursor (Iπterferon-gamma receptor accessory factor-1) (AF-1) (Interferon-gamma transducer-1) 1NGR2-HUMAN
477 Interferon-alpha induced 11 5 kDa protein (p27) (lSG12(a) protein) INI7_HUMAN
478 Neuron specific protein family member 1 (Brain neuron cytoplasmic protein 1) (D4S234) NSGI-HUMAN
479 Nuclear pore glycoprotein p62 (62 kDa nucleopoπn) NUP62_HUMAN
480 lnterleukιn-12 receptor beta-1 chain precursor (IL-12R-beta1) (lnterleukιn-12 receptor beta) (IL-12 receptor beta component) I12R1JHUMAN
481 ATP-sensitive inward rectifier potassium channel 1 (Potassium channel, inwardly rectifying, subfamily J, member 1) (ATP-regulated potassium !RK1_HUMAN
482 G protein-activated inward rectifier potassium channel 1 (GIRK1) (Potassium channel, inwardly rectifying, subfamily J, member 3) IRK3_HUMAN
483 Inward rectifier potassium channel 4 (Potassium channel, inwardly rectifying, subfamily J, member 4) (Inward rectifier K(+) channel IRK4_HUMAN
484 G protein-activated inward rectifier potassium channel 4 (GIRK4) (Potassium channel, inwardly rectifying subfamily J, member 5) IRK5_HUMAN
485 G protein-activated mward rectifier potassium channel 2 (GIRK2) (Potassium channel, inwardly rectifying subfamily J1 member 6) 1RK6_HUMAN
486 lnterieukin-15 precursor (IL-15) IL15_HUMAN
487 Killer cell immunoglobulin like receptor 2DL1 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 1) (NKAT-1) K!2L1_HUMAN
488 Killer cell immunoglobulin like receptor 2DL2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 6) (NKAT-6) KI2L2_HUMAN
489 Killer cell immunoglobulin like receptor 2DL3 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 2) (NKAT-2) KI2L3_HUMAN
490 Killer cell immunoglobulin-like receptor 2DS2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 5) (NKAT-5) KI2S2_HUMAN
491 Killer cell immunoglobulin-like receptor 2DS4 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 8) (NKAT-8) KI2S4_HUMAN
492 Killer cell immunoglobulin-like receptor 3DL1 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 3) (NKAT-3) KI3L1 JHUMAN
493 Killer cell immunoglobuliπ-like receptor 3DL2 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 4) (NKAT-4) KI3L2_HUMAN
494 Matnn3 MATR3 HUMAN
495 Galectιn-7 (Gal-7) (HKL-14) (PI7) (p53-mduced protein 1) LEG7JHUMAN
495 Platelet-activaing factor acetylhydrolase IB alpha subunit (PAF acetylhydrolase 45 kDa subunit) (PAF-AH 45 kDa subunit) (PAF-AH LIS1JHUMAN
497 ERGIC-53 protein precursor (ER-Golgi intermediate compartment 53 kDa protein) (Lectin, maπnose-binding 1) (Gp58) (Intracellular mannose LMAN1_HUMAN
498 Interleukιn-6 receptor beta chain precursor (IL-6R beta) (Interleukin 6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oπcostabn M 1L6RB_HUMAN
499 Mpv17 protein MPV17_HUMAN
500 Metabotropic glutamate receptor 5 precursor (mGluR5) MGR5_HUMAN
501 Melanocorbn-3 receptor (MC3-R) MC3RJHUMAN
502 Probable G-protein coupled receptor 12 GPR12_HUMAN
503 Cell surface glycoprotein MUC18 precursor (Melanoma-associated antigen MUC18) (Melanoma associated antigen A32) (S-eπdo 1 endotheh MUC18_HUMAN
504 Melanoma-associated antigen 1 (MAGE-1 antigen) (Antigen MZ2-E) MAGA1_HUMAN
505 Leukemia inhibitory factor receptor precursor (UF-R) UFR_HUMAN
506 ϋgatin (Hepatocellular carcinoma-associated antigen 56) LIGA_HUMAN
507 Lamina-associated polypeptide 2 isofoπn alpha (Thymopoietin isoform alpha) (TP alpha) (Thymopoietin-related peptide isoform alpha) (TPRP LAP2AJ-IUMAN
508 Lamina-associated polypeptide 2 isoforms beta/gamma (Thymopoietin, isoforms beta/gamma) (TP beta/gamma) (Thymopoietin-related pepti LAP2B_HUMAN
509 Leptiπ receptor precursor (LEP-R) (OB receptor) (OB-R) (HuB219) LEPR-HUMAN
510 Interferon delta-1 precursor IFND-T.HUMAN
511 Complement-activating component of Ra-reactive factor precursor (EC 3421 -) (Ra-reactive factor serine protease p100) (RaRF) MASP1_HUMAN
512 Melatonin receptortype 1A (MeI-IA-R) (MeIIa melatonin receptor) MTR1AJHUMAN
513 Melatonin receptortype 1B (MeI IB-R) (MeHb melatonin receptor) MTR1B~HUMAN
514 Integππ alpha-E precursor (Mucosal lymphocyte-1 antigen) (HML-1 antigen) (CD103 antigen) (Integπn alpha-IEL) ITAE-HUMAN
515 Choline-phosphate cytidylyliransferase A (EC 2771S) (Phosphorylcholine transferase A) (CTP phosphocholiπe PCY1A_HUMAN
516 Potassium voltage-gated channel subfamily C member 1 (Voltage-gated potassium channel subunit Kv3 1) (Kv4) (NGK2) KCNC1_HUMAN
517 Phosphatidylmositol N-acetylglucosaminyltransferase subunit A (EC 241 198) (GIcNAc-PI synthesis protein) (Phosphatidylmositol- PlGA-HUMAN
518 Neurogenic locus notch homolog protein 1 precursor (Notch 1) (Translocation-associated notch protein TAN-1) NOTC1_HUMAN
519 NOV protein homolog precursor (NovH) (Nephroblastoma overexpressed gene protein homolog) NOV-HUMAN
520 Dolichyl-diphosphooligosacchande-protein glycosyltransferase 48 kDa subunit precursor (EC 241 119) (Oligosaccharyl transferase 48 kDa OST48_HUMAN
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Grou
PlD Descπption UniProt ACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3 521 Delta-type opioid receptor (DOR-1) OPRD_HUMAN 522 Kappa-type opioid receptor (KOR-1) OPRKJHUMAN 523 Nociceptin receptor (Orphaniπ FQ receptor) (Kappa-type 3 opioid receptor) (KOR-3) OPRX_HUMAN 524 Cytosolic phospholipase A2 (cPLA2) (Phospholipase A2 group IVA) [Includes Phospholipase A2 (EC 3 1 1 4) (Phosphatidylcholine PA24AJHUMAN 525 Melanocyte protein Pme! 17 precursor (Melanocyte lineage-specific antigen GP100) (Melanoma-associated ME20 antigen) (ME20M/ME20S) PME17JHUMAN 526 Leptin precursor (Obesity factor) (Obese protein) OB-HUMAN 527 Macrophage metalloelastase precursor (EC 342465) (HME) (Matrix metalloproteιnase-12) (MMP-12) (Macrophage elastase) (ME) MMP12_HUMAN 528 Collagenase 3 precursor (EC 3424 -) (Matrix metalloproteιnase-13) (MMP-13) MMP13_HUMAN 529 Peroxisomal biogenesis factor 19 (Peroxin 19) (Peroxisomal famesylated protein) (33 kDa housekeeping protein) PEX19JHUMAN 530 Parathyroid hormone receptor precursor (PTH2 receptor) PTHR2JHUMAN 531 Prostaglandin F2-alpha receptor (Prostanoid FP receptor) (PGF receptor) (PGF2 alpha receptor) PF2R_HUMAN 532 Calcium dependent phospholipase A2 precursor (EC 31 1 4) (Phosphatidylcholine 2-acylhydrolase) (PLA2-10) (Group V phospholtpase PA2G5JHUMAN 533 Neuropeptide Y receptor type 2 (NPY2-R) (NPY-Y2 receptor) NPY2RJHUMAN 534 OX-2 membrane glycoprotein precursor (CD200 antigen) (MyO33 protein) 0X2G_HUMAN 535 Olfactory receptor 1D4 (Olfactory receptor 17-30) (OR17-30) OR1D4_HUMAN 538 Olfactory receptor 1E2 (Olfactory receptor 17-93/17-135/17-136) (OR17-93) (OR17-135) (OR17-136) 0R1E2_HUMAN
537 Olfactory receptor 1G1 (Olfactory receptor 17-209) (OR17-209) 0R1G1 JHUMAN
538 Olfactory receptor3A1 (Olfactory receptor 17-40) (OR17-40) OR3A1_HUMAN
539 Olfactory receptor3A2 (Olfactory receptor17-228) (OR17-228) OR3A2 JHUMAN
540 Olfactory receptor 3A3 (Olfactory receptor 17-201) (OR17-201) OR3A3 JHUMAN
541 Olfactory receptor 3A4 (Olfactory receptor 17-24) (OR17-24) OR3A4JHUMAN
542 Pituitary adenylate cyclase activating polypeptide type I receptor precursor (PACAP type I receptor) (PACAP-R-1) PACR_HUMAN
543 Prostaglandin E2 receptor, EP2 subtype (Prostanoid EP2 receptor) (PGE receptor, EP2 subtype) PE2R2JHUMAN
544 Prostaglandin E2 receptor, EP3 subtype (Prostanoid EP3 receptor) (PGE receptor, EP3 subtype) (PGE2-R) PE2R3_HUMAN
545 Phosphatidylsenne synthase I (EC 278-) (PtdSer synthase-1) (PSS-1) (Seπne-exchange enzyme I) PTSS1 JHUMAN
546 Natural resistance-associated macrophage protein 1 (NRAMP 1) NRAM1_HUMAN
547 Natural resistance-associated macrophage protein 2 (NRAMP 2) (Divalent metal transporter 1) (DMT1) (OK/SW-cl 20) NRAM2_HUMAN
548 Prostacyclin receptor (Prostanoid IP receptor) (PGI receptor) (Prostaglandin I2 receptor) PI2RJHUMAN
549 Ran GTPase-achvating protein 1 RGP1 JHUMAN
550 Rap1 GTPase-actlvatlng protein 1 (RapiGAP) RGP2JHUMAN
551 RPE-retinal G protein-coupled receptor RGR_HUMAN
552 P2Y punnoceptor 1 (ATP receptor) (P2Y1) (Punnergic receptor) P2RY1_HUMAN
553 P2Y punnoceptor 2 (P2Y2) (P2U punnoceptor 1) (P2U1) (ATP (Punnergic receptor) P2RY2_HUMAN
554 P2Y punnoceptor 5 (P2Y5) (Punnergic receptor 5) (RB intron G-protein coupled receptor) P2RY5JHUMAN
555 Oligopeptide transporter, small intestine isoform (Peptide transporter 1) (Intestinal H(÷)/peptιde cotransporter) (Solute earner family 15 S15A1JHUMAN
556 Folate transporter 1 (Solute carrier family 19, member 1) folate transporter) (FOLT) (Reduced folate earner protein) (RFC) S19A1_HUMAN
557 Chloπde anion exchanger (DRA protein) (Down-regulated in adenoma) (Solute earner family 26, member 3) S26A3JHUMAN
558 Solute earner organic anion transporter family, member 1 A2 (Solute carrier family 21 , member 3) (Sodium-independent organic anion SO1 A2J-1UMAN
559 Amiloπde-sensitive sodium channel alpha-subunit (Epithelial Na+ channel alpha subumt) (Alpha ENaC) (Nonvoltage-gated sodium channel 1 SCNAA_HUMAN
560 Sodium- and chlonde-dependent GABA transporter 3 S6A11 JHUMAN
561 Sodium- and chlonde-dependent betaine transporter (Na+/CI- betaine/GABA transporter) (BGT-1) S6A12JHUMAN
562 Prostaglandin H2 D isomerase precursor (EC 53992) (Lipocalin-type prostaglandin D synthase) (Glutathione-iπdepeπdent PGD synthetase) PTGDS_HUMAN
563 Secretin receptor precursor (SCT-R) SCTR_HUMAN
564 Small inducible cytokine B5 precursor (CXCL5) (Epithelial-denved neutrophil activating protein 78) (Neutrophil-activating peptide SCYB5 HUMAN
565 Sodium/hydrogen exchanger 3 (Na(+)/H(+) exchanger 3) (NHE-3) SL9A3 JHUMAN
566 Transmembrane 4 Euperfamily member2 (Cell surface glycoprotein A15) (T-cell acute lymphoblastic leukemia associated antigen 1) (TALLA- T4S2JHUMAN
567 Transmembrane 4 superfamily member 4 (Intestine and liver tetraspan membrane protein) (IL-TMP) T4S4JHUMAN
568 T-cell surface protein tactile precursor (CD96 antigen) TACTJHUMAN
569 Stromal cell deπved factor 1 precursor (SDF-1) (CXCL12) (Pre-B cell growth stimulating factor) (PBSF) (hlRH) [Contains SDF-1 beta(3-72), SDF1_HUMAN
570 Ollgosaccharyl transferase STT3 subumt homolog (B5) (Integral membrane protein 1) (TMC) STT3_HUMAN
571 Ubiquinol-cytochrome c reductase iron-sulfur subumt, mitochondrial precursor (EC 1 102.2) (Rieske iron-sulfur protein) (RISP) UCRIJHUMAN
572 Vacuolar ATP synthase catalytic subumt A, ubiquitous isoform (EC363 14) (V-ATPase A subumt 1) (Vacuolar proton pump VATA1_HUMAN
573 Vacuolar ATP synthase catalytic subumt A, osteoclast isoform (EC 36314) (V ATPase A subumt 2) (Vacuolar proton pump VATA2 JHUMAN
574 Translocon-associated protein, alpha subumt precursor (TRAP-alpha) (Signal sequence receptor alpha subumt) (SSR alpha) SSRAJHUMAN
575 Translocon-associated protein, beta subumt precursor (TRAP-beta) (Sigjial sequence receptor beta subumt) (SSR-beta) SSRBJHUMAN
576 Neutral ammo acid transporter A (SATT) (Alanine/senne/cysteine/ threonine transporter) (ASCT1) SATT_HUMAN
577 Epilepsy holoprosencephaly candιdate-1 protein (EHOC-1) (Transmembrane protein 1) (GT334 protein) TMEM1_HUMAN
578 Tissue factor pathway inhibitor 2 precursor (TFPI-2) (Placental protein 5) (PP5) TFPI2_HUMAN
579 Alpha-taxihπ TAXA JHUMAN
580 Vasoactive intestinal polypeptide receptor 2 precursor (VIP-R-2) (Pituitary adenylate cyclase activating polypeptide type III receptor) VIPR2JHUMAN
581 Sodium- and chlonde-dependent creatine transporter 1 (CT1) (Creatine transporter 1) (Solute earner family 6 member 8) SC6A8JHUMAN
582 Sodium- and chlonde-dependent glycine transporter 1 (GIyTI) (GlyT-1) (Solute carrier family 6 member 9) SC6A9JHUMAN
583 TGF-beta receptor type Il precursor (EC 27 1 37) (TGFR-2) (TGF-beta type Il receptor) TGFR2 JHUMAN
584 Voltage-dependent anion selective channel protein 2 (VDAC-2) (hVDAC2) (Outer mitochondrial membrane protein poππ 2) VDAC2JHUMAN
585 Tumor necrosis factor ligand superfamily member 6 (FAS antigen (Apoptosis antigen ligand) (APTL) (CD178 antigen) TNFL6 JHUMAN
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Group
PlD Descnption UniProtACC reticulum Nuclear cellular skeletal somal anchor soma! 1 2 3
781 Transmembrane protein Tmp21 precursor (21 kDa Transmembrane trafficking protein) (p24delta) (S31III125) (S31I125) (Tmp-21-l) TMP21 JHUMAN
782 Tubenn (Tuberous sclerosis 2 protein) TSC2_i-ΪUMAN
783 Chromaffin granule amine transporter (Vesicular amine transporter 1) (VAT1) (Solute earner family 18 member 1) VMAT1 JHUMAN
784 Retinoic aαd receptor responder protein 1 (Tazarotene induced gene 1 protein) (RAR-responsive protein TIG1) TIG1_HUMAN 785 Secreted Ly-6/uPAR related protein 1 precursor (SLURP-1) (ARS component B) (ARS(Component B)-81/S) (Anti-neoplastic uπnary protein) SLUR1_HUMAN
788 Tumor necrosis factor ligand superfamily member 10 (TNF-related apoptosiε inducing ligand) (TRAIL protein) (Apo 2lιgand) (Apo-2L) TNF10_HUMAN 787 Putative tyrosine protein phosphatase TPTE (EC 3 1 348) TPTE_HUMAN 788 Tyrosyl-tRNA synthetase, cytoplasmic (EC 6 1 1 1) (Tyrosyl-tRNA ligase) (TyrRS) SYYCJ-IUMAN 789 Vacuolar assembly protein VPS41 homolog (S53) VPS4ΪJ-1UMAN 790 Thrombospondin-3 precursor TSP3JHUMAN 791 Stanniocalcin 1 precursor (STC-1) STC1_HUMAN 792 Wnt-3a protein precursor WNT3A_HUMAN 793 Wnt-3 proto-oncogene protein precursor WNT3_HUMAN 794 Wnt-4 protein precursor (UNQ426/PRO864) WNT4 JHUMAN 795 Wht-7b protein precursor WNT7B_HUMAN 796 Solute earner family 12 member2 (Bumetanide-sensitive sodium- (potassium) chloπde cotransporter 1) (Basolateral Na-K-Cl symporter) S12A2_HUMAN 797 Solute earner family 12 member 3 (Thiazide sensitive sodium chloπde cotransporter) (Na Cl symporter) S12A3_HUMAN 798 XG glycoprotein precursor (Protein PBDX) XG_HUMAN 799 Membrane transport protein XK (Kx antigen) (KeII complex 37 component) XKJHUMAN 800 Tπcarboxylate transport protein mitochondπal precursor (Citrate transport protein) (CTP) (Tncarboxylate earner protein) TXTP-HUMAN 801 ADAM 17 precursor (EC 342486) (A disintegπn and metalloproteinase domain 17) (TNF alpha converting enzyme) (TNF-alpha convertase) ADA17JHUMAN 802 Small inducible cytokine A20 precursor (CCL20) (Macrophage inflammatory protein 3 alpha) (MIP 3 alpha) (Liver and activation- CCL20_HUMAN 803 Small inducible cytokine A7 precursor (CCL7) (Monocyte chemotactic protein 3) (MCP-3) (Monocyte chemoattractant protein 3) (NC28) CCL7 JHUMAN 804 Small inducible cytokine A8 precursor (CCL8) (Monocyte chemotactic protein 2) (MCP 2) (Monocyte chemoattractant protein 2) (HC14) CCLβlHUMAN 805 CD81 antigen (26 kDa cell surface protein TAPA-1) (Target antiproliferative antibody 1) CD81_HUMAN 806 Contactin associated protein 1 precursor (Caspr) (Caspri) (Neurexin 4) (Neurexin IV) (p190) CNTP1JHUMAN 807 Cell division control protein 42 homolog (G25K GTP-binding protein) CDC42_HUMAN 808 Beta-secretase 1 precursor (EC 342346) (Beta-site APP cleaving enzyme 1) (Beta site amyloid precursor protein cleaving enzyme 1) BACE1_HUMAN 809 Anthrax toxin receptor 2 precursor (Capillary morphogenesis proteιn-2) (CMG-2) ANTR2_HUMAN 810 Defender against cell death 1 (DAD-1) DAD1JHUMAN 811 Calmodulin (CaM) CALM-HUMAN 812 Retπal-specificATP-bmding cassette transporter (ATP-binding cassette, sub-family A member 4) (RlM ABC transporter) (RlM ABCA4_HUMAN 813 Brain acid soluble protein 1 (BASP1 protein) (Neuronal axonal protein NAP-22) (Neuronal tissue eππched acidic protein) 814 B(0,+)-type amino acid transporter 1 (B(O +)AT) (Glycoprotein- associated ammo acid transporter bo +AT1 ) BAT1_HUMAN 815 Bladder cancer-associated protein (Bladder cancer 10 kDa protein) (Bd 0) BC10 HUMAN 816 Adapter-related protein complex 1 sigma 1 A subunit (Sigma-adaptin 1A) (Adaptor protein complex AP 1 Sigma 1A subunit) (Golgt adaptor HA AP1S1_HUMAN 817 Adapter-related protein complex 2 beta 1 subunit (Beta adaptin) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit) (Clathnn AP2B1_HUMAN 818 Adapter-related protein complex 3 Sigma 2 subunit (Sigma-adaptin 3b) (AP-3 complex Sigma 3B subunit) (Sigma 3B-adaptιn) AP3S2 JHUMAN 819 Aortic aneurysm-associated antigenic proteiπ-40 (AAAP-40) (Microfibπl associated glycoprotein 3) (MAGP 3) (Fragment) AP40 JHUMAN
820 AADDAAMMTTSS--1122 pprreeccuurrssoorr ((EECC 3344..2244 --)) ((AA ddiissiinntteeggππnn aanndd mmeettaalllloopprrootteeiinnaassee wwiitthh tthhrroommbboossppoonnddiiππ mmoottiiffss 1122)) ((AADDAAMM--TTSS 1122)) ((AADDAAMM--TTSS1122)) ATS12JHUMAN
821 AADDAAMMTTSS--2200 pprreeccuurrssoorr ((EECC 33442244 --)) ((AA ddiissmmtteeggππππ aanndd mmeettaalllloopprrootteeiinnaassee wwiitthh tthhrroommbboossppoonnddiiππ mmoottiiffss 2200)) ((AADDAAMM--TTSS 2200)) ((AADDAAMM--TTSS2200)) ATS20JHUMAN
822 AACCAA pprrootteeiinn ((FFraraggmmeennttss)) ACAJHUMAN
823 AAmmiilloonnddee--sseennssiittiivvee ccaattiioonn cchhaannnneell 22 nneeuurroonnaall ((BBrraaiinn ssooddiiuumm cchhaannnneell 22)) ((BBNNaaCC22)) BNA2J-IUMAN
824 AADDAAMM 88 pprreeccuurrssoorr ((EECC 33442244 )) ((AA ddiissiinntteeggππnn aanndd mmeettaalllloopprrootteeiinnaassee ddoommaaiinn 88)) ((CCeellll ssuurrffaaccee aannttiiggeenn MMSS22)) ((CCDD115566aa aannttiiggeenn)) ((CCDD115566)) ADAM8JHUMAN
825 ADP-πbosylation factor 1 ARF1 JHUMAN
826 Beta-defensiπ 1 precursor (BD-1) (Defensin, beta 1) (h.BD-1) BD01JHUMAN
827 C(audιn-10 (OSP like protein) CLD10_HUMAN
828 Claudιn-12 CLD12JHUMAN
829 Claudiπ-17 (UNQ758/PRO1489) CLD17JHUMAN
830 Claudιn-18 (UNQ778/PRO1572) CLD18JHUMAN
831 Claudιn-20 CLD20 JHUMAN
832 Claudιn-2 (UNQ705/PRO1356) (SP82) CLD2JHUMAN
833 Claudιn-8 (UNQ779/PRO1573) CLD8JHUMAN
834 Delta-like protein precursor (DLK) (pG2) [Contains Fetal antigen 1 (FA1)] DLKJHUMAN
835 Butyrophilin subfamily 3 member A2 precursor BT3A2JHUMAN
836 Gap junction alpha-10 protein (Connexin 59) (Cx59) (Connexin 58) (Cx58) CXA10JHUMAN
837 Coxsackievirus and adenovirus receptor precursor (Coxsackievirus B adenovirus receptor) (hCAR) (CVB3 binding protein) CXARJHUMAN
838 C-X-C chemokine receptor type 4 (CXC R4) (CXCR-4) (Stromal cell- derived factor 1 receptor) (SDF-1 receptor) (Fuεin) (Leukocyte-denved CXCR4JHUMAN
839 Coatomerzeta-1 subunit (Zeta 1 coat protein) (Zeta-1 COP) (CGl-120) (HSPC181) COPZ1JHUMAN
840 Voltage-dependent calcium channel gamma-7 subunit (Neuronal voltage- gated calcium channel gamma 7 subunit) CCG7JHUMAN
841 3-keto-steroid reductase (EC 1 1 1 270) (Estradiol 17-beta- dehydrogenase 7) (EC 1 1 1 62) (17-beta-HSD 7) (17-beta-hydroxysteroιd DHB7 JHUMAN
842 HERV-T_19q1311 provirus ancestral Env polyproteiπ precursor (Envelope polyprotein) (HERV-T Env protein) [Includes Surface protein (SU) ENT1 JHUMAN
843 HERV-F(c)1_Xq21 33 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (Fdenv) (HERV-Fdenv) [Contains Surface EFC1 JHUMAN
844 HERV-F(c)2_7q362 provirus ancestral Env polyprotein (Envelope polyprotein) (Fc2deltaeπv) [Includes Surface protein (SU)1 EFC2JHUMAN
845 Conserved oligomenc Golgi complex component 7 (UNQ3082/PRO10013) COG7JHUMAN
Figure imgf000203_0001
Figure imgf000204_0001
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Group
PID Description UniProt ACC reticulum Nuclear cellular skeletal somal anchor soma! 1 2 3
97Θ Tumor necrosis factor-inducible protein TSG-β precursor (TNF- stimulated gene 6 protein) (Hyaluronate-binding protein) TSG6_HUMAN
977 Mitochondria! import inner membrane translocase subunit TIM13 A TI13A_HUMAN
978 Protein transport protein SEC61 gamma subunit SC61GJHUMAN
979 WD repeat protein S (BMP2-ιπduced 3-kb gene protein) WDRS-HUMAN
980 Mitochondna! import inner membrane translocase subunit TIM10 TIM10_HUMAN
981 Somatostatin precursor [Contains Somatostatιn-28, Somatostatιn-14] SMS_HUMAN
982 Usher syndrome type 3 protein USH3A_HUMAN
983 Totl-interleukin 1 receptor domain containing adapter protein (TIR domain-containing adapter protein) (MyD88 adapter-like protein) TlRAP_JHUMAN
984 Synovial stimulatory protein p205 (Fragments) SNSP_HUMAN
985 Alpha-2,8-sιalyltransferase 8F (EC 2499 -) (ST8Sιa Vl) SIA8FJHUMAN
986 Vacuolar ATP synthase subunit d (EC 36314) (V-ATPase d (Vacuolar proton pump d subunit) (V-ATPase AC39 subunit) (V-ATPase VAODJHUMAN
987 Fractalkine precursor (CX3CL1) (Neurotactm) (CX3C membrane-anchored chemokine) (Small inducible cytokine D1) X3CL1_HUMAN
988 Veside-associated membrane protein 2 (VAMP-2) (Synaptobreviπ 2) VAM2_HUMAN
989 Zona pellucida sperm binding protein 1 precursor (Zona pellucida glycoprotein 1) (Zp-1) ZP1_HUMAN
990 HP47 protein (Fragment) P78328_HUMAN
991 Protein tyrosine phosphatase receptor omicron P78399_HUMAN
992 Somatomammotropin (hormone) (Fragment) P78451_HUMAN
993 Leukocyte antigen (Fragment) P78376JHUMAN
994 Heavy chain of HLA-A antigen (Fragment) P79484_HUMAN
995 HLA-A2 antigen (Fragment) P79495_HUMAN
996 HLA-A (Fragment) P79557_HUMAN
997 Butyrophllin P78409_HUMAN
998 MHC class I molecule (Stress inducible class I homolog) P79525_HUMAN
999 HLA-B protein P79612_HUMAN
1000 Lectiπ-like oxidized LDL receptor (Lectin-typa oxidized LDL receptor) (LOX1) (Oxidised low density lipoprotein (Lectin-like) receptor 1) P78380_HUMAN
1001 HLA class I histocompatibility antigen, A-80 alpha chain precursor (MHC class I antigen A1SO) (Aw-80) (A-1) 1A80_HUMAN
1002 HLA class I histocompatibility antigen, B-40 alpha chain precursor (MHC class I antigen BMO) (Bw-60) 1B40_HUMAN
1003 HLA class I histocompatibility antigen, Cw-15 alpha chain precursor (MHC class I antigen Cw*15) 1C15_HUMAN
1004 CMRF35-A antigen precursor (CMRF-35) CM35AJHUMAN
1005 Leukocyte surface antigen CD47 precursor (Antigenic surface determinant protein OA3) (Integπn associated protein) (IAP) (MER6) CD47_HUMAN
1006 Early activation antigen CD69 (Early T-cell activation antigen p60) (GP32/28) (Leu-23) (MLR-3) (EA1) (BL-AC/P26) (Activaton inducer CD69_HUMAN
1007 CD83 antigen precursor (Cell surface protein HB15) (B-cell activaton protein) CD83_HUMAN
1008 Contactin 2 precursor (Axonin-1) (Axonal glycoprotein TAG-1) (Transient axonal glycoprotein 1) (TAX-1) CNTN2_HUMAN
1009 Collagen alpha 3(IV) chain precursor (Goodpasture antigen) CO4A3_HUMAN
1010 Collagen alpha 1(VlI) chain precursor (Long-chain collagen) (LC collagen) CO7A1_HUMAN
1011 Collagen alpha 1(X) chain precursor COAA1_HUMAN
1012 Sulfonylurea receptor 1 ABCCe^HUMAN
1013 Apoptosis regulator BAX membrane isoform alpha BAXA_HUMAN
1014 Adapter-related protein complex 1 beta 1 subunit (Beta-adaptiπ 1) (Adaptor protein complex AP-1 beta-1 subunit) (Golgi adaptor HA1/AP1 AP1B1JHUMAN
1015 Caveolιn-1 CAV1_HUMAN
1016 Glutamyl aminopeptidase (EC 3411 7) (EAP) (Ammopeptidase A) (APA) (Differentiation antigen gp160) AMPE-HUMAN
1017 Adenylyl cydase-associated protein 1 (CAP 1) CAP1JHUMAN
1018 Aspartyl/asparaginyl beta-hydroxylase (EC 1 1411 16) (Aspartate beta- hydroxylase) (ASP beta hydroxylase) (Peptide-aspartate beta- ASPH_HUMAN
1019 Adenylate cyclase, type I (EC 461 1) (ATP pyrophosphate-lyase 1) (Ca(2+)/calmodulιn activated adenylyl cyclase) ADCY1_HUMAN
1020 Adenylate cyclase type M (EC 46 1 1) (ATP pyrophosphate-lyase 2) (Adenylyl cyclase 2) ADCY2_HUMAN
1021 Apoptosis regulator BcI-X (BcI 2-lιke 1 protein) BCLX_HUMAN
1022 Copper-transporting ATPase 1 (EC 3634) (Copper pump 1) (Menkes disease-associated protein) ATP7A_HUMAN
1023 Potential phospholipid transporting ATPase IH (EC 3631) (ATPase class I type 11A) (ATPase IS) AT11A_HUMAN
1024 Amyloid like protein 2 precursor (Amyloid protein homolog) (APPH) (CDEI-box binding protein) (CDEBP) APLP2_HUMAN
1025 Adrenocorticotropic hormone receptor (ACTH receptor) (ACTH-R) (Melanocortιn-2 receptor) (MC2-R) (Adrenocorticotropiπ receptor) ACTHRJHUMAN
1026 Bullous pemphigoid antigen 1 isoforms 1/2/3/4/5/8 (230 kDa bullous pemphigoid antigen) (BPA) (Hemidesmosomal plaque protein) (Dystonia BPA1_HUMAN
1027 Voltage-dependent N-type calcium channel alpha-1 B subunit (Voltage- gated calcium channel alpha subunit Cav22) (Calcium channel, L CAC1 B_HUMAN
1028 Voltage-dependent L-type calcium channel alpha-ID subunit (Voltage- gated calcium channel alpha subunit Cav1 3) (Calcium channel, L CAC1D_HUMAN
1029 Voltage-dependent L-type calcium channel beta-1 subunit (CAB1) (Calcium channel voltage dependent, beta 1 subunit) CACB1_HUMAN
1030 Plasma membrane calcium transporting ATPase 2 (EC 3638) (PMCA2) (Plasma membrane calcium pump isoform 2) (Plasma membrane c. AT2B2_HUMAN
1031 Calcium-transporting ATPase type 2C. member 1 (EC 3638) (ATPase 2C1) (ATP-dependent Ca(2+) pump PMR1) (HUSSY-28) AT2C1JHUMAN
1032 ATP synthase lipid-bindmg protein, mitochondnal precursor (EC 36314) (ATP synthase proteolipid P2) (ATPase protein 9) AT5G2_HUMAN
1033 Clathnn heavy chain 1 (CLH-17) CLH1_HUMAN
1034 Ankynn 2 (Brain ankynn) (Ankynn B) (Ankynn, πonerythroid) ANK2_HUMAN
1035 Activin receptortype I precursor (EC 271 37) (ACTR-I) (Seπne/threonine-proteiπ kinase receptor R1) (SKR1) (Activin ACVR1_HUMAN
1036 Neuronal acetylcholine receptor protein, beta-3 chain precursor ACHB3_HUMAN
1037 Acetylcholine receptor protein, delta chain precursor ACHD_HUMAN
1038 Acetylcholine receptor protein, epsilon chain precursor ACHE_HUMAN
1039 Voltage-dependent calcium channel gamma-1 subunit (Dihydropyπdine- sensitive L-type, skeletal muscle calcium channel gamma subunit) CCG1_HUMAN
1040 ADP-πbosyl cyclase 2 precursor (EC 3225) (Cyclic ADP-πbose hydrolase 2) (cADPr hydrolase 2) (Bone marrow stroma! antigen BST1JHUMAN
Figure imgf000206_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Group
PID Descnption UπiProt ACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
1106 Lamιπ B2 LAM2_HUMAN Y
1107 Putative mucin core protein 24 precursor (MULTI-glycosylated core protein 24) (MGC-24) (MUC 24) (CD164 antigen) MUC24_HUMAN
1108 Mucin 2 precursor (Intestinal mucin 2) MUC2_HUMAN
1109 Mucin 3A (Intestinal mucin 3A) (Fragments) MUC3A_HUMAN
1110 Protein KIAA0195 K0195_HUMAN
1111 lnterleukιn-9 receptor precursor (IL-9R) IL9R_HUMAN
1112 lnterleukιn-1 receptor-like 1 precursor (ST2 protein) ILRLIJHUMAN
1113 Nomn precursor (Nome disease protein) NDP_HUMAN
1114 Large neutral amino acids transporter small subunit 1 (L-type acid transporter 1) (4F2 light chain) (4F2 LC) (4F2LC) I_AT1_HUMAN
1115 Induced myeloid leukemia cell differentiation protein McH MCLΪJIUMAN
1116 Interferon-induced transmembrane protein 2 (Interferon-inducible protein 1-8D) IFM2_HUMAN
1117 interferon-induced transmembrane protein 3 (Interferon-inducible protein 1-8U) IFM3_HUMAN
1118 Lysyl oxidase homolog 1 precursor (EC 143 -) (Lysyl oxidase-like protein 1) (LOL) LOXLΪJHUMAN
1119 Phosphate earner protein mitochondπal precursor (PTP) (OK/SW- cl 48) MPCPJHUMAN
1120 Protein kinase C, delta type (EC 271 -) (nPKC-delta) KPCD_HUMAN
1121 NKG2-E type Il integral membrane protein (NKG2-E activating NK receptor) (NK cell receptor E) NKG2EJHUMAN
1122 Potassium voltage gated channel subfamily C member 4 (Voltage gated potassium channel subunit Kv34) (KSHIIIC) KCNC4_HUMAN
1123 Potassium voltage-gated channel subfamily H member 2 (Voltage gated potassium channel subunit Kv11 1) (Ether-a-go-go related gene KCNH2_JHUMAN
1124 Pancreatitis-associated protein 1 precursor (Regenerating islet- derived protein 3 alpha) PAP1_HUMAN
1125 Mitochondnal processing peptidase alpha subunit, mitochondπal precursor (EC 342484) (Alpha-MPP) (P-55) (HA1523) MPPAJHUMAN
1126 Phosphatidylinositol-glycan biosynthesis, class F protein (PIG-F) PIGF_HUMAN
1127 Neurogenic locus notch homolog protein 2 precursor (Notch 2) NOTC2_HUMAN
1128 CDC42 effector protein 1 (Serum protein MSE55) MSE55_HUMAN
1129 Melanocyte stimulating hormone receptor (MSH-R) (Melanotropin receptor) (Melanocortiπ 1 receptor) (MC1-R) MSHR_HUMAN
1130 Basic salivary proline-nch protein 3 precursor (Parotid salivary glycoprotein G1) (Proline-πch protein G1) PRB3_HUMAN
1131 Glutamate [NMDA] receptor subunit zeta 1 precursor (N-methyl-D- aspartate receptor subunit NR1) NMDZ1_HUMAN
1132 Peπpheral myelin protein 22 (PMP 22)
1133 Inositol polyphosphate 5-phosphatase OCRL-1 (EC 31 336) (Lowe's oculocerebrorenal syndrome protein) OCRL_HUMAN
1134 Protein kinase C, zeta type (EC 271 37) (nPKC-zeta) KPCZ-HUMAN
1135 Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor) PTHR1_HUMAN
1136 Basement membrane-specific heparan sulfate proteoglycan core protein precursor (HSPG) (Perlecan) (PLC) PGBM_HUMAN
1137 Polycyεtin 1 precursor (Autosomal dominant polycystic kidney disease protein 1) PKD1_HUMAN
1138 Pregnancy-specific beta-1 -glycoprotein 4 precursor (PSBG-4) (PSBG-9) PSG4_HUMAN
1139 Pregnancy-specific beta-1-glycoproteιn 6 precursor (PSBG 6) PSG6_HUMAN
1140 Pregnancy-specific beta-1-g[ycoproteιn 9 precursor (PSBG-9) (Pregnancy-specific glycoprotein 9) (Pregnancy-specific beta-1 PSG9_HUMAN
1141 Protocadheπn 1 precursor (Protocadhenn 42) (PC42) (Cadheπn-like protein 1) PCDH1_HUMAN
1142 Renal sodium-dependent phosphate transport protein 2 (Sodium/phosphate cotransporter 2) (Na(+)/Pι cotransporter 2) (Renal sodium-phospt NPT2_HUMAN
1143 P protein (Melanocyte-specific transporter protein) (Pink-eyed dilution protein homolog) P_HUMAN
1144 1-phosphatidylιnosιtoM,5-bιsphosphate phosphodiesterase beta 3 (EC 3 1 4 11) (Phosphoinositide phospholipase C) (PLC-beta 3) PLCB3_HUMAN
1145 Sodium channel beta-1 subunit precursor SCN1B_HUMAN
1146 Pro-neuregulin-1 precursor (Pro-NRG1) [Contains Neuregulιn-1 (Neu differentiation factor) (Heregulin) (HRG) (Breast cancer cell NRG1_HUMAN
1147 Regulator of G-proteιπ signaling 1 (RGS1) (Eariy response protein 1R20) (B-cell activation protein BL34) RGS1_HUMAN
1148 Rhesus blood group-associated glycoprotein (Rhesus blood group- associated ammonia channel) (Erythrocyte plasma membrane 50 kDa RHAG__HUMAN
1149 Blood group Rh(D) polypeptide (Rhesus D antigen) (RHXIII) (Rh polypeptide 2) (RhPII) RHD-HUMAN
1150 Dihydroorotate dehydrogenase mitochondπal precursor (EC 1 331) (Dihydroorotate oxidase) (DHOdehase) PYRD_HUMAN
1151 Procollagen-lysine 2-oxoglutarate 5 dioxygenase 1 precursor (EC 1 1411 4) (Lysyl hydroxylase 1) (LH1) PLOD1_HUMAN
1152 Proteolipid protein 2 (Intestnal membrane A4 protein) (Differentiation-dependent protein A4) (Proteolipid protein 2) PLP2_HUMAN
1153 Sodium channel protein type VII alpha subunit (Putative voltage-gated sodium channel alpha subunit Nax) (Sodium channel protein, cardiac SCN7A__HUMAN
1154 Semenogelιn-2 precursor (Semenogelin II) (SGlI) SEMG2~ HUMAN
1155 Small inducible cytokine B9 precursor (CXCL9) (Gamma interferon induced monokine) (MlG) SCYB9_HUMAN
1156 Neutral and basic amino acid transport protein rBAT (B(0,+)-type acid transport protein) (NBAT) (D2H) SLC31_HUMAN
1157 ROD outer segment membrane protein 1 (ROSP1) ROM1_HUMAN
1158 Macrophage-stimulating protein receptor precursor (EC 271 112) (MSP receptor) (p185-Ron) (CDW136) (CD136 antigen) RON_HUMAN
1159 Tyrosine-protein kinase transmembrane receptor ROR1 precursor (EC 271 112) (Neurotrophic tyrosine kinase, receptor-related 1) ROR1_HUMAN
1160 Tyrosine-protein kinase transmembrane receptor ROR2 precursor (EC 27 1 112) (Neurotrophic tyrosine kinase, receptor-related 2) ROR2_HUMAN
1161 Trefoil factor 3 precursor (Intestinal trefoil factor) (hP1 B) TFF3_HUMAN
1162 TGF-beta receptor type 111 precursor (TGFR-3) (Transforming growth factor beta receptor 111) (Betaglycan) TGBR3__HUMAN
1163 Antigen peptide transporter 1 (APT1) (Peptide transporter TAP1) (ATP- binding cassette, sub family B, member 2) (Peptide transporter PSF1)TAP1_HUMAN
1164 Synaptic vesicular amine transporter (Monoamine transporter) (Vesicular amine transporter 2) (VAT2) (Solute carrier family 18, VMAT2_HUMAN
1165 Testican-1 precursor (SPOCK protein) T1C1_HUMAN
1166 Aπgiopoietin 1 receptor precursor (EC 271 112) (Tyrosine-protein kinase receptor TIE 2) (Tyrosine-protein kinase receptor TEK) (P140 TIE2_HUMAN
1167 Sperm-associated antigen 11 precursor (EP2 protein) (Sperm antigen HE2) SPA11_HUMAN
1168 Spectπn beta chain, brain 1 (Spectrin, non-erythroid beta chain (Beta-ll spectrin) (Fodrin beta chain) SPTB2_HUMAN
1169 Vigilin (High density lipoprotein binding protein) (HDL-bindiπg protein) VIGLN_HUMAN
1170 Sodium-dependent dopamine transporter (DA transporter) (DAT) SC6A3_HUMAN
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Grou
PID Description UniProtACC reticulum Nuclear cellular skeletal somal anchor soma! 1 2 3
1431 Gamma-ammobutyπc-acid receptor aIpha-6 subunit precursor (GABA(A) receptor) GBRA6 JHUMAN
1432 GPI-anchored protein p137 (p137GPI) (Membrane component chromosome 11 surface marker 1) GP137_HUMAN
1433 Cadhenn-refated tumor suppressor homolog precursor (Fat protein homolog) FATH HUMAN
1434 Homocysteiπe-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (Methyl methanesulfonate (MMF) inducible HERPUJHUMAN
1435 Glutamate receptor, ionotropic kaiπate 4 precursor (Glutatnate receptor KA-1) (KA1) (Excitatory ammo acid receptor 1) (EAA1) GRIK4_HUMAN 1438 Glutamate receptor, ionotropic kainate 5 precursor (Glutamate receptor KA 2) (KA2) (Excitatory amino acid receptor 2) (EAA2) GRIK5_HUMAN
1437 lmportin beta-1 subunit (Karyopheππ beta-1 subunit) (Nuclear factor P97) (Importin 90) IMB1_HUMAN
1438 Early placenta insulin-like peptide precursor (EPIL) (Placentin) (Insulin-like peptide 4) INSL4_HUMAN
1439 Sodium/bile acid cotransporter (Na(+)/bile acid cotransporter) (Na(+)/taurocholate transport protein) (Sodium/taurocholate NTCPJHUMAN
1440 NT-3 growth factor receptor precursor (EC 271 112) (Neurotrophic tyrosine kinase receptor type 3) (TrkC tyrosine kinase) (GP145-TrkC) NTRK3_HUMAN
1441 Indian hedgehog protein precursor (IHH) (HHG-2) IHHJHUMAN
1442 lnterleukιπ-11 receptor alpha chain precursor (IL-11R-alpha) (IL-11RA) I11RA_HUMAN
1443 lnterieukiπ-13 receptor alpha-2 chain precursor (lnterieukιn-13 binding protein) I13R2_HUMAN
1444 Type I ιnosιtol-1 ,4,5-tnsphosphate S phosphatase (EC 31 358) (5PTase) 15P1 JHUMAN
1445 Receptor tyrosine-protein kinase erbB-4 precursor (EC 271 112) (p180erbB4) (Tyrosine kinase-type cell surface receptor HER4) ERBB4JHUMAN
1446 ATP-sensitive inward rectifier potassium channel 11 (Potassium channel inwardly rectifying, subfamily J, member 11) (Inward IRK11JHUMAN Y
1447 ATP-sensitive inward rectifier potassium channel 12 (Potassium channel, inwardly rectifying, subfamily J, member 12) (Inward IRK12_HUMAN Y
1448 ATP-sensitive inward rectifier potassium channel 8 (Potassium channel, inwardly rectifying, subfamily J, member 8) (Inwardly rectifier K(+) IRK8_HUMAN Y
1449 Inward rectifying K(+) channel negative regulator Kιr22v IRKI-HUMAN
1450 Killer cell immunoglobulin like receptor 2DS1 precursor (MHC class I NK cell receptor Eb6 Actl) KI2S1JHUMAN
1451 Killer ceil immunoglobuliπ-like receptor 2DS3 precursor (MHC class I NK cell receptor) (Natural killer associated transcript 7) (NKAT-7) KI2S3JHUMAN
1452 Kilter cell immunoglobulin like receptor 2DS5 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 9) (NKAT-9) KI2S5_HUMAN
1453 Killer cell immunoglobulin like receptor 3DS1 precursor (MHC class I NK cell receptor) (Natural killer associated transcnpt 10) (NKAT-10) KI3S1 JHUMAN
1454 Insulin-like growth factor binding protein 7 precursor (IGFBP-7) (IBP-7) (IGF-binding protein 7) (MAC25 protein) (Prostacyclin- IBP7_HUMAN
1455 Intercellular adhesion molecule-4 precursor (lCAM-4) (Landsteiner- Wiener blood group glycoprotein) (LW blood group protein) (CD242 ICAM4JHUMAN
1456 Inter-alpha-trypsin inhibitor heavy chain H4 precursor (ITI heavy chain H4) (Inter-alpha-inhibitor heavy chain 4) (Inter-alpha-trypsin 1TIH4_HUMAN
1457 Inositol 1,45-tπsphosphate receptor type 1 (Type 1 inositol 1,4,5-tπsphosphate receptor) (Type 1 lnsP3 receptor) (IP3 receptor ITPR1_HUMAN
1458 Inositol 1,4,5-tπεphosphate receptor type 2 (Type 2 inositol 1,4,5-trιsphosphate receptor) (Type 2 lnsP3 receptor) (IP3 receptor ITPR2JHUMAN
1459 Inositol 1,4,5-tnsphosphate receptor type 3 (Type 3 inositol 1 ,4,5-tnsphosphate receptor) (Type 3 lnsP3 receptor) (IP3 receptor ITPR3_HUMAN
1460 Squalene monooxygeπase (EC 1 14997) (Squalene epoxidase) (SE) ERG1JHUMAN
1461 C-4 methylsterol oxidase (EC 1 141372) (Methylsterol monooxygenase) ERG25JHUMAN
1462 Voltage-gated potassium channel beta-1 subunit (K(+) channel beta-1 subunit) (Kv-beta-1) KCAB1 J-IUMAN
1463 Lamiπiπ alpha-4 chain precursor LAMA4J-1UMAN
1464 Metabotropic glutamate receptor 3 precursor (mGluR3) MGR3_HUMAN
1465 Metabotropic glutamate receptor 4 precursor (mGluR4) MGR4JHUMAN
1466 Metabotropic glutamate receptor 7 precursor (mGluR7) MGR7J-1UMAN 1487 Membrane-bound transcnptioπ factor site-1 protease precursor (EC 3421 -) (Sιte-1 protease) (Subtιlιsin/kexin-ιsozyme-1) (SKI-1) MBTP1 JHUMAN
1468 Transmembrane glycoprotein NMB precursor (Transmembrane glycoprotein HGFIN) (UNQ1725/PRO992S) GPNMBJHUMAN
1469 Lamm B receptor (Integral nuclear envelope inner membrane protein) (LMN2R) LBRJHUMAN
1470 Pro-MCH vaπant (Pro-melanιn-coπcentratιng hormone-like 1 protein) MCHL1 JHUMAN
1471 Mitochondnal import receptor subunit TOM34 (Translocase of outer membrane 34 kDa subunit) (hTom34) OM34_HUMAN
1472 Lysoεomal-associated transmembrane protein 4A (Golgi 4-transmembrane spanning transporter MTP) (UNQ1846/PRO3574) MTRPJHUMAN
1473 Potassium voltage-gated channel subfamily B member 1 (Voltage-gated potassium channel subunit Kv21) (h-DRK1)
1474 Membrane protein MLC1 MLC1_HUMAN
1475 MLN 64 protein (StAR related lipid transfer protein 3) (SIARD3) domain-containing protein 3) (CAB1 protein) MLN64JHUMAN
1476 Opioid binding protein/cell adhesion molecule precursor (OBCAM) (Opioid-binding cell adhesion molecule) (OPCML) OPCM_HUMAN
1477 Leukotnene B4 receptor 1 (LTB4-R 1) (P2Y purinoceptor 7) (Chemoattractant receptor-like 1) LT4R1 JHUMAN
1478 Latent transforming growth factor beta binding protein, isoform 1L precursor (LTBP-1) (Transforming growth factor beta-1 binding protein LTB1 LJHUMAN
1479 Latent transforming growth factor-beta-binding protein 2 precursor (LTBP-2) LTBP2 JHUMAN
1480 Monocyte to macrophage differentiation protein (Progestin and adipoQ receptor family member Xl) PAQRBJHUMAN
1481 Glutamate [NMDA] receptor subunit epsilon 3 precursor (N-methyl D-aspartate receptor subtype 2C) (NR2C) (NMDAR2C) NMDE3JHUMAN
1482 Programmed cell death protein 1 precursor (Protein PD-1) (hPD-1) PDCD1 JHUMAN
1483 cGMP-inhibited 3',5'-cyclιc phosphodiesterase A (EC 31 417) (Cyclic GMP inhibited phosphodiesterase A) (CGI-PDEA) PDE3AJHUMAN
1484 Protein kinase C, mu type (EC 271 -) (nPKC-mu) (Protein KPCM JHUMAN
1485 Olfactory receptor 1C1 (Olfactory receptor TPCR27) OR1C1JHUMAN
1486 Phosphatidylinositol-glycan-specific phosphohpase D 2 precursor (EC 31450) (Pl-G PLD) (Glycoprotein phospholipase D) (Glycosyl- PHL2JHUMAN
1487 Pregnancy-specific beta 1-glycoprotein 10 precursor (PSBG-10) (PSBG-12) PSG10JHUMAN
1488 Pregnancy-specific beta-1 glycoprotein 5 precursor (PSBG-5) (Fetal liver non-specific cross reactive antιgen-3) (FL-NCA-3) PSG5JHUMAN
1489 Renal sodium-dependent phosphate transport protein 1 (Sodium/phosphate cotransporter 1) (Na(+)/PI cotransporter 1) (Renal sodium-phosp! NPT1 JHUMAN
1490 Neuropeptide Y receptor type 5 (NPY5-R) (NPY-Y5 receptor) (Y5 receptor) (NPYY5) NPY5R JHUMAN
1491 Inner membrane protein OXA1L, mitochondnal precursor (Oxidase assembly 1-lιke protein) (OXAI-like protein) (OXAIHs) (Hsa) OXA1LJHUMAN
1492 Potassium channel tetrameπsation domain containing protein 2 KCTD2JHUMAN
1493 Olfactory receptor 1Q1 (Olfactory receptor TPCR106) (Olfactory receptor 9-A) (OR9 A) (OST226) OR1Q1JHUMAN
1494 Olfactory receptor 2H3 (Olfactory receptor-like protein FAT11) OR2H3 JHUMAN
1495 Poliovirus receptor related protein 1 precursor (Herpes virus entry mediator C) (HveC) (Nectin 1) (Herpesvirus Ig-like receptor) (HIgR) PVR 1 JHUMAN
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Grou
PID Description UniProt ACC reticulum Nuclear cellular skeletal soma! anchor somal 1 2 3
2276 Motilin receptor (G-protein coupled receptor 38) MTLR_HUMAN
2277 Leucine πch repeat neuronal protein 2 precursor (Leucine-nch repeat transmembrane neuronal 2 protein) LRRN2_HUMAN
2278 Canalicular multispecific organic anion transporter 2 (Multidrug resistance-associated protein 3) (Multi specific organic anion MRP3_HUMAN
2279 Multidrug resistance-associated protein 4 (MRP/cMOAT-related ABC transporter) (Multi-specific organic anion tranporter-B) (MOAT-B) MRP4_HUMAN
2280 Multidrug resistance-associated protein 5 (Multi-specific organic anion tranporter-C) (MOAT-C) (pABC11) (SMRP) MRP5_HUMAN
2281 Membrane-bound transcription factor site 2 protease (EC 342485) (S2P endopeptidase) (Sιte-2 protease) (Sterol-regulatory element- MS2P_HUMAN
2282 Monocarboxylate transporter 4 (MCT 4) (MCT 3) M0T4_HUMAN
2283 Monocarboxylate transporter 5 (MCT S) (MCT 4) M0T5JHUMAN
2284 Monocarboxylate transporterβ (MCT 6) (MCT 5) M0T6JHUMAN
2285 Monocarboxylate transporter 7 (MCT 7) (MCT 6) M0T7_HUMAN
2286 Metastasis suppressor protein 1 (Missing in metastasis protein) (Metastasis suppressor YGL-1) MTSS1_HUMAN
2287 NKG2-F type Il integral membrane protein (NKG2-F activating NK receptor) (NK cell receptor F) NKG2F_HUMAN
2288 Dynamin-like 120 kDa protein, mitochondπal precursor (Optic atrophy 1 gene protein) OPA1J-IUMAN
2289 Olfactory receptor 10H2 O10H2JHUMAN
2290 Olfactory receptor 10H3 O10H3_HUMAN
2291 Peroxisomal membrane protein PMP34 (34 kDa peroxisomal membrane protein) (Solute earner family 25, member 17) PM34_HUMAN
2292 ϋpid phosphate phosphohydrolase 2 (EC 3 1 34) (Phosphatidic acid phosphatase 2c) (Phosphatidate phosphohydrolase type 2c) (PAP2c) LPP2JHUMAN
2293 Glutamate [NMDA] receptor subunit 3B precursor (N-methyl-D-aspartate receptor subtype NR3B) (NR3B) (NMDAR3B) (Fragment) NMD3B_HUMAN
2294 Glutamate [NMDA] receptor subunit epsilon 4 precursor (N-methyl D-aspartate receptor subtype 2D) (NR2D) (NMDAR2D) (EB11) NMDE4JHUMAN
2295 Neural cell adhesion molecule 2 precursor (N CAM 2) NCAM2JHUMAN
2296 Peroxisome biogenesis factor 1 (Peroxιn-1) (Peroxisome biogenesis disorder protein 1) PEX1_HUMAN
2297 Prostate stem cell antigen precursor (UNQ206/PRO232) PSCA_HUMAN
2298 Lymphocyte antigen 75 precursor (DEC-205) (CD205 antigen) (gp200-MR6) LY75_HUMAN
2299 3-phosphoιπosιtιde dependent protein kιnase-1 (EC 271 37) (hPDK1) PDPK1_HUMAN
2300 Group X secretory phospholipase A2 precursor (EC 31 14) (Phosphatidylcholine 2-acylhydrolase GX) (GX SPLA2) (sPLA2-X) PA2GX_HUMAN
2301 Protocadheπn gamma A12 precursor (PCDH-gamma-A12) (Cadhenn-21) (Fibroblast cadheπn 3) PCDGC_HUMAN
2302 Protocadheπn 7 precursor (Brain-heart protocadheπn) (BH-Pcdh) PCDH7_HUMAN
2303 Orexin receptortype 1 (OxIr) (Hypocretin receptortype 1) OX1R_HUMAN
2304 Orexin receptor type 2 (Ox2r) (Hypocretin receptor type 2) OX2R_HUMAN
2305 Intermediate conductance calcium-activated potassium channel protein 4 (SK4) (KCa4) (IK1) (IKCaI) (Putative Gardos channel) KCNN4_HUMAN
2306 Potassium voltage-gated channel subfamily KQT member 2 (Voltage-gated potassium channel subunit Kv72) (Neuroblastoma-specific potas' KCNQ2_HUMAN
2307 Potassium voltage-gated channel subfamily KQT member 3 (Voltage-gated potassium channel subunit Kv73) (Potassium channel alpha subi KCNQ3_HUMAN
2308 Olfactory receptor 1F1 (Olfactory receptor 16-35) (OR16-35) OR1F1_HUMAN
2309 Olfactory receptor 1F10 (Olfactory receptor 3-145) (OR3-145) (Fragment) OR1FA_HUMAN
2310 Olfactory receptor 111 (Olfactory receptor 19-20) (OR19-20) OR1I1_HUMAN
2311 Olfactory receptor 2H7 (OLFR42B-90796) (Fragment) OR2H7_HUMAN
2312 Olfactory receptor 7C2 (Olfactory receptor 19-18) (OR19-18) OR7C2_HUMAN
2313 Pendππ (Sodium-independent chloπde/iodide transporter) (Solute earner family 26, member 4) PEND-HUMAN
2314 Prominin 1 precursor (Prominm-like protein 1) (Antigen AC133) (CD133 antigen) PROM1_HUMAN
2315 P2X punnoceptor 6 (ATP receptor) (P2X6) (Puπnergic receptor) (P2XM) (Puπnergic receptor P2X-lιke 1) P2RX6_HUMAN
2316 Sialic acid binding Ig like lectin 6 precursor (Sιglec-6) (Obesity- binding protein 1) (OB-BP1) (CD33 antigen-like 1) SIGL6_HUMAN
2317 Sodium/πudeoside cotransporter 2 (Na(+)/πuc[eoside cotransporter 2) (Sodium-coupled nucleoside transporter 2) (Concentrative nucleoside S28A2_HUMAN
2318 Apoptosis regulatory protein Siva (CD27-bιπdιπg protein) (CD27BP) SIVA_HUMAN
2319 Testis-specific protein TEX28 TEX28_HUMAN
2320 Small inducible cytokine B13 precursor (CXCL13) (B lymphocyte chemoattractant) (CXC chemokine BLC) (B cell-attracting chemokiπe 1) SCYBD_HUMAN
2321 Transmembrane 4 superfamily member 6 (Tetraspanin 6) (Tspan-β) (T245 protein) (Tetraspanin TM4-D) (A15 homolog) (UNQ767/PRO1560) T4S6_HUMAN
2322 Toll like receptor 3 precursor TLR3_HUMAN
2323 Plexin BI precursor (Semaphoπn receptor SEP) PLXB1_HUMAN
2324 Syntaxιn-6 STX6_HUMAN
2325 Syntaxιn-7 STX7_HUMAN
2326 Synaptotagmιn-7 (Synaptotagmιn VII) (SytVII) SYT7_HUMAN
2327 Kunite type protease inhibitor 1 precursor (Hepatocyte growth factor activator inhibitor type 1) (HAI-1) (UNQ223/PRO256) SPIT1_HUMAN
2328 Kunitz-type protease inhibitor 2 precursor (Hepatocyte growth factor activator inhibitor type 2) (HAl-2) (Placental bikunin) SPIT2_HUMAN
2329 Vascular endothelial growth factor D precursor (VEGF-D) (c-fos induced growth factor) (FIGF) VEGFD_HUMAN
2330 Transmembrane 7 superfamily member 1 TM7S1_HUMAN
2331 Transmembrane 9 superfamily protein member 1 precursor (hMP70) TM9S1_HUMAN
2332 Transmembrane protease, seπne 2 precursor (EC 3421 -) TMPS2_HUMAN
2333 Epsilon-sarcoglycaπ precursor (Epsilon-SG) SGCE_HUMAN
2334 Sprouty homolog 1 (Spry-1) SPY1JHUMAN
2335 Sprouty homolog 2 (Spry-2) SPY2_HUMAN
2336 Sprouty homolog 3 (Spry 3) SPY3_HUMAN
2337 Trans-Golgi network integral membrane protein 2 precursor (Trans-Golgi network protein TGN51) (TGN46) (TGN48) (TGN38 homolog) TG0N2_HUMAN
2338 Tumor necrosis factor ligand superfamily member 12 (TNF-related weak inducer of apoptosis) (TWEAK) (APO3 ligand) (UNQ181/PRO207) TNF12_HUMAN
2339 Tumor necrosis factor ligand superfamily member 14 (Herpesvirus entry mediator-ligaπd) (HVEM-L) (UNQ391/PRO726) TNF14_HUMAN
2340 Tapasiπ precursor (TPSN) (TPN) (TAP-bmdiπg protein) (TAP-associated protein) (NGS 17) TPSNJHUMAN
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Group
PID Description UmProtACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 "
4226 GDP-fucose transporter 1 (Solute earner family 35 member C1) FUCT1JHUMAN
4227 Ectodysplasin A (Ectodermal dysplasia protein) (EDA protein) EDA_HUMAN
4228 ER degradation enhancing alpha-mannosidase-Iike EDEM1_HUMAN
4229 Lysophosphatidic acid receptor Edg 2 (LPA receptor 1) (LPA-1) EDG2_HUMAN
4230 EMI domain containing protein 1 precursor (Emu1 protein) (Emilin multimeπn-domam containing protein 1) EMID1_HUMAN
4231 Collagen alpha 1(XXVI) chain precursor (EMI domain containing protein 2) (Emu2 protein) (Emilin and multimeππ-domam containing protein 2 EMID2_HUMAN
4232 Exostosin-2 (EC 24 1 224) (EC 241 225) (Glucuronosyl-N- acetylg!ucosamιnyl-proteoglycan/N-acety[glucosamιnyl-proteoglycaπ EXT2_HUMAN
4233 Exostosin-like 1 (EC 241 224) (Glucuronosyl-N-acetylglucosaminyl- proteoglycan 4-alpha-N-acetylglucosamιnyItransferase) (Exostosin-L) EXTL1_HUMAN
4234 Golgi apparatus protein 1 precursor(Golgι sιaIoglycoproteιn MG-160) (E-selectin ligand 1) (ESL-1) (Cysteine rich fibroblast growth factor GSLG1_HUMAN
4235 Fibroblast growth factor-11 (FGF-11) (Fibroblast growth factor homologous factor 3) (FHF-3) FGF11_HUMAN
4236 Fibroblast growth factor-13 (FGF-13) (Fibroblast growth factor homologous factor 2) (FHF-2) FGF13_HUMAN
4237 Fibroblast growth factor-14 (FGF-14) (Fibroblast growth factor homologous factor 4) (FHF-4) FGF14_HUMAN
4238 Hyaluroπan synthase 1 (EC 241212) (Hyaluronate synthase 1) (Hyaluronic acid synthase 1) (HA synthase 1) (HuHASI) HAS1JHUMAN
4239 Hyaluronan synthase 2 (EC 241212) (Hyaluronate synthase 2) (Hyaluronic acid synthase 2) (HA synthase 2) HAS2_HUMAN
4240 Hermansky-Pudlak syndrome 1 protein HPS1_HUMAN
4241 FXYD domain-containing ion transport regulator 5 precursor (Dysadheπn) (HSPC113) (UNQ2561/PRO6241) FXYD5JHUMAN
4242 Growth hormone secretagogue receptor type 1 (GHS-R) (GH-re[easιng peptide receptor) (GHRP) (Ghrelm receptor) GHSR_HUMAN
4243 Protein FAM3D precursor (UNQ567/PRO1130) FAM3D_HUMAN
4244 Fetal and adult testis expressed transcπpt protein (BJ-HCC-2 protein) FATE1_HUMAN
4245 Polypeptide N-acetylgalactosaminyltransferase 14 (EC 241 41) (Protem-UDP acetylgalactosaminyltransferase 14) (UDP- GLT14~HUMAN
4246 Type Il iodothyronine deiodmase (EC 1 97 1 10) (Type-I! 5'deιodιnase) (DION) (Type 2 Dl) (SDIlJ IOD2_HUMAN
4247 Netnn G2 precursor (Lamιnet-2) (UNQ9381/PRO34206) NTNG2_HUMAN
4248 Nuclear pore complex protein Nup205 (Nucleoponn Nup205) (205 kDa nucleoponn) NU205_HUMAN
4249 lnterleukin 17 receptor precursor (IL-17 receptor) I17R1_HUMAN
4250 lπterleukιn-22 receptor aIpha-2 chain precursor (lL-22R-alpha-2) (Interieukin 22-bιndιng protein) (1L22BP) (Cytokine receptor family I22RA_HUMAN
4251 G protein-activated inward rectifier potassium channel 3 (GIRK3) (Potassium channel, inwardly rectifying subfamily J1 member 9) IRK9_HUMAN
4252 Seπne protease HTRA1 precursor (EC 3421 -) (L56) HTRA1_HUMAN
4253 Membrane-spanning 4-domaιns subfamily A member 6E M4A6E_HUMAN
4254 GPI-anchor traπsamidase precursor (EC 3 ) (GPI transamidase) (Phosphatidylmositol glycan biosynthesis, class K protein) (PIG-K) GPI8_HUMAN
4255 Potassium channel tetrameπsatioπ domain containing protein 12 (Pfetin) (Predominantly fetal expressed T1 domain) KCD12_HUMAN
4256 WSS-1 receptor (WSS-1R) (Kisspeptins receptor) (Metastin receptor) (G-proteιπ coupled receptor 54) (Hypogonadotropιn-1) (hOT7T175) KISSR_HUMAN
4257 MAL2 protein MAL2_HUMAN
4258 Kallikrein 6 precursor (EC 3421 -) (Protease M) (Neurosin) (Zyme) (SP59) KLK6_HUMAN
4259 Mas-related G-protein coupled receptor member F (Mas-related gene F protein) MRGRF_HUMAN
4260 Melanin-concentrating hormone receptor 2 (MCH receptor 2) (MCHR-2) (MCH-R2) (MCH2R) (MCH-2R) (MCH2) (G-protein coupled receptor MCHR2_HUMAN
4261 Canalicular multispeαfic organic anion transporter 1 (ATP-binding cassette, sub-family C, member 2) (Multidrug resistance-associated MRP2_ HUMAN
4262 Neogenin precursor NEO1_HUMAN
4263 Ecto-ADP-πbosyltransferase 4 precursor (EC 24231) (NAD(P)(+)- arginine ADP-πbosyltransferaεe 4) (Mono(ADP-nbosyl)transferase 4) NAR4JHUMAN
4264 Nmjuπn 1 (Nerve injury-induced protein 1) NINJ1_HUMAN
4265 Potassium voltage-gated channel subfamily B member 2 (Voltage-gated potassium channel subunit Kv22) KCNB2_HUMAN
4266 GPI transamidase component PIG-T precursor (Phosphatidylmositol- glycan biosynthesis, classT protein) (CGI 06) (UNQ716/PRO1379) PIGT-HUMAN
4267 Peroxisomal membrane protein PEX13 (Peroxιn-13) PEX13_HUMAN
4268 Small conductance calcium-activated potassium channel protein 1 (SK1) KCNN1_HUMAN
4269 Proprotein convertase subtilisin/kexin type 5 precursor (EC 3421 -) (Proprotein convertase PCS) (Subtilisin/kexin-like protease PC5) (PC6) PCSK5JHUMAN
4270 Poliovirus receptor related protein 2 precursor (Herpes virus entry mediator B) (HveB) (Nectin 2) (CD112 antigen) PVR2JHUMAN
4271 Peroxisomal membrane protein 11B (Peroxιn-11B) (Peroxisomal biogenesis factor 11B) (PEXHbeta) (Pex11pbeta) PX11BJHUMAN
4272 Receptor-type tyrosiπe-protein phosphatase N2 precursor (EC 31 348) (R-PTP-N2) (Islet cell autoantigen related protein) (ICAAR) (IAR) PTPN2_HUMAN
4273 Receptor-type tyrosine-protein phosphatase U precursor (EC 3 1 348) (R-PTP-U) (Protem-tyrosine phosphatase J) (PTP-J) (Pancreatic PTPRU_HUMAN
4274 11-cιs retinol dehydrogenase (EC 1 1 1 105) (11-cιs RDH) RDH1_HUMAN
4275 Neuronal cell adhesion molecule precursor (Nr-CAM) (NgCAM-related cell adhesion molecule) (Ng CAM related) (hBravo) NRCAMJHUMAN
4276 GTP-binding protein Rhes (Ras hσmolog enπched in stπatum) (Tumor endothelial marker 2) RHES-HUMAN
4277 P2X punnoceptor 5 (ATP receptor) (P2X5) (Puπnergic receptor) P2RX5_HUMAN
4278 Receptor-transporting protein 4 (28 kDa interferon responsive protein) RTP4_HUMAN
4279 Semaphonn 4D precursor (Leukocyte activation antigen CD100) (BB18) (A8) (GR3) SEM4*D_HUMAN
4280 PIeckstnn homology domain containing protein family B member2 (Evectiπ 2) PLEB2_HUMAN
4281 Ribonudease K6 precursor (EC 3 1.27 -) (RNase K6) RNAS6_HUMAN
4282 Rho-related GTP-binding protein Rho6 (Rho family GTPase 1) (Rnd1) RND1_HUMAN
4283 Solute earner organic anion transporter family, member 2A1 (Solute carrier family 21, member 2) (Prostaglandin transporter) (PGT) SO2A1_HUMAN
4284 Solute earner organic anion transporter family, member 4A1 (Solute earner family 21 , member 12) (Sodium-independent organic anion SO4A1_HUMAN
4285 RECS1 protein homolog (PP1201) RECS1_HUMAN
4286 Stathmin 2 (SCG10 protein) (Supeπor cervical gaπglioπ-10 protein) STMN2_HUMAN
4287 Signal-induced proliferation-associated protein 1 (Sιpa-1) (GTPase- activating protein Spa-1) (p130 SPA-1) SIPA1_HUMAN
4288 Transmembrane 4 superfamily member 17 (Tetraspan protein SB134) (F-box only protein 23) T4S17_HUMAN
4289 Sodium/hydrogen exchanger 6 (Na(+)/H(+) exchanger 6) (NHE-6) SL9A6JHUMAN
4290 SLAM family member 6 precursor (NK-T-B-antigen) (NTB-A) (Activating NK receptor) (UNQ6123/PRO20080) SLAF6_HUMAN
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001
Figure imgf000262_0001
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Group
PlD Descπption UniProtACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
4746 GluR6 kainate receptor Q96KS6JHUMAN
4747 Hypothetical protein FLJ31675
4748 Hypothetical protein FLJ31575 Q96N13_HUMAN
4749 Hypothetical protein FLJ31364 Q96N62 JHUMAN
4750 Hypothetical protein FU31227 Q96N91JHUMAN
4751 Hypothetical protein FLJ31168 Q96NA6JHUMAN
4752 Hypothetical protein FLJ31101 Q96NC3_HUMAN
4753 Hypothetical protein FLJ14400 (Cisplatin resistance related protein CRR9p) Q96KA5 JHUMAN
4754 Lysozyme-llke 4 (LYC4) Q96KX0JHUMAN
4755 MGC27165 protein Q96KX8 JHUMAN
4756 SYNGR3 protein Q96L30 JHUMAN
4757 Hypothetical protein FLJ25059 Q96LU5JHUMAN
4758 Hypothetical protein FLJ32908 (MYADML protein) Q96M12JHUMAN
4759 Hypothetical protein HJ31293 (Claudin 10) Q96N78_HUMAN
4760 Transient receptor potential channel 4 zeta splice vanant (Transient receptor potential cation channel, subfamily C, member 4) Q96P03JHUMAN
4761 Putative ion channel protein CATSPER2 variant 1 (Sperm-associated cation channel 2, isoform 1) Q96P56JHUMAN
4762 GOSR1 protein Q96QI9JHUMAN
4763 Glycoprotein hormones, alpha polypeptide, Q96QJ4JHUMAN
4764 Hypothetical protein FLJ32603 Q96MC7JHUMAN
4765 Hypothetical protein FLJ31425 Q96N44_HUMAN
4766 Hypothetical protein FLJ31393 (Seven transmembrane helix receptor) Q96N54 JHUMAN
4767 Prolactin receptor short isoform 1a Q96P35_HUMAN
4768 Erythroid membrane-associated protein (Erythroblast membrane- associated protein) Q96PL5JHUMAN
4769 Voltage gated potassium channel Kv32b (Potassium voltage-gated potassium channel subfamily C member 2) Q96PR1 JHUMAN
4770 Putative 40-9-1 protein Q96QD8JHUMAN
4771 RAS guanyl releasing protein 4 Q96QN7 JHUMAN
4772 Olfactory receptor (Fragment) Q96R43JHUMAN
4773 Olfactory receptor (Fragment) Q96R54JHUMAN
4774 KIAA0523 protein Q96G45JHUMAN
4775 Solute earner family 35, member A4 (Hypothetical protein DKFZp586D071) Q96G79 J-IUMAN
4776 Lipid phosphate phosphatase-related protein type 2 (Plasticity related gene 4) Q96GM1 JHUMAN
4777 NRP2 protein Q96GU8JHUMAN
4778 TMEM30A protein Q96H09JHUMAN
4779 KDELR1 protein Q96H29JHUMAN
4780 SLC39A13 protein Q96H72JHUMAN
4781 Hypothetical protein KIAA0446 (Hypothetical protein FLJ90431) (Hypothetical protein FLJ90521) (Novel protein) Q96H78 JHUMAN
4782 Wingless-type MMTV integration site family, member 7A, Q96H90JHUMAN
4783 ST6GAL2 protein Q96HE4JHUMAN
4784 Transmembrane protein 19 Q96HH6JHUMAN
4785 IMMP2L protein Q96HJ2 JHUMAN
4786 DPYD protein (Dihydropyπmidme dehydrogenase) Q96HL6JHUMAN
4787 ATP5A1 protein (Fragment) Q96HW2JHUMAN
4788 GPR108 protein Q96I30 JHUMAN
4789 YME1-llke 1, isoform 2 Q96I63JHUMAN
4790 Hypothetical protein Q96I69 JHUMAN
4791 Hypothetical protein MGC15619 Q96IS5JHUMAN
4792 COL2A1 protein (Collagen, type II, alpha 1) (Pπmary osteoarthπtis, spondyloepiphyseal dysplasia, congenital) Q96IT5JHUMAN
4793 SEC22 vesicle trafficking protein-like 2 Q96IW7 JHUMAN
4794 PMS1 protein (PMS1 postmeiotic segregation increased 1) (S cerevisiae) Q96HL0 JHUMAN
4795 ABC-transporter Q96PT8 JHUMAN
4796 Small inducible cytokine A13 precursor (CCL13) (Monocyte chemotactic protein 4) (MCP-4) (Monocyte chemoattractant protein 4) (CK-beta-1 CCL13 JHUMAN
4797 Small inducible cytokine A19 precursor (CCL19) (Macrophage inflammatory protein 3 beta) (MIP-3-beta) (EBM-hgand chemokine) CCL19JHUMAN
4798 CD180 antigen precursor (Lymphocyte antgen 64) (Radioprotective 105 kDa protein) CD180JHUMAN
4799 Chemokine receptor-like 1 (G-protein coupled receptor DEZ) (G-protein coupled receptor ChemR23) CML1 JHUMAN
4800 Chemokine receptor-like 2 (G-protein coupled receptor 30) (IL8-related receptor DRY12) (Flow-induced endothelial G-protein coupled recepto CML2JHUMAN
4801 3-hydroxyacyl-CoA dehydrogenase type Il (EC 1 1 1 35) (Type Il HADH) (Endoplasmic reticulum associated amyloid beta-peptide binding HCD2JHUMAN
4802 Cyclic-AMP-dependent transcπption factor ATF-6 beta (Activating transcnption factor 6 beta) (ATF6-beta) (cAMP responsive element ATF6BJHUMAN
4803 ATP-biπding cassette, sub-family A, member 3 (ATP-binding cassette transporter 3) (ATP-bindiπg cassette 3) (ABC-C transporter) ABCA3JHUMAN
4804 Amelogeπm, X isoform precursor AMEXJHUMAN
4805 Amelogemπ, Y isoform precursor AMEYJHUMAN
4806 ADAM 2 precursor (A disintegπn and metalloproteinase domain 2) (Fertilm beta subumt) (PH-30) (PH30) ADAM2JHUMAN
4807 Succinate dehydrogenase cytochrome b560 subumt, mitochondnal precursor (Integral membrane protein Cll-3) (QPS1) (QPs-1) (Succinate C560JHUMAN
4808 Adipophilin (Adipose differentiation-related protein) (ADRP) ADFPJHUMAN
4809 Apolipoprotein-U (Apolipoprotein L-Il) (ApoL-ll) APOL2 JHUMAN
4810 Apolιpoproteιπ-L4 precursor (Apolipoprotein L-IV) (ApoL-IV) APOL4 JHUMAN
Figure imgf000264_0001
Figure imgf000265_0001
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
Endoplasmic Extra- Cyto- Peroxi GPI- Micro- Group Group Group
PID Description UniProtACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
5266 GDP-fucose protein O-fucosyltraπsferase 1 precursor (EC 24 1 221) (Peptlde-O-fucosyltransferase) (O-FucT-1) OFUT1 HUMAN Y
5267 Protocadhenn alpha C1 precursor (PCDH-alpha-C1) PCDC1 JHUMAN
5268 Potassium voltage-gated channel subfamily H member 6 (Voltage-gated potassium channel subunit Kv112) (Ether-a-go-go related gene KCNH6 JHUMAN
5269 Potassium channel subfamily K member 13 (Tandem pore domain inhibited potassium channel 1) (THIK-1) KCNKD HUMAN
5270 Potassium channel subfamily K member 15 (Acid sensitive potassium channel protein TASK-5) (TWlK-related acid-sensitive K(+) channel 5) KCNKF_HUMAN
5271 Small conductance calcium-activated potassium channel protein 2 (SK2) KCNN2JHUMAN
5272 Olfactory receptor 2D2 (Olfactory receptor 11-610) (OR11-610) (HB2) OR2D2JHUMAN
5273 Ran-bmding protein 17 RBP17_HUMAN
5274 Regulatng synaptic membrane exocytosis protein 4 (Rab-3 interacting molecule 4) (RIM 4) (RIM4 gamma) RIMS4_HUMAN
5275 P2Y punnoceptor 12 (P2Y12) (P2Y12 platelet ADP receptor) (P2Y(ADP)) (ADP-glucose receptor) (ADPG-R) (P2Y(AC» (P2Y(cyc)) (P2T(AC)) P2Y12JHUMAN
5276 Semaphoππ 4A precursor (Semaphoπn B) (Sema B) (UNQ783/PRO1317) SEM4A_HUMAN
5277 Pleckstnn homology domain-containing protein family A member 4 (Phosphoinositol 3-phosphate binding proteιn-1) (PEPP-1) PLEA4JHUMAN
5278 Sulfate anion transporter 1 (SAT-1) (Solute earner family 26, 1) S26A1 JHUMAN
5279 Protein transport protein Sec61 alpha subunit isoform 2 (Sec61 alpha 2) S61A2 JHUMAN
5280 Ribonuclease 7 precursor (EC 3 1 27 -) (RNase 7) (Skin-denved antimicrobial protein 2) (SAP-2) (UNQ2516/PRO6006) RNAS7_HUMAN
5281 Solute earner organic anion transporter family, member 5A1 (Solute carrier family 21 , member 15) (Organic anion transporter polypeptide- SO5A 1 JHUMAN
5282 Orphan sodium- and chloπde-dependent neurotransmitter transporter NTT73 (Orphan transporter v7-3) (Solute earner family 6 member S6A15_HUMAN
5283 Orphan sodium- and chloπde-dependent neurotransmitter transporter NTT4 (Solute earner family 6 member 17) S6A17_HUMAN
5284 Semaphoπn 6A precursor (Semaphoπn VIA) (Sema VIA) (Semaphoπn 6A-1) (SEMA6A-1) SEM6A_HUMAN
5285 Semaphoπn 6B precursor (Semaphoππ Z) (Sema 2) (UNQ1907/PRO4353) SEM6B_HUMAN
5286 Semaphoπn 6C precursor (Semaphonπ Y) (Sema Y) SEM6C_HUMAN
5287 Small inducible cytokine B16 precursor (Transmembrane chemokine CXCL16) (SR-PSOX) (Scavenger receptor for phosphatdylseπne and SCYBGJHUMAN
5288 Src-Ilke-adapter 2 (Src-hks adapter proteιn-2) (SLAP 2) (Modulator of antigen receptor signaling) (MARS) SLAP2_HUMAN
5289 SLIT and NTRK-like protein 6 precursor SLIK6_HUMAN
5290 Tnpartite motif protein 45 (RING finger protein 99) TRI45JHUMAN
5291 Syntenin-2 (Syndecan binding protein Z) SDCB2 JHUMAN
5292 UDP-glucuronosyltransferase 1-10 precursor, microsomal (EC241 17) (UDPGT) (UGT1*10) (UGT1-10) (UGT1 10) (UGT-U) (UGTU) UD110_HUMAN
5293 UDP-glucuronosyltransferase 1-7 precursor, microsomal (EC 24117) (UDP-glucuronosyltransferase 1A7) (UDPGT) (UGT1*7) (UGT1-07) (UUD17_HUMAN
5294 UDP-glucuronosyltransferase 1-8 precursor, microsomal (EC 241 17) (UDP-glucuronosyltransferase 1A8) (UDPGT) (UGT1*8) (UGT1-08) (UUD18JHUMAN
5295 Synaptotagmιπ-4 (Synaptotagmin IV) (SytlV) SYT4_HUMAN
5296 Transmembrane protease, seπne 5 (EC 3421 -) (Spinesin) TMPS5 JHUMAN
5297 Sideroflexin 1 SFXN1_HUMAN
5298 Vesicular inhibitory amino acid transporter (GABA and glycine transporter) (Vesicular GABA transporter) (hVIAAT) (Solute earner VIAATJHUMAN
5299 Transient receptor potential cation channel subfamily V member 6 (TrpV6) (Epithelial calcium channel 2) (ECaC2) (Calcium transport TRPV6JHUMAN
5300 Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain (Beta-IV spectnn) SPTN4_HUMAN
5301 Tenomodulin (TeM) (hTeM) (Chondromodulin-I like protein) (ChMIL) (hChMU) (Myodulin) (Tendin) (UNQ771/PRO1565) TNMD_HUMAN
5302 SPARC related modular calαum-bindmg protein 1 precursor (Secreted modular calαum-bmding protein 1) (SMOC-1) SMOC1_HUMAN
5303 SPARC related modular calcium-binding protein 2 precursor (Secreted modular calαum-bindiπg protein 2) (SMOC-2) (Smooth muscle-associ, SMOC2 JHUMAN
5304 Vacuolar protein sorting 33B (hVPS33B) VP33B_HUMAN
5305 Aipha-N-acetyl-neuramιnyl-2,3-beta galactosyl-1 3-N acetyl- galactosaminide alpha-2,6-sιalyltransferase (EC 24997) (NeuAc- SIA7D_HUMAN
5306 Vacuolar protein sorting 11 (hVPS11) (RING finger protein 108) (PP3476) VPS11JHUMAN
5307 Vacuolar protein sorting 16 (hVPS16) VPS16JHUMAN
5308 Tumor necrosis factor receptor superfamily member 27 (X-linked ectodysplasιn-A2 receptor) (EDA-A2 receptor) TNR27JHUMAN
5309 Wnt-5b protein precursor WNT5B_HUMAN
5310 Wnt-8a protein precursor (Wnt-8d) WNT8A_HUMAN
5311 Solute earner family 12, member 5 (Electroneutral potassium chloπde cotransporter 2) (Erythroid K-Cl cotransporter 2) (Neuronal K Cl S12A5JHUMAN
5312 Zinc finger DHHC domain containing protein 11 (Zinc finger 399) ZDH11_HUMAN
5313 Zinc finger DHHC domain containing protein 6 (Zinc finger (Transmembrane protein H4) ZDHC6_HUMAN
5314 Thioredoxin domain containing protein 1 precursor (Transmembrane Trx- related protein) (Thioredoxin-related transmembrane protein) TXNDCJHUMAN
5315 Hypothetical protein FLJ21120 Q9H7A2_HUMAN
5316 FLJ00046 protein (Fragment) Q9H7M4JHUMAN
5317 FU00016 protein (Fragment) Q9H7Q1 JHUMAN
5318 FLJ00015 protein (Fragment) Q9H7Q2_HUMAN
5319 FU00009 protein (Fragment) Q9H7Q8 J-IUMAN
5320 Xylosyltransferase Il Q9H1B5JHUMAN
5321 Hypothetical protein FU13246 Q9H8T4 JHUMAN
5322 Hypothetical protein FLJ12925 Q9H985JHUMAN
5323 Hypothetical protein FLJ12871 Q9H9B8J-1UMAN
5324 Hypothetical protein FLJ12791 Q9H9F5JHUMAN
5325 Hypothetical protein FLJ12132 Q9HA73 J-IUMAN
5326 Hypothetical protein FLJ11853 Q9HAB4JHUMAN
5327 Xylosyltransferase I (EC 24226) (Fragment) Q9H1B6JHUMAN
5328 Transmembrane protein Q9H1C5 JHUMAN
5329 Sodium bicarbonate cotransporter Q9H262JHUMAN
5330 Junctate Q9H291 HUMAN
Figure imgf000272_0001
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0001
Figure imgf000276_0001
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Group
PID Descπptioπ UniProtACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
5656 Membrane progestin receptor gamma (mPR gamma) (Progestin and adipoQ receptor family member V) MPRGJHUMAN
5657 LIN-7 homolog C (UN-7C) (Mammalian UN-seven protein 3) (MALS-3) (Vertebrate LIN 7 homolog 3) (Velι-3 protein) UN7C_HUMAN
5658 Killer cell lectin-hke receptor subfamily F, member 1 (Lectin-like receptor F1) (Activating coreceptor NKp80) KLRF1_HUMAN
5659 Nmjuπn 2 (Nerve injury-induced protein 2) NINJ2 JHUMAN
5660 Potassium voltage-gated channel subfamily D member 1 (Voltage gated potassium channel subunit Kv41) KCND^JHUMAN
5661 Neuroligin 3 precursor (Gliotactiπ homolog) NLGN3JHUMAN
5662 Myoferliπ (Fer-1 like protein 3) MYOFJHUMAN
5663 NADH-ubiqumone oxidoreductase ESSS subunit, mitochoπdnal precursor (EC 1 653) (EC 1 6993) (Complex I-ESSS) (CI-ESSS) (Neuronal NESMJHUMAN
5664 Group III secretory phospholipase A2 precursor (EC 31 1 4) (Phosphatidylcholine 2-acylhydrolase GUI) (GUI SPLA2) PA2G3JHUMAN
5665 Group UE secretory phospholipase A2 precursor (EC 31 1 4) (Phosphatidylcholine 2-acylhydrolase GIIE) (GIIE SPLA2) (sPLA(2) IiE) PA2GEJHUMAN
5666 Polycystic kidney disease 2-lιke 2 protein (Polycystin-U) PK2L2 JHUMAN
5667 Polycystic kidney disease and receptor for egg jelly related precursor (PKD and REJ homolog) PKDREJHUMAN
5668 Opioid growth factor receptor (OGFr) (Zeta-type opioid receptor) (7-60 protein) OGFRJHUMAN
5669 Protocadheπn beta 16 precursor (PCDH-beta16) (Protocadhenn 3X) PCDBGJHUMAN
5670 Potassium voltage-gated channel subfamily H member7 (Voltage-gated potassium channel subunit Kv11 3) (Ether-a-go-go related gene KCNH7JHUMAN
5671 Potassium channel subfamily K member 4 (TWIK-related arachidoπic acid- stimulated potassium channel protein) (TRAAK) (Two pore K(+) crKCNK4JHUMAN
5672 Potassium channel tetrameπsation domain containing protein 5 KCTD5JHUMAN
5673 1-acyl sn-glycerol-3-phosphate acyltransferase gamma (EC 23 1 51) (1-AGP acyltransferase 3) (1-AGPAT3) (Lysophosphatidic acid PLCCJHUMAN
5674 1-acyl-sn-gIycerol-3 phosphate acyltransferase delta (EC 231 51) (1-AGP acyltransferase 4) (1-AGPAT 4) (Lysophosphatidic acid PLCDJHUMAN
5675 1-acyl-sn glycerol 3-phoεphate acyltransferase epsilon (EC 23 1 51) (1-AGP acyltransferase 5) (1-AGPAT 5) (Lysophosphatidic acid PLCEJHUMAN
5676 Olfactory receptor 5AC2 (HSA1) (Fragment) OR5AC J-IUMAN
5677 Olfactory receptor 6C2(HSA3) (Fragment) OR6C2 JHUMAN
5678 Olfactory receptor 6C3 (HSA8) (Fragment) OR6C3JHUMAN
5679 Gamma secretase subunit PEN-2 (Presemlin enhancer protein 2) (MDS033) PEN2JHUMAN
5680 Sodium channel protein type III alpha subunit (Voltage-gated sodium channel alpha subunit Nav1 3) (Sodium channel protein, brain 111 SCN3AJHUMAN
5681 Sodium channel beta-3 subunit precursor SCN3BJHUMAN
5682 Rhomboid-related protein 2 (EC 3421 -) (RRP2) (Rhomboid-like protein 2) RHBD2 JHUMAN
5683 E3 ubiquitin ligase TRIAD3 (EC 632-) (Ubiquitin conjugating enzyme 7 interacting protein 1) (Zinc finger protein inhibiting NF-kappa B) UB711 JHUMAN
5684 Ubiquιlιn-4 (Ataxιn-1 ubiquitin-like interacting protein A1 U) UBQL4 JHUMAN
5685 Relaxin 3 receptor 1 (Somatostatin- and angiotensin-like peptide receptor) (G protein coupled receptor SALPR) (GPCR135) R3R1 JHUMAN
5686 Sialic acid binding Ig like lectin 8 precursor (Sιglec-8) (Sialoadhesiπ family member-2) (SAF-2) SIGL8JHUMAN
5687 PleckstnnZ PLEK2 JHUMAN
5688 UDP-glucuronic aαd/UDP-N-acetylgalactosamine transporter (UDP- GlcA/UDP GaINAc transporter) (Solute earner family 35 member D1) S35D1 JHUMAN
5689 Solute earner organic anion transporter family, member 1C1 (Solute earner family 21, member 14) (Organic anion transporter F) SO1C1 JHUMAN
5690 Sodium- and chlonde-dependent GABA transporter 2. S6A13JHUMAN
5691 Semaphonn 4G precursor SEM4GJHUMAN
5692 Taste receptortype 2 member 10 (T2R10) (Taste receptor member2) (TRB2) T2R10JHUMAN
5693 Taste receptor type 2 member 13 (T2R13) (Taste receptor member 3) (TRB3) T2R13JHUMAN
5694 Taste receptortype 2 member 14 (T2R14) (Taste receptor member 1) (TRB1) T2R14JHUMAN
5695 Taste receptor type 2 member 16 (T2R16) T2R16JHUMAN
5696 Phospholipid scramblase 2 (PL scramblase 2) (Ca(2+)-dependent phospholipid scramblase 2) PLS2 JHUMAN
5697 Phospholipid scramblase3 (PL scramblase 3) (Ca(2+)-dependent phospholipid scramblasa 3) PLS3JHUMAN
5698 Phospholipid scramblase 4 (PL scramblase 4) (Ca(2+)-dependent phospholipid scramblase 4) PLS4JHUMAN
5699 Taste receptor type 2 member 1 (T2R1) (Taste receptor 7) (TRB7) TA2R1 JHUMAN
5700 Taste receptor type 2 member 3 (T2R3) TA2R3JHUMAN
5701 Taste receptor type 2 member 4 (T2R4) TA2R4JHUMAN
5702 Taste receptortype 2 member 5 (T2R5) TA2R5JHUMAN
5703 Taste receptor type 2 member 7 (T2R7) (Taste receptor 4) (TRB4) TA2R7 JHUMAN
5704 Taste receptor type 2 member 8 (T2R8) CTaste receptor 5) (TRB5) TA2R8JHUMAN
5705 Taste receptor type 2 member 9 (T2R9) (Taste receptor 6) (TRB6) TA2R9JHUMAN
5706 Low affinity sodium-glucose cotransporter (Sodium/glucose cotransporter 3) (Na(+)/glucose cotransporter 3) SC5A4JHUMAN
5707 Toll-like receptor 7 precursor (UNQ248/PRO285) TLR7JHUMAN
5708 Transmembrane protein 14B TM14Ϊ JHUMAN
5709 Transmembrane 7 superfamily protein member 3 precursor (Seven span transmembrane protein) TM7S3JHUMAN
5710 Transmembrane protease, seπne 4 (EC 3421 -) (Membrane-type senne protease 2) (MT-SP2) (UNQ776/PRO1570) TMPS4 JHUMAN
5711 Tryptase gamma precursor (EC 3421 -) (Transmembrane tryptase) TRYG1 JHUMAN
5712 Stabilm 1 precursor (FEEL-1 protein) (MS-1 antigen) STAB1 JHUMAN
5713 Transient receptor potential cation channel subfamily V member 1 (TrpV1) (osm-9 like TRP channel 1) (OTRPC1) (Vanilloid receptor 1) TRPV1 JHUMAN
5714 Alpha-N-acetylgalactosaminide alpha 2,6-sιalyltraπsferase 1 (EC 24993) (GaINAc alpha-2,6-sιalyltransferase I) (ST6GalNAc I) SIA7 AJHUMAN
5715 Vacuolar protein sorting associated protein 45 (h-VPS45) (hlVps45) VPS45JHUMAN
5716 Tnggeπng receptor expressed on myeloid cells 2 precursor (Tπggenng receptor expressed on monocytes 2) (TREM-2) TREM2JHUMAN
5717 Tumor necrosis factor receptor superfamily member 19 precursor (Toxicity and JNK inducer) (TRADE) (UNQ1888/PRO4333) TNR19JHUMAN
5718 USE1 like protein (Hematopoietic stem/progenitor cells protein MDS032) (Putative MAPK activating protein PM26) (Protein p31) USE1JHUMAN
5719 Gamma-1-syπtrophιn (G1SYN) (Syntrophin 4) (SYN4) SNTG1 JHUMAN
5720 Gamma-2-εyntrophιπ (G2SYN) (Syntrophin 5) (SYN5) SNTG2 JHUMAN
Figure imgf000278_0001
Figure imgf000279_0001
Figure imgf000280_0001
Figure imgf000281_0001
Endoplasmic Extra- Cyto- PeroxiGPI- MicroGroup Group Group
PID Descnptioπ UniProt ACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
5981 PDZ domain-containing guanine nucleotide exchange factor I Q9UHV4_HUMAN
5982 HSPC222 (JTB protein) (Jumping translocation breakpoint) Q9P0Q4_HUMAN
5983 HSPC202 (Adoplιn-1) (0RMDL1) (Hypothetical protein FLJ90275) (Hypothetical protein FLJ90679) (Hypothetical protein DKFZp686G141) Q9P0S3 J-IUMAN
5984 Differentiation-associated Na-depeπdent inorganic phosphate cotransporter (Differentiation-associated Na-dependent inorganic Q9P2U8_HUMAN
5985 OTTHUMP00000018017 (Major histocompatibility complex, class II, DR alpha,) (OTTHUMP00000029406) (OTTΗUMP00000029839) Q9TP70JHUMAN
5986 Rh type C glycoprotein (Tumor-related protein DRC2) (Rhesus blood group, C glycoprotein) Q9UBD6_HUMAN
5987 Transmembrane adapter protein KAP10 (Membrane protein DAP10) (Hypothetical protein DKFZp58βC1522) (DNAX-activation protein 10) Q9UBK5_HUMAN
5988 MMP-23 (MIFR/Femalysin) (Metalloprotease isoform A) (Matnx metalloproteinase 23B) (MIFR-1) Q9UBR9_HUMAN
5989 BK65A62 (Novel Sushi domain (SCR repeat) containing protein similar to Mucins) (Sushi domain containing 2) Q9UGT4_HUMAN
5990 ProSAAS precursor (Proprotein convertase subtilisin/kexin type 1 inhibitor,) Q9UHG2_HUMAN
5991 Neuronal potassium channel alpha subunit (Potassium channel Kv81) Q9UHJ4_HUMAN
5992 A6(IV) collagen (Fragment) Q9UEH6_HUMAN
5993 Hypothetical protein DKFZp586O1922 Q9UFT3_HUMAN
5994 ADAM 21 precursor (EC 3424 -) (A dismtegπn and metalloproteinase domain 21) ADA21_HUMAN
5995 ADAM 28 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 28) (Metalloproteinase-hke, disintegnn-like, and cysteine ADA28__HUMAN
5996 ADAM 29 precursor (A disintegnn and metalloproteinase domain 29) ADA29_HUMAN
5997 Alpha-1,4-N-acetylglucosamιnyltransferase (EC 241 -) (Alpha4GnT) A4GCT_HUMAN
5998 Calcium-binding mitochondπal earner protein Aralar2 (Mitochondπal aspartate glutamate earner 2) (Solute earner family 25, member CMC2JHUMAN
5999 Contactiπ 6 precursor (Neural recognition molecule NB 3) (hNB-3) CNTN6_HUMAN
6000 Potassium/sodium hypeφolaπzation-activated cyclic nucleotide-gated channel 2 (Brain cyclic nucleotide gated channel 2) (BCNG-2) HCN2_HUMAN
6001 Acetylcholinesterase collagenic tail peptide precursor (AChE Q subunit) (Acetylcholinesterase-associated collagen) COLQ_HUMAN
6002 ATP-bmdmg cassette, sub-family G, member2 (Placenta-specific ATP- binding cassette transporter) (Breast cancer resistance protein) ABCG2_HUMAN
6003 Autocrine motility factor receptor, isoform 2 (EC 632 -) (AMF receptor) (gp78) AMFR2_HUMAN
6004 Adapter-related protein complex 4 epsilon 1 subunit (Epsilon subunit of AP-4) (AP-4 adapter complex epsiloπ subunit) AP4E1_HUMAN
6005 ADAMTS-5 precursor (EC 3424 -) (A diεintegπn and metalloproteinase with thrombospondin motifs 5) (ADAM-TS 5) (ADAM-TS5) (Aggrecan ATS5_HUMAN
6006 ADAMTS-6 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 6) (ADAM-TS 6) (ADAM-TS6) ATS6JHUMAN
6007 Brain specific membrane-anchored protein precursor BMAP_HUMAN
6008 ADAM 30 precursor (EC 3424 -) (A disintegnn and metalloproteinase domain 30) (UNQ2509/PRO5997) ADA30_HUMAN
6009 Loπg-chain-fatty-acid-CoA ligase 5 (EC 621 3) (Long-chain acyl-CoA synthetase 5) (LACS 5) (UNQ633/PRO1250) ACSL5_HUMAN
6010 Long chain-fatty-acid -CoA ligase 6 (EC 621 3) (Long-chain acyl-CoA synthetase 6) (LACS 6) ACSL6_HUMAN
6011 ADAMTS-7 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 7) (ADAM-TS 7) (ADAM-TS7) ATS7JHUMAN
6012 ADAMTS-8 precursor (EC 3424 -) (A disintegnn and metalloproteinase with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) ATS8_HUMAN
6013 X/potassium transporting ATPase beta-m chain (X,K-ATPase beta-m subunit) AT1B4_HUMAN
6014 ALK tyrosine kinase receptor precursor (EC 271 112) (Anaplastic lymphoma kinase) (CD246 antigen) ALK_HUMAN
6015 C type lectin εuperfamily member 6 (Dendπtic cell immunoreceptor) (Lectin-like immunoreceptor) (C-type lectin DDB27) (HDCGC13P) CLEC6_HUMAN
6016 C-type lectin superfamily member 9 (Macrophage-inducible C-type lectin) (UNQ218/PRO244) CLEC9_HUMAN
6017 Aπgiopoietin-related protein 2 precursor (Angiopoietin like 2) (UNQ170/PRO196) ANGL2J-IUMAN
6018 130-kDa phosphatidylinositol 4,5 biphosphate-dependent ARF1 GTPase- activating protein (PIP2-dependent ARF1 GAP) (ADP-πbosylaton fi DDEF1_HUMAN
6019 Bassoon protein (Zinc-finger protein 231) BSN_HUMAN
6020 Gap junction alpha-9 protein (Connexin 36) (Cx36) CXA9_HUMAN
6021 Cysteine-nch hydrophobic domain 2 protein (BrX-like translocated in leukemia) CHlC2_HUMAN
6022 Coronin 2B (Coronin like protein C) (ClipiπC) (Protein FC96) COR2B_HUMAN
6023 ATP-dependeπt RNA helicase DDX19 (DEAD-box protein 19) (DEAD box RNA helicase DEAD5) DDX19JHUMAN
6024 Ectonucleoside tπphosphate diphosphohydrolase 4 (EC 361 6) (NTPDase4) (Undine-diphosphatase) (UDPase) (Lysosomal apyrase-like ENP4_HUMAN
6025 Ectonucleotide pyrophosphatase/phosphodiesterase 5 precursor (EC 31 - -) (E-NPP5) (NPP-5) (UNQ550/PRO1107) ENPP5_HUMAN
6026 DCC-interacting protein 13 alpha (Dιp13 alpha) (Adapter protein containing PH domain, PTB domain and leucine zipper motif DP13A_HUMAN
6027 Cadhenn-22 precursor CAD22_HUMAN
6028 Cadheπn-7 precursor CADH7_HUMAN
6029 Cadheπn-9 precursor CADH9J-IUMAN
6030 Drebnn-like protein (SH3 domain-containing protein 7) (Drebπn F) (Cervical SH3P7) (HPKI-interactlng protein of 55 kDa) (HIP-55) DBNL_HUMAN
6031 Feline leukemia virus subgroup C receptor-related protein 2 (Calcium- chelate transporter) (CCT) FLVC2_HUMAN
6032 Conserved oligomeπc Golgi complex component 5 (13S Golgi transport complex 90 kDa subunit) (GTC-90) (Golgi transport complex 1) COG5_HUMAN
6033 HERV-W_7q21 2 provirus ancestral Env polyprotein precursor (Envelope polyprotein) (HERV-7q Envelope protein) (HERV-W envelope protei ENW1_HUMAN
6034 Protein C20orf103 precursor CT103JHUMAN
6035 Protein C20orf155 (GCD10 protein homolog) CT155_HUMAN
6036 Carbonic anhydrase XIV precursor (EC 421 1) (Carbonate dehydratase XIV) (CA-XIV) (UNQ690/PRO1335) CAH14JHUMAN
6037 Cytochrome P4508B1 (EC 1 14 --) (CYPVIIIB1) (Sterol 12-alpha- hydroxylase) (7 alpha hydroxy-4-cholesten-3-one 12-alpha hydroxylase) CP8B1JHUMAN
6038 Endothelial protein C receptor precursor (Endothelial cell protein C receptor) (Activated protein C receptor) (APC receptor) (CD201 EPCR_HUMAN
6039 Collagen alpha 1(XVII) chain (Bullous pemphigoid antigen 2) (180 bullous pemphigoid antigen 2) COHA1JHUMAN
6040 Seπne protease DESC1 precursor (EC 3421 -) (UNQ742/PRO1461) [Contains Seππe protease DESC1 non-catalytic chain, Seπne protease DESC1_HUMAN
6041 Tumor necrosis factor receptor superfamily member EDAR precursor (Anhidrotic ectodysplasin receptor 1) (Ectodysplasin-A receptor) EDAR_HUMAN
6042 Growth/differentiation factor 2 precursor (GDF-2) (Bone morphogenetic protein 9) (BMP-9) GDF2_HUMAN
6043 Probable G-protein coupled receptor 34 GPR34_HUMAN
6044 Dickkopf-like protein 1 precursor (Soggy-1 protein) (SGY-1) (UNQ735/PRO1429) DKKL1JHUMAN
6045 Guanine nucleotide-binding protein G(l)/G(S)/G(O) gamma-8 subunit (Gamma 9) GBG8JHUMAN
Figure imgf000283_0001
Figure imgf000284_0001
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
Figure imgf000288_0001
Figure imgf000289_0001
Figure imgf000290_0001
Figure imgf000291_0001
Figure imgf000292_0001
Figure imgf000293_0001
Figure imgf000294_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Group
PiD Description UniProtACC reticulum Nuclear cellular skeletal εomal anchor somal 1 2 3
6826 T-cell receptor beta chain V region YT35 precursor TVB1_HUMAN
6827 Cholecystokiπins precursor (CCK) [Contains Cholecystokinin 58 (CCK58), Cholecystokinin 39 (CCK39), Cholecystokinin 33 (CCK33), CCKN_HUMAN
6828 HLA class I histocompatibility antigen, A-24 alpha chain precursor (MHC class I antigen A*24) (Aw-24) (A-9) 1A24 JHUMAN
6829 HLA class I histocompatibility antigen, B-27 alpha chain precursor (MHC class I antigen B*27) 1B27_HUMAN
6830 HLA class I histocompatibility antigen, Cw 3 alpha chain precursor (MHC class I antigen Cw"3) 1C03_HUMAN
6831 HLA class Il histocompatibility antigen, DO alpha chain precursor class Il antigen DOA) (MHC DZ alpha) (MHC DN-alpha) 2D0A_HUMAN
6832 Alpha-1B-glycoproteιπ precursor (Alpha-1-B glycoprotein) A1BG_HUMAN
6833 T-cell surface glycoprotein CD1a precursor (CD1a antigen) (T-cell surface antigen T6/Leu-6) (hTa1 thymocyte antigen) CDIA-HUMAN
6834 Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (Proteasi A4JHUMAN
6835 T-cell surface antigen CD2 precursor (T-cell surface antigen T11/Leu-5) (LFA-2) (LFA-3 receptor) (Erythrocyte receptor) (Rosette CD2JHUMAN
6836 T-cell surface glycoprotein CD3 delta chain precursor (T-cell receptor T3 delta chain) CD3D_HUMAN
6837 T-cell surface glycoprotein CD3 epsilon chain precursor (T-cell surface antigen T3/Leu-4 epsilon chain) CD3EJHUMAN
6838 T-cell surface glycoprotein CD5 precursor (Lymphocyte glycoprotein T1/Leu-1) (Lymphocyte antigen CD5) CD5_HUMAN
6839 Complement C2 precursor (EC 3421 43) (C3/C5 convertase) C02_HUMAN
6840 Collagen alpha 2(V) chain precursor CO5A2 JHUMAN
6841 Complement component C8 alpha chain precursor (Complement component 8 alpha subunit) C08AJ-1UMAN
6842 Complement component C8 beta chain precursor (Complement component 8 beta subunit) C08B_HUMAN
6843 Complement component C8 gamma chain precursor C08G_HUMAN
6844 Annexin A2 (Annexin II) (Lipocortin II) (Calpactin I heavy (Chromobindin 8) (p36) (Protein I) (Placental anticoagulant protein ANXA2JHUMAN
6845 Cathepsιn D precursor(EC34235) CATD_HUMAN
6846 Cathepsin L precursor (EC 342215) (Major excreted protein) (MEP) CATL_HUMAN
6847 Colipase precursor COL_HUMAN
6848 Asialoglycoproteiπ receptor 1 (Hepatic lectin H1) (ASGPR) (ASGP-R) ASGR1 JHUMAN
6849 Asialoglycoprotein receptor2 (Hepatic lectin H2) (ASGP-R) (ASGPR) ASGR2 JHUMAN
6850 C4b-bιnding protein alpha chain precursor (C4bp) (Proline-nch protein) (PRP) C4BPJHUMAN
6851 Pancreatic alpha-amylase precursor (EC 32 1 1) (PA) (1,4-alpha-D- glucan glucanohydrolase) AMYPJHUMAN
6852 Serum albumin precursor (PRO0903) (UNQB96/PRO1341) ALBU_HUMAN
6853 Apohpoprotein A-IV precursor (Apo-AIV) (ApoA-IV) AP0A4JHUMAN
6854 Apolipoprotein B-100 precursor (Apo B 100) [Contains Apolipoprotein B-48 (Apo B-48)] APOBJHUMAN
6855 ATP synthase protein 8 (EC 36314) (ATPase subunit 8) ATP8_HUMAN
6856 Carcinoembryonic antigen-related cell adhesion molecule 5 precursor (Carcinoembryonic antigen) (CEA) (Meconium antigen 100) (CD66e CEAM5JHUMAN
6857 Sodium/potassium transporting ATPase alpha-1 chain precursor (EC 3639) (Sodium pump 1) (Na+/K+ ATPase 1) AT1A1 JHUMAN
6858 Sodium/potassium-transportiπg ATPase beta-1 chain (Sodium/potassium- dependent ATPase beta-1 subunit) AT1B1JHUMAN
6859 ATP synthase lipid-biπding protein, mitochondπal precursor (EC 363 14) (ATP synthase proteolipid P1) (ATPase protein 9) AT5G1JHUMAN
6860 Apolipoprotein D precursor (Apo D) (ApoD) APOD_HUMAN
6861 ATP synthase beta chain, mitochondπal precursor (EC 36314) ATPBJHUMAN
6862 Acetylcholine receptor protein, gamma chain precursor ACHGJHUMAN
6863 Anion exchange protein 2 (Non-erythroid band 3-like protein) (BND3L) B3A2_HUMAN
6864 Cytochrome P450 11A1, mitochondrial precursor (EC 1 14156) (CYPXIA1) (P450(scc)) (Cholesterol side-chain cleavage enzyme) (Choleste CP11AJHUMAN
6865 Cytochrome P450 17A1 (EC 1 14999) (CYPXVIl) (P450-C17) (P450C17) (Steroid 17-alpha-hydroxylase/17,20 lyase) CP17AJHUMAN
6866 Cytochrome P4501A1 (EC 1 14 141) (CYPIA1) (P450-P1) (P450 form (P450-C) CP1A1JHUMAN
6867 Cytochrome P450 1A2 (EC 1 1414 1) (CYPIA2) (P450-P3) (P(3)450) (P4504) CP1A2 JHUMAN
6868 Beta casein precursor CASBJHUMAN
6869 Kappa casein precursor CASK_HUMAN
6870 Coagulation factor Xl precursor (EC 3421 27) (Plasma thromboplastin antecedent) (PTA) (FXl) FA11 j-WMAN
6871 Estrogen receptor (ER) (Estradiol receptor) (ER-alpha) ESR1_HUMAN
6872 Cholinesterase precursor (EC 3 1 1 8) (Acylcholine acylhydrolase) (Choline esterase II) (Butyrylcholine esterase) CHLEJHUMAN
6873 Cytochrome P4502E1 (EC 1 14141) (CYPIIE1) (P450-J) CP2E1 JHUMAN
6874 Beta-2 adrenergic receptor (Beta-2 adrenoceptor) (Beta-2 adrenoreceptor) ADRB2JHUMAN
6875 ADP1ATP earner protein, fibroblast isoform (ADP/ATP translocase 2) (Adenine nucleotide translocator 2) (ANT 2) (Solute earner family ADT2JHUMAN
6876 Corticohbeπn precursor (Corticotropin-releasing factor) (CRF) (Corticotropin-releasing hormone) CRF_HUMAN
6877 Cytochrome B-245 heavy chain (P22 phagocyte B cytochrome) (Neutrophil cytochrome B, 91 kDa polypeptide) (CGD91-PHOX) (GP91-PHO>CY24BJHUMAN
6878 Low affinity immunoglobulin epsilon Fc receptor (Lymphocyte IgE receptor) (Fc-epsilon RII) (CD23 antigen) (BLAST-2) (Immunoglobulin FCER2JHUMAN
6879 Complement factor I precursor (EC 3421 45) (C3B/C4B inactivator) CFAIJHUMAN
6880 Calcitonin gene-related peptide I precursor (CGRP-I) (Alpha-type CGRP) CALCAJHUMAN
6881 Cytochrome P4503A3 (EC 1 14141) (CYPIIIA3) (HLp) CP3A3 JHUMAN
6882 Alpha-fetoprotein precursor (Alpha-fetoglobuliπ) (Alpha-1-fetoproteιn) FETA_HUMAN
6883 Glycophoπn B precursor (PAS-3) (Sialoglycoprotein delta) (SS-actve sialoglycoprotem) (CD235b antigen) GLPB-HUMAN
6884 Glycophoππ C (PAS-2) (Glycoprotein beta) (GLPC) (Glycoconnectin) (Sialoglycoprotem D) (Glycophonπ D) (GPD) GLPC-HUMAN
6885 Eπdothelιn-1 precursor (Preproendothelιn-1) (PPET1) [Contains Endothelin-1 (ET-1), Big endothelial] EDN1 JHUMAN
6886 Glucosylceramidase precursor (EC 321 45) (Beta-glucocerebrosidase) (Acid beta-glucosidase) (D-glucosyl N acylsphingosine glucohydrolas GLCM J-IUMAN
6887 Macrophage colony stimulating factor I receptor precursor (CSF-1 -R) (EC 271 112) (Fms proto-oncogene) (c-fms) (CD115 antigen) CSF1 RJHUMAN
6888 Granulocyte-macrophage colony stimulating factor precursor (GM-CSF) (Colony-stimulating factor) (CSF) (Sargramostim) (Molgramostin) CSF2_HUMAN
6889 Coagulation factor XIIl B chain precursor (Protein-glutamine gamma- glutamyltransferase B chain) (Transglutaminase B chain) (Fibπn F13B_HUMAN
6890 Hepaππ-binding growth factor 1 precursor (HBGF-1) (Acidic fibroblast growth factor) (aFGF) (Beta-endothelial cell growth factor) (ECGF- FGF1 JHUMAN
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Group
PID Descπption UniProt ACC reticulum Nuclear cellular skeletal somal anchor somal 1 2 3
6891 Glia denved πexin precursor (GDN) (Protease nexin I) (PN-1) inhibitor 7) GDN-HUMAN Y
6892 Gelsolin precursor (Actin-depolymeπzing factor) (ADF) (Brevin) (AGEL) GELS_HUMAN
6893 HLA class Il histocompatibility antigen, DQ(W3) beta chain precursor HB23_HUMAN
6894 Interferon omega-1 precursor (Interferon alpha-ll-1) IFNW1_HUMAN
6895 Insulin-like growth factor IB precursor (IGF-IB) (Somatomedin C) IGF1 B_HUMAN
6896 Platelet glycoprotein Ib alpha chain precursor (Glycoprotein Ibalpha) (GP-Ib alpha) (GPIbA) (GPIb-alpha) (CD42B-alpha) (CD42B) [Contains GP1 BAJHUMAN
6897 Hemopexin precursor (Beta-1B-glycoprotein) HEMO-HUMAN
6898 Hepann cofactor Il precursor (HC-II) (Protease inhibitor leuserpin 2) (HLS2) HEP2 JHUMAN
6899 Seππe protease hepsin (EC 3421 -) (Transmembrane protease, serine 1) HEPS-HUMAN
6900 Histidine-πch glycoprotein precursor (Histidine-proline πch glycoprotein) (HPRG) HRG-HUMAN
6901 Epoxide hydrolase 1 (EC 3323) (Microsomal epoxide hydrolase) (Epoxide hydratase) HYEP-HUMAN
6902 HLA class Il histocompatibility antigen, SB beta chain (Clone beta) (Fragment) HB2T_HUMAN
6903 HLA class Il histocompatibility antigen, DX beta chain precursor HB2X_HUMAN
6904 3-hydroxy-3-methylglutaryl coenzyme A reductase (EC 1 1 1 34) (HMG CoA reductase) HMDH-HUMAN
6905 ϋpoprotem lipase precursor (EC 3 1 1 34) (LPL) LIPL-HUMAN
6906 Ig kappa chain V-II region GM607 precursor (Fragment) KV2EJHUMAN
6907 Ig kappa chain V-Il region RPMI 6410 precursor KV2FJHUMAN
6908 Ig kappa chain V-III region GOL (Rheumatoid factor) KV3G_HUMAN
6909 Ig kappa chain V-III region CLL precursor (Rheumatoid factor) KV3H_HUMAN
6910 Ig kappa chain V-III region VG precursor (Fragment) KV3I_HUMAN
6911 Ig kappa chain V-III region VH precursor (Fragment) KV3J_HUMAN
6912 Ig kappa chain V-III region IARC/BL41 precursor KV3K_HUMAN
6913 Ig kappa chain V-IV region precursor (Fragment) KV40JHUMAN
6914 Ig kappa chain V-IV region JI precursor KV4BJ1UMAN
6915 Ig kappa chain V-IV region B17 precursor KV4CJHUMAN
6916 Ig kappa chain V region EV15 precursor
6917 HLA class Il histocompatibility antigen, gamma chain (HLA-DR antigens associated invanant chain) (Ia antigen-associated invariant chain) HG2A_HUMAN
6918 Inhibiπ alpha chain precursor INHA-HUMAN
6919 Insulin receptor precursor (EC 27 1 112) (IR) (CD220 antigen) INSR-HUMAN
6920 Plasma senne protease inhibitor precursor (PCI) (Protein C inhibitor) (Plasminogen activator ιnhιbιtor-3) (PAI3) (Acrosomal seπne protease IPSP-HUMAN
6921 NADH-ubiqumoπe oxidoreductase chain 5 (EC 1 653) (NADH dehydrogenase subunit 5) NU5M_HUMAN
6922 NADH-ubiquinone oxidoreductase chain 6 (EC 1 653) (NADH dehydrogenase subunit 6) NU6MJHUMAN
6923 High affinity nerve growth factor receptor precursor (EC 27 1 112) (Neurotrophic tyrosine kinase receptor type 1) (TRK1 transforming NTRK1_HUMAN
6924 NADH-ubiquinone oxidoreductase chain 1 (EC 1 653) (NADH dehydrogenase subunit 1) NUIM-HUMAN
6925 NADH-ubiquinone oxidoreductase chain 2 (EC 1 653) (NADH dehydrogenase subunit 2) NU2MJHUMAN
6926 lntegnn alpha-V precursor (Vitronectin receptor alpha subunit) (CD51 antigen) ITAV-HUMAN
6927 lntegnn beta-1 precursor (Fibronectin receptor beta subunit) (CD29 antigen) (lntegnn VLA-4 beta subunit) ITBI-HUMAN
6928 lntegnn beta-2 precursor (Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 bεta-subunit) (CD18) (Complement receptor C3 beta- ITB2_HUMAN
6929 lntegnn beta-3 precursor (Platelet membrane glycoprotein Ilia) (GPIIIa) (CD61 antigen) ITB3_HUMAN
6930 Ferntin heavy chain (EC 1 163 1) (Ferπtin H subunit) (Proliferation inducing gene 15 protein) FRlH-HUMAN
6931 Receptor tyrosine-protein kinase erbB-2 precursor (EC 271 112) (p185erbB2) (C-erbB-2) (NEU proto-oncogeπe) (Tyrosine kinase-type cell ERBB2_HUMAN
6932 Plasma protease C1 inhibitor precursor (C1 Inh) (C1lnh) ICI-HUMAN
6933 Intercellular adhesion molecule-1 precursor (ICAM-1) (Major group rhinovirus receptor) (CD54 antigen) !CAMI-HUMAN
6934 HLA class II histocompatibility antigen, DQ(2) alpha chain precursor HA22_HUMAN
6935 HLA class Il histocompatibility antigen, DQ(4) alpha chain precursor (DQ DRW9 alpha chain) (Fragment) HA24_HUMAN
6936 HLA class Il histocompatibility antigen, DQ(W3) alpha chain precursor HA27_HUMAN
6937 lnterIeukin-4 precursor (IL-4) (B-cell stimulatory factor 1) (BSF-1) (Lymphocyte stimulatory factor 1) IL4_HUMAN
6938 lnterleukιn-5 precursor (IL-5) (T-cell replacing factor) (TRF) (Eosinophil differentiation factor) (B cell differentiation factor I) IL5JHUMAN
6939 lnterleukin 6 precursor (IL-6) (B-cell stimulatory factor 2) (BSF-2) (Interferon beta-2) (Hybπdoma growth factor) (CTL differentiation IL6_HUMAN
6940 Ig heavy chain V-I region MoL HVIF-HUMAN
6941 Ig heavy chain V-H region SESS precursor HV2H_HUMAN
6942 Ig heavy chain V-Il region ARH-77 precursor HV2I_HUMAN
6943 Muellerian inhibiting factor precursor (MIS) (Anti-Musllenan hormone) (AMH) (Mullerian inhibiting substance) MIS-HUMAN
6944 Prostate specific antigen precursor (EC 34.21 77) (PSA) (Gamma- seminoprotein) (Kallikrein 3) (Semenogelase) (Seminiπ) (P-30 antigen) KLK3_HUMAN
6945 Plasma kallikrein precursor (EC 3421 34) (Plasma prekallikrein) (Kininogenin) (Fletcher factor) KLKB1_HUMAN
6946 Phosphatidylcholine-sterol acyltransferase precursor (EC 231 43) (Lecithin-cholesterol acyltransferase) (Phospholipid-cholesterol LCAT-HUMAN
6947 Keratin, type II cytoskeletal 1 (Cytokeratin 1) (K1) (CK cytokeratin) (Hair alpha protein) K2C1_HUMAN
6948 Interferon alpha-16 precursor (Interferon alpha-WA) IFN16_HUMAN
6949 Interferon alpha-4 precursor (Interferon alpha-4B) (Interferon alpha M1) (Interferon alpha-76) IFNA4_HUMAN
6950 fπterferon alpha-6 precursor (Interferon alpha-K) (LeIF K) (Interferon alpha-54) IFNA6_HUMAN
6951 Protein kinase C, beta type (EC 271 37) (PKC-beta) (PKC-B) KPCB-HUMAN
6952 Ig kappa chain V-I region BAN KVIV-HUMAN
6953 Ig kappa chain V-I region Walker precursor KVIW-HUMAN
6954 Ig kappa chain V-I region Daudi precursor KVIX-HUMAN
6955 Decoπn precursor (Bone proteoglycan II) (PG-S2) (PG40) PGS2JHUMAN
Endoplasmic Extra- Cyto- PeroxiGPI- Micro- Group Group Group
PID Description UπiProt ACC reticulum Nuclear cellular skeletal somal anchor soma! 1 2 3
6956 Thyroid peroxidase precursor(EC 1 11 1 8) (TPO) PERT-HUMAN
6957 Basic salivary proline-πch protein 2 (Salivary pro[ιne-πch protein) (Con1 glycoprotein) [Contains Basic peptide P-F] (Fragment) PRB2_HUMAN
6958 Osteocalcin precursor (Gamma carboxyglutamic acid-containing protein) (Bone GIa protein) (BGP) OSTC_HUMAN
6959 MAS proto-oncogene MAS-HUMAN
6960 Vitamin K-dependeπt protein S precursor PROS_HUMAN
6961 Platelet-denved growth factor A chain precursor (PDGF A-chain) (Platelet-deπved growth factor alpha polypeptide) (PDGF-1) PDGFA_HUMAN
6962 Protein disulfide-isomerase precursor (EC 534 1) (PDI) (Prolyl 4-hydroxylase beta subuπit) (Cellular thyroid hormone binding protein) PDIA1_HUMAN
6963 Blue-sensitive opsin (BOP) (Blue cone photoreceptor pigment) OPSB-HUMAN 69S4 Interstitial collagenase precursor (EC 34247) (Matnx metalloproteιnase-1) (MMP-1) (Fibroblast collagenase) MMP1JHUMAN
6965 Ig lambda chain V region 4A precursor LVOA-HUMAN
6966 Ig lambda chain V-I region WAH LVIF-HUMAN
6967 Ig lambda chain V-I region BL2 precursor LVIG-HUMAN
6968 Ig lambda chain V-I region MEM LVIH-HUMAN
6969 Ig lambda chain V-I region EPS LV1I_HUMAN
6970 Ig lambda chain V-Il region NIG-84 LV2K.HUMAN
6971 Ig lambda chain V-IV region MOL LV4E_HUMAN
6972 Ig lambda chain V-Vl region WLT LV6D_HUMAN
6973 !g lambda chain V-Vl region EB4 precursor LV6E_HUMAN
6974 Basic salivary proline-πch protein 1 precursor (Salivary proline-πch protein) [Contains Basic peptide IB-6 Peptide P-H] PRPI-HUMAN
6975 Basic proline-πch peptide IB-1 PRP5_HUMAN
6976 Salivary acidic proline-πch phosphoprotein 1/2 precursor (PRP-1/PRP-3) (PRP-2/PRP-4) (PIF-F/PIF-S) (Protein A/protein C) PRPC-HUMAN
6977 Basic proline-nch peptide P-E (IB-9) PRPE-HUMAN
6978 Alkaline phosphatase, placental type precursor (EC 3 1 31) (PLAP-1) (Regan isozyme) PPB1_HUMAN
6979 Alkaline phosphatase, tissue-nonspecific isozyme precursor (EC 3 1 3 1) (AP-TNAP) (Liver/bone/kidney isozyme) (TNSALP) PPBT-HUMAN
6980 Green-sensitive opsin (Green cone photoreceptor pigment) OPSG-HUMAN
6981 Red sensitive opsin (Red cone photoreceptor pigment) OPSR-HUMAN
6982 DolichyWiphosphooligosacchaπde-protein glycosyltransferase 67 kDa subunit precursor (EC 241 119) (Ribophoπn I) (RPN I) RIBI-HUMAN
6983 Dolichyl-diphosphooligosacchaπde-protein glycosyltransferase 63 kDa subunit precursor (EC 24 1 119) (Ribophonn II) (RPN-II) (RIBIIR) RIB2_HUMAN
6984 Vitamin K-depeπdent protein C precursor (EC 3421 69) (Autoprothrombiπ HA) (Anticoagulant protein C) (Blood coagulation PROC-HUMAN
6985 Plasminogen activator ιnhιbιtor-1 precursor (PAH) (Endothelial plasminogen activator inhibitor) (PAI) PAII-HUMAN
6986 Proline-πch protein 3 precursor (Proline-πch peptide P-B) [Contains Peptide P-A, Peptide D1 A] PR0L3__HUMAN
6987 NADH-ubiquinone oxidoreductase chain 3 (EC 1 653) (NADH dehydrogenase subunit 3) NU3M_HUMAN
6988 NADH-ubiquinone oxidoreductase chain 4L (EC 1653) (NADH dehydrogenase subunit 4L) NU4LM_HUMAN
6989 NADH-ubiquinone oxidoreductase chain 4 (EC 1 653) (NADH dehydrogenase subunit 4) NU4M_HUMAN
6990 RAF proto-oncogene seπne/threomne-protein kinase (EC 27 1 37) (RaM) (C-RAF) (cRaf) RAFI-HUMAN
6991 Platelet factor4 precursor (PF-4) (CXCL4) (Oncostatiπ A) (Iroplact) PLF4JHUMAN
6992 Semenogelιn-1 precursor (Semenogelin I) (SGI) [Contains Alpha- ιnhιbιn-92, Alpha-inhibin 31 , Seminal basic protein] SEMG1_HUMAN
6993 Tetranectin precursor (TN) (Plasminogen kπngle 4 binding protein) TETN-HUMAN
6994 Platelet basic protein precursor (PBP) (Small inducible cytokine B7) (CXCL7) (Leukocyte-denved growth factor) (LDGF) (Macrophage-deπved SCYB7_HUMAN
6995 Small inducible cytokine B10 precursor (CXCL10) (10 kDa interferon- gamma induced protein) (Gamma IP10) (IP-10) [Contains CXCL10(1-7
6996 Prorelaxin H1 precursor RELI-HUMAN
6997 Prorelaxin H2 precursor REL2JHUMAN
6998 Proactivator polypeptide precursor [Contains Saposin A (Protein A), Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebroside SAP-HUMAN
6999 Ubiquinol-cytochrome c reductase complex 11 kDa protein mitochondnal precursor (EC 1 10.22) (Mitochondrial hinge protein) (Cytochrome (UCRH-HUMAN
7000 Ubiquitin cross-reactive protein precursor (Iπterferon-induced 17 kDa protein) (Interferon-induced 15 kDa protein) UCRP-HUMAN
7001 UDP-glucuronosyltransferase 2B4 precursor (EC 24 1 17) (UDPGT) (Hyodeoxycholic acid) (HLUG25) (UDPGTh-1) UDB4_HUMAN
7002 Thy-1 membrane glycoprotein precursor (Thy-1 antigen) (CDw90) (CD90 antigen) THYI-HUMAN
7003 Transfemn receptor protein 1 (TfRI) (TR) (TfR) (Trfr) (CD71 (T9) (p90) TFRI-HUMAN
7004 Trypsin I precursor (EC 34214) (Cationic trypsinogeπ) TRYI-HUMAN
7005 T-cell receptor gamma chain C region PT-gamma-1/2 TCC-HUMAN
7006 Uromodulin precursor (Tamm-Horsfall uππary glycoprotein) (THP) UROM-HUMAN
7007 Secretαgranιn-1 precursor (Secretogranin I) (SgI) (Chromogranin B) (CgB) [Contains GAWK peptide, CCB peptide] SCGI-HUMAN
7008 Sex hormone-binding globulin precursor (SHBG) (Sex steroid-binding protein) (SBP) (Testis-specific androgen binding protein) (ABP) SHBG-HUMAN
7009 Transthyretin precursor (Prealbumin) (TBPA) (TTR) (ATTR) TTHY-HUMAN
7010 Thrombomodulin precursor (TM) (Fetomodulin) (CD141 antigen) TRBM-HUMAN
7011 Stathenn precursor STAT_HUMAN
7012 Thyroxine-binding globulin precursor (T4-bιndιng globulin) THBG-HUMAN
7013 Vitamin D-binding protein precursor (DBP) (Group-specific component) (Gc-globulin) (VDB) VTDB-HUMAN
7014 Vitronectin precursor (Serum spreading factor) (S-protein) (V75) [Contains Vitronectin V65 subunit, Vitronectin V10 subunit, VTNC-HUMAN
7015 Wnt-1 proto-oncogene protein precursor WNTI-HUMAN
7016 S-100 calcium binding protein beta subunit (S-100 protein, beta chain) S100B_HUMAN
7017 Calcyclin (Prolactin receptor associated protein) (PRA) (Growth factor-mduαble protein 2A9) (S100 calcium binding protein A6) (MLN S10A6_HUMAN
7018 Calgranuliπ A (Migration inhibitory factor-related protein 8) (MRP-8) (Cystc fibrosis antigen) (CFAG) (P8) (Leukocyte L1 complex light S10A8_HUMAN
7019 Calgranulin B (Migration inhibitory factor-related protein 14) (MRP-14) (P14) (Leukocyte L1 complex heavy chain) (S100 calcium- S10A9_HUMAN
7020 Serotransferπn precursor (Transfemn) (Siderophilin) (Beta-1-metaI binding globulin) (PRO1400) TRFE-HUMAN
Figure imgf000298_0001
Figure imgf000299_0001
Figure imgf000300_0001
Figure imgf000301_0001
Endoplasmic Extra- Cyto- Peroxi- GPI- Micro- Group Group Group
PlD Description UniProt ACC reticulum Nuclear cellular skeletal soma! anchor somal 1 2 3
7281 Carboxypeptidase N catalytic chain precursor (EC 34173) (Lysine carboxypeptidase) (Arginine carboxypeptidase) (Kiπiπase 1) (Serum CBPN_HUMAN Y + +
7282 D(2) dopamine receptor (Dopamine D2 receptor) DRD2_HUMAN
7283 Cytochrome c oxidase polypeptide Vlla-liver/heart, mitochondrial precursor (EC 1 93 1) (Cytochrome c oxidase subunit ViIa-L) (VIIaL) CX7A2_HUMAN
7284 Gap junction alpha-1 protein (Connexin 43) (Cx43) (Gap junction heart protein) CXA1_HUMAN
7285 Eπdoglin precursor (CD105 antigen) EGLNJ-IUMAN
7286 Muscarinic acetylcholine receptor M3 ACM3JHUMAN
7287 Eπdoplasmm precursor (94 kDa glucose-regulated protein) (GRP94) (gp96 homolog) (Tumor rejection antigen 1) ENPL_HUMAN
7288 Neural-cadheπn precursor (N-cadheπn) (Cadhenn-2) CADH2_HUMAN
7289 Cytochrome P4502A7 (EC 1 14 14 1) (CYPIIA7) (P450-IIA4) CP2A7_HUMAN
7290 Cytochrome P4502B6 (EC 1 14141) (CYPIIB6) (P450 IIB1) CP2B6_HUMAN
7291 Beta-3 adrenergic receptor (Beta-3 adrenoceptor) (Beta-3 adrenoreceptor) ADRB3JHUMAN
7292 Cysteme-πch secretory proteιn-2 precursor (CRISP-2) (Testis-specific protein TPX-1) CRIS2_HUMAN
7293 Follistatin precursor (FS) (Activin-binding protein) FST-HUMAN
7294 Cytotoxic T-!ymphocyte protein 4 precursor (Cytotoxic T-lymphocyte- associated antigen 4) (CTLA-4) (CD152 antigen) CTLA4_HUMAN
7295 Cytochrome P4503A5 (EC 1 14 14 1) (CYPIIIA5) (P450-PCN3) (HLp2) CP3A5_HUMAN
7296 Erythrocyte membrane protein band 4.2 (Erythrocyte protein 42) (P42) EPB42_HUMAN
7297 EIaBn precursor (Elastase-specific inhibitor) (ESI) (Skin-denved aπtileukoproteinase) (SKALP) (WAP four-disulfide core domain protein ELAF_HUMAN
7298 Elastin precursor (Tropoelastin) ELN-HUMAN
7299 Desmoplakin (DP) (250/210 kDa paraneoplastic pemphigus antigen) DESP_HUMAN
7300 Chymotrypsinogen B precursor (EC 3421 1) CTRB1_HUMAN
7301 5-lιpoxygenase activating protein (FLAP) (MK-886-bιnding protein) FLAP_ffuMAN
7302 Glyccphoπn E precursor GLPE-HUMAN
7303 Folate receptor alpha precursor (FR-alpha) (Folate receptor 1) (Folate receptor, adult) (Adult folate-binding protein) (FBP) (Ovanan tumor- FOLR1_HUMAN
7304 Folate receptor beta precursor (FR-beta) (Folate receptor 2) (Folate receptor, fetal/placental) (Placental folate-binding protein) (FBP) FOLR2_HUMAN
7305 Ephnn-A1 precursor (EPH-related receptor tyrosine kinase ligand 1) (LERK-1) (Immediate early response protein B61) (Tumor necrosis EFNA1_HUMAN
7306 Eπdothelιn-2 precursor (ET-2) (Preproendothelιn-2) (PPET2) EDN2JHUMAN
7307 Endothelιn-3 precursor (ET-3) (Preproenαothelιn-3) (PPET3) EDN3_HUMAN
7308 Grave's disease earner protein (GDC) (Grave's disease autoantigen) (GDA) (Mitochondπal solute earner protein homolog) GDC_HUMAN
7309 Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor (GM-CSF-R-alpha) (GMR) (CDw116) (CD116 antigen) CSF2R_HUMAN
7310 Ezπn (p81) (Cytovillin) (Villin 2) EZRI_HUMAN
7311 Galactoside 2-alpha-L-fucosyltransferase 1 (EC 241 69) (GDP-L- fucose beta-D-galactoside 2-alpha-L-fucosyltransferase 1) FUT1_HUMAN
7312 Galactoside 3(4)-L-fucosyltransferase (EC 241 65) (Blood group Lewis alpha-4-fu∞syltransferase) (Lewis FT) (Fucosyltraπsferase 3) (FUCT FUT3_HUMAN
7313 Hexokmase, type I (EC 271 1) (HK I) (Brain form HXK1 J-IUMAN
7314 Guanine nucleotide-bindiπg protein G(t), alpha-2 subunit (Traπsducin alpha-2 chain) GNAT2_HUMAN
7315 Guanine nucleotide-binding protein G(z) alpha subunit (G(x) alpha chain) (Gz-alpha) GNAZ_HUMAN
7316 Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 3 (Transduαn beta chain 3) GBB3_HUMAN
7317 HLA class I histocompatibility antigen, alpha chain G precursor antigen) HLAG_HUMAN
7318 Histatin 3 precursor (Histidme-πch protein 3) (PB) (Basic histidine- nch protein) [Contains Hιstatιn 3 Hιstatιn 4 Hιstatιπ 5, HIS3_HUMAN
7319 Gamma-glutamyltranspeptidase 1 precursor (EC 2322) (Gamma- glutamyltransferase 1) (CD224 antigen) [Contains Gamma- GGT1JHUMAN
7320 Gamma-ammobutyπc acid receptor alpha-1 subunit precursor (GABA(A) receptor) GBRA1_HUMAN
7321 Gamma-aminobutyπc-aαd receptor beta-1 subunit precursor (GABA(A) receptor) GBRB1_HUMAN
7322 Gamma-aminobutyπc-acid receptor gamma-2 subunit precursor (GABA(A) receptor) GBRG2_HUMAN
7323 Ig kappa chain V-III region HAH precursor KV3L_HUMAN
7324 Ig kappa chain V-III region HIC precursor KV3MJ-IUMAN
7325 Iπterferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC) INAR1_HUMAN
7326 Interferon-gamma receptor alpha chain precursor (IFN-gamma-R1) (CD119 antigen) (CDw119) INGR1_HUMAN
7327 Insulin receptor-related protein precursor (EC 271 112) (IRR) (IR-related receptor) INSRR_HUMAN
7328 Integπn alpha-L precursor (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1 A) (Leukocyte function associated molecule 1 , alpha lTALJHUMAN
7329 Integπn alpha-X precursor (Leukocyte adhesion glycoprotein p150,95 alpha chain) (Leukocyte adhesion receptor p150,95) (CD11c) (Leu M5) ITAX_HUMAN
7330 Integπn beta-4 precursor (GP150) (CD104 antigen) ITB4_HUMAN
7331 lntegnn beta-5 precursor ITB5JHUMAN
7332 Integπn beta-6 precursor ITB6_HUMAN
7333 Inter-alpha-trypsin inhibitor heavy chain H1 precursor (ITI heavy chain H1) (Inter-alpha inhibitor heavy chain 1) (Inter-alpha-trypsin 1TIH1_HUMAN
7334 Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin 1TIH2_HUMAN
7335 Immunoglobulin tambda-like polypeptide 1 precursor (Immunoglobulin- related 141 protein) (Immunoglobulin omega polypeptide) (Lambda 5) IGLL1JHUMAN
7336 Solute earner family 2, facilitated glucose transporter, member 4 (Glucose transporter type 4, insulin-responsive) GTR4_HUMAN
7337 Erythropoietin receptor precursor (EPO-R) EPORJHUMAN
7338 Histatin 1 precursor (Histdine-πch protein 1) (Post-PB protein) (PPB) [Contains Histatin 2] HIS1_HUMAN
7339 Leukosialm precursor (Leucocyte sialoglycoproteiπ) (Sialophonn) (CD43 antigen) (Galactoglycoprotein) (GALGP) LEUK-HUMAN
7340 Lymphocyte function-associated antigen 3 precursor (Ag3) (Antigen CD58) (Surface glycoprotein LFA-3) LFA3_HUMAN
7341 lnterleukιn-11 precursor (IL-11) (Adipogenesis inhibitory factor) (AGIF) (Oprelvekm) IL11_HUMAN
7342 lnterleukιπ-1 receptor, type I precursor (IL-1 R-1) (IL-1 R-alpha) (P80) (Antigen CD121a) IL1 P."Ϊ_HUMAN
7343 lnterleukιπ-1 receptor antagonist protein precursor (IL-1ra) (IRAP) (IL1 inhibitor) (IL-1 RN) (ICIL-1RA) IL1RA_HUMAN
7344 Insulin-like growth factor binding protein 2 precursor (IGFBP-2) (IBP-2) (IGF-binding protein 2) IBP2_HUMAN
7345 Insulin-like growth factor binding protein 3 precursor (IGFBP-3) (IBP-3) (IGF-binding protein 3) IBP3_HUMAN
Figure imgf000303_0001
Figure imgf000304_0001
Figure imgf000305_0001
Figure imgf000306_0001
Figure imgf000307_0001

Claims

1. A target-specific imaging reagent, comprising an antibody coupled to an imaging agent detectable by magnetic resonance, wherein said antibody specifically binds to Glypican-3, wherein expression of Glypican-3 is predictive of liver cancer.
2. A target-specific imaging reagent, comprising an antibody coupled to an imaging agent detectable by magnetic resonance, wherein said antibody specifically binds to MAGE- 1, wherein expression of MAGE-I is predictive of liver cancer.
3. A method of diagnosing or monitoring liver cancer comprising: administering to a mammal the target-specific imaging reagent of claim 1, imaging said mammal using magnetic resonance, and diagnosing or monitoring liver cancer.
4. A method of diagnosing or monitoring liver cancer comprising: administering to a mammal the target-specific imaging reagent of claim 2, imaging said mammal using magnetic resonance, and diagnosing or monitoring liver cancer.
PCT/US2006/034703 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer Ceased WO2007030531A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71479005P 2005-09-06 2005-09-06
US60/714,790 2005-09-06

Publications (2)

Publication Number Publication Date
WO2007030531A2 true WO2007030531A2 (en) 2007-03-15
WO2007030531A3 WO2007030531A3 (en) 2007-11-15

Family

ID=37836417

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/034703 Ceased WO2007030531A2 (en) 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer
PCT/US2006/034777 Ceased WO2007030571A2 (en) 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034777 Ceased WO2007030571A2 (en) 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease

Country Status (1)

Country Link
WO (2) WO2007030531A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US8900822B2 (en) 2011-11-21 2014-12-02 Ethicon, Inc. Fibrinogen assay
US9200055B2 (en) 2007-02-26 2015-12-01 Oxford Biotherapeutics, Ltd. Protein
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
CN107328746A (en) * 2017-06-14 2017-11-07 宁波大学 The preparation and application of Multifunction fluorescent biology sensor based on class nucleic acid coordination polymer
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
CN109701039A (en) * 2019-01-17 2019-05-03 浙江大学 A kind of preparation method of liver cancer dual-target magnetic nanoparticle
CN109897900A (en) * 2019-03-13 2019-06-18 温州医科大学 Application of the EPB42 gene in liver cancer SBRT curative effect evaluation
CN111273010A (en) * 2018-12-04 2020-06-12 北京蛋白质组研究中心 Application of the kit for detecting the expression level of SOAT1 protein in the preparation of products for screening hepatocellular carcinoma
CN111337676A (en) * 2018-12-18 2020-06-26 欧蒙医学实验诊断股份公司 Method for diagnosing autoimmune gastritis
CN113151482A (en) * 2021-05-21 2021-07-23 深圳泰莱生物科技有限公司 Method for identifying benign and malignant lung nodules based on monochromatic multiple fluorescence quantitative PCR
CN113249476A (en) * 2021-05-12 2021-08-13 复旦大学 Key protein BLT2 affecting dryness of tumor cells and application thereof
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU (CLU) and composition thereof in diagnosis of bile duct cancer and bile duct cancer diagnosis kit
CN117647645A (en) * 2024-01-29 2024-03-05 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
CN118471472A (en) * 2024-05-22 2024-08-09 中国人民解放军海军军医大学第三附属医院 Marker, kit, system and application for screening or diagnosing early liver cancer
CN120758627A (en) * 2025-06-30 2025-10-10 南方医科大学南方医院 A biomarker, scoring model and application for predicting the prognosis of BPA-induced intrahepatic cholangiocarcinoma

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127293B2 (en) 2006-07-26 2015-09-08 The University Of Chicago Receptor-mediated delivery: compositions and methods
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
DE102008039417A1 (en) 2008-08-13 2010-02-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agent for the detection and treatment of prostate cells
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
BR112021024853A2 (en) * 2019-06-14 2022-01-18 Seegene Inc Computer-implemented method for collaborative development of reagents for the detection of target nucleic acids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6774223B2 (en) * 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
ATE478041T1 (en) * 2002-04-30 2010-09-15 Univ Emory COMPOUNDS FOR IMAGING TUMORS
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200055B2 (en) 2007-02-26 2015-12-01 Oxford Biotherapeutics, Ltd. Protein
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US9394358B2 (en) 2008-11-10 2016-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
US8900822B2 (en) 2011-11-21 2014-12-02 Ethicon, Inc. Fibrinogen assay
US9017955B2 (en) 2011-11-21 2015-04-28 Ethicon, Inc. Fibrinogen assay
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN107328746A (en) * 2017-06-14 2017-11-07 宁波大学 The preparation and application of Multifunction fluorescent biology sensor based on class nucleic acid coordination polymer
CN111273010B (en) * 2018-12-04 2023-04-18 北京蛋白质组研究中心 Application of kit for detecting SOAT1 protein expression level in preparation of hepatocellular carcinoma screening product
CN111273010A (en) * 2018-12-04 2020-06-12 北京蛋白质组研究中心 Application of the kit for detecting the expression level of SOAT1 protein in the preparation of products for screening hepatocellular carcinoma
CN111337676A (en) * 2018-12-18 2020-06-26 欧蒙医学实验诊断股份公司 Method for diagnosing autoimmune gastritis
CN109701039A (en) * 2019-01-17 2019-05-03 浙江大学 A kind of preparation method of liver cancer dual-target magnetic nanoparticle
CN109897900A (en) * 2019-03-13 2019-06-18 温州医科大学 Application of the EPB42 gene in liver cancer SBRT curative effect evaluation
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU (CLU) and composition thereof in diagnosis of bile duct cancer and bile duct cancer diagnosis kit
CN113249476A (en) * 2021-05-12 2021-08-13 复旦大学 Key protein BLT2 affecting dryness of tumor cells and application thereof
CN113151482A (en) * 2021-05-21 2021-07-23 深圳泰莱生物科技有限公司 Method for identifying benign and malignant lung nodules based on monochromatic multiple fluorescence quantitative PCR
CN117647645A (en) * 2024-01-29 2024-03-05 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
CN117647645B (en) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
CN118471472A (en) * 2024-05-22 2024-08-09 中国人民解放军海军军医大学第三附属医院 Marker, kit, system and application for screening or diagnosing early liver cancer
CN120758627A (en) * 2025-06-30 2025-10-10 南方医科大学南方医院 A biomarker, scoring model and application for predicting the prognosis of BPA-induced intrahepatic cholangiocarcinoma

Also Published As

Publication number Publication date
WO2007030571A2 (en) 2007-03-15
WO2007030571A3 (en) 2007-08-30
WO2007030531A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2007030531A2 (en) Reagents for testing and molecular imaging of liver cancer
Hausner et al. Preclinical development and first-in-human imaging of the integrin αvβ6 with [18F] αvβ6-binding peptide in metastatic carcinoma
Keliher et al. Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease
EP3440101B1 (en) Cd8-specific capture agents, compositions, and methods of using and making
Gonzales et al. In-vivo detection and tracking of T cells in various organs in a melanoma tumor model by 19F-fluorine MRS/MRI
CN113444146B (en) Targeted fibroblast activation protein probe, preparation method and application thereof in preparation of PET imaging agent
Hausner et al. In vitro and in vivo evaluation of the effects of aluminum [18F] fluoride radiolabeling on an integrin αvβ6-specific peptide
Zhang et al. The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in beta-cell-targeted MRI
Valliant A bridge not too far: linking disciplines through molecular imaging probes
Pastorino et al. Two novel PET radiopharmaceuticals for endothelial vascular cell adhesion molecule-1 (VCAM-1) targeting
Tian et al. An albumin sandwich enhances in vivo circulation and stability of metabolically labile peptides
Bapst et al. Glycosylated DOTA− α-melanocyte-stimulating hormone analogues for melanoma targeting: influence of the site of glycosylation on in vivo biodistribution
Wang et al. Druggability of Targets for diagnostic radiopharmaceuticals
Li et al. Noninvasive radionuclide molecular imaging of the CD4-positive T lymphocytes in acute cardiac rejection
Hicks Functional imaging techniques for evaluation of sarcomas
Newton et al. Melanoma imaging with pretargeted bivalent bacteriophage
Chuang et al. Development of a universal anti–polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes
CN106061512B (en) Composition for imaging atherosclerosis and method for diagnosing atherosclerosis using the composition
Lauwerys et al. Radionuclide imaging of cytotoxic immune cell responses to anti-cancer immunotherapy
Prigent et al. Advances in radiopharmaceutical sciences for vascular inflammation imaging: focus on clinical applications
CA2991013A1 (en) Albumin-sugar chain complex
US12427212B2 (en) Nectin-4 binding miniproteins, conjugates and uses thereof
CN116570736B (en) Radioactive probe for targeting angiotensin receptor II based on SARS-CoV series virus S protein sequence
Chen et al. A preliminary study of a 68 Ga-labeled PET probe for HER2 imaging
Pan et al. 68Ga-WRWWWW Is a Potential Positron Emission Tomography Probe for Imaging Inflammatory Diseases by Targeting Formyl Peptide Receptor 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06803033

Country of ref document: EP

Kind code of ref document: A2